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TARGETING AUTOPHAGY TO IMPROVE EFFICACY OF CDK4/6 INHIBITION IN
BREAST CANCER

Smruthi Vijayaraghavan, B.S
Advisory Professor: Khandan Keyomarsi, Ph.D.

Deregulation of the cell cycle machinery is a hallmark of cancer, leading to aberrant
proliferation and tumorigenesis. The crucial role of the CDK4/6-Cyclin D pathway has led to the
development and FDA approval (palbociclib, ribociclib) of CDK4/6 inhibitors for the treatment of
advanced estrogen receptor positive breast cancer. However, three major clinical challenges
remain: i) adverse events leading to discontinuation of therapy and ii) lack of reliable
biomarkers to identify responsive patients and iii) acquired resistance to CDK4/6 inhibitors.
Previous in vitro studies have shown that palbociclib mediated CDK4/6 inhibition induces G1
arrest and senescence in ER+ breast cancer cells, and a recent study in fibroblasts implicated
a role for palbociclib in inducing autophagy, a catabolic process that facilitates survival of the
cells under stress. Thus, we hypothesize that in the presence of an intact G1/S checkpoint,
autophagy protects ER positive breast cancer cells from palbociclib induced
senescence. Further, based on our preliminary results, we hypothesize that cancer stem cells
and EMT mediates acquired resistance to palbociclib. Results from this study show that breast
cancer cells activate autophagy in response to palbociclib, and that the combination of
autophagy and CDK4/6 inhibitors induces irreversible growth inhibition and senescence in vitro,
and diminishes growth of cell line and patient-derived xenograft tumors in vivo. Furthermore,
intact G1/S transition is necessary and predictive of preclinical sensitivity to this drug
combination, and Rb positive and low-molecular-weight isoform of cyclin E negative status are
reliable prognostic biomarkers in advanced estrogen receptor positive breast cancer patients.
Inhibition of CDK4/6 and autophagy was also synergistic in other solid cancers with an intact
vi

G1/S checkpoint, providing a novel and promising biomarker-driven combination therapeutic
strategy to treat breast and other solid tumors. Lastly, combined targeting with STAT-3 and
PARP inhibitors can effectively target acquired resistant to palbociclib. Collectively, results from
this study can help improve the efficacy, selectivity and treat acquired resistance to CDK4/6
inhibition in breast and other solid tumors.
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CHAPTER 1: INTRODUCTION

1.1. BREAST CANCER
1.1.1. EPIDEMIOLOGY OF BREAST CANCER
Breast cancer is the most commonly diagnosed cancer in women worldwide, with an
estimated 252,710 new patients expected to be diagnosed with the disease in 2017 (Siegel,
Miller et al. 2016). It is also the second most common cause of cancer death in women,
accounting for about 15% of all cancer related deaths and an estimated 40,610 deaths in 2017
(Siegel, Miller et al. 2016). While there has been a decrease in breast cancer deaths over the
years, the continued increase in cancer incidence emphasizes the need for more reliable and
efficacious treatment strategies to combat the disease.

1.1.2. BREAST CANCER SUBTYPING
Like most cancers, breast cancer is highly heterogeneous. Breast cancers can be
classified based on numerous features such as histopathology, grade, stage, receptor status
and genomic / DNA based classification (Sotiriou, Neo et al. 2003, Onitilo, Engel et al. 2009).
Historically, breast cancer was classified based on staining for the hormone receptors such as
estrogen receptor (ER), progesterone receptor (PR), and Her-2 (Onitilo, Engel et al. 2009).
Based on the presence or absence of these receptors, breast cancer can be divided into four
subtypes: i) hormone receptor positive (ER+/PR+/HER2-), ii) hormone receptor and Her-2
positive (ER+/PR+/HER2+), iii) Her-2 amplified (ER-/PR-/HER2+) and iv) triple negative (ER/PR-/HER2-) (Figure 1) (Sorlie, Perou et al. 2001, Sorlie, Tibshirani et al. 2003). The hormone
receptor positive is the most prevalent subtype, comprising about 66% of all breast tumors
(Figure 1) (Sorlie, Perou et al. 2001, Sorlie, Tibshirani et al. 2003). They can also be classified
based on histopathological features of the tumor biopsy specimens such as ducts and lobules
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Breast Cancer
ER+/PR+/HER2+
(8.5%)
HER2+ (5.9%)
TNBC
(18.9%)
ER+/PR+/HER2(66.5%)

Figure 1: Breast cancer subtypes: Pie chart showing the subtypes of
breast cancer based on the receptor status

Subtype

ER PR
HER2
expression

Frequency

Luminal A

ER+, PR+,
HER2-

50-60%

Luminal B

ER+, PR+,
HER2

10-18%

HER2
positive

ER-, PR-,
HER2+

Basal-like

Prognosis

Current
treatments

Good

Endocrine therapy

high Ki67

Intermediate
/ Poor

Endocrine therapy
plus chemotherapy

10-15%

Her2
amplification

Poor

Trastuzumab,
lapatinib (plus
chemotherapy)

ER-,PR-,
HER2-

10-20%

CK 5/6, EGFR

Very poor

Chemotherapy,
surgery

Normallike

ER-/+,
HER2-

3-10%

Low PARP1,
Chk1, high
ALDH

Good

Undetermined

Claudinlow

ER-,PR-,
HER2-

12-14%

Low claudin
3,4,7, Ecadherin, high
CSC

Poor

Chemotherapy
(dependent upon
HR/HER2 status)

Characteristics
low Ki67

Table 1: Breast cancer subtypes: Table showing the subtypes of breast cancer and their characteristics
when classified based on gene expression profiles
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into i) Invasive ductal carcinoma, ii) Invasive lobular carcinoma and iii) Ductal carcinoma in situ
(DCIS) (Eheman, Shaw et al. 2009)
A more recent classification of breast tumors was carried out based on gene expression
profile of normal and tumor tissues using cDNA microarray (Perou, Sorlie et al. 2000).
Classification of 42 patient tumors identified four distinct molecular subtypes within breast
cancer namely, ER positive / luminal, Her2 / ErbB2 positive, basal-like and normal subtypes
(Perou, Sorlie et al. 2000). Further classification was performed using microarray based gene
expression profiles from 99 breast tumors to yield six intrinsic subtypes namely Luminal A,
Luminal B, Her2 positive, basal-like, normal breast and claudin-like subtypes (Table 1)
(Sotiriou, Neo et al. 2003, Eroles, Bosch et al. 2012). Luminal A breast cancer, which is the
most common type is characterized by the expression of ER, PR, absence of expression of
Her2 and low expression of Ki67. This subtype is currently being treated using aromatase
inhibitors, selective ER modifiers or selective regulators of ER, depending on the menopausal
status of the patient and the source of estrogen (Baum, Budzar et al. 2002). In pre-menopausal
women, ovaries are the primary source of estrogen, making anti-estrogens such as tamoxifen
or fulvestrant as the mainstay treatment (Baum, Budzar et al. 2002). In post-menopausal
women, however, since estrogen is produced by the conversion of androgens (from the
adipose tissue) by the aromatase enzyme, the aromatase inhibitors such as letrozole and
anastrazole are more commonly used (Baum, Budzar et al. 2002). Luminal B tumors have a
more aggressive phenotype and exhibit expression of ER, presence or absence of Her2 and
high levels of Ki67 (Sotiriou, Neo et al. 2003). Her2 positive breast cancers are characterized
by high levels of expression of Her2 and have poor prognosis. Basal-like or triple negative
breast cancers have the absence of the key receptors of ER, PR and Her2. They have very
poor prognosis and high relapse rates and frequently harbor mutations in critical tumor
suppressor genes like p53 and BRCA1 (Liedtke, Mazouni et al. 2008, Hernandez-Aya, ChavezMacgregor et al. 2011). The normal breast subtype is very poorly classified and comprise of
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fibroadenomas and some normal breast samples. They have characteristics intermediate
between the luminal and basal subtypes, and they do not respond to neoadjuvant
chemotherapy (Sotiriou, Neo et al. 2003). Finally, the claudin-like, subtype which was a newly
identified subtype has low expression of cell adhesion and tight junction genes. These tumors
also have a high expression of genes involved in EMT and exhibit a cancer stem cell
phenotype, which makes them resistant to standard chemotherapy (Sotiriou, Neo et al. 2003).
Hence, genomic analysis of these tumors might help to understand their mutation profile, and in
turn utilize targeted therapy options such as PARP, EGFR inhibitors to treat this subtype
(Sotiriou, Neo et al. 2003).

1.1.3. HORMONE RECEPTOR POSITIVE BREAST CANCER – CURRENT TREATMENTS
The hormone receptor (HR) positive subtype is the most common subtype of breast
cancer comprising of over 65% of all breast cancer patients (Figure 1) (Eroles, Bosch et al.
2012). Due the presence of the hormone receptors, the mainstay treatment for these tumors
are hormonal therapy (Goldhirsch, Wood et al. 2011). Typically, early stage HR positive
cancers are treated with anti-estrogens, which includes tamoxifen in the case of
premenopausal women and aromatase inhibitors in the case of post-menopausal women
(Baum, Budzar et al. 2002). The biology of these treatments and the modes of resistance will
be discussed in detail later in this chapter. While anti-estrogens are currently administered for a
period of 5 years, studies propose longer treatment regiments, which have been shown to
improve the disease free survival by 48% when patients were treated with letrozole following 5
year tamoxifen (Jin, Tu et al. 2012). However, this prolonged treatment with tamoxifen or
aromatase inhibitors might give rise to side-effects including enhanced risk of endometrial
cancer and joint pain or fracture respectively (Jin, Tu et al. 2012, Davies, Pan et al. 2013).
Unlike early HR positive breast cancer, patients presented with metastatic disease are
often inherently resistance to the anti-hormonal therapy or acquire resistance within few
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months (Piccart, Hortobagyi et al. 2014). Hence, fulvestrant, a drug that directly inhibits and
downregulates ER protein is used in the metastatic setting to treat these patients (Agrawal,
Robertson et al. 2016). The last few years has seen the advent of targeted therapies,
specifically the CDK4/6 inhibitors, which showed great results in clinical trials, by prolonging
progression free survival by 12 months, and are currently approved for the treatment of
advanced ER positive breast cancers (Clark, Karasic et al. 2016, Sherr, Beach et al. 2016).
Finally, several pre-clinical and clinical studies have shown promising results for the use of
PI3K and mTOR inhibitors as single or combination treatments in HR positive breast cancer
(Paplomata and O'Regan 2014). These targeted therapies and their application has been
explained in detail later in this chapter.

1.1.4. HER2 POSITIVE BREAST CANCER – CURRENT TREATMENTS
About 15 to 20% of all breast cancers express Her-2 receptor (Figure 1) (Yaziji,
Goldstein et al. 2004). Her-2 belongs to the EGFR family and is a trans-membrane receptor
that is amplified or overexpressed in breast cancer patients (Owens, Horten et al. 2004). Thus,
targeted therapy directly blocking the pathway, such as herceptin, lapatinib, pertuzumab and TDM1 are currently used to treat early and advanced Her-2 positive breast cancer patients
(Romond, Perez et al. 2005, Lewis Phillips, Li et al. 2008, Piccart-Gebhart, Holmes et al. 2016).
Trastuzumab (herceptin) is a monoclonal antibody that binds to and inhibits the
extracellular domain of Her-2 receptor. Results from a phase II study conducted on 235
metastatic Her-2 positive breast cancer patients who received chemotherapy vs herceptin +
chemotherapy, revealed that herceptin significantly prolonged time to progression and
improved objective response rate (~50%) compared to chemotherapy alone (32%) (Slamon,
Leyland-Jones et al. 2001). However, over time patients develop resistance to herceptin
treatment as well (Oliveras-Ferraros, Vazquez-Martin et al. 2010). This resistance occurs either
by loss of the receptor’s extracellular domain (which prevents recognition by herceptin) or
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formation of a heterodimer complex between the Her-2 sand Her-3 receptors (which mediates
tyrosine kinase activity despite herceptin treatment) (Hellyer, Kim et al. 2001, Scaltriti, Rojo et
al. 2007, Junttila, Akita et al. 2009).
Lapatinib is a tyrosine kinase inhibitor, which binds to the intracellular domain of Her-2
and inhibits its kinase activity. Since lapatinib functions by targeting the receptor’s intracellular
domain, it can be effective even in tumors that have acquired resistance to herceptin by
acquiring modifications in the extracellular domain (Scaltriti, Chandarlapaty et al. 2010). Hence,
studies have shown that the combination of lapatinib and trastuzumab in Her-2 positive
xenograft model results in enhanced tumor growth inhibition (Scaltriti, Verma et al. 2009).
Pertuzumab, is a monoclonal antibody, similar to herceptin and to bind to the
extracellular domain of Her-2 at a site different from that of herceptin, which prevents the
hetero-dimerization between Her-2 and Her-3, one of the resistance mechanisms to herceptin
(Agus, Akita et al. 2002). Thus, preclinical studies have shown enhanced antitumor activity
upon combination treatment with pertuzumab and herceptin (Scheuer, Friess et al. 2009),
which was further confirmed in phase III clinical trial show, where the addition of pertuzumab to
herceptin in Her-2 positive breast cancer patients proved to be an effective combination
strategy (Baselga, Cortes et al. 2012)
TDM-1 is a conjugate of an antibody (herceptin) with a microtubule inhibitor emtasine
(T-DM1). Upon binding of the antibody to Her-2 receptor, the chemotherapy agent is
internalized and released resulting in cytotoxicity exclusively in the cancer cells. Phillips at al
examined the combination of T-DM1 with pertuzumab in a xenograft model of breast cancer
using Her-2 expressing cell lines. The results revealed that the combination synergistically
inhibited cell proliferation and induced cell death in vitro and induced tumor regression in vivo
(Phillips, Fields et al. 2014).
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1.1.5. TRIPLE NEGATIVE BREAST CANCER – CURRENT TREATMENTS
About 15% of all cancers is characterized by the absence of ER, PR and Her2 and
termed as Triple Negative or basal tumors (Figure 1). They show increased expression of
cytokeratin, c-kit and epidermal growth factor receptor and frequently harbor mutations in tumor
suppressors like p53 and BRCA (Foulkes, Stefansson et al. 2003). Several critical signaling
pathways including MAPK, PI3K-Akt, NF-Kb, Wnt are seen to be deregulated in these cancers
(Miki, Swensen et al. 1994. Genetic aberrations like copy number variation, gene amplification
is also common in this cancer subtype (Foulkes, Stefansson et al. 2003). Further, epigenetic
modifications, mainly DNA methylation has a distinct signature of basal or TNBC tumors
(Wooster, Bignell et al. 1995). Given this diversity within the TNBC tumors, a recent study
classified them further based on gene expression profile from 386 triple negative tumors
(Lehmann, Bauer et al. 2011). This clustering resulted into 6 new TNBC subtypes namely
basal, mesenchymal, mesenchymal stem-like (MSL), immunomodulatory (IM), luminal
androgen receptor (LAR), basal like 1 (BL1), and basal like 2 (BL2), each having their own
characteristic enrichment of genes and pathways (Lehmann, Bauer et al. 2011). For example,
the LAR subtype showed enrichment in the androgen receptor signaling and metabolism
pathways, while the BL1 subtype showed enrichment of the cell cycle and DNA replication
pathways (Lehmann, Bauer et al. 2011). Further, the currently used TNBC cell lines can also
be classified into these subtypes based on the gene expression profiles, and will facilitate
better pre-clinical investigation (Lehmann, Bauer et al. 2011). Another recent study, which
analyzed the RNA and DNA profiles of 198 TNBC tumors, classified them into four distinct
molecular subtypes, each having their own characteristic gene amplification or target molecule:
i) Luminal androgen receptor (LAR) subtype which overexpresses the cell surface mucin
MUC1, ii) Mesenchymal (MES) subtype overexpressing the growth factor receptors, PDGF
receptor A and c-kit, iii) Basal-like immune suppressed (BLIS) which expresses the immune
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suppressing molecule VTCN1 and iv) Basal-like immune activated (BLIS) expresses STAT3
molecules and cytokines (Hartkopf, Taran et al. 2016).
By definition, the triple negative breast cancer (TNBC) tumors are negative for ER, PR
and HER-2, and hence these patients will not benefit from hormonal therapy or Her-2 targeting
therapies, leaving cytotoxic chemotherapy as the current standard of care for these patients
(Rocca, Bravaccini et al. 2014). Overall, among all the breast cancer subtypes, patients with
TNBC tumors have the worst prognosis (Carey, Perou et al. 2006, Liedtke, Mazouni et al.
2008). While there is no standard of care drug for TNBC, patients are usually treated with a
variety of chemotherapy drugs including anthracyclines, fluropyrimidines, taxanes and
platinum-based drugs (Levine, Pritchard et al. 2005, Zeichner, Terawaki et al. 2016).
Anthracyclines, such as doxorubicin, epirubicin and etoposide, which are one of the most
commonly used class of chemo drugs in TNBC, work by intercalating the DNA or inhibiting the
topoisomerase II activity (Zeichner, Terawaki et al. 2016). In many cases, the chemotherapy
drugs are also given in combination to increase therapeutic benefit (Zeichner, Terawaki et al.
2016). TNBC patients are often given anthracyclines as adjuvant chemotherapy combination
with taxanes, such as docetaxel and paclitaxel, which work by binding to ß-tubulin and
stabilizing the microtubules (Zeichner, Terawaki et al. 2016). Further, TNBC patients can also
receive platinum-based chemotherapy, such as cisplatin or carboplatin both as a single agent
and in combination therapy, with TNBC patients responding better to the platinum based drugs
compared to other subtypes of breast cancer (Levine, Pritchard et al. 2005).
While TNBC tumors are highly prone to genetic mutations compared to the other
subtypes, the lack of complete knowledge about the deregulated genes has made it difficult to
develop targeted therapies for TNBC (Zeichner, Terawaki et al. 2016). Basal like or TNBC
breast tumors frequently have mutations (commonly germline mutations) in the BRCA family of
DNA repair genes, which are involved in repairing double strand DNA breaks via the efficient
and homologues recombination (HR) pathway (Moynahan, Chiu et al. 1999). About 10-15% of
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TNBC patients harbor BRCA-1 mutation and is associated with high-grade tumor (Foulkes,
Stefansson et al. 2003). Interestingly, over 75% of the breast cancers that develop BRCA1
mutation belong to the TNBC subtype (Bayraktar, Gutierrez-Barrera et al. 2011). Cells deficient
in BRCA1 are unable to repair the double strand breaks efficiently, forcing them to activate the
alternate repair pathway, base excision repair (BER), which is regulated by the PARP (poly
ADP ribose polymerase) family of proteins and are typically used to repair single strand DNA
breaks (Ashworth 2008). PARP is a family of DNA binding proteins that are recruited to the site
of single strand DNA breaks and repair them via the BER mechanism (Eustermann, Videler et
al. 2011, Langelier, Planck et al. 2011). This results in synthetic lethality and increased
genomic instability and apoptosis observed with PARP inhibitor treatment in BRCA1/2 deficient
cell lines and Brca1−/−, p53−/− mouse model (Farmer, McCabe et al. 2005, Ashworth 2008).
Tumors developed in the BRCA1−/− p53−/− mouse model were treated with the PARP inhibitor
(olaparib - AZD2281) and cisplatin as single agents or in combination and results revealed that
PARP inhibitor treated tumors had improved survival compared to vehicle treatment, and the
combination treatment further improved mouse survival, demonstrating synthetic lethality of
PARP inhibition with BRCA mutation (Rottenberg, Jaspers et al. 2008).
The PARP inhibitors, olaparib, rucaparib and more recently niraparib have been FDA
approved for the treatment of advanced ovarian cancers harboring BRCA1/2 mutation (2017,
Lin and Kraus 2017). These drugs are under phase II/III clinical trials in TNBC tumors and are
the one of the most promising results targeted therapies currently under investigation for TNBC
(2017, Lin and Kraus 2017). A phase II clinical trial in which 54 breast cancer patients
harboring BRCA1 or BRCA2 mutation, received two different doses of olaparib, 400 mg twice
daily or 100 mg twice daily showed that 41% of the patients who received the higher dose
displayed objective response while 22% of those who received the lower dose responded (Tutt,
Robson et al. 2010). Olaparib treatment was largely well tolerated with the fatigue, nausea, and
anemia being the most common side effects (Tutt, Robson et al. 2010). Another study showed
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that the combination of PARP inhibitor (velaparib) with platinum based chemotherapy
(carboplatin) in TNBC patients doubled the rate of pathologic complete response 52%
compared to 26% with carboplatin alone (2014).
Apart from PARP inhibitors, other targeted treatment strategies that are currently under
investigation in TNBC patients include angiogenesis inhibitors, EGFR inhibitors and
immunotherapy (Baselga, Gomez et al. 2013, Stagg and Allard 2013, Makhoul, Klimberg et al.
2015). TNBC patients exhibit higher expression of EGFR compared to non-TNBC tumors,
which led to a phase II study with the addition of the EGFR inhibitor, cetuximab to cisplatin in
metastatic TNBC patients, which showed an increase in the response rate from 10% to 20%
and prolonged progression free survival time (Baselga, Gomez et al. 2013). Similarly, TNBC
tumor specimens also express higher levels of the angiogenesis factor VEGF, leading to a
phase III clinical study combining bevacizumab, the monoclonal antibody against VEGF, along
with docetaxel in metastatic Her2 negative breast cancer patients, and showed that addition of
bevacizumab delayed tumor progression with no additional toxicity (Senger, Galli et al. 1983,
Presta, Chen et al. 1997). (Miles, Chan et al. 2010). Finally, while breast cancer is considered
non-immunogenic, they can induce an adaptive immune response and this has led to recent
studies aimed at making the breast cancer tumors sensitive to immunotherapy and checkpoint
blockade (Stagg and Allard 2013). Studies have shown that the TNBC subtype of breast
tumors are particularly attractive for cancer immunotherapy since they have the presence of
PD-1+ve TILs (tumor infiltrating lymphocytes) and higher rates of PD-L1 expression by the
tumor and the immune cells (Cimino-Mathews, Thompson et al. 2016). This led to a phase I
clinical study with the PD-1 inhibitor atezolizumab as a monotherapy in 112 heavily pretreated
metastatic TNBC, which showed pathological complete response in 11 patients and partial
response in 15 patients (2017). While only 10% of the patients responded to the anti–PD-L1
therapy, those who did had a median duration of response of 21 months (2017), Further, a
combination treatment of atezolizumab with paclitaxel in metastatic TNBC patients exhibited an
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overall response rate of 41.7% (Sylvia Adams 2016). These studies provide evidence to
develop immunotherapy as a promising treatment strategy for TNBC in the future.

1.2. ER POSITIVE BREAST CANCER
1.2.1 ROLE OF ESTROGEN AND ER IN BREAST CANCER
Estrogen, which is the primary female sex hormone is primarily secreted by the ovaries
in premenopausal women (Ryan 1959). In post-menopausal women, estrogen is obtained by
the enzyme aromatase via the conversion of androgens (testosterone) produced from the
adipose tissues (Ryan 1959, Thompson and Siiteri 1974). Estrogen mediated its function and
biologic activity by binding to and activating its hormone receptor, estrogen receptor (ER)
(Deroo and Korach 2006). There are two estrogen receptors, ERα and ERβ, encoded by ESR1
and ESR2, respectively (Deroo and Korach 2006). The binding of estrogen to the receptor
facilitates dimerization of ER and translocation into the nucleus, where it binds to ER
responsive elements (ERE element) on the promoter region of the target genes (Yi, Driscoll et
al. 2002). This is the classical and canonical pathway by which ER functions as a transcription
factor in response to estrogen (Deroo and Korach 2006). The transcriptional function of the
estrogen receptor is regulated by several coactivator and corepressor proteins, which interact
with ER at the DNA and regulate gene transcription (Deroo and Korach 2006). Some of the
crucial co-activators and co-repressors in breast cancer include, TRAP-220 (a link between ER
alpha and RNA polymerase II), CARM1 (which is overexpressed in breast cancer), nuclear
receptor co-repressor NCoR (represses ER gene transcription), RTA (repressor of tamoxifen
activity, interacts with and represses ER) (Deroo and Korach 2006). Additionally, ER signaling
can be directly activated in a ligand (estrogen) independent manner through MAPK and cAMP
induced protein kinase A (PKA) (Arnold, Obourn et al. 1995, Chen, Washbrook et al. 2002,
Carascossa, Dudek et al. 2010).
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Data from clinical and animal studies show that estrogen and ER play a crucial role in
mammary development and breast cancer (Deroo and Korach 2006). Two current hypothesis
have been proposed to functionally explain this relationship: i) Increased estrogen activates ER
and ER signaling, which increases cell division and DNA synthesis and the risk for replication
errors, resulting in the acquisition of detrimental mutations, which lead to mammary tumor
formation (Henderson and Feigelson 2000); ii) estrogen metabolism produces genotoxic
products which directly induce DNA damage leading to mutations and cancer formation.
Further, epidemiologic studies also show a strong link between estrogen and breast cancer
formation (Trichopoulos, MacMahon et al. 1972), with greater duration of exposure to estrogen
increasing the risk for breast cancer (Clavel-Chapelon and Group 2002, Press and Pharoah
2010).

1.2.2. CURRENT TREATMENTS FOR ER POSITIVE BREAST CANCER
Due to significant role of estrogen pathway in breast cancer and given that 65% of
breast cancers being estrogen receptor (ER) positive, drugs targeting the hormone receptor
have been developed and are currently used (Table 2). The estrogen pathway can be targeted
by three different strategies: i) selective estrogen receptor modulator (SERM), such as
tamoxifen, which inhibits binding of estrogen to ER (Sini, Cinieri et al. 2016); ii) selective
estrogen receptor down regulator (SERD) such as fulvestrant, which competitively inhibits ER,
by binding to it and degrading it (Dauvois, White et al. 1993, Nicholson, Gee et al. 1995); and
iii) aromatase inhibitors (AI), which are primarily used in post-menopausal women and target
aromatase, the enzyme required for the conversion of androgens to estrogen (Furet, Batzl et al.
1993). Recent years have witnessed the development of more specific and targeted agents
such as CDK4/6 inhibitors, PI3K and mTOR inhibitors (Paplomata and O'Regan 2014, Sherr,
Beach et al. 2016). The development and current clinical use of these drugs have been
discussed in detail in sections below.
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Class of drug

Drug

Structure

Selective estrogen
receptor modulator
(SERM)

Tamoxifen

Selective estrogen
receptor downregulator
(SERD)

Fulvestrant

Letrozole

Aromatase inhibitors

Anastrozole

Exemestane

Table 2: Anti-estrogens: Table listing the anti-estrogens used for the treatment of
ER positive breast cancer and their chemical structures.

1.2.3. SERM - TAMOXIFEN
The rationale for developing an anti-estrogen to treat breast cancer arises to from the
principle block hormone production, which was achieved in the 1970s by irradiate ovaries of
newly diagnosed ER positive breast cancer patients (Lees, Giuffre et al. 1980). The first trial
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with tamoxifen (originally known as IC146474) in 1971 reported response in 10 out of 46 breast
cancer patients (Cole, Jones et al. 1971), and the drug has revolutionized the field of breast
cancer treatment since then. The primary mechanism of action of tamoxifen as a selective
estrogen receptor modulator (SERM) involves binding of the drug to the estrogen receptor (ER)
and preventing the binding of estrogen to ER, thus turning off the ER signaling pathways. The
ability of tamoxifen to block the binding of estrogen to ER and prevent the induction and growth
of ER dependent tumors was first tested in ER positive carcinogen-induced rat mammary
carcinomas (Jordan 1976, Jordan and Dowse 1976). The anti-tumor effects of tamoxifen were
further confirmed in a nude mouse model with subcutaneously implanted (in the presence of
estrogen pellets) ER positive breast tumor (generated by injecting ER positive breast cancer
cells lines, MCF7 or T47D) treated with daily dose of tamoxifen, exhibiting significant anti-tumor
activity (Long, Jelovac et al. 2004). This led to about 28 clinical studies conducted in over
16,000 breast cancer patients, the consensus of which demonstrated that tamoxifen treatment
provides significant advantage with reduction in mortality, leading to the recommendation that
tamoxifen should be also be used as an adjuvant therapy for postmenopausal ER positive
breast cancer patients with breast cancer (1985, Early Breast Cancer Trialists' Collaborative
1988).
Further, animal studies in mice with low burden or early mammary tumors showed that
long term tamoxifen treatment in animals is better than shorter term adjuvant therapy in
providing better efficacy and a longer tumor free state (Jordan and Brodie 2007). These studies
combined with results from pilot clinical studies showed that long term tamoxifen treatment
would prove to be more effective in treating women with ER positive breast cancer, and led to
the current treatment regimen of 5-year anti-estrogen treatment. (Jordan and Brodie 2007).
However, one of the concerns with long terms anti-estrogens is the non ER associated and
side effects with this treatment (Love, Mazess et al. 1992, Zidan, Keidar et al. 2004). For
example, tamoxifen has been shown to have oncogenic effect on uterus, results in higher
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incidence (rate of 1.2% annually) of endometrial cancer in patients receiving long-term
tamoxifen (Fisher, Costantino et al. 1994). Patients receiving long term estrogen treatment also
suffered from higher rate of hot flashes, vaginal discharge and menstrual irregularities (Powles,
Jones et al. 1994). On the other hand, tamoxifen treatment has beneficial effects such as
reduction in cholesterol levels and decreased death from myocardial infarction (Bagdade,
Wolter et al. 1990, Love, Newcomb et al. 1990, Love, Wiebe et al. 1991).
While tamoxifen has proven to be highly effective over the years in treating ER positive
breast cancer, one concern is the development of resistance over time (Toy, Shen et al. 2013).
Hence, several studies over the years have focused on understanding the molecular
mechanism of resistance to tamoxifen, which include mutation of the estrogen receptor, loss of
ER expression and non-canonical ER signaling pathways (Encarnacion, Ciocca et al. 1993,
Fuqua, Wiltschke et al. 2000). Mutations in ER are more commonly detected in the resistant
tumors compared to treatment naïve tumors (Toy, Shen et al. 2013). These mutations in the
receptor allow ER to dimerize even in the absence of the ligand (estrogen) (Toy, Shen et al.
2013). This would result in activation of the downstream ER signaling pathway, even in the
presence of anti-estrogens such as tamoxifen (Toy, Shen et al. 2013). Specifically, a study in
59 tissues with hyperplasia observed a Lys to Arg mutation (K303R) in the estrogen receptor in
20 tissues (Fuqua, Wiltschke et al. 2000). While mutations in ER are not common, they are
frequently found in metastatic patients who have progressed on anti-estrogen therapy (Toy,
Shen et al. 2013). These mutations are frequently located in the ligand-binding domain of the
receptor and facilitates estrogen independent activity of the mutants (Toy, Shen et al. 2013).
Further, loss of expression of the hormone receptor ERα is another established mechanism of
resistance to tamoxifen (Encarnacion, Ciocca et al. 1993, Ellis, Tao et al. 2008). Given that
tamoxifen functions by binding direct ER, loss of the receptor makes the cells / tumors become
unresponsive to the drug (Ellis, Tao et al. 2008). Finally, another known mechanism of
resistance to tamoxifen is the non-canonical crosstalk between ER and other major growth
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factor signaling pathways such as Her-2, PI3K and MAPK pathways (Campbell, Bhat-Nakshatri
et al. 2001, Riggio, Polo et al. 2012). ER can activate growth factor receptors such as Her-2
and EGFR (Lee, Cui et al. 2001), while PI3K and MAPK pathways can phosphorylate and
activate ER in a ligand independent manner (Campbell, Bhat-Nakshatri et al. 2001, Riggio,
Polo et al. 2012), ultimately resulting in cellular proliferation even in the absence of estrogen
and resistant to tamoxifen treatment (Shou, Massarweh et al. 2004, Britton, Hutcheson et al.
2006). This suggests combination treatment strategies with the inhibitors targeting these
signaling pathways to combat tamoxifen resistance. This has led to pre-clinical studies with the
combination of tamoxifen and trastuzumab or lapatinib or the EGFR inhibitor, gefitinib, which
significantly prolonged response to tamoxifen and delayed the acquired resistance (Benz, Scott
et al. 1992, Massarweh, Osborne et al. 2008). Further, results from a phase II clinical study
showed the efficacy of trastuzumab in breast cancer patients who have become resistant to
tamoxifen (Kaufman, Mackey et al. 2009).

1.2.4. SERD - FULVESTRANT
Fulvestrant, an analogue of 17β-estradiol, acts as an anti-estrogen by selectively
binding to the estrogen receptor (ER) preventing its dimerization and nuclear localization
(Fawell, White et al. 1990, Dauvois, White et al. 1993). The drug also mediates degradation of
ER, resulting in complete shutdown of the ER signaling pathway (Nicholson, Gee et al. 1995).
Given that its mechanism of action is different from that of tamoxifen, early clinical studies
focused on utilizing fulvestrant to treat patients who have acquired resistance to prior tamoxifen
or aromatase inhibitor therapy (Freedman, Amir et al. 2009). A study in 19 patients who
progressed on tamoxifen treatment showed that fulvestrant can successfully extend the
duration of response of breast tumors to anti-estrogens (Howell, DeFriend et al. 1995). More
recently, clinical studies have also been conducted to test the efficacy of fulvestrant in
treatment naïve patients (Robertson, Llombart-Cussac et al. 2009). For example, on
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comparison with the aromatase inhibitor, anastrazole in a phase II study in advanced postmenopausal breast cancer patients, patients on the fulvestrant arm had a longer time to
progression compared to the anastrozole arm (Robertson, Llombart-Cussac et al. 2009).
Further, a recently published phase III study confirmed that fulvestrant treatment improved
progression free survival by 2.8 months compared to anastrazole treatment arm (Robertson,
Bondarenko et al. 2016). Moreover, unlike tamoxifen, fulvestrant does not have an oncogenic
effect and hence does not increase the risk of endometrial cancer (Bergman, Beelen et al.
2000). Thus, these studies show that fulvestrant can serve as an effective anti-estrogen
treatment in early and advanced (resistant to other anti-estrogen treatment) stage ER+ breast
cancer patients.

1.2.5. AROMATASE INHIBITORS
Aromatase inhibitors (AI) are a class of antiestrogens, primarily used to treat postmenopausal women with ER positive breast cancer, and functions by inhibiting the activity of
aromatase, the enzyme required for the generation of estrogen in post-menopausal women
(Yue, Wang et al. 2005). They are typically divided into two classes based on their structure: i)
non-steroidal AIs such as letrozole and anastrozole and ii) steroidal AI such as exemestane
(Yue, Wang et al. 2005). The non-steroidal AIs, letrozole and anastrozole, competitively inhibit
aromatase in a reversible manner by binding to the enzyme non-covalently (Soudon 2000).
They are FDA approved are currently the standard of care drugs for post-menopausal ER
positive breast cancer patients (Howell, Cuzick et al. 2005). The steroidal class of AI,
exemestane, resembles in structure to androstenedione and inhibit aromatase in an irreversible
manner by binding to the enzyme covalently (Oliveras-Ferraros, Vazquez-Martin et al. 2010).
Exemestane has also been FDA approved for use in postmenopausal ER positive breast
cancer patients (Coombes, Goss et al. 1984).
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Numerous clinical studies have been performed to compare the efficacy of aromatase
inhibitors against tamoxifen in post-menopausal breast cancer patients (Mouridsen,
Gershanovich et al. 2001, Breast International Group 1-98 Collaborative, Thurlimann et al.
2005, Howell, Cuzick et al. 2005). Treatment of anastrozole in combination with tamoxifen a
phase III randomized clinical trial in the adjuvant setting showed that anastrazole treated
patients had significantly higher disease-free survival, time to recurrence and time to distant
metastasis compared to treatment with tamoxifen alone (Howell, Cuzick et al. 2005). Further, to
test the effectiveness of AI in the adjuvant setting, a phase III clinical trial was performed in
8010 postmenopausal ER+ non-metastatic patients by comparing long term letrozole treatment
to tamoxifen (Breast International Group 1-98 Collaborative, Thurlimann et al. 2005). Results
showed that the letrozole arm had greater disease-free survival with lower rates of distant
metastasis compared to tamoxifen treatment arm (Breast International Group 1-98
Collaborative, Thurlimann et al. 2005). A similar phase III clinical study in advanced (stage IIIb
with recurrent tumors) postmenopausal ER positive breast cancer where patients received
letrozole or tamoxifen as first line therapy revealed that a significantly higher (increased by 15
weeks) time to progression and higher rate of objective response in the letrozole treated
patients compared to tamoxifen treatment arm, indicating that AI treatment with letrozole is also
beneficial in the advanced disease stage (Mouridsen, Gershanovich et al. 2001).
While aromatase inhibitors have been successful in the treating advanced and
treatment naïve ER positive post-menopausal breast cancer patients, these tumors tend to
eventually acquire resistance via numerous mechanisms (Jordan and Brodie 2007, Ma, Reinert
et al. 2015). Research in the recent years have hence focused on elucidating these
mechanisms, including androgen receptor (AR) expression, signaling through growth receptor
pathways such as Her-2, PI3K and MAPK pathways, epithelial mesenchymal transition (EMT)
and cancer stem cells (Ma, Reinert et al. 2015). Androgen receptor (AR) is a nuclear hormone
receptor, similar to AR that gets activated when bound to androgen regulates downstream
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effector genes (Schoenmakers, Alen et al. 1999), Since AR can activate the ER pathway
independent of estrogen, it has been shown to mediate de novo resistance of AIs (Rechoum,
Rovito et al. 2014). Hence, treatment with an AR antagonist (abiraterone) or an ER degrading
drug (fulvestrant) can restore sensitivity to the aromatase inhibitors even in the AR
overexpressing resistant cell (Rechoum, Rovito et al. 2014). Similar to tamoxifen resistance,
the activation of the parallel growth signaling pathways is a common mechanism by which
tumors acquire resistance to AIs (Ma, Reinert et al. 2015). This involves upregulation and
activation of the growth factor receptors such as PI3K, MAPK, Her-2 and their downstream
pathway proteins, thus enabling the AI resistant cells to adapt to and survive in low estrogen
conditions (Sabnis, Schayowitz et al. 2009, Ma, Reinert et al. 2015). Hence, the AI resistant
cells are significantly sensitive to the MAPK inhibitor (PD98059) or a MEK inhibitor (UO126)
resulting in decreased proliferation (Jelovac, Sabnis et al. 2005). Moreover, drugs targeting the
PI3K downstream protein, mTOR (everolimus) have been tested clinically (phase III study) in
combination with exemestane in ER+ patients who have progressed on aromatase inhibitors
(anastrozole or letrozole) and showed that addition of everolimus significantly improved
progression-free survival in these patients (Baselga, Campone et al. 2012). Thus, these studies
show that combined targeting of these growth signaling pathways might help re-sensitize the
cells to AI treatment. Further, studies have shown a link between mutations in ER and other
genes, and resistance (intrinsic and acquired resistance) to aromatase inhibitors (Ma, Reinert
et al. 2015). A study using whole genome sequencing of 77 ER positive tumor biopsies before
and after treatment with aromatase inhibitors, showed a correlation between ESR1 mutations
and response to treatment (Ellis, Ding et al. 2012). This study also examined mutations in other
genes such as Pi3K, p53, Rb and p27, and showed that mutations in PI3K (41.3%) and p53
(16.1%) correlated with resistance (measured by change in Ki67) to aromatase inhibitor
therapy (Ellis, Ding et al. 2012). A more recent study examined the ESR1 mutations in the
plasma and correlated it with response to aromatase inhibitors (exemestane) or fulvestrant
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(Fribbens, O'Leary et al. 2016). Results showed that while ESR1 mutations did not affect
response to fulvestrant, a correlate between mutations and resistance to exemestane was
observed (Fribbens, O'Leary et al. 2016). Finally, a link between EMT, cancer stem cells and
resistance to AIs has also been shown by in vitro studies (Creighton, Li et al. 2009).
Further, ER alpha has been shown to promote progression through the cell cycle by
binding to p27, which is one of the mechanisms by which ER alpha regulates cell proliferation
(Moghadam, Hanks et al. 2011). A recent study shows a novel mechanism by which antiestrogens control the cell cycle, where the stabilization of ER alpha delays cell cycle
progression leading cell cycle arrest (Moghadam, Hanks et al. 2011). Results from this study
also showed that ER alpha is cell cycle regulated, and the presence or absence of the estrogen
ligand on the receptor (ER alpha) determines the duration of the cell cycle in both ER positive
(MCF7) and TNBC cell lines (MDA-MB-231) (JavanMoghadam, Weihua et al. 2016). Thus,
deregulation of the cell cycle is a mechanism of resistance to anti-estrogens, making it an
attractive drug target in ER positive breast cancer.

1.3. CELL CYCLE
1.3.1. CELL CYCLE REGULATION
Cell cycle is the complex and highly regulated process by which a cell divides to form
two daughter cells (Vermeulen, Van Bockstaele et al. 2003). The normal mammalian cell cycle
typically lasts for 24 hours and comprises of two major phases, the interphase, which is the
period during which the cells grow, undergo DNA replication and prepare for cell division and
the mitotic phase, when the DNA, nuclear material and cytoplasm is separated into two
daughter cells (Harper and Brooks 2005). The interphase in turn comprises of 3 phases, i) G1
phase, which is the longest phase of the cell cycle and the phase when the cells prepare for
DNA synthesis, ii) S phase, the phase when the replication of the DNA content occurs, and iii)
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CELL CYCLE

Figure 2: Mammalian cell cycle: Model depicting the mammalian cell cycle
with its different phases, checkpoints and regulatory proteins, CDKs and cyclins

G2 phase, the phase when the cells increase their protein and other content to prepare for
mitosis or cellular division (Figure 2) (Harper and Brooks 2005, Malumbres and Barbacid
2009). The mitotic phase or the M phase in turn comprises of four phases called prophase,
metaphase, anaphase and telophase (Harper and Brooks 2005). The M phase is characterized
by the condensation of the chromosomes, formation of the spindle fibers which enables
separation of the sister chromatid and finally leading to cytokinesis, which gives rise to two
identical daughter cells (Harper and Brooks 2005).
Tight regulation of the cell cycle is necessary for controlled cell division in a normal cell
(Vermeulen, Van Bockstaele et al. 2003). This is achieved by regulatory checkpoints at
different points in the cell cycle and through regulatory proteins – the CDKs and cyclins (Harper
and Brooks 2005). There are three cell cycle checkpoints, namely i) G1/S, which ensures that
there is no DNA damage and that the cell has accumulated sufficient materials for DNA
synthesis, ii) G2/M, which ensures that the replicated DNA is intact and the proteins required
for cell division are present and iii) M phase checkpoint, which is present at the end of the
metaphase to ensure the proper attachment of the spindle fibers to the sister chromatids
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(Figure 2) (Harper and Brooks 2005, Malumbres and Barbacid 2009). These checkpoints help
regulate which cells can move forward and complete the cell division process (Malumbres and
Barbacid 2009). The presence of any defect in the normal cell cycle process will halt the cells
at checkpoint until the defect is repaired (Vermeulen, Van Bockstaele et al. 2003). The G1/S
checkpoint is the most crucial transition checkpoint, since cells that have passed this
checkpoint no longer rely on external stimuli are committed to divide (Bertoli, Skotheim et al.
2013).
Progression through the cell cycle is further regulated by the cyclin dependent kinases
(CDKs) and their activating subunit, the cyclins (Figure 2) (Satyanarayana and Kaldis 2009)
While CDKs are expressed at constant levels throughout the cell cycle, the expression levels of
the cyclins oscillate through the different phases and regulate the kinase activity of the cyclinCDK complex (Malumbres and Barbacid 2009). The activity of CDKs are inhibited by the cyclin
dependent kinase inhibitors (CKIs), which belong to two families of CKIs, INK family proteins
that inhibit CDK4/6 such as p15, p16, p18 and p19 and the Cip/Kip family proteins that inhibit
CDK1 and CDK2 such as p21 and p27 (Hirai, Roussel et al. 1995) (Ball, Lain et al. 1997). Rb
protein, a well-known tumor suppressor regulates the G1/S checkpoint (Malumbres and
Barbacid 2009). While the hypophosphorylated state of Rb keeps the transcription factor E2F in
its inactive state, the sequential phosphorylation of Rb by cyclin D-CDK4/6 and cyclin E-CDK2
complexes inactivates the protein, releasing E2F, which in turn transcriptionally activates genes
needed for DNA synthesis (Ikeda, Jakoi et al. 1996, Connell-Crowley, Harper et al. 1997).
Since the expression of cyclin E and cyclin A are also regulated by E2F, cyclin E protein levels
increase through the G1 phase, reaching its peak at the of G1/S transition, where its activity is
required for entry into the S phase (Duronio, Brook et al. 1996). Further, the expression of
cyclin A increases through G2 phase and is replaced by cyclin B during mitosis to form a
complex with CDK1 and enable cells to cross the G2/M checkpoint and enter mitosis (Lindqvist,
van Zon et al. 2007). Finally, the degradation of cyclin B is required for the cells to exit mitosis
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Gene
deleted

Phenotypes

Lethality

Cdk1

None

E2.5

Cdk2
Cdk4
Cdk6

Reduced body size, impaired neural
progenitor cell proliferation
Reduced body size, insulin deficient
diabetes
Hypoplasia of thymus and spleen and
defects in hematopoiesis

Viable
Viable
Viable

Fertility

Both males and
females are sterile
Male and female
infertility
Fertile

Cdk2/4

Heart defects

E15.5

Cdk2/6

Reduced body size, hematopoietic defects

Viable

Cdk4/6

Severe anemia

E14.5-E18.5

Cdk2/4/6

Heart defects, hematopoietic defects

E13.5

Cdk5

Severe neurological defects

Died
immediately
after birth

Not known

Cdk11

Mitotic defects

E3.5

Not known

Cyclin A1

No abnormalities

Viable

Only males are
sterile

Cyclin A2

Not-known

E5.5

Not-known

Cyclin B1

Not-known

E10.5

Not-known

Cyclin B2

No abnormalities

Viable

Fertile

Viable

Fertile

Viable

Females sterile;
males fertile with
hypoplastic testes
Fertile

Cyclin D1
Cyclin D2

Reduced body size, neurological
abnormalities, mammary gland defects
Defects in B-lymphocyteand pancreatic cell proliferation, adult neurogenesis and
hypoplastic thymus

Cyclin D3

Defects in T-lymphocyte development

Viable

Cyclin
D1/D2

Reduced body size, hypoplastic cerebella

Viable but die
within 3 weeks

Both male and
female are sterile

Cyclin
D1/D3
Cyclin
D1/D2/D3

Neurological abnormalities

Die soon after
birth

Proliferative defects in hematopoietic cells
and cardiac myocytes

E16.5

Cyclin E1

No abnormalities

Viable

Fertile

Cyclin E2

No abnormalities

Viable

Reduced male
fertility

Cyclin
E1/E2

Severe defects in extraembryonic tissues

E11.5

Not known

Table 3: Defects in CDK and cyclin knockout mice: Table summarizing the defects and
survival of mice without knockout in the different cyclins and CDKs
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(Malumbres and Barbacid 2009). The expression of the different cyclins and the activity of the
CDKs tightly regulate the cell cycle and progression through the cell cycle checkpoints. To
understand in detail the function of the different cyclins and the CDKs, knockout mice have
been made over the years for the cyclin or the CDK proteins alone or multiple cyclins and
CDKs in combination (Table 3).

1.3.2. CELL CYCLE IN CANCER
Deregulation of cell cycle is a common hallmark in cancers, causing uncontrolled proliferation
and cell division (Figure 3), resulting in tumorigenesis (Malumbres and Barbacid 2009). This
occurs due to the numerous alterations present in the components of cell cycle (CDKs, cyclins
and CKIs) seen in cancers (Vermeulen, Van Bockstaele et al. 2003). For example, cyclin D1 is
amplified in about 15% and overexpressed in about 50% of all breast cancers (Bartkova, Lukas
et al. 1995). While cyclin E is rarely amplified, it is overexpressed in about 40% of all breast
cancer, contributing to poor prognosis in breast cancer and hyper activation of CDK2
(Keyomarsi, Conte et al. 1995, Hunt, Karakas et al. 2016). Further, high cyclin B1 expression
correlated with poor overall survival in breast cancer (Vermeulen, Van Bockstaele et al. 2003).
Apart from aberrant expression of the cyclins, CKIs are also deregulated in cancer. p27 has
lower expression and is seen to be mislocalized (localized in the cytoplasm instead of the
nucleus) in breast cancer, thus correlating with high tumor grade, absence of ER and
decreased disease free survival (Wu, Shen et al. 1999). Further, hypermethylation is seen
about 20 to 30% of breast cancer, which can inactivate the CKIs by methylation at the promoter
region, as seen with silencing of p16 (Merlo, Herman et al. 1995). p21, while is rarely mutated
in breast cancer, p53, which is transcription factor of p21 is mutated in 54-82% of TNBC tumors
(Vermeulen, Van Bockstaele et al. 2003). Thus, these alterations and the deregulated cell cycle
make it an attractive target for drug development.
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CANCER CELL
CYCLE

NORMAL CELL
CYCLE

Figure 3: Cell cycle in normal and cancer cells: Models showing the regulation of the
cell cycle in normal vs cancer cells. Normal cell cycle depicts the growth and division of the
cells (green cartoon) along the difference phases. The cancer cell cycle depicts the
uncontrolled division of the cancer cells (red cartoon).

1.3.3. CDK INHIBITORS IN BREAST CANCER
Given the importance of the cell cycle and CDKs in cancer, several drugs have been
developed over the years. Typically, CDK inhibitors are small molecule inhibitors that inhibit the
CDK kinase activity by competitively binding to the ATP pocket of the CDK proteins (De
Azevedo, Leclerc et al. 1997). The first generation CDK inhibitors that were developed lacked
specificity to a particular CDK and underwent clinical trials without a biomarker, resulting in
increased toxicity and early termination of the clinical trials (Asghar, Witkiewicz et al. 2015).
Hence these drugs cannot be used effectively as monotherapy (Asghar, Witkiewicz et al.
2015). Recent studies have given rise to a new class of more specific and potent CDK4/6
inhibitors, namely palbociclib, ribociclib and abemaciclib (Fry, Harvey et al. 2004). Given their
promising results in clinical studies, they were FDA approved and are currently used to treat
advanced ER positive breast cancer (O'Leary, Finn et al. 2016).
Flavopiridol (alvocidib) is one of the first generation of CDK inhibitors that was tested
clinically. While flavopiridol can target CDK2, it is a pan-CDK inhibitor as it inhibits multiple
other CDKs such as CDK1, CDK4, CDK6, CDK7 and CDK9 (Carlson, Dubay et al. 1996).
Treatment with flavopiridol results in cell cycle arrest and apoptosis as measured by Annexin V
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(Wirger, Perabo et al. 2005). A phase I study examined flavopiridol in two breast cancer patient
among a cohort of 34 patients with advanced solid tumors, and showed no response in both
the two breast cancer patients (Ramaswamy, Phelps et al. 2012). Another phase I trial which
tested the combination of flavopiridol with docetaxel in breast cancer did not yield satisfactory
results and had high toxicity (neutropenia) in most patients (Tan, Yang et al. 2004). Given their
high levels of toxicity and lack of efficacy, flavopiridol was not pursued clinically beyond phase
II in advanced colorectal cancer patients and malignant melanoma (Aklilu, Kindler et al. 2003,
Burdette-Radoux, Tozer et al. 2004).
Roscovitine (seliciclib), is another first generation CDK2 inhibitor that can inhibit CDK1,
CDK5, CDK7, and CDK9 in addition to CDK2 (IC50 0.7μM) (Meijer, Borgne et al. 1997). Preclinical analysis of roscovitine in vitro using ER positive breast cancer cell lines showed that
degu treatment resulted in cell cycle arrest (G2 arrest) and cell death via apoptosis and
enhanced anti-proliferative activity when combined with tamoxifen (Gritsch, Maurer et al. 2011).
The effect of roscovitine of breast tumorigenesis was interrogated in an MCF7 xenograft mouse
model, where treatment of tumors with roscovitine or doxorubicin resulted in decreased tumor
volume in almost 50% of mice, with combination of roscovitine and doxorubicin resulting in a
70% tumor shrinkage. (Appleyard, O'Neill et al. 2009). Clinically, in a phase I study of 21
patients bearing solid tumors, treatment with roscovitine at a range of doses resulted in stable
disease in about 8 out of the 21 patients (Benson, White et al. 2007).
Dinaciclib (SCH 727965), is another small pan-CDK inhibitor that targets multiple CDKs
including CDK2 (IC50=1nM), CDK5 (IC50=1nM), CDK1 (IC50=3nM) and CDK9 (IC50=4nM)
(Parry, Guzi et al. 2010). Pre-clinical studies have primarily tested the use of dinaciclib in triple
negative cell lines, where it showed significant anti-proliferative effects in vitro and tumor
regression in xenograft tumors in vivo (Horiuchi, Kusdra et al. 2012). Further, studies in ovarian
cancer cell line A2780 showed that dinaciclib treatment decreased Rb phosphorylation and
induced apoptosis (measured by PARP cleavage) (Chen, Xie et al. 2015). This led to clinical
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studies in breast cancer patients, with a randomized phase II trial in patients with advanced
breast cancer (patients who failed previous chemotherapy), who received either dinaciclib
(50mg/m2 once every three weeks) or capecitabine (Mita, Joy et al. 2014). While the study had
to be stopped due to increased toxicity (neutropenia in 47% of patients and leukopenia in 21%
of patients) and lower progression free survival in the dinaciclib arm, significant antitumor
activity was seen in 2 out of 7 breast cancer (Mita, Joy et al. 2014). Further, a phase I clinical
trial conducted at MD Anderson Cancer Center, which tested the combination of dinaciclib and
epirubicin in advanced metastatic triple negative breast cancer patients also showed severe
side effects (febrile neutropenia), resulting in early termination of the study (Mitri, Karakas et al.
2015). This suggests that while dinaciclib has shown promise in pre-clinical studies in breast
cancer, the dosage and treatment regimen has to be optimized for efficacious clinical studies.

1.4. CDK4/6 INHIBITORS IN BREAST CANCER
1.4.1. DISCOVERY AND DEVELOPMENT OF CDK4/6 INHIBITORS
While pan-CDK inhibitors have been available since the early 1990's, they were mostly
non-specific and toxic, limiting their clinical applicability (Asghar, Witkiewicz et al. 2015). The
emerging significance of the G1/S checkpoint and the deregulation of the CDK4/6-cyclin D
pathway in cancers fueled efforts for the discovery a selective and potent drug targeting
CDK4/6 (Sherr, Beach et al. 2016). These drugs target the kinase activity of CDK4 and CDK6,
resulting in decreased phosphorylation of Rb, which keeps the Rb protein bound to the E2F
transcription factor (Figure 4) (Bertoli, Skotheim et al. 2013). This prevents E2F mediated
transcription of the cell cycle proteins, resulting in the arrest of the cells at the G1 phase of the
cell cycle (Bertoli, Skotheim et al. 2013). Thus, chemists at Parke-Davis developed the specific
CDK4/6 inhibitor, PD0332991, which eventually became Pfizer's Palbociclib (Ibrance™) (Sherr,
Beach et al. 2016). Palbociclib is now FDA approved for clinical use in advanced ER positive
breast cancer (O'Leary, Finn et al. 2016). The other two CDK4/6 inhibitors, ribociclib and
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Figure 4: CDK4/6 inhibitors in cancer cells: Models how treatment with the
CDK4/6 inhibitors molecular affects the G1/S transition and the cell cycle

abemaciclib were subsequently developed by Novartis and Eli Lilly respectively (O'Leary, Finn
et al. 2016). Of these, ribociclib was recently approved for clinical use in advanced ER positive
breast cancer and abemaciclib has obtained breakthrough FDA approval in the same group of
cancers (Sherr, Beach et al. 2016). Table 4 summarizes the basic characteristics of the three
CDK4/6 inhibitors, with the stage of approval and clinical characteristics. The pre-clinical and
clinical development of the individual CDK4/6 inhibitors along with their future utility has been
described in detail in the sections below.

1.4.2. PALBOCICLIB
Palbociclib (PD-0332991) is an oral specific and potent inhibitor of the CDK4/6
developed by Pfizer (O'Leary, Finn et al. 2016). A study in 2009 examined the sensitivity (IC50
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Palbociclib (Pfizer)
(PD0332991,Ibrance)

Ribociclib (Novartis)
(LEE011, Kisqali)

Abemaciclib (Eli Lilly)
(LY2835219)

Approval
status

FDA approved - 1st
and 2nd line ER+
HER2- metastatic
breast cancer (2015)

FDA approved – 1st line
ER+ HER2- metastatic
breast cancer (2017)

FDA breakthrough
designation (2016)

IC50 (in vitro
kinase assay)

CDK4 (D1): 11 nM
CDK4 (D3): 9 nM
CDK6 (D2): 15 nM
CDK1: >10 μM
CDK2: >10 μM

CDK4:
CDK6:
CDK1:
CDK2:

CDK4 (D1): 0.6-2 nM
CDK6 (D1): 2.4-5 nM
CDK 9: 57 nM
CDK1: > 1 μM
CDK2: > 500 nM

PK

Tmax 4.2-5.5 hr
t½ 25.9-26.7 hr

Tmax 4 hr
t½ 24-36 h

Tmax 4-6 hr, t½ 17-38 hr
(crosses blood brain
barrier)

PD

Reduced RB
phosphorylation in
paired tumor biopsies,
and reduced fluorothymidine-PET uptake

Reduced RB
phosphorylation and
Ki67 expression in
paired tumor biopsies

Reduced RB
phosphorylation and
topoisomerase IIα
expression in paired
tumor and skin biopsies

Dosing

125 mg daily (3 weeks
on 1 week off)

600 mg daily (3 weeks
on 1 week off)

200 mg twice daily
(continuous dosing)

Dose-limiting
toxicities

Neutropenia,
Thrombocytopenia

Neutropenia,
Thrombocytopenia

Fatigue

Drug

Structure

10 nM
39 nM
>100 μM
>50 μM

Table 4: CDK4/6 inhibitors in breast cancer: Table showing the CDK4/6 inhibitors that are currently
used in breast cancer and their characteristics.

value) of a panel of breast cancer cell lines to palbociclib treatment, which showed that most of
the sensitive cell lines belonged to the ER positive subtype of breast cancer (Finn, Dering et al.
2009). Further, analysis of the gene expression profile between sensitive and resistant lines
revealed that sensitive lines have a higher expression of cyclin D1, Rb1 and reduced
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expression or loss of p16 (Finn, Dering et al. 2009). Mechanistically, palbociclib decreased Rb
phosphorylation and induced G1 arrest exclusively in the sensitive cell lines (Finn, Dering et al.
2009). A more recent study that examined the changes in gene expression in the MCF7 cell
line following palbociclib treatment showed that unlike long term estrogen deprivation or antiestrogen treatment, palbociclib did not directly affect the ER target genes, but only reduced
expression of the cell cycle regulatory genes (Knudsen and Witkiewicz 2016). The induction of
palbociclib mediated G1 arrest and senescence has been verified further by numerous preclinical studies including a study which showed that expression of FOXM1, a CDK4/6 target
decreases with palbociclib treatment and is required for the induction of senescence by the
drug (Anders, Ke et al. 2011). Moreover, palbociclib has been shown be synergistic in
combination with tamoxifen in a tumor explant model of breast cancer, which showed a
significant decrease in Ki67 and Rb protein in 11 out of the 13 explants (Dean, McClendon et
al. 2012). A more recent study even evaluated the use of palbociclib in tamoxifen resistant
tumors, expressing ESR1 mutations, and showed that the combination of palbociclib with
SERDs such as fulvestrant was effective in decreasing growth of the patient derived xenograft
(PDX) tumors (Wardell, Ellis et al. 2015). More detailed mechanistic studies have been
discussed in Chapter 3 (in breast cancer) and Chapter 8 (in other solid tumors). These studies
provided the pre-clinical basis for testing the use of palbociclib clinically in ER advanced
positive breast cancer cell lines in combination with anti-estrogens (O'Leary, Finn et al. 2016).
A phase I single arm dose finding and toxicity study in Rb positive advanced solid
tumors, where patients received escalating doses of palbociclib (3 weeks on and 1 week off
schedule) showed that neutropenia was the only significant toxicity suggested a dose of 125
mg of palbociclib for future clinical studies (Flaherty, Lorusso et al. 2012). Further, a single-arm
phase II clinical trial was conducted in 37 advanced breast cancer patients (acquired resistance
to prior hormonal therapy), where patients were treated with a dose of 125 mg for three week
on and on week off regiment (DeMichele, Clark et al. 2015). Results showed partial response in
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2 patients and stable disease in 5 patients, with non-febrile (not accompanied by fever),
neutropenia detected 50 to 60% of the patients, with no bone marrow damage (DeMichele,
Clark et al. 2015). These studies showed that palbociclib is well-tolerated. Further clinical
studies were conducted to interrogate the efficacy of palbociclib in advanced ER positive breast
cancer in comparison with the current standard of care treatments, such as aromatase
inhibitors and fulvestrant (studies summarized in Table 5).
PALOMA-1, a randomized multicenter phase II study tested letrozole alone or letrozole
in combination with palbociclib in postmenopausal advanced ER positive /HER2-ve breast
cancer patients (Finn, Crown et al. 2015). Results showed that combining palbociclib with
letrozole increased the median progression-free-survival from 10.2 months (letrozole alone
arm) to 20.2 months, with neutropenia reported in 54% and leucopenia reported in 19% of
patients who received the combination drug treatment (Finn, Crown et al. 2015). However, the
overall survival of patients did not significantly change upon addition of the CDK4/6 inhibitor
palbociclib to letrozole (37.5 months in combination arm vs 33.3 months in the letrozole arm)
(Finn, Crown et al. 2015). The improved progression free survival in patients receiving
palbociclib plus letrozole was further confirmed in phase III randomized clinical trial (PALOMA2) conducted in 666 ER+/HER2- breast cancer patients (Finn, Martin et al. 2016). Results
showed that the combination of palbociclib with letrozole increased the progression-free
survival from 14.5 months to 24.8 months, compared to letrozole alone, with neutropenia (nonfebrile), however, detected in a majority (79%) of combination treated patients (Finn, Martin et
al. 2016). Finally, the benefit of adding palbociclib to fulvestrant was tested in PALOMA-3, a
phase III randomized study in 521 advanced ER+/Her-2- patients, who have relapsed on prior
on endocrine therapy (Turner, Ro et al. 2015). Results revealed that addition of palbociclib to
fulvestrant regimen prolonged the median progression-free survival to 11.2 months compared
to 3.6 months with fulvestrant alone, with grade 3 and 4 neutropenia seen in 62% of the
combination treated patients (similar to PALOMA-2) (Turner, Ro et al. 2015). Further, the pre-
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Trial

Drugs

PALOMA-1

Palbociclib
Letrozole

PALOMA-2

Palbociclib
Letrozole

Phase

Results

Identifier

II

Median PFS: 20.2 months
for the combination vs
10.2 months with letrozole
alone

NCT00721409
NCT01740427

III

Median PFS: 24.8 months
for the combination vs
14.5 months with letrozole
alone

NCT00721409
NCT01740427

NCT01942135

PALOMA-3

Palbociclib
Fulvestrant

III

Median PFS: 11.2 months
for the combination vs
4.6 months with
fulvestrant alone

MONARCH-1

Abemaciclib

II

Median PFS: 5.95 months
for abemaciclib
monotherapy

NCT02102490

MONARCH-2

Abemaciclib
Fulvestrant

III

Not reported

NCT02107703

MONARCH-3

Abemaciclib
Aromatase
Inhibitors

III

Not reported

NCT02246621

MONALEESA-2

Ribociclib
Letrozole

III

Median PFS: 25.3 months
for the combination vs
16 months with letrozole
alone

NCT01958021

MONALEESA-3

Ribociclib
Fulvestrant

III

Not reported

NCT02422615

Table 5: CDK4/6 inhibitor clinical trials in ER+ breast cancer: Table showing the seminal clincial trials
that have been completed and are underway with CDK4/6 inhibitors in advanced ER+ve breast cancer

clinical and the clinical studies examining the use of palbociclib in cancers other than breast
have been discussed in detail in Chapter 8.

1.4.3. RIBOCICLIB
Ribociclib is another selective CDK4/6 inhibitor that inhibits phosphorylation of Rb in a
dose dependent manner, inducing G1 arrest in vitro cell cycle arrest and delayed tumor growth
in glioblastoma xenograft tumors in vivo (Rader, Russell et al. 2013). Ribociclib was first tested
in patient in a phase I study with 132 advanced cancer patients including 18 breast cancer
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patients, which showed neutropenia as being the only significant side-effect similar to
palbociclib (Infante, Cassier et al. 2016). Further, MONALEESA-2, a multi-center randomized
phase III study examined the efficacy of combining ribociclib with letrozole in 669 postmenopausal advanced or metastatic ER positive breast cancer patients, with ribociclib given in
a 3 week on 2 week off treatment regimen (Table 5) (Hortobagyi, Stemmer et al. 2016). Study
results showed that addition of ribociclib significantly delayed the progression to 25.3 months
compared to 16 months with letrozole alone (Hortobagyi, Stemmer et al. 2016). The study
showed that toxicity with ribociclib treatment is similar to that seen with palbociclib, with 59% of
the patients experience neutropenia and 21% of patients experience leukopenia (Hortobagyi,
Stemmer et al. 2016). Further, a randomized phase III trial (MONALEESA-3) is currently
underway examine the effect of the combination of ribociclib and fulvestrant in advanced ER
positive breast cancer (Table 5).

1.4.4. ABEMACICLIB
Abemaciclib is the third CDK4/6 inhibitor currently under clinical investigation for breast
and other solid tumors (O'Leary, Finn et al. 2016). It inhibits CDK4/6 at low nanomolar
concentrations and reduced Rb1 phosphorylation in colorectal cancer and melanoma
xenografts (Patnaik, Rosen et al. 2016).
A phase I study examined the safety and efficacy of abemaciclib in solid tumors
including 47 breast cancer patients, who received abemaciclib as a monotherapy (Patnaik,
Rosen et al. 2016). Results showed that overall response was seen in almost 35% of the
breast cancer patients, accompanied by a marked decrease in Ki67 expression in the tumor
tissues (Patnaik, Rosen et al. 2016, 2017). In an expansion cohort, where abemaciclib was
administered as a monotherapy in 25 patients with advanced HR+/HER2− disease, clinical
benefit rate was seen in 72% of the patients, with only one of the partial responders receiving
concomitant hormonal therapy (O'Leary, Finn et al. 2016, Patnaik, Rosen et al. 2016). Thus,
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the ER positive subtype of breast cancer patients exhibited a median duration of response of
13.4 months and median PFS of 8.8 months (Patnaik, Rosen et al. 2016), suggesting the
clinical utility of abemaciclib as a single agent than palbociclib. Moreover, results from
MONARCH-1, a phase II study of abemaciclib as monotherapy in 132 HR+/HER2- advanced
breast cancer was recently reported (Maura N. Dickler 2017). Results showed a clinical benefit
rate of 42.4%, with patients exhibited a median progression-free survival of 5.95 months and
median overall survival of 22.3 months (Maura N. Dickler 2017).
Unlike palbociclib and ribociclib, abemaciclib is administered to patients on a continuous
daily or twice a day regimen, which has been shown to be highly tolerated (Patnaik, Rosen et
al. 2016, Maura N. Dickler 2017). Further, the common dose limiting side-effects associated
with abemaciclib fatigue and diarrhea, and not high-grade neutropenia and leukopenia as seen
with palbociclib and abemaciclib (Patnaik, Rosen et al. 2016, Sherr, Beach et al. 2016, Maura
N. Dickler 2017). While reason for this remains uncertain, it may be due to the preferential
selectivity of abemaciclib for CDK4 over CDK6 and its reported potential activity against CDK9,
although, preliminary studied show that this may not translate into inhibition of the cellular
activity of CDK9 (Patnaik, Rosen et al. 2016, Sherr, Beach et al. 2016). Moreover, another
characteristic of abemaciclib is its ability to cross the blood brain barrier and its appearance in
the cerebrospinal fluid in animal models, which suggests that the drug might possess additional
activity in treating brain metastasis in patients with breast cancer (Raub, Wishart et al. 2015,
Tate, Burke et al. 2016).

1.4.5. BIOMARKER STUDIES WITH CDK4/6 INHIBITORS
Since biomarkers are essentially for the selectivity of drug treatment, numerous preclinical and clinical studies have been conducted to identify biomarkers for this treatment
(O'Leary, Finn et al. 2016). While pre-clinical studies identified Rb, cyclin D and p16 among
other proteins as biomarkers for the CDK4/6 inhibitors, clinical studies showed that none of
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these proteins can efficiently predict response to therapy (Sherr, Beach et al. 2016). The
summary and results of the pre-clinical and the clinical studies conducted with the CDK4/6
inhibitors have been described in detail in Chapters 6 and 7.

1.4.6. MECHANISMS OF RESISTANCE TO CDK4/6 INHIBITORS
While CDK4/6 inhibitors have shown promising results in the clinic in ER positive breast
cancer, about 16% of the ER positive cancer patients exhibit progression within 24 weeks,
resulting in no overall survival benefit with the treatment (Finn, Martin et al. 2016). More than
half the patients acquire clinical resistance with progression on therapy within 25 months (Finn,
Martin et al. 2016), and it is expected that most will eventually become resistant to the drugs.
Hence, numerous studies are currently underway in trying to understand the mechanism of
resistance to CDK4/6 inhibitors, both intrinsic and acquired resistance (Sherr, Beach et al.
2016). Early pre-clinical studies aimed at identifying biomarkers showed that loss of Rb
mediates resistance to CDK4/6 inhibition in breast cancer cells lines and xenograft tumors
(Finn, Dering et al. 2009). A study in breast cancer showed the activation of the PI3K mediated
growth signaling pathways as a mode of resistance to CDK4/6 inhibitor (ribociclib) mediated
growth inhibition and senescence, particularly in PIK3CA mutant cell lines (Vora, Juric et al.
2014). Hence, combination treatment with PI3K inhibitor was synergistic with ribociclib in the
ER positive breast cancer cell lines, MCF7 and T47D, and also prevented acquired resistance
to ribociclib (Vora, Juric et al. 2014)
Moreover, an ovarian cancer pre-clinical study showed that expression of cyclin E
mediates resistance to palbociclib mediated growth inhibition and senescence (Taylor-Harding,
Aspuria et al. 2015). Further, a more recent study showed that high levels of CDK2 and cyclin
E can mediate early adaptation (intrinsic drug resistance) and acquired resistance in breast
cancer (Herrera-Abreu, Palafox et al. 2016). This study showed that high CDK2 levels maintain
Rb phosphorylation despite palbociclib treatment and showed that high expression of cyclin E

35

post mitotic exit determines early adaptation and resistance to CDK4/6 inhibitors (HerreraAbreu, Palafox et al. 2016). Another recently reported study confirmed this observation, by
showing that cell lines that have a greater CDK high population are more resistant to
palbociclib treatment since the CDK2 activity mediates mitotic exist and resistance to
palbociclib mediated cell cycle arrest (Uzma Asghar 2016). Thus, knockdown of CDK2 or
combined treatment with the CDK2 inhibitor, dinaciclib, was synergistic with the CDK4/6
inhibitor, ribociclib and helped reverse drug resistance (Herrera-Abreu, Palafox et al. 2016,
Jansen, Bhola et al. 2017). Finally, activation of the AKT1 signaling pathway via PI3K-PDK1
has been shown to mediate resistance to ribociclib treatment, which was effectively reversed
upon treatment with a PDK1 inhibitor (GSK2334470) or PI3K inhibitor (alisertib) in vitro and in
vivo (Jansen, Bhola et al. 2017).
Thus, while these studies have suggested potential mechanism of intrinsic and acquired
resistance to palbociclib and other CDK4/6 inhibitors, more detailed study is essential to devise
efficient treatment regimens to combat drug resistance.

1.5. LIMITATIONS WITH CDK4/6 TREATMENT AND GAPS IN KNOWLEDGE
Despite these promising clinical advances with CDK4/6 inhibitors in ER positive breast
and other cancers, there are three major clinical limitations with this treatment strategy: (i)
adverse events leading to treatment interruption/ discontinuation, (ii) lack of overall survival
benefit and (iii) lack of predictive biomarkers.
Both palbociclib and ribociclib treatment is associated with increased toxicity and
adverse events in patients, with over 55% of the patients having grade 3&4 neutropenia and
about 25% of patients having leukopenia (Finn, Crown et al. 2015) (Hortobagyi, Stemmer et al.
2016). This often requires delay in treatment delays or even discontinuation of treatment, which
might attenuating therapy benefit , thus highlighting the need to improve efficacy of CDK4/6
inhibitor treatment (Finn, Crown et al. 2015, Turner, Ro et al. 2015). Further, about 16% of the
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ER positive breast cancer patients do not respond (intrinsic resistance) exhibit progression
within 24 weeks (early adaptive resistance) to palbociclib treatment (Finn, Martin et al. 2016).
Additionally, more than half the patients develop clinical resistance accompanied disease
progression within 25 months, resulting in no overall survival benefit (Finn, Martin et al. 2016).
Finally, while previous in vitro studies showed that Rb, Cyclin D and p16 could predict response
to palbociclib (Wiedemeyer, Dunn et al. 2010, Konecny, Winterhoff et al. 2011, Cen, Carlson et
al. 2012), results from Phase II/III trials showed no significant correlation between progressionfree survival or clinical response and the expression of p16, CCND1 amplification (Finn, Crown
et al. 2015), Ki67, PIK3CA or ESR1 mutational status (Turner, Jiang et al. 2016). Similarly,
biomarker analysis with ribociclib also showed no correlation between response and the
expression of Rb, p16, CDKN2A amplification, cyclin D and PIK3CA mutation (Hortobagyi,
Stemmer et al. 2016). This leaves us with no established predictive biomarkers for CDK4/6
inhibitors.

1.6. GOAL OF THE PROJECT
Thus, the goal of this thesis and project is to address the aforementioned limitations of
CDK4/6 inhibitor therapy and to improve the selectivity and efficacy of CDK4/6 inhibition.
This has been achieved in this project through a biomarker-driven combination treatment
approach that targets CDK4/6 and autophagy in breast and other solid tumors. Further, the
project also aims at understanding the mechanisms of acquired resistance to CDK4/6
inhibition via palbociclib.
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CHAPTER 2: MATERIALS AND METHODS

2.1. CELL LINES
All cell lines used in this study were obtained from ATCC. MCF7, T47D, ZR75-1, MCF7T, MDA-MB-231, HCC38, HCC1806, MDA-MB-157, HeyA8, 59M, and FUOV1 were maintained
in minimum essential medium Eagle alpha modification (alpha MEM) supplemented with 10%
fetal bovine serum (FBS), 10mM HEPES, nonessential amino acids, 2mM L-glutamine, sodium
pyruvate, and hydrocortisone. 293T and MDA-MB-468 cells were cultured in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% FBS. SUM-159 and BT-549 cells were
cultured in a 1:1 mixture of alpha MEM and nutrient F-12 Ham medium supplemented with 10%
FBS and 5% insulin. Calu-1, H358, A549, PC3, and Du145 cells were cultured in RPMI-1640
medium supplemented with 10% FBS. The pancreatic cancer cell lines (Panc-1 and BxPC-3)
were a gift from the laboratory of Dr. Anirban Maitra (MD Anderson Cancer Center) and were
cultured in DMEM and RPMI 1640, respectively, supplemented with 10% FBS. The colon
cancer cell lines (Colo-205, SW-620, and HCT-116) were obtained from the laboratory of Dr.
Jae-II Park (MD Anderson Cancer Center) and cultured in DMEM supplemented with 10%
FBS.
The MCF7 aromatase expressing cells were maintained in DMEM supplemented with
10% tet-free FBS + 4μg/ml blasticidin, 1 μg/ml puromycin (InvivoGen, San Diego, CA) and 400
μg/ml G418. Prior to experimental setup, they were estrogen deprived for 4 days using phenol
red free IMEM supplemented with 10% charcoal dextran treated tet-free FBS. During the
experiment, the cells were maintained in estrogen deprivation condition in the presence of
25nM 4-Androstene-3,17-dione. To induce the expression of empty vector and LMW-E, the
cells were treated with 5 ng/ml Doxycyclin (Sigma) for 24 hours before the start of the
experiment. The aromatase resistant cell lines were maintained in phenol red DMEM
supplemented with 10% charcoal dextran treated FBS + 25nM 4-Androstene-3,17-dione + 400
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μg/ml G418. All cell lines were maintained free of mycoplasma contamination and
authenticated on a regular basis by karyotype and short tandem repeat analysis at MD
Anderson’s Characterized Cell Line core facility.

2.2. ANTIBODIES AND DRUGS
Antibodies against p-Rb (Ser807/811), FOXM1, total Rb (4H1), PARP, caspase-7,
LC3B, p62 (SQSTM1), Beclin-1, Atg-5, and p53 were purchased from Cell Signaling
Technology (Danvers, MA). Antibodies against CDK4 (C-22), CDK6 (C-29), cyclin E (HE-12),
and Mdm2 were purchased from Santa Cruz Biotechnology (Dallas, TX); antibodies against
actin (C-4) and vinculin were purchased from Millipore and Sigma-Aldrich (St. Louis, MO).
Palbociclib was obtained from Pfizer, Inc (San Diego, CA). It was diluted in dimethyl
sulfoxide (DMSO) for in vitro use and in 0.5% methylcellulose (Sigma-Aldrich, St. Louis, MO)
for in vivo use and administered to mice via oral gavage. Hydroxychloroquine sulfate (HCQ)
was purchased from Sigma-Aldrich and Selleckem. Lys-05 was provided by Dr. Ravi
Amaravadi (University of Pennsylvania). HCQ and Lys-05 were diluted in sterile water for in
vitro use and in sterile phosphate-buffered saline solution (PBS) for in vivo use and
administered to mice via intraperitoneal injection. N-acetyl-L-cysteine (NAC), trolox [(±)-6hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid], bafilomycin A1, spautin-1, and
chloroquine diphosphate (CQ) were all purchased from Sigma-Aldrich. Ribociclib was
purchased from Selleckem and abemaciclib from MedChem Express; NAC and CQ were
diluted in sterile water. Trolox, bafilomycin A1, spautin-1, ribociclib, and abemaciclib were
diluted in DMSO.

2.3. siRNA KNOCKDOWN
siRNA knockdown of CDK4 and CDK6 were generated as described
previously(Jabbour-Leung, Chen et al. 2016). ON-TARGETplus SMARTpool siRNA for CDK4
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(L-003238-00-0005) and CDK6 (L-003240-00-0005) were purchased from Dharmacon. Briefly,
cells were plated on 6-well or 12 well plates and transfected with siRNA targeting CDK4 and/or
CDK6 using JetPRIME transfection reagent (Polyplus transfection, New York, NY), as per
manufacturer’s protocol. Non-coding siRNA pool (siNT) was used as a negative control for
comparison. Cells were harvested 72 hours post transfection for western blot analysis, MDC
analysis, CellROX assay and on days 3 and 6 for cell counting.

2.4. shRNA KNOCKDOWN AND CYCLIN E OVEREXPRESSION
Stable shRNA knockdown cells were generated as described previously(JabbourLeung, Chen et al. 2016, Nanos-Webb, Bui et al. 2016). All shRNA constructs were purchased
from Thermo Scientific (Open Biosystems, Waltham, MA). For single knockdown of CDK4,
CDK6, Beclin-1, Atg-5, or Rb, GIPZ lentiviral shRNA was used [CDK4: V3LHS_641689,
V3LHS_641690; CDK6: V2LHS_112906, V3LHS_404083; Beclin-1: V3LHS_349514,
V3LHS_349513; Atg-5: V2LHS_67978, V3LHS_301131; Rb: V2LHS_130611, V2LHS_130606,
V3LHS_340829]. For dual knockdown of CDK4 and CDK6, TRIPZ inducible shRNA for CDK6
was utilized for better selection of knockdowns. To generate lentivirus expressing shRNA, HEK
293T cells were transfected with pCMVdeltaR8.2, pMD2.G (produced by the Didier Trono
laboratory and made available through the Addgene repository) and pGIPZ vector (scrambled
shRNA or shRNA against gene of interest) using LipoD293 (SignaGen) or polyethylenimine
transfection reagent according to manufacturer’s protocol. After 48 hours of transfection, the
virus-containing medium was collected, filtered through a 0.45-µm filter, and added to the cells
of interest in the presence of 8 μg/mL of polybrene (Millipore). GFP or RFP expression was
confirmed and the lentivirus-infected cells were selected with 1 μg/mL puromycin (InvivoGen,
San Diego, CA). MCF7 and T47D cells overexpressing different isoforms of cyclin E (vector,
full-length cyclin E [EL], or low-molecular-weight cyclin E [LMW-E]) were generated
previously(Akli, Zheng et al. 2004) and verified in this study by western blot.
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2.5. DOSE-RESPONSE STUDIES
For dose-response studies, 1000 to 3000 cells (depending on plating efficiency of each
cell line; data not shown) were plated in each well of a 96-well plate and treated with increasing
concentrations (0.01 to 12 μM) of palbociclib, ribociclib, or abemaciclib for 1, 2, 4, 6, or 8 days.
The medium was replaced with drug-containing medium every other day. At completion of drug
treatment, cultures were continued in drug-free medium (also replaced every other day) until
day 12, after which they were stained with 0.5% crystal violet solution. The plates were then
solubilized with a solution of 0.1% sodium citrate in 50% ethanol, and absorbance was
measured at 570 nm using the Epoch Microplate Spectrophotometer (BioTek Instruments, Inc,
Winooski, VT). Values were normalized to those of their no treatment controls and analyzed in
GraphPad Prism by non-linear regression to obtain the half-maximal inhibitory concentrations
(IC50 values) as used in Figure 1a.

2.6. CELLULAR PROLIFERATION ASSAY
For cell proliferation studies, 7,500 to 15,000 cells (depending on plating efficiency of
each cell line; data not shown) were plated in each well of 6-well plates and treated with the
indicated agents for 6 days and cells were allowed to recover for 4 days in the absence of drug
to examine reversibility. The medium was replaced every other day during the course of the
experiment, either with drug-containing medium (days 2 and 4) or drug-free medium (days 6
and 8). Cells were then harvested and counted using the BioRad TC20 Automated Cell
Counter on days 0, 3, 6, and 10.
For clonogenic/colony-formation assay, 5,000 to 10,000 cells (depending on the plating
efficiency of each cell line; data not shown) were plated in each well of 6-well plates, treated for
6 days, and allowed to recover for 6 days in the absence of drug. Cells were then washed with
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PBS and stained with a 0.5% crystal violet solution in 25% methanol for 10 minutes. Plates
were then scanned to obtain pictures.

2.7. CELL CYCLE AND BRDU ANALYSES
Cells were plated (1´105 cells/plate) on 10-cm plates and treated with the indicated
agents for 6 days; they were allowed to recover without drug(s) for 4 days to examine
reversibility. Medium was replaced every other day during the course of the experiment, either
with drug-containing medium (days 2 and 4) or drug-free medium (days 6 and 8). For cell cycle
analysis, following treatment or treatment (6 days) and recovery (6 days + 4 days of recovery),
cells were subjected to trypsinization, washed with PBS, and fixed with 3.5 mL ice-cold PBS
and 1.5 mL of 95% ethanol. Cells were prepared as described previously(Jabbour-Leung, Chen
et al. 2016) and incubated in a solution of propidium iodide (PI; 1 mg/mL) and RNAase (1
mg/mL) at 4°C overnight. Samples were then analyzed on the Beckman Coulter Gallios Flow
Cytometer, and data were analyzed with the Kaluza software (Beckman Coulter) after
excluding doublet cells.
For BrdU analysis, following treatment or recovery, cells were incubated with 10 μM 5bromo-2′-deoxyuridine (BrdU; Sigma-Aldrich) for 1 hour, after which they were subjected to
trypsinization, washed with PBS, and fixed with 70% ethanol. Cells were then washed with PBS
containing 0.5% bovine serum albumin (BSA) and denatured with a solution of 2M HCl + 0.5%
Triton X-100 at room temperature for 20 minutes. Cells were washed again and incubated in
200 μL 0.1 M sodium borate, pH 8.5, to neutralize any residual acid for 2 minutes at room
temperature. Cells were then stained with fluorescein isothiocyanate–conjugated anti-BrdU (BD
Biosciences) for 20 minutes at room temperature, protected from light. Cells were finally
washed and incubated in a solution of 0.5 mL PI (10 µg/mL in PBS) for 30 minutes at room
temperature, protected from light. Samples were analyzed on the Beckman Coulter Gallios
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Flow Cytometer and data were analyzed with Kaluza software to obtain the percentages of
BrdU-positive cells.

2.8. MEASUREMENT OF SENESCENCE
For in vitro studies, senescence was measured by the senescence-associated
galactosidase (SA-ß gal) staining kit (Millipore, Billerica, MA) according to the manufacturer’s
standard protocol. Briefly, cells were plated at a low density of 2,000 to 4,000 cells (depending
on the plating efficiency of the cell line; data not shown) in each well of 12-well plates and
treated with the indicated agents for 72 hours or 6 days. The medium was replaced every other
day during the course of the experiment with drug-containing medium (days 2 and 4). Cells
were then washed with PBS, fixed, and stained with SA-ß gal solution overnight. The cells were
then photographed using the Evos XL Core cell imaging system (ThermoFischer, Waltham,
MA) and senescent cells were quantified by counting 100 cells in three different fields for each
replicate. A minimum of three technical and three biological replicates were performed for each
condition.
For in vivo studies, mouse tumors tissues were snap-frozen in liquid nitrogen,
embedded in OCT, and cut into thin sections (5 μm). Senescence was measured by the SA-ß
gal detection kit (Biovision, Milpitas, CA) by following the manufacturer’s protocol. Briefly, slides
were washed with PBS and incubated in staining solution (prepared according to protocol)
overnight. Slides were then washed with PBS and fixed in 70% glycerol. Images of the tissue
sections were obtained by a Leica DM light microscope using the 20´ and 40´ optical lenses.
Images were acquired with a SPOT Imaging Solutions camera and SPOT Advanced software.
For quantitation of cellular granularity, cells were plated (1´105 cells/plate) on 10-cm
plates and treated for 6 days; some of the cells were allowed to recover for 4 without drug.
Following treatment, cells were harvested, stained with PI (1 mg/mL), and analyzed on the
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Beckman Coulter Gallios Flow Cytometer. The data were then analyzed with the FlowJo
software to obtain a distribution curve of side-scatter vs normalized cell counts.

2.9. ANNEXIN V AND CASPASE-3 APOPTOSIS ASSAYS
Apoptotic cells were measured by using the Alexa Fluor 488 Annexin V Dead Cell
Apoptosis kit (Invitrogen, Waltham, MA) according to the manufacturer’s protocol. Briefly, cells
were plated (1´105 cells/plate) on 10-cm plates and treated with the indicated agents for 6 days
and allowed to recover for 4 days. Cells were harvested at the end of treatment (6 days) or
after treatment + recovery, washed with 1´ Annexin binding buffer and stained with a solution
of Alexa Fluor 488 Annexin V and PI (100 μg/mL) as directed by the protocol. Samples were
then analyzed on the Beckman Coulter Gallios Flow Cytometer, and data were analyzed with
Kaluza software to obtained the percentages of Annexin V–positive/PI-negative (early
apoptosis) and Annexin V–positive/PI-positive (late apoptosis) cells.
For the caspase-3 activity assay, following drug treatment, cells were harvested,
washed with a solution of PBS with 2% FBS and fixed with 100 μL of the fixation solution from
the Cytofix/CytoPerm kit (BD Biosciences). Cells were then washed with Perm/Wash buffer and
stained with phycoerythrin-conjugated rabbit active caspase-3 antibody (BD Biosciences) for 30
minutes on ice. Cells were finally washed, resuspended in the PBS with 2% FBS solution, and
analyzed on the Becton Dickinson FACS Calibur Flow Cytometer to obtain the percentage of
caspase-3–positive cells.

2.10. CELLULAR ROS MEASUREMENT
Cellular ROS levels were measured by using the CellROX Deep Red Flow Cytometry
assay kit (ThermoFischer Scientific, Waltham, MA) according to the manufacturer’s protocol.
Briefly, cells were plated (1´105 cells/dish) on 10-cm dishes and treated for 6 days. Cells were
then harvested and stained with 500 nM CellROX reagent for 1 hour at 37°C. Samples were
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analyzed on the Beckman Coulter Gallios Flow Cytometer using the 635-nm laser; data were
analyzed with the FlowJo software, and mean fluorescence intensity (MFI) was obtained.

2.11. MONODANSYLCADAVARINE MEASUREMENT
Cells were seeded at a density of 1´105 cells on 10-cm plates and treated for 6 days
with various concentrations of palbociclib. At the end of drug treatment, cells were incubated
with 50μM monodansylcadavarine (MDC; Sigma-Aldrich) at 37°C for 45 minutes. Cells were
then harvested, washed with PBS, and suspended in a solution of PBS with 1% FBS. Samples
were analyzed on the Becton Dickinson FACS LSR II Flow Cytometer using the 355-nm
ultraviolet laser. Data were analyzed with the FlowJo software, and percentages of MDCpositive cells and Mean Fluorescence Intensity (MFI were obtained.

2.12. IMMUNOFLUORESCENCE
For the GFP-LC3 puncta assay, MCF7, MDA-MB-231 and MDA-MB-468 cells stably
expressing GFP-LC3 were plated in 6-well plates and treated with drug for 48 hours. Following
treatment, cells were washed with 1X PBS, fixed with 4% paraformaldehyde for 10 mins and
mounted with Vectashield mounting media with DAPI. Cells were then visualized with Zeiss
Confocal microscope LSM880 using the 488nm laser (GFP) for the presence of GFP-LC3
puncta. The puncta was quantified using ImageJ.
For RFP-GFP-LC3 dual reporter assay, cells were transfected with ptf-LC3 vector and
analyzed as described previously(Kimura, Noda et al. 2007). Briefly, ptfLC3 vector was
transfected using Lipofectamine 2000 as per manufacturer’s instructions. Cells were then
treated with the drug for 48 hours, washed with 1X PBS, fixed briefly (for 10 mins) with 4%
paraformaldehyde and mounted with Vectashield mounting media. They were then visualized
using with Zeiss Confocal microscope LSM880 using the 488nm and 643nm channels to image
the GFP+ve and RFP+ve LC3 puncta respectively. The puncta was quantified using ImageJ to
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obtained the number of autophagosomes (yellow – RFP+ GFP+) and autophagolysosomes
(red – RFP+).

2.13. TRANSMISSION ELECTRON MICROSCOPY
For cell lines, ~5000 cells were plated in each well of 12-well plates and treated with the
drug for 6 days. For xenografts, tumors were harvested and samples were cut into 1-mm3
pieces. The cell lines and tumor samples were processed similarly and Electron microscopy
was performed at the High Resolution electron microscopy facility at MD Anderson Cancer
Center as described previously(Chauhan, Goodwin et al. 2013). Briefly, they were fixed with a
solution containing 3% glutaraldehyde plus 2% paraformaldehyde in 0.1M cacodylate buffer,
pH 7.3. Samples were then washed in 0.1M sodium cacodylate buffer and treated with 0.1%
Millipore-filtered cacodylate-buffered tannic acid. They were fixed with 1% buffered osmium
tetroxide for 30 minutes and stained en bloc with 1% Millipore-filtered uranyl acetate. The
samples were dehydrated in increasing concentrations of ethanol, filtrated, and embedded in
LX-112 medium. They were then polymerized in a 60°C oven for approximately 3 days.
Ultrathin sections were cut in a Leica Ultracut microtome (Leica, Deerfield, IL), stained with
uranyl acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010
transmission electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage
of 80 kV. Digital images were obtained at magnifications of 5000´, 25000´, and 50000´ using
the AMT Imaging System (Advanced Microscopy Techniques Corp, Danvers, MA).

2.14. IN VIVO XENOGRAFT STUDIES
For all xenograft experiments, estrogen pellets (0.72 mg 17-beta estradiol pellet, 90-day
release, Innovative Research of America, Sarasota, FL) were implanted subcutaneously into 4to 6-week-old female nude mice. MCF7-T cells (5´106 in a 1:1 ratio with matrigel [BD
Biosciences]) were injected into the 5th and 10th inguinal mammary fat pads bilaterally. For the
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dose-determining experiment, once the tumors reached an average volume of 200 mm3, the
tumor-bearing mice were randomized into five groups (n=3/group) and treated with vehicle
(0.5% methylcellulose) or 25 mg/kg, 50 mg/kg, 75 mg/kg, or 150 mg/kg palbociclib. Palbociclib
was administered daily via oral gavage for 7 consecutive days. For the combination treatment
experiment, once the tumors reached an average volume of 250 mm3, the tumor-bearing mice
were randomized into four groups (n=9/group) and treated with vehicle (0.5% methylcellulose
and PBS), hydroxychloroquine (60mg/kg), palbociclib (25 mg/kg), or a combination of
palbociclib (25 mg/kg) and hydroxychloroquine (60mg/kg). Drugs were administered daily via
oral gavage (palbociclib) or intraperitoneally (HCQ) for 21 days.
For Lys-05 toxicity experiment, non-tumor bearing female nude mice were treated with
varying concentrations of Lys-05 (1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg) daily for 21 days
via I.P. For the Lys-05 combination treatment experiment, once the orthotopic xenograft tumors
reached an average volume of 250 mm3, the tumor-bearing mice were randomized into four
groups (n=5/group) and treated with vehicle (0.5% methylcellulose and PBS), Lys-05
(10mg/kg), palbociclib (25 mg/kg), or a combination of palbociclib (25 mg/kg) and Lys-05
(10mg/kg). Drugs were administered daily via oral gavage (palbociclib) or intraperitoneally (Lys05) for 21 days.
For all xenograft studies, tumor volumes [(L x W2) /2)] were measured twice per week
with calipers and mouse weight was measured every day. At the end of the treatment and
recovery periods, mice were euthanized and the tumors were collected for further analysis. At
the time the mice were euthanized, blood (0.2 mL) was collected by cardiac puncture through
the left ventricle. Blood samples were subjected to complete blood count analysis (white blood
cells, platelets, and red blood cells) by the Siemens Adiva 120 Hematology System (Erlangen,
Germany). Nude mice for all experiments were obtained from the Department of Experimental
Radiation Oncology at The University of Texas MD Anderson Cancer Center, and mice
received care in accordance with the Animal Welfare Act and the institutional guidelines of MD
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Anderson Cancer Center. The protocol for this study was approved by the Institutional Animal
Care and Use Committee (IACUC) at The University of Texas MD Anderson Cancer Center
(Houston, TX).

2.15. PATIENT-DERIVED XENOGRAFT STUDIES
Breast tumor samples were obtained during routine surgery after informed consent was
obtained under protocols approved by the MD Anderson Institutional Review Board. Patientderived xenograft (PDX) models were developed as previously described(McAuliffe, Evans et
al. 2015). Briefly, fresh primary tumors were collected using sterile technique, and
approximately 3-mm3 fragments of the tissue were transplanted to the fat pad of the 4th pair of
mammary glands (both sides) in immunodeficient (SCID) mice within 1 hour of surgical
resection. When the primary tumor outgrowths reached 10 mm in diameter, 3-mm3 fragments of
the outgrowths were explanted to new hosts (n=3/tumor) as secondary passage. Since the
tumor tissues can stably grow after two passages with our protocol, we considered the PDX
line to have been successfully established at that point. The histology of the patient tumors of
origin and the corresponding PDX lines were compared by hematoxylin and eosin (H&E)
staining and had very similar histology (data not shown). For the drug treatment experiment, 3mm3 fragments of the PDX line were transplanted into the fat pat of the 4th mammary gland of
female nude mice. Once the tumors reached an average volume of 200 mm3, mice were
randomized into four groups (n=4/group) and treated with vehicle (0.5% methylcellulose and
PBS), hydroxychloroquine (60mg/kg), palbociclib (25 mg/kg), or combination of palbociclib
(25mg/kg) and hydroxychloroquine (60mg/kg). Drugs were administered daily via oral gavage
(palbociclib) or intraperitoneally (HCQ) for 21 days. Tumor volumes [(L x W2) /2)] were
measured twice per week with calipers, and mouse weight was measured every day.
At the end of the treatment period, mice were euthanized and their tumors were
collected for further analysis. All mice were obtained from the Department of Experimental
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Radiation Oncology at The University of Texas MD Anderson Cancer Center and received care
in accordance with the Animal Welfare Act and the institutional guidelines of MD Anderson
Cancer Center. The protocol for this study was approved by the IUCUC at MD Anderson
Cancer Center.

2.16. IMMUNOHISTOCHEMISTRY ANALYSIS OF MOUSE TUMOR TISSUES
For BrdU assessment, mice were administered BrdU solution (5 mg/kg intraperitoneally)
2 hours before euthanasia. After death, the tumor was resected and snap-frozen in liquid
nitrogen, embedded in OCT, cut, and utilized for measurement of senescence by SA-ß gal
staining. The remaining tissue was fixed in formalin and used for assessment of histology and
of proliferation by BrdU as described previously(Nanos-Webb, Bui et al. 2016). Briefly, 5-µm
sections from the formalin-fixed, paraffin-embedded tumor tissues were stained with standard
hematoxylin and eosin. Other sections of the tumor blocks were subjected to
immunohistochemical (IHC) staining. After paraffin removal, tumor sections were heated in a
water bath for 20 minutes in 10 mM sodium citrate buffer (pH 6.0) at 90°C to retrieve nuclear
antigens. Endogenous peroxidase activity was quenched with a 3% hydrogen peroxide
solution. Sections were blocked with 1.5% normal goat serum and incubated overnight at 4°C
with rat monoclonal antibody to BrdU (clone BU1/75 [ICR1]; GeneTex Inc, San Antonio, TX)
diluted at 1:500. Slides were developed using the VECTASTAIN Elite ABC kit (PK4004; Vector
Laboratories, Burlingame, CA), followed by staining with DAB substrate (Vector Laboratories)
and counterstaining with hematoxylin (DAKO), and then were mounted. Staining was evaluated
with a Leica DM light microscope using the 40´ optical lenses. Images were acquired on a
SPOT Imaging Solutions camera with SPOT Advanced software. BrdU was quantified as
percentage of BrdU-positive cells, which was calculated as percentage of BrdU-positive nuclei
from a total of 300 tumor cells from three fields of view.
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For 4HNE and Anti-8OHdG immunostaining; after paraffin removal, heat induced
antigen retrieval was performed for 10 minutes in 10 mM sodium citrate buffer (pH 6.0) at 98°C.
Endogenous peroxidase activity was blocked with 3% hydrogen peroxidase for 15 minutes.
Slides were then incubated for 1 hour with diluted rabbit blocking serum. The sections were
incubated for overnight at 4 °C with Anti-8-OHdG mouse monoclonal antibody (clone N45.1,
Genox, Baltimore, MD, 1:100 dilution) and Anti-4-HNE mouse monoclonal antibody (clone
HNEJ-2, Genox, Baltimore, MD, 1:50 dilution). The slides were incubated for 30 minutes with
diluted biotinylated secondary antibody and 30 minutes with Vectastain Elite ABC kit (Vector
Laboratories, United States). For the evaluation of 4HNE and Anti-8OHdG antibody expression,
slides were scored separately for percentage and intensity of the cells. Percentage positivity
was graded using 0 to 4 scale, where 0 represented no stained cells, 1 was 1 to 5% stained
cells, 2 was 6 to 30% stained cells, 3 was 31 to 70% stained cells, and 4 was 71 to 100%
stained cells. Staining intensity was scored as follows: 0, no staining; 1, weak positive; 2,
intermediate positive; and 3, strong positive. H score calculated by multiplying the percentage
of positive cells and intensity of staining.

2.17. WESTERN BLOT ANALYSIS
Western blot analysis was performed as described previously(Jabbour-Leung, Chen et
al. 2016). Briefly, cells were seeded at a density of 1´105 cells on 10-cm plates and treated for
6 days with the indicated drugs. Following treatment, cells were harvested and subjected to
lysis with RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.3, 0.1% sodium dodecyl sulfate [SDS],
1% Triton X-100, 1% deoxycholate, and 5 mM ethylene-diaminetetraacetic acid) containing
protease inhibitors. For mouse tissues, the tumors were minced into small pieces on dry ice
and immersed in RIPA buffer for lysis. Lysates were then subjected to centrifugation at
45,000rpm for 45 minutes at 4°C to obtain the protein lysates in the supernatant. Protein
concentration was determined by Bradford Protein Assay dye (Bio-Rad), and 50 μg of protein
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per sample was resolved by SDS–polyacrylamide gel electrophoresis as described
previously(Akli, Zheng et al. 2004). Blots were blocked with Blotto milk for 1 hour at room
temperature and incubated with primary antibody overnight at 4°C. They were then incubated
with goat anti-rabbit or goat anti-mouse immunoglobulin–horseradish peroxidase conjugates
(Pierce, Rockford, IL) at a dilution of 1:5000 in Blotto for 1 hour. Blots were then washed and
developed using a Renaissance chemiluminescence system (Perkin Elmer Life Sciences, Inc.)
by following the manufacturer’s instructions. The developed and scanned blots were then
analyzed by the ImageJ software to obtain densitometry values.

2.18. RPPA AND DATA ANALYSIS
The mouse tumor tissues were dissected on dry ice and subjected to lysis in RIPA
buffer (1% Triton X-100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
100 mM NaF, 10 mM Na pyrophosphate, 1 mM Na3VO4, 10% glycerol, and freshly added
protease and phosphatase inhibitors; Roche Applied Science, Indianapolis, IN). Tumor lysates
were then subjected to centrifugation and protein concentration was determined by using the
Bradford reagent. Protein concentration was adjusted to 1.5 μg/μL and mixed with 4´ SDS
Sample Buffer containing 40% glycerol, 8% SDS, 0.25M Tris-HCL, and 2-mercapto-ethanol at
pH 6.8. Samples were boiled for 5 minutes, and the reverse-phase protein array (RPPA)
analysis was performed by the Functional Proteomics core facility at MD Anderson Cancer
Center. The slide images were quantified using MicroVigene 4.0 (Vigene-Tech, Carlisle, MA).
The spot level raw data was processed with the R package SuperCurve (https://r-forge.rproject.org/ projects/supercurve), which returns the estimated protein concentration (raw
concentration) and a quality control (QC) score for each slide. The raw concentration data was
then normalized by median-centering for each sample across all the proteins, to correct for
loading bias.
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For RPPA data analysis, one-way ANOVA was used to identify proteins that are
differentially expressed between treatment groups. To adjust for multiple comparisons,
Benjamini-Hochberg procedure was used to estimate false discovery rate (FDR). Tukey HSD
tests were used for post hoc pairwise comparisons. To compare the different Palbociclib doses
treatments in vivo (Vehicle, 25 mg/kg, 75 mg/kg and 150 mg/kg), proteins with 20% FDR in
ANOVA, Tukey p < 0.05 and fold change > ±1.2 was identified as significantly differentially
expressed between groups. A heat map was then drawn using significant proteins from the
ANOVA analysis, and ordered based on KEGG cell cycle, senescence and
autophagy/catabolism pathways. Pearson distance metric and Ward's minimum variance was
used to cluster the samples in the heat map. For comparing the combination treatments
(Vehicle, HCQ, Palbociclib, and Palbociclib + HCQ) in vivo, proteins with 15% FDR in ANOVA,
Tukey p < 0.05 and fold change > ±1.2 were identified as significantly differentially expressed in
pairwise analysis. Pathway score for cell cycle and senescence pathways was calculated using
mean expression level (in log2 scale) of the selected proteins from ANOVA analysis.

2.19. BIOINFORMATICS AND TCGA ANALYSIS
Alterations in CDK4, CDK6, CCND1, Rb1 and CCNE1 were obtained using cBio Portal
(Cerami, Gao et al. 2012) from the TCGA RNA seq data for breast, ovarian, lung, pancreatic,
colon and prostate cancer. For biomarker analysis, gene expression data for the 23 cell lines
under study was obtained from Kao et. al.(Kao, Salari et al. 2009), and Gene Set Enrichment
Analysis (GSEA) was performed against the BioCarta gene sets(Subramanian, Tamayo et al.
2005) to obtain a heat map of the cell cycle genes.

2.20. BREAST CANCER PATIENT SAMPLES AND STATISTICAL ANALYSIS
The Department of Medical Oncology at MD Anderson maintains a prospective curated
database of patients from 1997 onward. This database was searched for all patients with
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breast cancer who had received palbociclib, and this search was supplemented with a manual
search. Key demographic, clinical, and pathologic data, cancer treatment details, and response
to therapy were abstracted into a working database for analysis under an IRB-approved
protocol. Outcomes of interest that were recorded included response, stable disease, and
progression (based on the physician’s determination, but not always based on RECIST criteria)
and associated durations of disease response and stability. To demonstrate the applicability of
our staining procedure, blocks with the largest available tumor specimen was chosen for each
patient and retrieved from the archives of the Department of Pathology at MD Anderson under
an IRB-approved protocol; this included specimens from the primary tumor and/or local and/or
metastatic recurrences. Our working database includes results of pathology reports, including
tumor histology and grade and standard IHC analyses for ER and progesterone receptors for
primary breast cancer biopsies and surgical specimens as well as local and distant recurrences
that were subject to biopsy or surgical excision.
Patient, tumor, and treatment characteristics were evaluated and compared between
patients who were or were not free from progression; 6-month and 12-month progression rates
were calculated for each of factor using the Kaplan-Meier method, and differences were
examined using the log-rank test (Supplementary Tables 1 and 2). Univariable and
multivariable Cox model analyses were used to determine the influence of patient, tumor, and
treatment factors of known or potential prognostic value on progression-free survival
(Supplementary Tables 3 and 4). All factors with P ≤0.1 in the univariable analyses were
entered into a full model, and the final model was selected by using a backwards elimination
procedure. Model performance was quantified using Harrell’s concordance index.(Gonen and
Heller 2005) The discriminative ability of the model was assessed using the concordance index
(C-index) for comparative purposes with the literature, as well as the concordance probability
estimate (CPE) due to the high degree of censoring in the data.(Gonen and Heller 2005) The
C-index can range from perfect concordance (1.0) to random predictions (0.5). Similar to the
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area under the receiver operating characteristic curve, CPE can range from perfect
concordance (1.0) to perfect discordance (0.0). In addition, Akaike’s information criterion (AIC)
was calculated.(Akaike 1974) The AIC takes into account how well the model fits the data as
well as the complexity of a model, thereby reducing the risk of overfitting. After comparisons,
the final model with the lowest AIC value and the highest C-index was reported. All statistical
analyses were performed using R 3.3.2 (http://www.r-project.org/). All P values were two-tailed,
and P≤0.05 was considered significant, and adjustments for multiple factors were not made.

2.21. IMMUNOHISTOCHEMICAL STAINING OF PATIENT SAMPLES
For the 109 breast cancer samples recovered, two serial 5-µm sections were cut and
mounted on Superfrost Plus glass slides. The antigen retrieval and washing steps were
performed as described for BrdU immunohistochemistry analysis. For cyclin E and Rb IHC, two
commercially available primary antibodies were used: rabbit polyclonal antibody to cyclin E
(clone C19; Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:1000 and Rb mouse
monoclonal antibody (Clone 4H1; Cell Signaling Technology, Denvers, MA) diluted 1:100.
Slides were developed using the VECTASTAIN Elite ABC kit (PK6101 and PK6102; Vector
Laboratories, Burlingame, CA) followed by staining with DAB substrate (Vector) and
counterstaining with hematoxylin (DAKO), and then were mounted. Tumor cell blocks known to
express high levels of LMWE and Rb were included in each batch as positive controls, and
negative controls were prepared by replacing the primary antibody with PBS buffer. Staining
was evaluated with a Leica DM light microscope using the 20´ and 40´ optical lenses. Images
were acquired by a SPOT Imaging Solutions camera and SPOT Advanced software.

2.22. IMMUNOHISTOCHEMICAL SCORING OF RB AND CYCLIN E
Cyclin E staining was scored by two pathologists blinded to patient outcomes (data not
shown). Scores (0=negative, 1=weak staining, 2=moderate staining, and 3=strong staining)
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were assigned for nuclear and cytoplasmic staining according to percentage of cells stained
and intensity of staining, as described previously(Karakas, Biernacka et al. 2016). Each tumor
sample was scored separately for nuclear and cytoplasmic cyclin E expression, and LMWE
status was assigned as follows: LMWE negative was defined as no staining or nuclear staining
only; LMWE positive was defined as nuclear + cytoplasmic staining or cytoplasmic staining
only.
For Rb staining, the intensity of staining and percentage of positive cells were evaluated
separately. Staining intensity was scored as follows: 0, no staining; 1, weak positive (faint
yellow staining); 2, intermediate positive; and 3, strong positive (brown staining). The number of
positive cells was visually evaluated and stratified as follows: <1%, 0 (negative); 1 to <5%
positive cells, 1 (weak); 5-50% positive cells, 2 (moderate); >50% positive cells, 3 (strong). The
sum of the staining intensity and percentage of positive cell scores was used to determine the
staining index for each section, with a minimum score of 0 and maximum score of 6; scores >1
were defined as Rb positivity. Using this cutoff, we compared Rb-positive to Rb-negative
tumors.
IHC analysis for Rb and cyclin E for the NCI TMA tumor samples were performed and
scored as described above for the Palbociclib treated patient samples.

2.23. MAMMOSPHERE FORMATION ASSAY
To generate primary mammospheres, the cells were grown in serum-free, media in low
attachment plates as previously described (Duong, Akli et al. 2013). Briefly, cells were
trypsinized, and single cells seeded in 6-well ultra-low attachment plates (10,000 cells/ml) in
serum-free MEM supplemented with 20 ng/ml bFGF, 20 ng/ml EGF and B27 (Invitrogen) and
incubated for 5- 7 days. For secondary mammosphere assay, cells from primary
mammospheres were dispersed with 0.05% trypsin, seeded in 6-well ultra-low attachment
plates (7,500 cells/ml) in mammosphere media and incubated for 5-7 days. Mammospheres
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with at least a size of 100μm were counted with an automated colony counter (Oxford Optronix,
Oxford, UK) following MTT staining (Sigma Aldrich, St. Louis, MO).

2.24. CD44/ CD24 FLOW CYTOMETRY ANALYSIS
Cells were plated (1´105 cells/dish) on 10-cm dishes then harvested by trypsinization.
Half a million cells were washed 3 times with PBS containing 1% horse serum and
resuspended in 10 μl PE anti-mouse CD24, 10 μl APC anti-mouse CD44 (BD Pharmingen) and
30 μl of the 1% serum PBS buffer. The samples were incubated for 20 minutes on ice, washed
with 1% serum PBS buffer and analyzed with the Beckman Coulter Gallios Flow Cytometer.
The data was analyzed by the Kaluza software to identify the CD44 high and CD24 low
population of cells. Cells with only a single antibody staining were used to set up the gates for
analysis.

2.25. ALDEFLUOR ASSAY
Measurement of cancer stem cells based on ALDH positivity was performed using the
Aldefluor kit (StemCell technologies, Cambridge, MA) according to the manufacturer’s protocol.
Briefly, cells were plated (1´105 cells/dish) on 10-cm dishes then harvested by trypsinization
and resuspended in the Aldefluor buffer. Each sample was divided into two tubes, Control and
Test, where the Aldefluor reagent was added to both tubes, while the Aldefluor DEAB reagent
(specific inhibitor of Aldefluor) was also added to the control tube alone. The samples were
incubated in 37C water bath for 30 minutes and then analyzed on the Beckman Coulter Gallios
Flow Cytometer to obtain the percentage of Aldefluor (ALDH) positive cells. Measurement for
each sample was done from the Test tube and using the control tube for gating the ALDH
negative population.
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2.26. MIGRATION ASSAY
The in vitro migration assay was performed as described previously (Justus, Leffler et
al. 2014). Briefly, cells were plated at a concentration of 0.5 million per well in a 6-well dish and
grown until they reach 90% confluence. A scratch was made in the wells with a pipette tip, and
cells were allowed to grow under normal culture conditions for 48 hours. Pictures were taken at
0hr, 24hr and 48hr to measure the migration capacity of the cells. The distance moved by the
cells divided by time was used to obtain the percentage of wound closure.

2.27. STATISTICAL ANALYSIS
All experiments were performed with a minimum of three technical and three biological
replicates, and values reported are the mean of the three biological replicates, unless otherwise
indicated. Error bars represent the standard deviation from the mean, unless otherwise
indicated. Pairwise comparisons were analyzed using multiple t-tests (one unpaired t-test per
row), with corrections applied (Holm-Sidak method) for multiple comparisons. When comparing
data from experiments with multiple groups, a regular one-way ANOVA (no matching) was
used with the Benjamini-Hochberg procedure to adjust for multiple comparisons. Tukey HSD
tests were used for post hoc analysis. Kaplan-Meier survival analysis was performed by using
the log rank (Mantel-Cox) test. For all tests, differences were considered statistically significant
at a p-value of 0.05 or less. For all figures, ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001. All statistical analyses were performed using the GraphPad Prism software and
R.

57

CHAPTER 3: CHARACTERIZING THE EFFECT OF CDK4/6 INHIBITION IN ER+
BREAST CANCER

3.1. INTRODUCTION
3.1.1. ROLE OF CDK4/6-CYCLIN D ON GROWTH OF BREAST CANCER
Deregulation of the cell cycle is a prevalent hallmark of cancers including breast cancer
(Malumbres and Carnero 2003). The G1/S checkpoint is one of the key checkpoints that
maintain cellular integrity and regulate passage through the cell cycle (Bertoli, Skotheim et al.
2013). Typically, cells that have successfully crossed the G1/S checkpoint and entered the S or
the DNA synthesis phase are committed to complete the cell cycle and undergo cellular
division (Bertoli, Skotheim et al. 2013). The G1/S checkpoint is regulated by the 2 families of
CDKs and cyclins: CDK/CDK6 - cyclin D and CDK2 – cyclin E (Figure 5) (Resnitzky, Gossen et
al. 1994).
The D-type cyclins, comprising of cyclin D1, cyclin D2 and cyclin D3 are the key drivers
of the G1/S checkpoint are often deregulated in several cancer such as breast, lung, bladder
and head and neck cancer (Berenson, Koga et al. 1990, Proctor, Coombs et al. 1991, Wang,
Pavelic et al. 1995). About 15% of all breast cancer patients exhibit amplification of the 11q13
locus, which contains CCND1, the gene encoding for cyclin D1 (Schuuring, Verhoeven et al.
1992). Further, about 50% of all breast cancers exhibit upregulation of cyclin D1 at both the
mRNA and protein levels (Arnold and Papanikolaou 2005). This suggests a crucial regulatory
role for cyclin D1 in the process of cell cycle and tumorigenesis. Moreover, cyclin D1
overexpression in transgenic mouse models resulted in the formation of mammary tumors,
suggesting a breast cancer specific oncogenic role for the protein (Wang, Cardiff et al. 1994).
Cyclin D1 in turn can be regulated by numerous pathways, including the estrogen receptor
(ER) signaling pathway, Her-2 pathways and other major growth signaling pathways such as
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Figure 5: Regulation of the G1/S checkpoint: Schematic showing how the cell
cycle proteins CDK4, CDK6 and cyclin D regulate progression through the cell cycle,
and how palbociclib treatment cause G1 arrest and senescence

PI3K and MAPK pathways, all of which have been shown to positive regulate cyclin D1
expression (Zwijsen, Wientjens et al. 1997, Paternot and Roger 2009). Thus, cyclin D1 acts as
a key point of convergence for growth signaling pathways and cell cycle progression, and an
ideal drug target in cancer.
The canonical interacting partners of cyclin D1 involved in the regulation of the G1/S
checkpoint are CDK4 and CDK6 (Otto and Sicinski 2017). These proteins work together with
cyclin D to phosphorylate the tumor suppressor Rb, which gets further phosphorylated by the
CDK2-cyclin E complex, inactivating the Rb protein and facilitates the release of E2F (Bertoli,
Skotheim et al. 2013, Otto and Sicinski 2017). The transcription factor, E2F, in turn regulates
expression of genes required for growth and progression through the cell cycle (Bertoli,
Skotheim et al. 2013). Thus, the crucial role of CDK4/6 – cyclin D in tumorigenesis and cell
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cycle progression, specifically in ER positive breast cancer, has led to the development of
drugs targeting this pathway in the recent years, the CDK4/6 inhibitors (Finn, Crown et al.
2015, Finn, Martin et al. 2016). The CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib
have shown great results in pre-clinical research and clinical trials, which has led to the FDA
approval of these drugs (palbociclib, ribociclib) for the treatment of advanced ER positive
breast cancer in combination with aromatase inhibitors (O'Leary, Finn et al. 2016, Sherr, Beach
et al. 2016).

3.1.2. MECHANISTIC STUDIES OF PALBOCICLIB IN BREAST AND OTHER CANCER
Palbociclib (PD-0332991) the potent and specific CDK4/6 inhibitor has been tested in
numerous pre-clinical cancer models including breast cancer (Toogood, Harvey et al. 2005).
Treatment of cancer cell lines with palbociclib, specifically breast cancer cell lines, has been
shown to decrease phosphorylation of Rb and induce a cell cycle arrest (G1 arrest) and
senescence (Fry, Harvey et al. 2004, Finn, Dering et al. 2009). Palbociclib treatment also
cause a reduction in Rb phosphorylation and Ki67 (marker of proliferation) in breast tumors in
vivo and a dose-dependent decrease in the growth of mouse tumor xenografts (Fry, Harvey et
al. 2004). One of the early studies in breast cancer with this drug examined the growth
inhibitory effect of the drug and its half maximal inhibitory concentrations (IC50 values) across
a panel of 44 breast cancer cell lines belonging ER positive, HER2 positive and TNBC
subtypes (Finn, Dering et al. 2009). Results from this study showed that a majority of the cell
lines that were sensitive to palbociclib belonged to the ER positive subtype of breast cancer
(Finn, Dering et al. 2009). While, majority of the ER negative or TNBC cell lines were resistant
to palbociclib, a small proportion of the sensitive cells belonged to this subtype (Finn, Dering et
al. 2009). The study also showed that the sensitive cell lines exhibited high expression of Rb,
cyclin D1 and loss of p16 (Finn, Dering et al. 2009). Another study which examined the
changes in gene expression following treatment with palbociclib in ER positive breast cancer
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cell line showed a significant downregulation in the proliferative and cell cycle regulatory genes
at the mRNA level (Knudsen and Witkiewicz 2016). These studies provided the rationale for
further pre-clinical and clinical investigation of CDK4/6 inhibition in ER positive breast cancer.
Additionally, numerous pre-clinical studies have been conducted with palbociclib in
other cancers such as mantle cell lymphoma, myeloma, acute myeloid leukemia, glioblastoma,
ovarian cancer, esophageal adenocarcinoma, mantle cell lymphoma and prostate cancer
(Baughn, Di Liberto et al. 2006, Marzec, Kasprzycka et al. 2006, Wang, Wang et al. 2007,
Michaud, Solomon et al. 2010, Ismail, Bandla et al. 2011, Konecny, Winterhoff et al. 2011,
Leonard, LaCasce et al. 2012, Comstock, Augello et al. 2013). All of these studies showed
significant and potent anti-proliferative activity accompanied by the induction of G1 arrest in
tumor cell lines in vitro and anti-tumor activity in tumors in vivo with palbociclib treatment, and
also showed an association between sensitivity to the drug and expression of Rb.
A study conducted primarily in U2OS cells and verified in other cancers identified
FOXM1 as a direct substrate of CDK4/6, which protects cells from the induction of senescence
(Anders, Ke et al. 2011). Results from this study showed that palbociclib mediated
downregulation of FOXM1 coupled with pRb and G1 arrest results in the induction of ROSmediated senescence (Anders, Ke et al. 2011). Another study in melanoma cells in vitro
showed that prolonged treatment with the CDK4/6 inhibitor along with mTOR expression is
required for the induction of an irreversible growth inhibition and senescence (Leontieva and
Blagosklonny 2013). Recent studies also suggest a role for palbociclib in regulating EMT and
cancer stem cells (Qin, Xu et al. 2015, Bonuccelli, Peiris-Pages et al. 2017). Finally, palbociclib
mediated CDK4/6 inhibition has been shown to regulate increase mitochondrial mass and
cause metabolic reprogramming in pancreatic cancer cell lines models, and regulate autophagy
in fibroblasts and promyelocytic leukemia (Capparelli, Chiavarina et al. 2012, Acevedo, Vernier
et al. 2016, Franco, Balaji et al. 2016).
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3.1.3. INTERPLAY BETWEEN ROS AND SENESCENCE
The concept of senescence first originated from studies that showed that primary cells
obtained from human tissues were mortal and had limited replicative potential (Hayflick and
Moorhead 1961). This is associated with shortening of the telomere length, which in turn has
been shown to trigger a DNA damage response leading to senescence (Harley, Futcher et al.
1990, d'Adda di Fagagna, Reaper et al. 2003). However, in cancers, senescence can be
induced even in the absence of telomere shortening, which may be stress induced, oncogene
induced or tumor suppressor loss induced senescence (Kuilman, Michaloglou et al. 2010). The
induction of senescence is typically characterized by the presence of prolonged cell cycle
arrest, morphological transformation (cells acquire a large and flat morphology), activation of
tumor suppressor networks such as p16 and p21, induction of SA-b gal activity, presence of
senescence associated heterochromatin foci (SAHF) and senescence associated secretory
phenotype (SASP) (pro-inflammatory cytokine factors that are secreted by senescent cells)
(Dimri, Lee et al. 1995, Serrano, Lin et al. 1997, Campisi 2005, Kuilman, Michaloglou et al.
2010).
The well-established triggers of stress-induced senescence in cancer model systems
include DNA damage and oxidative stress mediated by reactive oxygen species (ROS) (d'Adda
di Fagagna 2008, Lu and Finkel 2008, Kuilman, Michaloglou et al. 2010). Reactive oxygen
species (ROS) are highly reactive free radicals, ions or molecules that are generated as a
result of response to stress due to increased metabolic activity, mitochondrial dysfunction,
oncogene activity, etc. (Liou and Storz 2010, Jajic, Sarna et al. 2015). The levels of the reactive
oxygen species in cancer cells can determine its pro-tumorigenic vs anti-tumorigenic role (Liou
and Storz 2010). Low levels of ROS can promote tumor growth and cell cycle progression by
directly regulating the expression of cell cycle proteins including G1/S cyclins such as cyclin
B2, cyclin D3 and cyclin E (Felty, Singh et al. 2005, Liou and Storz 2010). However,
significantly higher levels of ROS can induce cell cycle arrest, senescence, and even turn on
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cell death signaling and apoptosis (Liou and Storz 2010). Moreover, numerous studies have
shown that ROS is indispensable for the induction of senescence in cancers. For example,
ROS has been shown to be required for anticancer drug induced DNA damage and
senescence in lung cancer, p21 mediated senescence in lung fibroblasts and radiation induced
senescence in human endothelial cells (Luo, Zou et al. 2011, Luo, Yang et al. 2013, Park, Kim
et al. 2016). Finally, treatment with the CDK4/6 inhibitor palbociclib and abemaciclib induces
ROS dependent senescence in cancers (Anders, Ke et al. 2011, Franco, Balaji et al. 2016,
Patnaik, Rosen et al. 2016).

3.1.4. GAP IN KNOWLEDGE
While current pre-clinical mechanistic studies provide insight into the mechanism of CDK4/6
inhibition mediated by palbociclib and other drugs, several questions remain:
1. Is there a time dependent difference in the growth inhibition mediated by palbociclib?
(i.e.) Is long term drug treatment required for the induction of senescence?
2. Is there a dose dependent variation in palbociclib action? Is there an off-target effect of
the drug observed at higher doses?
3. Does palbociclib induce cytotoxic effects or apoptosis?
4. Is ROS required for palbociclib mediated irreversible growth inhibition and senescence?
5. Is ROS induced in ER+ve breast tumors in vivo?
Thus, studies in this chapter are aimed at addressing these gaps in knowledge, which will
provide valuable information in understanding the mechanism by which CDK4/6 inhibition
impacts the growth ER positive breast cancer cells.
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3.2. RESULTS
3.2.1. DEREGULATION OF CDK4/6-CYCLIN D PATHWAY IN BREAST CANCER
To interrogate the importance of the G1/S checkpoint in breast tumors, The Cancer
Genome Atlas's (TCGA) breast cancer dataset was examined to mine for mutations,
amplifications, mRNA upregulation and protein upregulation of genes within the CDK4/6-Cyclin
D pathway. TCGA’s breast tumor cohort comprises of 971 completely annotated tumors, with
594 tumors belonging to the ER positive subtype, 58 tumors belonging to the Her2 positive
subtype and 82 tumors belonging to Triple Negative Breast Cancer (TNBC) subtype. Detailed
analysis revealed alterations in the CDK4/CDK6/Cyclin-D pathway in about 37% of all breast
cancer patients (CDK4 - 7%, CDK6 – 8%, cyclin D – 22%) (Figure 6A). Further, 35% of ER
positive breast cancer patients (CDK4 - 4%, CDK6 – 3%, cyclin D – 28%) (Figure 6A), 29% of
the Her2+ breast cancer patients (CDK4 - 10%, CDK6 – 0%, cyclin D – 19%) (Figure 6D), and
64% of TNBC patients (CDK4 - 22%, CDK6 – 37%, cyclin D – 5%) (Figure 6A) exhibited
alterations in the CDK4/6-cyclin D pathway. Moreover, gene amplification and mRNA
upregulation of cyclin D contributed the most to the pathway deregulation seen in the ER+ve
and Her2 +ve subtypes of breast cancer (Figure 6B,D), while mRNA upregulation of CDK4 and
CDK6 were the most prevalent alterations in the TNBC tumors (Figure 6C).
Thus, these results reveal the importance of the CDK4/6 pathway in all subtypes of
breast cancer and help identify ER positive breast cancer as an ideal population for targeting
CDK4 and CDK6, since 70% of all breast cancers are of the ER positive subtype.
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Figure 6: Deregulation of CDK4/6-Cyclin D pathway in Breast Cancer: A) Pie chart showing
alterations in CDK4, CDK6 and cyclin D at the gene and protein levels based on The Cancer genome
Atlas (TCGA) analysis of breast tumors. B,C) Detailed analysis of gene amplifications, mutations and
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3.2.2. IMPACT OF siRNA OR shRNA KNOCKDOWN OF CDK4/6
To interrogate the biological effect of downregulating CDK4 and CDK6, we utilized two
independent methods knockdown the two proteins namely, i) short hairpin RNA (shRNA) and ii)
small interfering RNA (siRNA). shRNA knockdown typically provides a stable downregulation of
the mRNA and protein, while siRNA provides a transient or temporary (usually lasting 72 hours)
but effective knockdown (Aagaard and Rossi 2007).
First, we performed shRNA mediated knockdown of CDK4 and/ or CDK6 in two
established ER positive breast cancer cell lines - MCF7 and T47D (Mackay, Tamber et al.
2009) using at least 2 different shRNA constructs (Figure 7A and 7B). Results revealed that
downregulation of the individual kinases had little to no growth inhibitory potential as measured
by doubling time and cell counting over a 10-day period (Figure 7C and 7D). In comparison, a
significant growth inhibition was observed upon combined shRNA knockdown of CDK4 and
CDK6 (Figure 7D), concomitant with an increase in their doubling time when compared to
Control (Scrambled) cells (Figure 7C).
Since the short term transient knockdown effect obtained with siRNA is considered
more similar to the effect observed in the presence of a pharmacological inhibitor, we next
performed siRNA mediated downregulation of CDK4 or CDK6 using pooled siRNA constructs
(used for better knockdown efficiency) (Figure 7E). Results from cell counting assay performed
over 6-day period showed little to no growth inhibition upon knockdown of the individual
proteins (Figure 7F). However, similar to the results from the shRNA experiments, siRNAmediated combined CDK4 and CDK6 knockdown (Figure 7E) elicited a significant growth
inhibitory effect on the ER positive breast cancer cells (Figure 7F).
Thus, these results provide a strong rational for combined targeting of CDK4 and CDK6
in ER positive breast cancer.
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3.2.3. DOSE DEPENDENT EFFECT OF PALBOCICLIB ON GROWTH, CELL CYCLE
ARREST AND SENESCENCE
Having shown the impact of downregulating CDK4 and CDK6 in ER positive breast
cancer, we next compared the growth inhibitory potential of the FDA approved CDK4/6
inhibitor, palbociclib, in three ER positive breast cancer cell lines, MCF7, T47D and ZR75-1, in
comparison with an immortalized human mammary epithelial cell line (HMEC - MCF10A). In
order to examine the time and dose-dependent effect of the drug, we performed dose response
studies where the cells were treated with varying concentrations of the drug for different time
periods (1,2,4,6, or 8 days), and provided with a recovery time to interrogate the reversibility of
drug action (Figure 8A). Results demonstrate that palbociclib inhibited the growth of ER
positive breast cancer cell lines in a time and dose-dependent manner, resulting in a significant
irreversible growth inhibition (Figure 8B), with half-maximal inhibitory concentrations (IC50) of
0.73μM to 0.93μM following 8 days of continuous treatment and 4 days of recovery (Figures
8C,D). In contrast, the HMEC cell line MCF-10A was more resistant to palbociclib, displaying a
>5-fold (5.98μM) higher IC50 value than the ER positive cell lines (Figures 8B-3D). These
results suggest that palbociclib induces a time and dose dependent growth inhibition that is
specific to the ER positive breast cancer cells, but not in HMECs.
To further investigate palbociclib mediated growth inhibition, we performed colony
formation assay with 6 days of drug treatment and 6-day recovery, which revealed that
palbociclib treatment of ER positive, but not HMEC cells, resulted in a dose-dependent
reduction in colony counts (Figure 8E). Next, to examine the ability of ER positive breast
cancer cells to recover from palbociclib-mediated growth inhibition, cells were treated
continuously for 6 days (which was the least duration of treatment having the lowest IC50 value
from Figure 3C) with increasing concentrations of the drug, and cultured in the absence of
palbociclib for another 4 days (Figure 8F). Cell counting and S-phase progression (BrDU
incorporation measured via flow cytometry) assays revealed that treatment with palbociclib at
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doses of 1μM or less resulted in a reversible growth inhibition (Figures 8G - compare solid
lines to dashed lines and Figure 9A –compare black vs white shaded bars). On the other hand,
higher doses of palbociclib (>2.5 μM) resulted in an irreversible inhibition of growth and Sphase progression (measured by BrdU incorporation) in the ER positive breast cancer cells
(Figures 8G - compare solid lines to dashed lines and Figure 9A –compare black vs white
shaded bars). Strikingly, this effect of palbociclib on growth and proliferation was not observed
in the HMEC cell lines MCF10A, where the growth inhibition induced was reversible at all
doses (Figures 8G - compare solid lines to dashed lines and Figure 9A –compare black vs
white shaded bars), thus demonstrating a dose-dependent growth inhibition mediated by
palbociclib, specifically in ER positive cancer cells.
Next, to interrogate the impact of palbociclib treatment on the cell cycle, we treated the
cells for 6 days and allowed the cells to recover for 4 days to examine reversibility of the drug
effect (Figure 8F). Results show that palbociclib treatment induces a dose-dependent cell cycle
arrest (G1 arrest), which was readily reversible at the lower doses (<1uM), while higher doses
of palbociclib induced an irreversible G1 arrest (Figure 9B and 9C - compare black vs white
shaded bars). Additionally, this dose-dependent induction of G1 arrest was observed only in
MCF7 and T47D cells and not in MCF10A (Figure 9B and 9C), further demonstrating
specificity of palbociclib to ER positive cancer cells, and not HMECs. Further, western blot
analysis showed a dose-dependent decrease in known palbociclib effectors such as Rb, pRb
and FOXM1 (Anders, Ke et al. 2011), but no alteration in the protein levels of CDK4 and CDK6
(Figure 9D).
Finally, we examined if palbociclib induces senescence in the ER positive breast cancer
cells, and if this occurs in a dose-dependent manner. Measurement of senescence activity by
senescence associated- ß galactosidase (SA-ß gal) assay indicates that palbociclib induces
moderate senescence at the lower doses (<1uM) and significant levels of senescence only at
higher doses (>2.5uM) in MCF7 and T47D cells (Figure 10A). Moreover, no induction of
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senescence was observed in the HMEC cell line, MCF10A at all doses of palbociclib (Figure
10A). Further, cells undergoing senescence display a change in morphology as well as an
increase in cellular complexity and granularity, which can be measured by changes in the side
scatter (Anders, Ke et al. 2011, Bielak-Zmijewska, Wnuk et al. 2014). Flow cytometry analysis
showed a significant increase in side-scatter of ER+ve breast cancer cells in a dose-dependent
manner, which the increase being reversible at the lower doses and irreversible at higher doses
of 5uM (Figure 10B).
The summary of these results is shown in Figure 10C, which depicts the effects of
palbociclib as a variant of dose: i) BrdU incorporation / cell proliferation – red solid line on the
right Y-axis, ii) sustained G1 arrest (post recovery) – blue solid line on the right Y-axis, iii)
protein levels of pRb (measured by densitometry) – orange solid line on the left Y-axis and iv)
measurement of senescence – green solid line on the left Y-axis. Collectively, these results
show that palbociclib treatment induces dose-dependent growth inhibition, G1 arrest, decrease
in Rb phosphorylation and increase in senescence, specifically in the ER positive breast cancer
cells.
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3.2.4. TIME DEPENDENT EFFECT OF PALBOCICLIB ON GROWTH, CELL CYCLE
ARREST AND SENESCENCE
Having shown that the dose of palbociclib treatment has a significant impact of the drug
effect, we next wanted to examine if the time of treatment plays a role, (i.e.) if long-term
treatment is necessary to achieve a sustained effect on ER positive breast cancer cells. Since
our previous results showing the induction of dose-dependent growth inhibition and
senescence (Figures 2-5) were performed long-term (6 day) treatments with palbociclib, we
wanted to examine the effect with shorter treatment times. Hence, we treated the ER positive
breast cancer cells for 72 hours with 2 doses, low (1uM) and high (5uM) doses of palbociclib
and then cultured the cells in the absence of the drug for another 3 days, to examine
reversibility of drug effect. Cell counting assay showed that the growth inhibition induced by
palbociclib was readily reversible at all concentrations once the drug was removed (Figure
11A). Further, BrdU analysis (a measure of cellular proliferation and S phase progression),
where cells were treated with varying concentrations of palbociclib, showed that 72 hour was
only able to induce a reversible growth inhibition in ER+ve and HMEC cell lines (Figures 11B –
compare black and white shaded bars). Finally, measurement of senescence activity by
senescence associated- ß galactosidase (SA-ß gal) assay revealed that short-term palbociclib
treatment (72 hours) does not induce significant levels of senescence in MCF7, T47D and
MCF10A cells (Figure 11C).
Thus, this data indicate that long term is required for palbociclib mediated CDK4/6
inhibition to have a sustained and irreversible growth inhibitory effect in ER positive breast
cancer.
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3.2.5. EFFECT OF PALBOCICLIB ON INDUCING APOPTOSIS IN ER+ve BREAST CANCER
Having shown that the CDK4/6 inhibitor palbociclib mediates a time and dose
dependent growth inhibition, cell cycle arrest and senescence, we next wanted to investigate if
palbociclib might have a cytotoxic effect in ER positive breast cancer. Flow cytometry analysis
of Annexin V and PI stained MCF7 and T47D cells revealed no significant increase in early
(Annexin V +ve /PI –ve) or late (Annexin V +ve /PI +ve) apoptotic cells upon treatment with the
CDK4/6 inhibitor (Figure 12A). Further, cell cycle analysis to examine sub G1 population and
Caspase 3 activity assay revealed no increase in sub G1 population (Figure 12B) and
Caspase 3 activity (Figure 12C) with drug treatment. Finally, western blot analysis of known
apoptotic genes, cleaved PARP, cleaved Caspase 7 showed no increase in apoptosis upon
treated with palbociclib (Figure 12D).
Thus, these results show that treatment with the CDK4/6 inhibitor palbociclib does not
induce a cytotoxic effect via apoptosis in ER+ve breast cancer cell lines.
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Figure 12: Effect of palbociclib on inducing apoptosis in ER+ breast cancer cells: A) Flow
cytometry measurement of apoptotic cells (early apoptosis: Annexin V+/ PI-; late apoptosis: Annexin
V+/PI+) in cells treated as in (a). B) Cell cycle analysis to determine percentage of cell in sub G1
phase, as a measure of apoptosis. C) Percentage of caspase-3 positive cells determined by flow
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concentrations of palbociclib for 6 days. D) Western blot analysis of apoptotic proteins in MCF7 and
T47D treated with DMSO or palbociclib (Palbo) for 6 days: PARP, cleaved PARP, caspase-7, and
cleaved caspase-7, with actin as loading control. All data represent mean±SD from three independent
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3.2.6. ON-TARGET vs OFF-TARGET EFFECTS OF PALBOCICLIB
Given that all kinase inhibitors can have potential off-target effects, we next wanted to
examine if the different doses of palbociclib that induce growth inhibition and / or senescence in
ER positive breast cancer cell lines are due to on-target (due to inhibition of CDK4 and CDK6)
or off-target (due to inhibition of other kinases). A recent chemical proteomic study revealed
that that the CDK4/6 inhibitor palbociclib interacts with targets other than CDK4 and CDK6,
such as CDK9, Caesin kinase 2, PIK3R4 and other Class III PI3 kinases (Sumi, Kuenzi et al.
2015).
To examine the specificity of palbociclib to CDK4 and CDK6, the two genes were
downregulated using either shRNA or siRNA technologies (Figure 7) in MCF7 and T47D cells.
Treatment of cells with knockdown of CDK4 and/ or CDK6 with increasing concentrations of
palbociclib showed that knockdown of either protein alone was not sufficient to recapitulate the
effect of the drug, as downregulation of just one kinase did not result in “rescue” from
palbociclib mediated growth inhibition (Figure 13A). However, combined knockdown of both
CDK4 and CDK6, recapitulated palbociclib treatment and mediates resistance (i.e. rescue) to
palbociclib-induced growth inhibition only at the lower concentrations (≤1µM) (Figure 13A).
Intriguingly, higher concentrations of palbociclib (>1 µM) had a growth inhibitory effect of the
CDK4/6 double knockdown cells, indicating potential off-target effects of palbociclib at these
higher concentrations (Figure 13A). To further understand the on-target vs off-target effects of
palbociclib in ER+ve breast cancer cell lines, we treated siRNA mediated CDK4/6 knockdown
cells with low (1uM) and high (5uM) dose palbociclib. Results show that that while low-dose
(1uM) palbociclib had no additional growth inhibitory effect on the CDK4/6 knockdown cells,
higher doses (5uM) of palbociclib induced additional growth inhibition (Figure 13B).
Thus, these results indicate that indicating that the irreversible grown inhibition and high
levels of senescence observed at 5μM could be due to off-target effects at higher palbociclib
concentrations.
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3.2.7. INDUCTION OF REACTIVE OXYGEN SPECIES (ROS) BY CDK4/6 INHIBITION
Recent studies have shown that CDK4/6 inhibition via palbociclib and ribociclib can
trigger and activate the reactive oxygen species (ROS) machinery (Anders, Ke et al. 2011,
Franco, Balaji et al. 2016). This led us to hypothesize that palbociclib may induce ROS in a
dose-dependent manner in ER positive breast cancer, and that levels of ROS may dictate the
induction of senescence. Consistent with this, siRNA knockdown of CDK4/6 in MCF7 and T47D
cell lines increased cellular ROS levels as measured by CellROX assay (Figure 14A).
Similarly, treatment of ER positive cells with low concentration (1uM) of Palbociclib for 6 days
also increased ROS levels, albeit moderately (measured by CellROX), while treatment with
high concentration (5uM) resulted in a significant increase in ROS levels, and this corresponds
to the palbociclib concentrations at which senescence is induced (Figure 14B). In contrast,
treatment of HMEC cells did not result in any significant changes in ROS levels at both low
(1µM) and high (5 µM) palbociclib concentrations (Figure 14B), indicating specificity of drug
action. Further, short-term (72hr) treatment with low or high doses of palbociclib did not
increase ROS levels or induce a senescence phenotype in ER positive breast cancer cells
(Figure 14C and 14D).
These results indicate that CDK4/6 inhibition via palbociclib induced reactive oxygen
species, which may be required for the induction of senescence by palbociclib.
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3.2.8. IMPACT OF ROS ABLATION ON PALBOCICLIB INDUCED GROWTH INHIBITION
AND SENESCENCE
Given the well-established link between Reactive oxygen species (ROS) and cell cycle
arrest and senescence and the known requirement of high ROS levels for the induction of
senescence (Boonstra and Post 2004, Kuilman, Michaloglou et al. 2010), we wanted to
examine if palbociclib induced ROS is required for the induction of sustained growth inhibition
and senescence in ER positive breast cancer cells. To interrogate this, we ablated ROS using
the ROS scavengers N-acetyl cysteine (NAC) or trolox (Hamad, Arda et al. 2010, Sun 2010),
by treating the cells with NAC or trolox in combination with palbociclib for the 6 day period
(Figure 15A). ROS ablation mediates significant resistance to the ability of palbociclib to
induce a sustained growth inhibition even at higher doses of 5uM, as measured by clonogenic
assay (Figure 15B). Further, measurement of cellular proliferation by cell counting after drug
treatment for 6 days and recovery for 4 days (to measure reversibility) also showed ROS
ablation by NAC or trolox prevented the induction of irreversible or sustained growth inhibition
in MCF7 and T47D cells even with high doses of palbociclib (Figure 15C). Moreover, ablation
of ROS by NAC or trolox also significantly decreased the induction of senescence by high
doses (5uM) of palbociclib in MCF7 and T47D cell lines, as measured by SA-ß gal, wherein a
significant decrease in SA-ß gal positive cells (blue staining) was observed with NAC or trolox
treatment in combination with 5uM palbociclib, compared to palbociclib alone (Figure 15D).
Thus, these results demonstrate the dependence of the palbociclib action (its ability to
induce sustained growth inhibition and senescence) on elevated ROS levels.
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Figure 15: Impact of ROS ablation on palbociclib induced growth inhibition and senescence:
MCF7 and T47D cells were treated with DMSO (Cnt), 5 μM palbociclib (Palbo), or a combination of
ROS scavenger (10 mM NAC or 0.1 mM trolox) with 5 μM palbociclib for 6 days and subjected to A)
measurement of cellular ROS levels with CellROX deep red; B) clonogenic assay; C) cell counting
to assess proliferation (p-values were calculated in comparison with cells treated with 5 μM
palbociclib) and D) Quantification and representative images of Senescence associated ß
galactosidase (SA-ß gal) activity as a measurement of senescence. All data represent mean±SD
from three independent experiments; p-values were calculated in comparison to cells treated with
DMSO (Control) or siNT unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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10mM

3.2.9. PALBOCICLIB MEDIATED TUMOR GROWTH INHIBITION AND SENESCENCE IN
VIVO
We next set out to translate our findings from cultured cells in vitro to tumor xenografts
in vivo. For the in vivo studies, since MCF7 cells are not very tumorigenic (ability to form
tumors in mice), we established MCF7T cells by passaging MCF7 cells through mice and
verified that they behave similar to MCF7 cells in response to CDK4/6 inhibition via palbociclib
in vitro. Results show that treatment of MCF7-T cells with increasing concentrations of
palbociclib resulted in a time and dose-dependent growth inhibition (Figure 16A and 16B) and
cell cycle arrest (G1 arrest) (Figure 16C), that were very similar to what observed in the MCF-7
cells (Figure 2-5). Further, palbociclib induced senescence in a dose-dependent manner in
MCF7-T cells (Figure 16D). Palbociclib treatment in MCF7-T cells also induced autophagy
(Figure 16E) and responded to autophagy inhibition (Figure 16F), similar to MCF7 cells
(described in Chapter 4 and 5). Thus, these results show that MCF7-T cells behave similar to
MCF7 and can be utilized for the in vivo mouse studies.
Next, to assess the therapeutic effect of CDK4/6 inhibition in vivo, we established a
mouse orthotropic xenograft model by injecting MCF7T cells into the mammary fat pad of
immunocompromised nude mice. Once the tumors reached an average volume of 200mm3, the
mice were treated with Vehicle (0.5% Methylcellulose) or varying concentrations of Palbociclib
(25, 50, 75 or 150 mg/kg/day) via oral gavage for 7 days (Figure 17A). Treatment with
palbociclib significantly decreased tumor volume in a dose-dependent manner, when compared
to the vehicle treated mice (Figures 17B and 17C). This resulted in significantly smaller tumors
and decreased tumor weight upon 7-day treatment with palbociclib in a dose-dependent
manner (Figure 17D). To examine palbociclib-mediated toxicity in mice, we measured mouse
weight every day during the 7-day treatment period. While treatment with Vehicle, 25 mg/kg
and 50 mg/kg Palbociclib was well tolerated by the mice, a moderate decrease in mouse
weight was observed with 75mg/kg and 150 mg/kg palbociclib (Figures 17E and 17F) This
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suggests potential toxicity by palbociclib at the higher concentrations, and emphasizes the
need to optimize the use of lower drug concentrations.
Treatment of in vivo xenograft tumors with palbociclib also resulted in decrease in
protein levels of G1/S checkpoint proteins and known palbociclib targets – Rb, pRb and
FOXM1 as measured by western blot analysis (Figure 17G). Next, the tumor tissues were
harvested, sectioned and stained with hematoxylin and eosin (H&E), to examine the
morphology of the tumor cells post treatment (Fischer, Jacobson et al. 2008).
The remaining tumors were sectioned for further immunohistochemistry (IHC) analysis,
which revealed that palbociclib treatment increased SA- ß gal activity (measure of induction of
senescence) and decreased expression of BrdU (indicator of decreased proliferation),
indicating the induction of a dose-dependent tumor growth inhibition and senescence (Figure
18A). Consistently, RPPA analysis of tumors (Figure 18B) treated with palbociclib showed a
dose-dependent downregulation of cell cycle and proliferation proteins, such as pRb, FOXM1,
cyclin B, CDK1, cdc25c, cdc2, PLK1, ARID1, BRD4, ATM and Wee1 (Figure 18C). A
concomitant up-regulation of proteins within the senescence pathway, such as Chk1, YAP,
TAZ, E!F4E, IGFFBP2, PEA15, 14-3-3-beta, 14-3-3-zeta and c-IAP (Figure 18D), when
compared to vehicle treated tumors.
Collectively, these results show that CDK4/6 inhibition via palbociclib induces a dosedependent reduction in tumor growth and induction of senescence in ER positive tumor
xenografts.
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Figure 18: Palbociclib mediated cell cycle arrest and senescence in vivo: A) Quantification (BrdU)
and representative images of hematoxylin and eosin (H&E), BrdU and SA-ß gal immunohistochemical
staining of tumor tissues harvested after treatment with vehicle (0.5% methylcellulose [MC]) or varying
concentrations of palbociclib for 7 days. Scale bars equal 50μm. B) Heat map obtained from RPPA
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indicated. ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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3.2.10. PALBOCICLIB MEDIATED INDUCTION OF ROS IN VIVO
Since our results showed that palbociclib mediated CDK4/6 inhibition has been shown
to induce ROS in ER positive breast cancer cell line model systems (Figure 14), which is
required for the induction of senescence (Figure 15), we wanted to examine if palbociclib would
induce ROS in vivo as well. For this purpose, we utilized tumors harvested post treatment with
vehicle or varying concentrations of palbociclib (25mg/kg, 50mg/kg, 75mg/kg and 150mg/kg)
(Figure 12A), and performed immunohistochemistry (IHC) analysis for known markers of
Reactive oxygen species (ROS): i) 8-hydroxydeoxy-guanosine (8-OHdG), a marker of oxidative
stress induced DNA damage (Valavanidis, Vlachogianni et al. 2009) and ii) 4-hydroxynonenal
4-HNE, a marker of oxidative stress induced lipid peroxidation (Liou and Storz 2015). Results
showed a significant dose dependent up-regulation of 8-OHdG and 4-HNE staining, with
highest staining with 150 mg/kg palbociclib, which has been shown to induce senescence
(Figures 19A and 19B). Further, RPPA analysis of the palbociclib treated tumors exhibited
downregulation a ROS sequestering gene Caveolin (CAV-1) (Chen, Barman et al. 2014) and
upregulation of SOD-2, which is known to be induced by higher ROS levels (Figure 19C).
Thus, palbociclib mediated CDK4/6 inhibition in vivo induces ROS levels, which is
required for the sustained tumor growth inhibition and senescence in vivo.
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3.3. DISCUSSION
Most preclinical studies conducted thus far with palbociclib have used the drug at low
conc. (<1uM) and for short exposure times (<72 hrs.). Under these treatment conditions, the
drug only induces a reversible cell cycle arrest at these conditions, leading to a poor
recapitulation of the effect seen in clinic, where patients are treated continuously for 3 weeks
(DeMichele, Clark et al. 2015). Hence in this study, we examined the action of the CDK4/6
inhibitors as a function of both time and dose, and also interrogated the reversibility of the drug
effect; making it the first clinically relevant model to investigate the mechanism of Palbociclib
action. Our results demonstrated that a biphasic effect was seen with palbociclib treatment in
ER positive breast cancer cells in vitro, where lower doses of the drug (~1uM) were more
specific to CDK4/6 and was able to induce only a reversible inhibition of growth and cell cycle
(G1 arrest), while the higher doses of the drug (>2.5uM) resulted in an irreversible inhibition of
cellular proliferation, an irreversible G1 arrest and senescence. Further, results show that longterm treatment with palbociclib is necessary for the induction of sustained drug effect and
senescence. While a previous study suggested that long-term treatment may be required to
prevent reversibility in the growth inhibition induced by palbociclib (Leontieva and Blagosklonny
2013), this has not been elucidated in detail. Further, the higher doses which resulted in the
induction of senescence (5uM) is significantly higher than higher than the clinically achievable
dose and the plasma concentration, which 3.4uM (Pfizer-Inc-and-Affiliates 2011).
Hence, understanding the dose-dependent mechanism of action of palbociclib is crucial to
improve the efficacy of CDK4/6 inhibition and potentially lower the dose of the drug
administered in patients.
Further, treatment with palbociclib failed to induce any apoptosis or cytotoxic effects,
indicting that the mechanism of drug mediated growth inhibition is likely due to the induction of
senescence. This was observed both in cultured cells in vitro and tumors in vivo, and
corroborates with previous studies (Anders, Ke et al. 2011). This effect might be specific to
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palbociclib since studies with the other CDK4/6 inhibitors such as abemaciclib have been
showed to induce apoptosis in breast cancer cells in vitro (Patnaik, Rosen et al. 2016).
Intriguingly, the induction of senescence observed at the higher doses of palbociclib
was coupled with drug effects not necessarily specific to CDK4/6 inhibition, indicating the
presence of potential off-target effects for palbociclib at the higher doses. A mass spectrometry
based chemoproteomics study in lung cancer aimed at identifying all possible direct and
indirect kinase targets of the CDK4/6 inhibitors, palbociclib and ribociclib, showed that apart
from CDK4 and CDK6, palbociclib has targets other kinases such as CDK9, casein kinase 2,
PIK3R4 (regulator of autophagy) and lipid kinases such as PIK3CD and PIP4K2A/B/C (Sumi,
Kuenzi et al. 2015). By pathway analysis, this study also showed that palbociclib treatment
affect PI3K signaling and autophagy apart from cell cycle regulation (Sumi, Kuenzi et al. 2015).
Hence, it is highly likely that palbociclib hits secondary targets at the higher concentrations
(5uM or 150mg/kg) and this accounts for the biphasic effect observed with palbociclib
treatment.
The results presented in this chapter also show that CDK4/6 inhibition and
palbociclib treatment induces oxidative stress, measured by reactive oxygen species (ROS) in
a dose-dependent manner, and that the high levels of ROS is required for the induction of
senescence. However, the molecular mechanism by which CDK4/6 inhibition induces ROS
remains unclear. Cyclin-D1 has been shown to bind to and phosphorylates Nrf1, which is a
regulator of mitochondrial biogenesis and ROS, and this occurs in a CDK dependent manner
(Wang, Li et al. 2006). Hence, it is possible that CDK4/6-cyclin D1 inhibition via palbociclib
increases Nrf1 levels, thus increasing ROS activity. The levels of ROS and the subsequent
induction of senescence, in turn, might also be controlled by c-jun through a previously
elucidated mechanism involving the ROS genes, MnSOD and catalase(Katiyar, Casimiro et al.
2010). This provides a direct molecular mechanism by which CDK4/6-cyclin D regulates ROS
through Nrf2 and c-jun. Alternatively, the induction of ROS might be mediated directly by the
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Rb targets FOXM1 and BIRC5 (survivin), which have been shown to negatively regulate
oxidative stress (Kwee, Luque et al. 2008, Park, Carr et al. 2009, Lim, Heo et al. 2015),
providing a novel link between Rb and the ROS machinery. Concordantly, we and others have
reported a significant decrease in FOXM1 levels (Figures 1G and 4C) (Anders, Ke et al. 2011),
and observed a decrease in Survivin mRNA levels. This suggests that downregulation of
FOXM1 and BIRC5, among other ROS regulating proteins might be the potential mechanism
by which Rb regulates oxidative stress, under palbociclib treatment conditions, and this
warrants further investigation.
These results suggest that there are potential mechanisms that are induced at the
lower doses of palbociclib, which prevent the high ROS levels and the induction of senescence.
Understanding this / these process(es) would help improve the efficacy of the drug at the lower
doses as we have addressed in Chapters 4 and 5.
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CHAPTER 4: INDUCTION OF AUTOPHAGY IN RESPONSE TO CDK4/6 INHIBITION
IN ER+ BREAST CANCER

4.1. INTRODUCTION
4.1.1. AUTOPHAGY – DEFINITION AND REGULATION
Autophagy, which is derived from the Greek word “eating of self” is a catabolic process
in cells that recycles cellular constituents as an efficient way of generating energy (Deter and
De Duve 1967). There are three types of autophagy: i) Macroautophagy, the most common
form of autophagy mediated by cellular structures such as autophagosomes and lysosomes, ii)
Micro autophagy, where the cellular components are directly transported to the lysosomes for
degradation and iii) Chaperone mediated autophagy (CMA), where the chaperone protein
Hsp70 mediates transport of the cargo to the lysosome by association with the lysosomal
protein, LAMP2A (Saftig, Beertsen et al. 2008, Glick, Barth et al. 2010).
Macroautophagy, the most well-characterized and common form of autophagy
(illustrated in Figure 20) begins with the formation of an isolation membrane, which surrounds
the cargo or the cellular components to the degraded and the develops into a doublemembraned vesicle called “autophagosomes” (Mizushima 2007). This is the structure that can
be visualized as double-membrane electron dense vesicles by Transmission Electron
Microscopy (TEM), which is the gold standard experiment to examine the induction of
autophagy (Yla-Anttila, Vihinen et al. 2009). The autophagosomes, containing the cargo, fuse
with the lysosomes, forming structures called autophagolysosomes, where the lysosomal acids
facilitate degradation of the cargo, thus generating energy (Glick, Barth et al. 2010). Autophagy
can be specific (degrades a single organelle) or non-specific (degrades multiple components),
and can target several types of cellular components for degradation including individual
proteins, protein aggregates, or entire organelles such as mitochondria (mitophagy), nucleus
(nucleophagy), peroxisomes (pexophagy) and ribosomes (ribophagy) (Glick, Barth et al. 2010).
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Figure 20: Regulation of autophagy: Schematic showing the steps and processes
involved in autophagy and its molecular regualtion.

While the molecular regulation of the autophagy pathway has not been fully
characterized, numerous studies have identified key points of regulation within the pathway and
characterized genes involved in this process. This primarily comprises of the core autophagy
related genes or Atg genes, which were originally identified in yeast, but have mammalian
homologs (Lamb, Yoshimori et al. 2013). About 32 genes belonging to the Atg family have
been identified and characterized to play key roles at different steps of the autophagic process
(Lamb, Yoshimori et al. 2013). Some of the crucial autophagy steps regulated by the Atg
proteins are detailed here (Figure 20). The process of nucleation or phagophore formation is
controlled by Atg6 or Beclin-1 which dissociates from the Bcl2/Beclin-1 complex to form a
complex with the class III PI3K protein Vps34, at the stage of autophagy initiation (Glick, Barth
et al. 2010). The next crucial step is the formation of the Atg5-Atg12-Atg16L complex, which is
facilitated by Atg7 and Atg10 and is required for the elongation of the phagophore and the
formation of the autophagosomes (Lamb, Yoshimori et al. 2013). Finally, the conjugation of the
microtubule-associated protein light chain 3 (LC3B) protein with phosphatidylethanolamine
(PE) to form the active LC3B-II is regulated by Atg3, Atg4 and Atg7 (Satoo, Noda et al. 2009).
Apart from these core autophagy proteins, there are several other molecular pathways that
regulate the process such as AMPK, PI3K/AKT and mTOR pathways (Mizushima 2007).
Deregulation of the autophagic process resulting from gains and losses of the
autophagy genes has been linked to numerous diseases including cancer, cardiovascular
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disease and neurodegenerative disorders (Mizushima 2007, Glick, Barth et al. 2010).
Deregulation of autophagy plays an integral role in neurodegenerative diseases such as
Alzheimer’s, ALS and Parkinson’s disease. For example, the ubiquitin ligase, Parkin and its
upstream kinase PINK1, which play key role in mitophagy are frequently mutated in
Parkinson’s disease (Lynch-Day, Mao et al. 2012). Further, in Alzheimer’s disease, autophagy
facilitates the removal of protein aggregates formed due to mutations in the tau gene (ZareShahabadi, Masliah et al. 2015). This has led to research aimed at developing drugs that
upregulate autophagy in a tissue specific manner in these disease settings.

4.1.2. ROLE OF AUTOPHAGY IN CANCER
The precise role of autophagy in oncogenesis has been a widely-debated topic for
numerous years, since studies have shown opposing roles for autophagy in cancer – as a prosurvival process (oncogenic role) and as a pro-death mechanism (tumor suppressor role)
(White, Mehnert et al. 2015). In normal cells, autophagy primarily plays a housekeeping role
wherein it removes the defective and damaged proteins and organelles, to maintain the
integrity of cells, survive stress and provide energy when needed (Mizushima 2007). Research
has shown that the role of autophagy in cancer is highly context-dependent – dependent on the
type of tumor, stage of development of the tumor, whether it is basal or induced autophagy, etc.
(White, Mehnert et al. 2015). Autophagy has been primarily shown to a play a tumor
suppressing role early on in the tumorigenesis, but later utilized by tumors as a mechanism to
maintain proliferation capacity even in the presence stresses such as hypoxia, metabolic
stress, hypoxia or drug induced stress (Mathew, Karantza-Wadsworth et al. 2007, White,
Mehnert et al. 2015).
One of the crucial autophagy proteins, Beclin-1, a Bcl-2 interacting protein, is
monoallelically deleted in about 40- 75% of all human cancers, including breast, ovarian and
prostate cancers (Aita, Liang et al. 1999). Reintroduction of Beclin-1 into established cancer
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cells such as MCF7, which exhibits a heterozygous loss of Beclin-1 resulted in a significant
reduction in cellular proliferation, clonogenicity and tumorigenic potential in vivo (Aita, Liang et
al. 1999). Further, allelic loss of Beclin-1 makes mice more susceptible to spontaneous tumor
formation such as lymphoma, breast, lung liver cancers, and also makes them prone to Wnt1
mediated mammary tumorigenesis (Cicchini, Chakrabarti et al. 2014, White, Mehnert et al.
2015). Similar observations have been seen with other autophagy genes such as Atg5, whose
loss has been shown to promote extensive liver damage and carcinoma, and the formation of
benign tumors in the case of pancreatic cancer (Takamura, Komatsu et al. 2011, Rosenfeldt,
O'Prey et al. 2013). These studies elucidate the tumor suppressive role of autophagy mainly at
the early stages of tumor development.
However, at the later stages of tumor development, autophagy is believed to play a prosurvival function, since the cells can now use autophagy as a recycling facility to backup
energy to survive under stress and maintain viability (Mathew, Karantza-Wadsworth et al. 2007,
White 2015). Atg7 deletion in a K-ras G12D driven lung cancer mouse model resulted in tumor
cells accumulating defective mitochondria, activating autophagy and the p53 tumor suppressor
protein resulting in lower cell proliferation and increased apoptosis (Guo, Karsli-Uzunbas et al.
2013). Further the tumors developed upon knockdown of Atg7 in mouse models at early stages
remained benign (Takamura, Komatsu et al. 2011). Also, deficiency of p62 causes suppression
of autophagy induced tumorigenesis in cell lines and mouse models (Jiang, Overholtzer et al.
2015, White, Mehnert et al. 2015). Moreover, recent studies in pancreatic cancer and other
Ras-driven tumors have shown that these cancers are addicted to autophagy to survive
metabolic stress and maintain oxidative metabolism and survive (White, Mehnert et al. 2015).
Finally, studies have shown an association between higher expression of autophagy proteins
like LC3B and aggressiveness of the tumor or the presence of residual disease post
chemotherapy (Karantza-Wadsworth and White 2007, Chen, Jiang et al. 2013).
Thus, these studies provide evidence for the dual role played by autophagy in cancers,
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and highlights the oncogenic or pro-survival role of autophagy in developed tumors, which be
required for the maintenance of the tumor phenotype and drug resistance.

4.1.3. CDK4/6 INHIBITION AND AUTOPHAGY
While the role of the G1 checkpoint proteins CDK4/6-cyclin D in cell cycle and cellular
proliferation is well established, its role in autophagy is very poorly understood. A study in a
breast cancer model showed that cyclin D1 can suppresses autophagy in mammary
tumorigenesis, since mice deficient in cyclin D1 upregulate autophagy and failed to induce
ErbB2 induced senescence (Brown, Jeselsohn et al. 2012). Further, genetic or
pharmacological downregulation of cyclin D1 in human mammary epithelial cells (HMEC)
showed significant upregulation of autophagy, the inhibition of which resulted in an increase in
senescence (Brown, Jeselsohn et al. 2012).
Lastly, two recent studies suggest a role for CDK4/6 inhibition in inducing autophagy. A
study in cancer-associated fibroblasts showed that CDK inhibitors such as p16, p21 and
pharmacological CDK inhibitors such as palbociclib can upregulate proteins involved in both
senescence and autophagy (Capparelli, Chiavarina et al. 2012). In addition, a recent study in
promyelocytic leukemia reported that palbociclib induces autophagy-dependent degradation of
the DNA methyl transferase DNMT1, which facilitates the induction of senescence in these
cancers (Acevedo, Vernier et al. 2016).

4.1.4. GAP IN KNOWLEDGE
While these previous studies highlight the importance of autophagy in cancers and its role as a
stress response process, the following questions remain to be addressed:
1. Does knockdown of CDK4/6 induce autophagy in breast cancer?
2. Does palbociclib induce autophagy in ER positive breast cancer?
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3. Is the autophagy induced by palbociclib functional (ie) does it have an intact autophagic
flux?
4. Is there a dose dependence in the induction of autophagy by palbociclib – effects of ontarget vs off-target doses?
5. Does ROS play a role in mediating the induction of autophagy by palbociclib?
Thus, the experiments conducted in this chapter aimed at addressing these questions, since
the ability of CDK4/6 inhibition to induce autophagy and its potential implications has not been
well understood.
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4.2. RESULTS
4.2.1. INDUCTION OF AUTOPHAGY WITH CDK4/6 KNOCKDOWN AND LOW DOSES OF
PALBOCICLIB
Autophagy is an adaptive cellular stress response that recycles dysfunctional cellular
organelles for energy and facilitates cancer cell survival (Glick, Barth et al. 2010). Hence, we
hypothesized that CDK4/6 inhibition-mediated cell cycle arrest (on-target effect at 1μM
palbociclib) triggers autophagy as a stress response, which mediates the reversal of sustained
growth inhibition and prevents the induction of senescence at these doses. To interrogate the
induction of autophagy upon knockdown of CDK4 and CDK6, we used Monodansylcadavarine
(MDC) staining, a marker of acidic vesicles including autophagosomes (Biederbick, Kern et al.
1995). Results showed a significant increase in MDC positive cells in MCF7 and T47D cells
upon double siRNA knockdown of CDK4 and CDK6, when compared to NT (Figure 21A).
Further, to examine the induction of autophagy upon palbociclib treatment, we used
several different assays in MCF7 and T47D cells: i) Monodansylcadavarine (MDC) staining, a
marker of acidic vesicles including autophagosomes, ii) Transmission Electron Microscopy
(TEM), which helps visualize the presence of double-membrane electron dense
autophagosomes (Yla-Anttila, Vihinen et al. 2009), iii) GFP-LC3 puncta, iv) qRT-PCR and
Reverse Phase Protein Array (RPPA) analysis to measure levels of key autophagy related
proteins and v) Western blot analysis of LC3B II, the active and phosphatidylethanolamine (PE)
conjugated form of microtubule-associated protein light chain 3 (LC3B) located on the surface
of autophagosomes (Satoo, Noda et al. 2009) and SQSTM1/ p62, an autophagy receptor
whose degradation can be indicative of an intact autophagic flux (Mathew, Karp et al. 2009).
Results showed that treatment of MCF7 and T47D cells with increasing concentrations of
palbociclib significantly increased levels of MDC staining (Figure 21B) and expression of key
autophagy proteins, such as BNIP3 (Figure 21C), Atg-7, Beclin-1 (Figure 21D), while
decreasing levels of BCl2 (a known inhibitor of autophagy (Pattingre, Tassa et al. 2005))
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(Figure 21D). Further, western blot analysis showed increase in LC3B II protein levels, while
decreasing SQSTM1 levels, indicating the induction of autophagy with palbociclib treatment
(Figure 21E) in ER positive breast cancer cell lines. Additionally, Transmission Electron
Microscopy (TEM) performed by comparing the Control (DMSO treated) vs the palbociclib
treated cells, showed significant accumulation of double-membrane electron-dense vesicles,
which are indicative of autophagosomes upon treatment with low dose (1uM) of palbociclib
(Figure 22A – red arrows). Further, examination of GFP positive puncta in MCF7 cells stably
expressing GFP-LC3 showed accumulation of LC3 puncta (indicative of autophagosomes)
upon treatment with 1uM palbociclib (Figure 22B).
Collectively, these results indicate that CDK4/6 inhibition and palbociclib treatment at
low concentrations induces autophagy in ER positive breast cancer cell lines.
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4.2.2. INDUCTION OF INTACT AUTOPHAGIC FLUX WITH LOW DOSES OF PALBOCICLIB
While our results show the induction of autophagy with CDK4/6 inhibition, examination
of the presence of an intact autophagic flux, which indicates completion of the autophagy
pathway and efficient recycling of the cellular cargo, is more critical than the induction of
autophagy. Hence, we examined the presence of an intact autophagic flux following palbociclib
treatment by: i) flux ratio (LC3B-II to LC3B-I and LC3B-II to p62), ii) treatment with lysosomal
block chloroquine (CQ), which elevates lysosomal pH and impairs autophagic flux
(Chittaranjan, Bortnik et al. 2015), iii) GFP-LC3 puncta with CQ treatment and iv) RFP-GFPLC3 dual-reporter assay (Kimura, Noda et al. 2007).
Treatment with low dose (concentrations lower than 2.5μM) palbociclib, exhibited higher
flux ratios, as indicated by the ratio of LC3BII protein levels to LC3BI (Figure 23A) and the ratio
of the protein levels of LC3BII to SQSTM1 (Figure 23B). Further, short term (1 hour) with
treatment with the lysosomal block, 25uM chloroquine significantly increases the protein levels
of LC3B-II, compared to treatment with palbociclib alone, as measured by western blotting
analysis (Figure 23C) and as quantified by densitometry analysis (Figure 23D). Additionally,
CQ treatment significantly increased GFP positive LC3 puncta compared to palbociclib
treatment alone at the on-target low doses of 1uM (Figure 22B). Finally, to confirm the
induction of an intact autophagy, we performed the RFP-GFP-LC3 dual-reporter assay
(Kimura, Noda et al. 2007), where pH-dependent degradation of GFP in the lysosomes enables
the differential visualization of autophagosomes ( as RFP+ve GFP+ve puncta – yellow puncta)
and autophagolysosomes (as RFP+ve puncta). Our results reveal that the presence of an intact
autophagic flux, which is indicated here by the increase in both RFP+ve GFP+ve puncta
(autophagosomes) and RFP+ve puncta (autophagolysosomes) as observed in cells treated
with 1uM palbociclib treatment (Figure 23E), while an impaired autophagic flux would be
indicated by the accumulation of only autophagosomes (yellow puncta).
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Thus, results demonstrate the presence of an intact autophagy flux at the low and ontarget concentrations of palbociclib.
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Figure 23: Induction of intact autophagy with low doses of palbociclib: A) Autophagic flux,
calculated as ratio of LC3B-II to LC3B-I from densitometry values (normalized to corresponding
levels of actin) of western blots from Figure 15E. B) Autophagic flux, calculated as ratio of LC3B-II
to p62 from densitometry values (normalized to corresponding levels of actin) of western blots
from Figure 15E. C) Western blot of LC3B and p62 in MCF7 and T47D cells treated with a
combination of 25µM Chloroquine (CQ) for 1 hour and palbociclib for 6 days. D) Densitometry
values for western blots in Figure 17C to obtain LC3B-II protein levels (normalized to
corresponding levels of actin). E) Quantification of RFP-GFP-LC3 puncta representative confocal
images of RFP-GFP-LC3 expressing MCF7 cells treated with 1 μM palbociclib for 48 hours. Scale
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4.2.3. DEREGULATED AUTOPHAGIC FLUX AT HIGH DOSES OF PALBOCICLIB
While our results show that autophagy induced by palbociclib at low (1μM) and ontarget doses have an intact flux (Figure 16 and 17), the induction of autophagy at the higher
palbociclib doses remain unexplored. Understanding this would help shed light on the
processes regulating the dose-dependent effect of palbociclib in ER positive breast cancer
cells. To interrogate this, we performed the autophagy assays as described in Figures 16 and
17 upon treatment with higher doses (>2.5μM) of palbociclib in the ER positive breast cancer
cell lines, MCF7 and T47D.
Measurement of autophagy by MDC analysis showed significant increase in the
percentage of MDC positive cells (Figure 24A), and western blotting analysis showed increase
in the protein levels of LC3B-II, but no decrease in p62 (Figure 24B) in MCF7 and T47D cell
lines. This indicated that high doses of palbociclib also induce autophagy, but the autophagy
induced at these doses has a deregulated flux, defined by the presence of an incomplete
autophagic process and no recycling of the cellular cargo occurs. This was confirmed by high
flux ratios as calculated by the ratio of LC3B-II to LC3B-I (Figure 23A) and the ratio of LC3B-II
to p62 (Figure 23B). Further, to examine the autophagic flux induced at the higher dose, MCF7
and T47D cells treated with palbociclib, were subjected to short term (24 hour) treatment with
the lysosomal block, chloroquine (CQ) and examined for the presence of MDC positivity.
Results show no significant change in the MDC levels, indicating that the flux was already
impaired (Figure 24C). Finally, deregulated autophagy at the higher off-target doses of
palbociclib was also corroborated by the presence of either dysfunctional lysosomes (multilamellar structures indicated by blue colored arrows) or early autophagosomes (non-electron
dense structures indicated by black colored arrows) in Transmission Electron Microscopy
(TEM) images (Figure 24D).
These results indicate that while higher doses of palbociclib induces autophagy at the
higher doses as well, the autophagic flux appears to be deregulated.
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Figure 24: Deregulated autophagy flux at high doses of palbociclib: A) Measurement of MDC
positive MCF7 and T47D cells treated with varying concentrations of palbociclib for 6 days. B)
Western blot analysis of autophagy proteins, LC3B I, II and p62 in MCF7 and T47D cells upon
treatment with varying concentrations of palbociclib for 6 days. C) Measurement of MDC positive
MCF7 and T47D cells treated with a combination of 25µM Chloroquine (CQ) for 1 hour and
palbociclib for 6 days. D) Representative Transmission Electron microscopy (TEM)
microphotographs of MCF7 and T47D cells treated with DMSO (Cnt) or 5 μM palbociclib (Palbo) for
6 days. Blue arrows indicate multi-lamellate structures indicative of dysfunctional lysosomes. Black
arrows indicate early stage autophagosomes. Scale bars equal 500 nm. All data represent mean±SD
from three independent experiments; p-values were calculated in comparison to cells treated with
DMSO (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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4.2.4. DEPENDENCE OF PALBOCICLIB-INDUCED AUTOPHAGY ON THE INDUCTION OF
ROS
Results from Figure 9 show that treatment of ER positive breast cancer cell lines with
palbociclib results in the induction of ROS at both on- and off-target doses. Given that
palbociclib treatment at low on-target doses induces autophagy, and that ROS is known to
induce autophagy (Kongara and Karantza 2012), we hypothesized that CDK4/6 inhibition
mediated by on-target effects of palbociclib (1μM) may induce ROS, which in turn triggers
autophagy.
Initially, we confirmed the induction of ROS at the on-target doses of palbociclib by
Reverse phase protein array (RPPA) analysis for ROS-related proteins, SOD-1, CAV-1 and
SOD-2, which showed a significant decrease in ROS ablating proteins SOD-1 (Papa, Manfredi
et al. 2014) and CAV-1 (Chen, Barman et al. 2014), while an increase SOD-2, which is known
to positively regulate ROS was observed (Figure 25A). This in combination with the results
showed in Figure 9B confirm the induction of ROS at the low (on-target) doses of palbociclib in
ER positive breast cancer cell lines.
Next, to directly interrogate the dependence of palbociclib-induced autophagy on ROS
induction, ROS was ablated using the ROS scavengers, NAC and Trolox (Hamad, Arda et al.
2010, Sun 2010) in palbociclib treated ER positive cancer cells, which resulted in a significant
decrease in MDC staining (Figure 25B). A concomitant decrease in LC3B-II protein expression
levels was also observed with ROS ablation in cells treated with low doses of palbociclib
(Figure 25C, 25D).
Thus, these results suggest that palbociclib-induced autophagy is dependent on ROS
induction and the levels of ROS levels.
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Figure 25: Dependence of palbociclib induced autophagy on the induction of ROS: A)
Expression (normalized log 2 level) of SOD-1, CAV-1 and SOD-2 determined by RPPA analysis of
MCF7 and T47D cell lines treated with palbociclib for 6 days. B) Quantification (MFI) of MDC
staining in MCF7 and T47D cells treated with a combination of ROS scavenger (10 mM NAC or
0.1 mM trolox) and DMSO or 1 μM palbociclib for 6 days. C,D) Western blot analysis showing
levels of LC3B and p62 proteins (C) and densitometry values of LC3B-II (D) in MCF7 and T47D
cells treated as in B. All data represent mean±SD from three independent experiments; p-values
were calculated in comparison to cells treated with DMSO (Control) or siNT unless indicated. ns:
p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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4.2.5. PALBOCICLIB MEDIATED INDUCTION OF DOSE-DEPENDENT AUTOPHAGY IN
VIVO
To assess the ability of the CDK4/6 inhibitor palbociclib to induce autophagy in vivo,
ER+ve mouse orthotopic xenograft tumors were treated with varying concentrations of
Palbociclib (25 mg/kg, 50mg/kg, 75 mg/kg or 150 mg/kg/day) daily via oral gavage for 7 days
and subject to autophagy assays: i) RPPA analysis, ii) Western blot analysis and flux
quantification and iii) Transmission electron microscopy (TEM).
Analysis of the altered pathways from RPPA analysis showed up-regulation of
autophagy related proteins (Figure 18B). Specifically, a significant increase in the protein
levels of LC3B and Atg-7 was observed in the palbociclib treated tumors in a dose-dependent
manner (Figure 26A). Further, western blot analysis of the tumors treated with palbociclib
exhibited an increase in the levels of LC3B-II, indicating the induction of autophagy in vivo in a
dose-dependent manner (Figure 26B). Specifically, tumor tissues treated with 25mg/kg
palbociclib showed increased protein levels of LC3BII and decreased levels of SQSTM1/p62
via western blot analysis, thus demonstrating an induction of autophagy with an intact flux at
this concentration (Figure 26B). This was confirmed by high autophagic flux ratio (calculated
by LC3B-II to LC3B-I) upon treatment with 25mg/kg palbociclib (Figure 26C). Additionally, TEM
showed the presence of double-membrane electron dense autophagosomes on the residual
tumors treated with 25mg/kg palbociclib (Figure 26D), demonstrating the induction of
autophagy.
However, in comparison, while treatment with 150mg/kg Palbociclib increased protein
levels of LC3B-II and Atg-7 (Figure 26A), this concentration failed to decrease SQSTM1 levels
(Figure 26B), exhibited low autophagic flux ratio (figure 26C), and displayed presence of
dysfunctional lysosomes (Figure 26D - multi-lamellar structures indicated by blue colored
arrows). These results are indicative of autophagy with impaired flux induced with high dose of
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palbociclib (150mg/kg), and are similar to results observed in vitro with the higher off-target
doses (>2.5μM) of palbociclib.
Collectively, these results show the induction of autophagy in vivo with palbociclib
treatment in a dose-dependent manner.
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Figure 26: Induction of dose-dependent autophagy in vivo by palbociclib: A) Expression
(normalized log 2 level) of LC3B and Atg-7 protein levels as determined from RPPA analysis of
tumors harvested after treatment with Vehicle (0.5% Methylcellulose) or varying doses of
palbociclib via oral gavage for 7 days. B) Western blot for autophagy proteins, LC3B and p62 in
mice tumors upon 7 days of drug treatment as described in A. C) Autophagic flux, calculated as
ratio of LC3B-II to LC3B-I from densitometry values (normalized to the corresponding levels of
actin) of western blots from B. D) Representative TEM microphotographs of tumors harvested from
mice treated with vehicle (0.5% MC), 25 mg/kg or 150 mg/kg of palbociclib for 7 days. Red arrows
indicate double-membraned autophagosomes. Blue arrows indicate multi-lamellate structures
indicative of dysfunctional lysosomes. Scale bars equal 500 nm. All data represent mean±SD from
three independent experiments; p-values were calculated in comparison to mice treated with
vehicle (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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4.3. DISCUSSION
Collectively, results from this chapter demonstrate that genetic downregulation of
CDK4/6 and pharmacological inhibition via palbociclib induces autophagy in a dose-dependent
manner. Palbociclib treatment of ER positive breast cancer induces ROS, which at low doses
triggers autophagy, while elevated levels lead to the induction of sustained growth inhibition
and induction of senescence (Figure 27B).
While the relationship between CDK4/6-cyclin D and autophagy is very poorly
understood, recent studies have suggested that CDK4/6 inhibitors such as palbociclib can
induce autophagy in fibroblast and promyelocytic leukemia as described in detail in the
introduction of this chapter (Brown, Jeselsohn et al. 2012, Capparelli, Chiavarina et al. 2012,
Acevedo, Vernier et al. 2016). Studies conducted in this chapter provided detailed evidence
corroborating this hypothesis and establishing that palbociclib treatment of the ER positive cell
lines in fact does trigger autophagy. Further, a biphasic effect on autophagy was observed with
palbociclib treatment, both in vitro and in vivo, wherein at lower or on-target doses, the
autophagy induced had an intact flux, while higher and possibly off-target doses of palbociclib
induced a defective autophagy (Figure 27A).
However, the molecular mechanism by which autophagy is induced by palbociclib has
not been understood yet. A possible mechanism could be that the drug directly regulates
autophagy by altering expression of the autophagic proteins required for this process such as
Beclin-1 or other class III PI3K proteins that are present in complex with Beclin-1, such as
Vps34 (Hammond, Brunet et al. 1998). Phophorylation of Beclin-1 and / or Vps34 has been
shown to regualate the induction of autophagy in cancer, CDKs have been known to directly
phosphorylate these proteins (Abrahamsen, Stenmark et al. 2012). This suggests a potential
mechanism by which palbociclib induces autophagy that needs to be explored further.
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A recent study in lung cancer revealed that palbociclib has unique kinase targets, apart
from CDK4 and CDK6, such as PIK3CD and PIK3R4 (Sumi, Kuenzi et al. 2015). Intriguingly,
PIK3R4 / Vps15 is a class III Phosphatidylinositol 3-Kinase (PI3K) that has been shown to be
required for autophagic clearance of proteins, and defects in Vps15 in the skeletal muscles
leads to autophagic vascular myopathy and dysfunctional lysosomes (Lindmo, Brech et al.
2008, Nemazanyy, Blaauw et al. 2013). This closely resembles the multi-lamellar electron
dense structures which represent defective lysosomes when treated with the higher doses
(5uM in vitro and 150 mg/kg in vivo) of palbociclib. Hence, it is highly likely that Palbociclib hits
secondary targets at the higher concentrations (5uM or 150mg/kg), and this accounts for the
inhibition of autophagic flux at these doses and the observed off-target effects with siRNA
against CDK4/6. This might also explain why treatment with the other CDK4/6 inhibitors
(ribociclib and abemaciclib) failed to elicit a biphasic response, given that these secondary
kinase targets were shown to be specific to palbociclib and not hit by ribociclib (Sumi, Kuenzi et
al. 2015).
Autophagy is regulated by several stress signals including oxidative stress (PoilletPerez, Despouy et al. 2015). Accumulation of oxidative stress induces ROS, which has been
shown to have both a tumor promoting role and tumor suppressing role and this is most often
controlled by the levels of ROS molecules (Azad, Chen et al. 2009, Liou and Storz 2010).
Lower or moderate induction of ROS typically promotes cell cycle progress and stress
response and survival processes such as autophagy (Boonstra and Post 2004). Results from
this chapter show that the low / moderate levels of ROS induced with low doses of palbociclib,
induces ROS-dependent autophagy in the ER positive breast cancer cells. Since autophagy
has been shown to eliminate ROS (Scherz-Shouval and Elazar 2011), it is possible that
autophagy induction also plays a role in maintaining the ROS levels low enough, such that it
prevents the induction of irreversible cell cycle arrest and senescence. This will be examined in
Chapter 5.
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Collectively, the studies presented in this Chapter results show that palbociclib
treatment intact autophagy in ER positive breast cancer in vitro and in vivo. Further, these
studies suggest that the autophagy induced is a stress response to treatment with palbociclib
and it may mediate resistance to palbociclib mediated sustained growth inhibition and
senescence at the on-target doses. The implications of this hypothesis is that inhibition of
autophagy could improve the efficacy of CDK4/6 inhibitor treatment, a topic that has been
explored in detail in Chapter 5.
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CHAPTER 5: IN VITRO AND IN VIVO SYNERGY BETWEEN CDK4/6 AND
AUTOPHAGY INHIBITION IN ER+ BREAST CANCER

5.1. INTRODUCTION
5.1.1. AUTOPHAGY AS A STRESS RESPONSE PROCESS IN CANCER
Autophagy, the cell’s recycling machinery, can be considered as a quality control
mechanism within cells, which recycles damaged cellular components and organelles to
maintain optimal cellular function and generate energy (White 2015). In established cancers,
the physiological role of autophagy is that it is a stress response process, enabling cancer cells
to combat various types of stresses, including nutrient deprivation, ER (endoplasmic reticulum)
stress, DNA damage, oxidative stress and drug-induced stress (White, Mehnert et al. 2015).
Many of these stresses are intrinsic to drug resistance suggesting that autophagy may mediate
resistance to numerous cancer targeting therapies
For example, studies in the past few years have demonstrated the induction of prosurvival (oncogenic) autophagy in response to drugs such as chemotherapy and targeted
therapy (Sui, Chen et al. 2013) Several of these agents are listed in Table 6, which lists the
agents that have been shown to induce autophagy along with the type of stress they induce
and the pathway the drugs activate leading to autophagy. These studies have shown that
autophagy is induced in response to chemotherapy such as platinum agents (i.e. cisplatin and
oxalating) in breast, ovarian and other solid cancers allowing the tumor cells to be rescued from
the toxic effects of these therapies (Li, Hou et al. 2010, Liu, Yang et al. 2011, Sun, Chen et al.
2011, Sasaki, Tsuno et al. 2012, Wang and Wu 2014). Similar induction of autophagy has been
reported in response to other targeted agents such as the angiogenesis inhibitor bevacizumab,
sarafenib in hepatocellular carcinoma (Shi, Ding et al. 2011, Guo, Li et al. 2013) and tyrosine
kinase inhibitors such as erlotinib, NVP-BEZ235 and imatinib in glioma, lung and renal cancer
(Shingu, Fujiwara et al. 2009, Han, Pan et al. 2011, Zhao, Yang et al. 2011, Li, Jin et al. 2013).
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Drug

Target / Stress

Cancer type

Reference

Aurora kinase A

mTOR

Breast

(Zou, Yuan et al. 2012)

Suberoylanilide
hydroxamic acid
(SAHA)

HDAC inhibitor

CML

(Carew, Nawrocki et al.
2007)

Tamoxifen

Antiestogen

Breast

(Sun, Chen et al. 2011)

Epirubicin (EPI)

Anthracyclines

Breast

(Schoenlein, PeriyasamyThandavan et al. 2009)

5-Fluorouracil

Thymidylate synthase
inhibitor

Colorectal

(Li, Hou et al. 2010, Sasaki,
Tsuno et al. 2012)

Irinotecan

MAPK14/p38α

Colorectal

(Paillas, Causse et al. 2012)

Esophageal

(Liu, Yang et al. 2011)

Ovarian

(Wang and Wu 2014)

Cisplatin

Genotoxic stress

Oxaliplatin

Genotoxic stress

Hepatocellular
carcinoma

(Guo, Li et al. 2013)

Bevacizumab

Angiogenesis
inhibitor

Hepatocellular
carcinoma

(Guo, Li et al. 2013)

Sorafenib

ER stress

Hepatocellular
carcinoma

(Shi, Ding et al. 2011)

High-mobility group
box 1 protein
(HMGB1)

DAMP molecule

CML

(Zhao, Yang et al. 2011)

Gefitinib or Erlotinib

EGFR tyrosine kinase
inhibitor

Lung

(Han, Pan et al. 2011)

Topotecan

Genotoxic stress

Lung

(Kang, Tang et al. 2010)

NVP-BEZ235

PI3K/AKT/mTOR
inhibitor

Renal

(Li, Jin et al. 2013)

Ursolic acid

Genotoxic stress

Prostate

(Shin, Kim et al. 2012)

Imatinib

Tyrosine kinase
inhibitor

Glioma

(Shingu, Fujiwara et al.
2009)

Table 6: Drug-induced autophagy in cancer: Summary of studies showing the induction of prosurvival autophagy in response to chemotherapy and targeted therapy in cancers.

In breast cancer, autophagy has been shown to be induced and mediate resistance to
epirubicin, aurora kinase inhibitor and antiestrogen treatment with tamoxifen (Schoenlein,
Periyasamy-Thandavan et al. 2009, Sun, Chen et al. 2011, Zou, Yuan et al. 2012). Thus, these
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studies indicate that autophagy may be a promising target in cancer, and has led to further
research aimed at understanding the role of autophagy in response to drug induced stress.

5.1.2. PHARMACOLOGICAL INHIBITORS OF AUTOPHAGY
For autophagy process to be successful in recycling components, the autophagic flux
has to be intact and the process needs to undergo completion, which involves the formation of
the autophagosomes and its subsequent fusion with the lysosomes leading to cargo
degradation (Mizushima 2007). Hence, autophagy can be inhibited at multiple steps and the
most common points of inhibition are i) initiation, where inhibitors prevent the formation of the
autophagosomes and ii) lysosomal fusion, where inhibitors prevent the fusion of the
autophagosomes to the lysosome, thus inhibiting the autophagic flux and resulting in
accumulation of autophagic vesicles (Yang, Hu et al. 2013, Wang, Hu et al. 2016). Thus,
research over the years has led to the development of drugs targeting autophagy at these two
points of intervention (Table 7) (Sui, Chen et al. 2013, Yang, Hu et al. 2013, Wang, Hu et al.
2016).
Given the key role of the class III PI3K proteins in the formation of the phagophore and
autophagosomes (initiation and elongation steps of autophagy), several drugs targeting these
proteins have been developed including 3-Methyladenine, Wortmannin, LY294002, etc, which
have the ability to effectively suppress autophagy (Table 7) (Yang, Hu et al. 2013). Recently,
Spautin-1, a drug that indirectly targets the class III PI3K complexes was developed, which
inhibits the activity of USP10 and USP13, causing proteosomal degradation of Class III PI3K
complexes and blocking autophagy induction (Shao, Li et al. 2014). Additionally, drugs
(MRT68921 and MRT67307) that specifically inhibit the kinase activity of Ulk1 and Ulk2 (crucial
for phagosome formation) have also been recently developed (Sui, Chen et al. 2013).
Drugs that inhibit the fusion of autophagosomes and lysosomes function either by
altering the pH of the lysosomes or by targeting the vacuolar-type H (+)-ATPases (V-ATPases)
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Drug

Target

Stage of autophagy inhibited

Chloroquine

Lysosomal pH

Fusion with lysosomes

Hydroxychloroquine

Lysosomal pH

Fusion with lysosomes

Bafilomycin A 1

Vacuolar-type H(+)ATPase inhibitor

Initiation / Expansion

3-Methyladenine

Class III PI3K inhibitor

Initiation / Expansion

Wortmannin

Class III PI3K inhibitor

Initiation / Expansion

LY294002

Class III PI3K inhibitor

Initiation / Expansion

Pyrvinium

Class III PI3K inhibitor

Initiation / Expansion

Lys-05

Lysosomal pH

Fusion with lysosomes

Spautin-1

USP10/13 inhbitor

Initiation / Expansion

MRT68921, MRT67307

Ulk1/2 inhibitor

Initiation / Expansion

Table 7: Autophagy targeting drugs: Table summarizing the list of that target autophagy
and the stage in the pathway they inhibit

that are found on the lysosomal membrane (Yang, Hu et al. 2013). BaflomycinA1, a specific
inhibitor of the V-ATPase, blocks the acidification of the lysosome and prevents maturation of
the autophagosomes, thus inhibiting autophagic flux (Yamamoto, Tagawa et al. 1998). The
other class of late stage autophagy inhibitors are lysosomal lumen alkalizers, which includes
the most commonly used autophagy drugs, chloroquine (CQ) and its analog hydroxychloroquine (HCQ) (Homewood, Warhurst et al. 1972, Wang, Hu et al. 2016). They prevent the fusion
of the lysosomes with the autophagic vesicles, thus inhibiting flux and resulting in accumulation
of autophagosomes in cells (Wang, Hu et al. 2016). These drugs are widely used as antimalarial and anti-rheumatoid agents and are currently the only clinically relevant autophagy
inhibitors (Homewood, Warhurst et al. 1972). A more recently developed modified analog of
HCQ is Lys-05, which has been shown to be 10-fold more potent as an autophagy inhibitor
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than HCQ in vitro and in vivo (McAfee, Zhang et al. 2012). It inhibits autophagy similar to CQ
and HCQ, by accumulating within and deacidifying the lysosome, resulting in impaired
autophagy (Amaravadi and Winkler 2012, McAfee, Zhang et al. 2012).
While there are several drugs available for targeting autophagy, the specificity of these
drug to the autophagy process has been under question, highlighting the need to develop more
specific and potent autophagy inhibitors.

5.1.3. CLINICAL DEVELOPMENT OF AUTOPHAGY INHIBITORS
While there are several autophagy inhibitors that are currently used for pre-clinical
studies (Table 7), their lack of specificity in inhibiting the autophagy pathways and high toxicity
in vivo has limited their translation into the clinic (Sui, Chen et al. 2013). Chloroquine (CQ) and
hydroxychloroquine (HCQ) are the only autophagy inhibiting drugs that are currently FDA
approved for human use (Sui, Chen et al. 2013, Wang, Hu et al. 2016). Clinical studies have
shown with CQ and HCQ have shown that compared to CQ, HCQ can be safely dose
escalated in cancer patients (Gunja, Roberts et al. 2009). This, coupled with the strong
rationale of targeted autophagy in cancer has led to about 175 clinical trials currently open
around the world with HCQ, more than 90% of which are in cancers (http://clinicaltrials.gov/).
Table 8 provides a list of the phase II clinical trials that are currently in progress with HCQ in
combination with chemo or targeted therapy in various cancers. A recent phase I study in 22
patients with relapsed myeloma showed that the addition of HCQ to the proteasome inhibitor
resulted in partial response in 28% of the patients and a stable disease in 45% of the patients
(Vogl, Stadtmauer et al. 2014). Similar phase I studies in melanoma and solid tumors showed
that the addition of HCQ to the current therapy of mTOR or HDAC inhibitors resulted in
improved survival and improved response (Mahalingam, Mita et al. 2014, Rangwala, Chang et
al. 2014).
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Cancer type

Drugs

Phase

Identifier

Recurrent Breast
cancer

HCQ+everolimus

II

NCT3132406

Breast cancer

HCQ+ixabepilone

I/II

NCT00765765

Platinum resistant
Ovarian cancer

HCQ+itraconazole

I/II

NCT03081702

NSCLC

HCQ+gefitinib

I/II

NCT00765765

Advanced NSCLC

HCQ+carboplatin, paclitaxel,
bevacizumab

II

NCT01649947

NSCLC

HCQ+carboplatin /gemcitabine

II

NCT02722369

Advanced NSCLC and
(EGFR) mutations

HCQ+erlotinib

II

NCT00977470

Pancreatic cancer

HCQ+gemcitabine/abraxane

I/II

NCT01506973

Pancreatic cancer

HCQ+gemcitabine

I/II

NCT01128296

Pancreatic cancer

HCQ+gemcitabine/abraxane

II

NCT01978184

Pancreatic cancer

HCQ+capecitabine+radiation

II

NCT01494155

Hepatocellular
carcinoma

HCQ+sorafenib

II

NCT03037437

Prostate cancer

HCQ+docetaxal

II

NCT00786682

Prostate cancer

HCQ+abiraterone+ABT-263

II

NCT01828476

Colorectal cancer

HCQ+vorinostat+regorafenib

II

NCT02316340

Colorectal cancer

HCQ+XELOX+bevacizumab

II

NCT01006369

Colorectal cancer

HCQ+FOLFOX/bevacizumab

I/II

NCT01206530

Melanoma

HCQ+trematinib

I/II

NCT02257424

Renal cell carcinoma

HCQ and IL-2

I/II

NCT01550367

Renal cell carcinoma

HCQ and RAD001

I/II

NCT01510119

Soft tissue sarcoma

HCQ+sirolimus

II

NCT01842594

Glioblastoma

HCQ+temozolomide

I/II

NCT00486603

Multiple myeloma

HCQ+bortezomib

I/II

NCT00568880

CML

HCQ+imatinib

II

NCT01227135

Table 8: Phase-II clinical trials with HCQ: Table summarizing the phase II clinical trials that
are currently ongoing in cancers in combination
with the autophagy inhibitor hydroxychloroquine
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While hydroxychloroquine is currently used as a bonafide autophagy inhibitor, a
concern with the use HCQ is the high doses required in humans to achieve successful
blockade of autophagy. This emphasizes the need to identify more specific, potent and
clinically relevant inhibitors. The recently developed inhibitor Lys-05, has been shown to be 10fold more potent than HCQ and has a better therapeutic index (Amaravadi and Winkler 2012).
Hence numerous phase I and II clinical trials are currently underway utilizing Lys-05 in
combination with chemotherapy or targeted therapy in cancers (Rebecca and Amaravadi
2016).

5.1.4. GAP IN KNOWLEDGE
While results from Chapter 4 show that CDK4/6 inhibition via palbociclib results in the induction
of autophagy, the following questions remain:
1. What is the role of the autophagy induced by palbociclib? Is it tumor suppressing or prosurvival and tumor promoting?
2. What is the impact of genetically ablating autophagy in breast cancer cells?
3. Would pharmacological inhibition of autophagy be synergistic with palbociclib in breast
cancer cells?
4. Would pharmacological inhibition of autophagy be synergistic with other CDK4/6
inhibitors (ribociclib, abemaciclib) in breast cancer cells?
5. Would pharmacological inhibition of autophagy be synergistic with palbociclib in breast
cancer cells?
6. Would HCQ treatment be synergistic with palbociclib in breast cancer cells resistant to
the aromatase inhibitors?
7. What is the effect of combinatorial inhibition of the CDK4/6 and autophagy pathways in
vivo?
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Given the minimal work carried out in investigating the relationship between CDK4/6 and
autophagy, studies conducted in this chapter are aimed at addressing the above gaps in
knowledge.

125

5.2. RESULTS
5.2.1. IMPACT OF BECLIN1 OR ATG5 DOWNREGULATION ON PALBOCICLIB ACTION
To interrogate the hypothesis that autophagy protects ER positive breast cancer cells
from palbociclib-induced senescence molecularly, we downregulated two crucial autophagy
genes, Beclin-1 and Atg-5, which play key roles in the initiation and elongation of the
autophagosomes respectively (Hammond, Brunet et al. 1998, Liang, Yu et al. 2001, Kang, Zeh
et al. 2011) (Figures 28A, B). While shRNA mediate knockdown of Beclin-1 and Atg-5 had no
significant impact on the growth of ER positive breast cancer cell lines (Figure 28C),
downregulation of Beclin-1 or Atg-5 significantly increased the sensitivity of MCF7 and T47D
cells to palbociclib, resulting in a 5-fold decrease in IC50 values (as measured by dose
response assay, where cells were treated for 6 days with a 6-day recovery), when compared to
cells with Scrambled shRNA (SCR) (Figure 28D, E). Further, cell counting assay and cell cycle
analysis showed that Beclin-1 or Atg-5 knockdown resulted in an irreversible growth inhibition
and irreversible G1 arrest respectively, when treated with low (on-target) doses of palbociclib
(0.5μM and 1μM), compared to Scr cells which exhibited a reversible growth inhibition at these
concentrations (Figure 28F, 29A). Additionally, Beclin-1 or Atg-5 knockdown significantly
elevated SA-ß gal activity with 6 day treatment, even at low on-target palbociclib concentrations
(1μM), indicating the induction of senescence when autophagy is ablated (Figure 29B).
Thus, these results suggest that ablation of autophagy significantly augments the drug’s
ability to induce a sustained growth inhibition and senescence, suggesting a pro-survival and
drug resistance mediating role for the autophagy induced by CDK4/6 inhibition.
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Figure 28: Impact of Beclin-1 or Atg-5 downregulation on palbociclib mediated growth
inhibition: A) Schematic depicting locations of the shRNA sequences on the autophagyassociated Beclin-1 and Atg5 genes. B) Western blot for Beclin-1 and Atg-5 in MCF7 and T47D
cells after transfection with Scrambled (Scr), Beclin1 or Atg5 shRNA. C) Crystal violet OD
measured on day 12 from drug response studies performed in MCF7 Scr and Beclin1 or Atg5
knockdown cells. D,E) MCF7 and T47D cells with Beclin1 or Atg5 knocked down were treated with
varying concentrations of palbociclib for 6 days and subjected to dose response assay after 6 days
of recovery (D) and their corresponding half-maximal inhibitory concentrations (IC50) values (E). F)
Beclin-1 or Atg5-knockdown MCF7 and T47D cells were treated with 0.5 or 1 μM of palbociclib
(Palbo) for 6 days and recovery for 4 days (release) to examine reversibility and subjected to cell
counting to assess proliferation. p-values were calculated in comparison to cells treated with
Scramble shRNA [SCR] and 1 μM palbociclib. All data represent mean ± SD from three
independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 29: Impact of Beclin-1 or Atg-5 downregulation on palbociclib mediated G1
arrest and senescence: A) Cell cycle analysis to determine the percentage change in G1
phase in Beclin-1 or Atg5-knockdown MCF7 and T47D cells treated with 0.5 or 1 μM of
palbociclib (Palbo) for 6 days and recovery for 4 days (release) to examine reversibility. pvalues were calculated by comparing values at the end of drug treatment with those at the
end of drug + release. B) SA-ß galactosidase assay as a measurement of senescence with
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***p<0.001; ****p<0.0001.
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5.2.2. SYNERGY BETWEEN siRNA OR shRNA MEDIATED KNOCKDOWN OF CDK4/6 AND
AUTOPHAGY INHIBITION
Having shown that molecular ablation of autophagy sensitizes ER positive breast
cancer cells to CDK4/6 inhibition via palbociclib, we next investigated if combined molecular
downregulation of CDK4 and CDK6 would synergize with pharmacological autophagy
inhibition. To interrogate this, we first downregulated CDK4 and CDK6 via siRNA mediated
knockdown. Cell counting and clonogenic assays were performed to measure proliferation
showed while that dual siRNA against CDK4 and CDK6 had moderate effect on cell
proliferation, that its combination with autophagy inhibition (treatment with hydroxychloroquine)
resulted in enhanced and synergistic growth inhibitory effect (Figure 30A - compare red to
orange solid lines and 30B). Similarly, shRNA mediated knockdown of CDK4 and CDK6 was
also synergistic in combination with autophagy inhibition via HCQ, resulting in significantly
enhanced growth inhibition of the ER+ve cell lines, MCF7 and T47D (Figure 30C – compare
red to orange lines)
These results show that genetic ablation of CDK4 and CDK6 is synergistic with
pharmacological inhibition of autophagy.
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Figure 30: Synergy between siRNA or shRNA mediated knockdown of CDK4/6 and
autophagy inhibition: A,B) MCF7 and T47D cell lines were transfected with siNT or
siRNA against CDK4 and CDK6 for dual knockdown and cells were treated with DMSO
or 15uM HCQ for 6 days and subjected to A) Cell counting and B) Clonogenic assay to
assess proliferation. C) Cell counting to asses proliferation of MCF7 and T47D cells with
shRNA mediated dual knockdown of CDK4 and CDK6 and treatment with DMSO or 15
μM HCQ for 6 days and recovery for 4 days. All data represent mean ± SD from three
independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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5.2.3. IMPACT OF AUTOPHAGY INHIBITION ON PALBOCICLIB MEDIATED GROWTH
INHIBITION, CELL CYCLE ARREST, ROS AND SENESCENCE
We next interrogated if pharmacological inhibition of autophagy would synergize with
pharmacological CDK4/6 inhibition via low dose (on-target) palbociclib (< 2.5 µM) to induce
senescence. To this end, MCF7 and T47D cells were treated with the autophagy inhibitor,
Hydroxychloroquine (HCQ), in combination with low dose palbociclib (0.5μM or 1μM) for 6 days
and recovery for 4 days, and results revealed that this combination induced a sustained and
irreversible inhibition of growth (measured via cell counting – Figure 31A – compare purple to
light blue lines and red to orange lines) and colony formation (Figure 31B), when compared to
the reversible inhibition induced by palbociclib alone. Next, to examine if combined treatment of
palbociclib (low and on-target dose) and HCQ could result in sustained and long-term growth
inhibition, MCF7 and T47D cells were treated for 6 days and allowed to recover in the absence
of the drug for 12 days. Results revealed that combination of palbociclib and HCQ was able to
achieve a sustained long lasting growth inhibition, compared to low-dose palbociclib alone
(Figure 31C – compared red to orange line).
Furthermore, treatment of ER positive cells (MCF7 and T47D) with low dose Palbociclib
in combination with HCQ resulted in an irreversible G1 arrest even after 4 days of recovery in
the absence of the drug (white bars) and was even comparable to continuous drug treatment
for 10 days (grey bars) (Figure 31D). However, combination treatment with on-target doses of
palbociclib (0.5 and 1uM) and HCQ did not did not trigger apoptosis, measured by Annexin V
positivity (Figure 31E).
Given our previous findings that elevated ROS levels is required for palbociclib-induced
senescence, and the known role of autophagy in protecting cells from oxidative stress by
eliminating ROS (Kongara and Karantza 2012), we interrogated if inhibition of autophagy can
also modulate ROS levels. Consistently, exposure of palbociclib treated ER positive breast
cancer to the autophagy inhibitor, hydroxychloroquine (HCQ), resulted in a significant increase
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in ROS levels (Figure 32A). This suggests that the autophagy induced by low (on-target)
doses of palbociclib degrades ROS, accounting for the lower ROS levels and the resistance to
the induction senescence at these concentrations. Additionally, a significant increase in SA-ß

gal activity (Figure 32B) and a shift in side-scatter (Figure 32C), upon treatment with the
combination of palbociclib and HCQ, when compared to treatment with palbociclib alone,
demonstrating the synergistic effect of the two drugs in inducing senescence.
Taken together, these results suggest that autophagy induced in response to palbociclib
eliminates ROS and has a pro-survival role in ER positive breast cancer. Hence,
pharmacological inhibition of autophagy via HCQ induces a synergistic response when
combined with palbociclib treatment, resulting in a sustained growth inhibition and significantly
elevated senescence.
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Figure 31: Impact of autophagy inhibition on palbociclib mediated growth inhibtion and G1
arrest: A,B) MCF7 and T47D cells were treated with combination of palbociclib and 15µM
hydroxychloroquine (HCQ) for 6 days. Cells were allowed to recover for 4 or 6 days in drug-free
media and subjected to A) Cell counting and B) Clonogenic assay. C) Effect on cell viability when
treated with a combination of DMSO or palbociclib (Palbo - 0.5 or 1 μM) and autophagy inhibitor
hydroxychloroquine (HCQ; 15 μM) for a) 6 days and allowed to recover for 12 days to examine
long-term reversibility. p-values were calculated in comparison to cells treated with 1 μM
palbociclib. D,E) MCF7 and T47D cells were treated with 15 μM HCQ and/or palbociclib (0.5 or 1
μM) for 6 days and subjected to D) cell cycle analysis to determine the percentage change in G1
phase (p-values were calculated by comparing values at the end of 6 days drug treatment with
those at the end of drug + release) and E) flow cytometry measurement of apoptotic cells (early
apoptosis: Annexin V+/PI-; late apoptosis: Annexin V+/PI+). All data represent mean ± SD from
three independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 32: Impact of autophagy inhibition on palbociclib induced ROS and
senescence: MCF7 and T47D cells were treated with 15 μM HCQ and/or palbociclib (0.5 or
1 μM) for 6 days and subjected to A) CellROX assay to measure cellular reactive oxygen
species (ROS) levels and it quantification (Mean fluorescence intensity), B) Quantification of
SA-ß gal assay to measure senescence and representative images and C) measurement
and quantification of side scatter analysis to assess cellular granularity. All data represent
mean ± SD from three independent experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001.
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5.2.4. SYNERGY BETWEEN AUTOPHAGY INHIBITION (HCQ) AND OTHER CDK4/6
INHIBITORS – RIBOCICLIB AND ABEMACICLIB
Given that autophagy inhibition synergizes with palbociclib to induce a sustained growth
inhibition, we next wanted to examine the effect of other clinically available CDK4/6 inhibitors,
abemaciclib and ribociclib. We first performed dose response studies by treating the ER
positive breast cancer cells, MCF7 and T47D, with ribociclib and abemaciclib (range of
concentrations from 0.01 to 12uM) for 6 days (Figure 33A), which revealed the IC50 values of
the two drugs to be ~4uM and 1.4uM respectively (Figure 33B). Next, the effect of the
combination treatment of ribociclib or abemaciclib along with the autophagy inhibitor, HCQ in
MCF7 and T47D cells was examined cell counting and colony formation / clonogenic assay
with treatment for 6 days and recovery for 4 or 6 days to examine reversibility of the drug
mediated effect. Results revealed the combined treated of CDK4/6 and autophagy inhibitors
induced a sustained inhibition of growth and colony formation when compared to control (no
treatment) or treatment with single drugs alone (Figures 33C-F). Additionally, co-treatment of
abemaciclib with autophagy inhibition (HCQ) resulted in significant apoptosis in a dosedependent manner, when compared to treatment with abemaciclib alone (Figure 33G).
These results show that CDK4/6 inhibitors other than palbociclib also synergize with
autophagy inhibition to induce an irreversible growth arrest or apoptosis, in the case of
abemaciclib.
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Figure 33: Synergy between autophagy inhibition (HCQ) and other CDK4/6 inhibitors – ribociclib
and abemaciclib: A,B )Proliferation of MCF7 and T47D cells treated with DMSO or increasing
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***p<0.001; ****p<0.0001.
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5.2.5. SYNERGISM BETWEEN PALBOCICLIB AND OTHER AUTOPHAGY INHIBITORS
Finally, we interrogated if autophagy inhibitors other than hydroxychloroquine also
synergize with low dose palbociclib to mediate sustained growth inhibition. To this end, we
utilized four additional autophagy-inhibiting drugs, which target the autophagy pathway at
different stages (Table 7): i) Chloroquine (a lysosomal blocker that acts similar to
hydroxychloroquine), ii) Lys05, a potent and selective autophagy inhibitor that blocks the
lysosomal fusion with the autophagosomes (McAfee, Zhang et al. 2012), iii) BaflomycinA1, a
drug that inhibits the fusion of autophagosomes and lysosomes (Yamamoto, Tagawa et al.
1998) and iv) Spautin-1, which inhibits activity of USP10 and USP13, causing proteosomal
degradation of Class III PI3K complexes and blocking autophagy induction (Shao, Li et al.
2014) (Figure 34A).
Results revealed that treatment of ER positive breast cancer cells (MCF7 and T47D)
with the combination of low-dose or on-target dose of palbociclib and the autophagy inhibitors
that target the lysosomal fusion, CQ or BaflomycinA1 results in an irreversible arrest of growth
(measured by cell counting assay where cells are treated for 6 days with a 4 day recovery in
the absence of the drug) and colony formation (with 6 day treated and 6 day recovery), when
compared to the single drug or no treatment (Cnt) controls (Figures 34B-D). Combination
treatment of palbociclib with the upstream autophagy inhibitor, Spautin-1 also resulted in a
similar synergistic effect with low-dose palbociclib resulting in an irreversible and sustained
inhibition of growth and colony formation (Figures 35A,B). Finally, treatment of on-target doses
of palbociclib with the more potent autophagy inhibitor, Lys-05 also results in an irreversible
growth inhibition (measured by cell counting assay) when compared to treatment with
palbociclib alone (Figure 35C – compare red to orange lines).
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Collectively, these results confirm the synergy between CDK4/6 and autophagy
inhibitors in ER positive breast cancer cell lines, irrespective of the drug used to achieve the
pharmacological inhibition.
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T47

5.2.6. SYNERGY BETWEEN CDK4/6 AND AUTOPHAGY INHIBITOR IN AROMATASE
INHIBITOR RESISTANT CELLS
Advanced ER positive breast cancer patients who are currently being treated with the
CDK4/6 inhibitor, palbociclib have in most cases received prior therapy including aromatase
inhibitors such as letrozole and anastrazole. Hence, we wanted to examine the sensitivity of
aromatase resistant cells to CDK4/6 inhibition as a single agent and in combination with
autophagy inhibitors. To do so, we made MCF7 aromatase expressing cells resistant to
letrozole or anastrazole by long term treatment with the respective drugs. Dose-response
studies showed that the letrozole resistant cells were 10-fold resistant to letrozole and
anastrazole resistant cells were 6-fold resistant to anastrazole (Figure 36A).
Interestingly the aromatase inhibitor resistant MCF7 and T47D cells remained sensitive
to palbociclib as a single agent (Figure 36B), exhibiting IC50 values for palbociclib comparable
to that of the parental cells (Figure 36C). Further, palbociclib treatment of the letrozole and
anastrazole resistant cells resulted in a dose-dependent growth inhibition similar to that
observed in the MCF7 aromatase expressing parental cells (Figure 36D). Further,
monodansylcadavarine (MDC) staining revealed induction of autophagy in response to
palbociclib treatment in the letrozole and anastrazole resistant MCF7 cells (Figure 36E).
Therefore, similar to the MCF7 parental cells, the aromatase resistant (letrozole or anastrazole)
were highly responsive to the combination of palbociclib and autophagy inhibition, resulting in
an irreversible and sustained growth inhibition even with low and on-target doses of palbociclib
(Figure 36F).
Thus, these results show that the aromatase inhibitor resistant cells remain sensitive to
CDK4/6 inhibition and highlights the clinical utility of the drug combination in the aromatase
inhibitor resistance setting.
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Figure 36: Synergy between CDK4/6 and autophagy inhibitors in aromatase inhibitor
resistant cells: A) Half-maximal inhibitory concentration (IC50) values of letrozole and anastrazole
in parental vs letrozole or anastrazole resistant cells respectively. B, C) Dose-response studies (B)
in MCF7 parental, letrozole and anastrazole resistant cells by treating with varying concentrations
of palbociclib for 6 days and recovery for 6 days, and their corresponding IC50 values (C). MCF7
parental and letrozole or anastrazole resistant cells were treated with varying concentrations of
palbociclib (Palbo) for 6 days with recovery for 4 days and subjected to D) cell counting to assess
cell proliferation, E) flow cytometry to quantify monodansylcadavarine (MDC) staining, a marker of
autophagic vesicles and F) cell counting to measure growth inhibition combination with 15μM
hydroxychloroquine (HCQ) for 6 days. All data represent mean ± SD from three independent
experiments; ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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5.2.7. SYNERGY BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION BY HCQ IN
VIVO
Having shown the synergy between CDK4/6 and autophagy inhibitor in vitro, we
interrogated if concomitant treatment of mice with an autophagy inhibitor and low dose
palbociclib can mediate a synergistic response. Previously, we showed that palbociclib induces
autophagy with an intact flux at 25mg/kg (Figure 20), which provided the optimal dose of
palbociclib for the combination study. To this end, MCF-7T cells were injected into the
mammary fat pad of nude mice, once the tumors grew to an average size of 250mm3, we
randomized them into 4 treatment arms: (i) vehicle, (ii) hydroxychloroquine (60mg/kg), (iii) low
dose palbociclib (25mg/kg/day) and (iv) HCQ + palbociclib (25mg/kg/day). Mice were treated
for 21 days (treatment phase) and maintained for an additional 21 days without treatment
(recovery phase) to examine the ability of the drug treatment to induce a sustained tumor
growth inhibition (Figure 37A).
Results revealed that mice treated with combination of low dose palbociclib and HCQ
had significantly decreased tumor volume at the end of treatment, compared to single drug or
vehicle arms (Figure 37B-D – at the end of 21-day treatment phase). More strikingly, the tumor
volumes in the HCQ + palbociclib combination arm did not increase even after the treatment
was stopped, while the tumor volumes in the palbociclib alone arm readily increased during the
end of the treatment phase and during the recovery phases of the experiment (Figure 37B-D –
at the end of the treatment + recovery phase). A concomitant decrease in tumor weight was
observed with the palbociclib + HCQ combination arm both at the end of the treatment and the
treatment + recovery phases compared to the vehicle or the single treatment controls. These
results suggest that co-treatment with HCQ enabled the induction of a sustained tumor growth
inhibition even at a low dose (25mg/kg) of palbociclib, which is one-fifth the dose of palbociclib
(150mg/kg) used in most preclinical studies (Fry, Harvey et al. 2004, Michaud, Solomon et al.
2010, Wardell, Ellis et al. 2015).
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To illustrate the induction of a cell cycle arrest and senescence at the end of the 21 day
treatment phase, we examined the protein levels of cell cycle proteins Rb and pRb via western
blot analysis, which showed that combination treated led to a more significant decrease in both
Rb and pRb compared to treatment with palbociclib alone (Figure 38A). Additionally, RPPA
analysis of tumors post 3 weeks of treatment demonstrated a significant enrichment for the
senescence and growth inhibition related proteins and a significant decrease in cell cycle
related proteins in the combination treatment arm, when compared to no treatment arms and
palbociclib alone arm (Figure 38B,C). As a proof of autophagy inhibition with the palbociclib +
HCQ combination arm, western blot analysis showed impaired autophagic flux as indicated by
increased LC3B-II levels and no decrease in p62, when compared to palbociclib alone arm,
which confirmed the induction of autophagy with 21 days treatment with palbociclib (Figure
38A).
Further, immunohistochemistry (IHC) analysis showed that combination treatment with
palbociclib and HCQ significantly increased SA-ß gal activity (marker of senescence) and
decreased expression of BrdU (a proliferation marker) at the end of the 21 day treatment period
and following the 21 day recovery phase, while the vehicle and HCQ arms showed no change
in BrdU or SA-ß gal staining (Figures 39A,B). The palbociclib alone arm, on the other hand,
showed an increase in SA-ß gal and decrease in BrdU staining only at the end of the 21
treatment period, while these levels increased at the end of the recovery phase, demonstrating
that palbociclib only induces a reversible tumor growth inhibition as a single agent (Figures
39A,B). Moreover, palbociclib + HCQ in vivo treatment resulted in significantly higher ROS
levels (measured by IHC by 8-OHdG and 4-HNE staining) at the end of both treatment and
recovery phases compared to the vehicle and HCQ treatment, while palbociclib alone treatment
arm exhibited a moderate increase in ROS levels only at the end of the treatment phase
(Figures 39A,C,D).
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Lastly, we examined the tolerability and the toxicity of the drug treatments in mice by
examining the changes in body weight and complete blood counts (given the induction of
neutropenia and leukopenia in patients) at the end of the treatment and treatment + recovery
phases. Measurement of mice weight every day during the 21-day treatment phase showed no
significant changes in body weight in any of the treatment arms including the combination arm
(Figure 40A). Additionally, analysis of the complete blood count profile revealed no significant
changes in WBC, RBC, platelet, Neutrophils. RBC and WBC differential count in any of the
treatment arms (including combination treatment), at the end of the treatment and treatment +
recovery phases (Figures 40B-D). These results suggest that the administered drug
treatments, including the combination of HCQ and low dose palbociclib, were well tolerated by
the mice at both time intervals assessed (treatment and treatment + recovery).
Collectively, these results suggest that autophagy inhibition (via HCQ) synergizes with
low doses of palbociclib to induce an irreversible tumor growth inhibition in mice xenograft
tumors in vivo.
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staining on tumor tissues harvested at the end of the 21 days treatment with vehicle, 60 mg/kg
hydroxychloroquine (HCQ), 25 mg/kg palbociclib (Palbo) or combination of palbociclib and HCQ, or
post 21 days of recovery in the absence of drug. Scale bars equal 50 μm. B) Quantification of BrdU
positive cells or H-score of 8-OHdG and 4-HNE staining on tumors harvested at the end of treatment
phase and treatment + recovery phase. All data represent mean±SD; p-values were calculated in
comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; *p<0.05; **p<0.01;
***p<0.001; ****p<0.0001.
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Figure 40: Toxicity profile of palbociclib and autophagy inhibitor treatment in vivo:
A) Mean mouse weight and Weight of individual mice upon 21 days treatment with vehicle,
60 mg/kg hydroxychloroquine (HCQ), 25 mg/kg palbociclib (Palbo) or combination of
palbociclib and HCQ. Mice were treated for 21 days as described in A and blood samples
collected at the end of treatment phase and at the end of the treatment + recovery phase
(21 days post treatment) and subjected to B) complete blood counts (red blood cells [RBC],
white blood cells [WBC], platelets, and neutrophils [Neutro]), C) RBC differential counts and
D) WBC differential count. All data represent mean±SD; p-values were calculated in
comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; *p<0.05;
**p<0.01; ***p<0.001; ****p<0.0001.
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5.2.8. SYNERGY BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION (LYS-05) IN
VIVO
Having showing the in vivo synergy between CDK4/6 and autophagy inhibition via HCQ,
we wanted to further confirm the synergy of the combination in vivo using another autophagy
inhibitor, Lys05, a more potent inhibitor of autophagy compared to HCQ (McAfee, Zhang et al.
2012). To first examine the toxicity profile of Lys-05 as a as a single agent, non-tumor bearing
mice were treated with varying concentrations of Lys-05 (1mg/kg, 5mg/kg, 10mg/kg or
20mg/kg) every day for 21 days and the mouse weight and their blood count were analyzed to
examine toxicity. Results show that treatment with different doses of Lys-05 had no deleterious
effect on mouse weight over the 21-day treatment period (Figure 41A). Similarly, there was no
difference in the complete blood counts, RBC and WBC differential counts upon treatment with
the varying concentrations of Lys-05 (Figures 41B-D).
Next, xenograft tumor-bearing mice (established by mammary fat pad injection of
MCF7T cells and tumors were allowed to reach an average of 200mm3) were treated with
vehicle, 10mg/kg/day Lys05 (chosen based on previous studies showing autophagy inhibition
at this dose), 25mg/kg/day palbociclib or the combination of palbociclib and Lys05 for 21 days
(treatment phase) with a recovery phase of 14 days. Treatment with the combination of
palbociclib + Lys05 significantly decreased tumor volume during both the treatment and
recovery phases, compared to no treatment (vehicle) or treatment with Lys-05 or palbociclib as
a single agent (Figures 42A,B). Further, combination treatment with palbociclib + Lys-05
resulted in significantly smaller tumors (Figure 42D) with lesser tumor weight (Figure 42C),
compared vehicle or single treatment controls. Treatment with the combination of palbociclib
and Lys-05 also resulted in prolonged mouse survival, with none of the mouse tumors reaching
1000mm3, compared to the other treatment arms, whose tumors grew to above 1000mm3 and
had to be sacrificed prior to the end of the experiment at 35 days (Figure 42E).
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Collectively, these results demonstrate that autophagy inhibition mediated by an
alternative inhibitor, Lys-05 also synergizes with low doses of palbociclib to induce irreversible
tumor growth inhibition in vivo.
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Figure 42: Synergism between palbociclib and Lys-05 mediated autophagy inhibition
in vivo: A,B) Percentage change in mean (A) or individual (B) tumor volumes (normalized
to Day 0) upon treatment with Vehicle, 5mg/kg palbociclib, 10mg/kg Lys-05 or combination
of palbociclib and Lys-05 daily for 21 days (treatment phase) and recovery phase of 14
days. Data represented as Mean±SEM. n≥5 for each group. C) Weights od tumors
harvested after treatment and recovery as described in A. D) Representative pictures of
tumors harvested after 21 days treatment and 14 days recovery. E) Kaplan Meier survival
curve with death and tumors exceeding 1000mm3 as endpoint upon treatment as in A. n≥5
for each group. F,G) Mean mouse weight (F) and weight of individual mice )G) during 21
days treatment phase. All data represent mean±SD; p-values were calculated in
comparison to mice treated with vehicle (Control) unless indicated. ns:p>0.05; *p<0.05;
**p<0.01; ***p<0.001; ****p<0.0001.
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5.3. DISCUSSION
Collectively, studies in this chapter demonstrate that inhibition of autophagy significantly
improves the efficacy of CDK4/6 inhibition and effectively induces a sustained growth inhibition
and senescence in vitro and in vivo, even at low doses of palbociclib (Figure 43).
While research has shown opposing roles for autophagy – as a pro-survival and a prodeath mechanism, numerous recent studies have highlighted the importance of autophagy as a
mediator of drug resistance, specifically in breast cancer (Chen, Jiang et al. 2013, Chittaranjan,
Bortnik et al. 2014, Lefort, Joffre et al. 2014). These studies have shown an association
between high expression of autophagy proteins like LC3B and tumor aggressiveness, providing
strong rationale for using autophagy inhibitors to combat drug resistance. Further, while
previous studies with the CDK4/6 inhibitor palbociclib, suggested a potential induction of
autophagy with drug treatment (Capparelli, Chiavarina et al. 2012), the role of the autophagy
induction was not examined. Hence this chapter provides a detailed analysis of drug induced
autophagy performed by downregulating autophagy genes Atg-5 and Beclin-1 and using
numerous pharmacological inhibitors of autophagy to show that targeting autophagy
significantly improves the efficacy of palbociclib treatment.
A potential issue with the molecular ablation of autophagy via Beclin-1 knockdown
might arise from the fact that Beclin-1 has been shown to have autophagic independent
functions in cancer (Rohatgi and Shaw 2016). Recent study shows that apart from its role in
autophagy, Beclin-1 can also regulate growth factor signaling pathways such as Pi3K (Rohatgi
and Shaw 2016). However, we observed similar results with both Atg5 and Beclin1 knockdown,
which would eliminate the possibility of autophagy independent functions of Beclin1 playing a
role in this scenario. Another issue that might be of concern is the specificity of the autophagy
inhibiting drugs utilized in the study. To address this, we employed 5 different autophagy drugs
in vitro, which target the pathway at multiple sites (Autophagosome initiation - Spautin-1;
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Figure 43: Working Model: Schematic showing the synergistic effect
between CDK4/6 and autophagy inhibitors in ER+ve breast cancer cells in
vitro and in vivo resulting in senescence.

lysosome fusion – CQ, HCQ, Lys-05 and Baf-A1 (Wang, Hu et al. 2016)), all which yielded
similar results. We even performed in vivo xenograft studies with two different
autophagy inhibitors, HCQ and Lys-05, both of which showed a similar synergistic effect
between CDK4/6 and autophagy inhibition.
Further, the in vivo drug dose used for palbociclib in most preclinical studies is 150
mg/kg, which translates to plasma concentration of 7.7uM, significantly higher than the clinically
achievable dose of 3.4 µM (Pfizer-Inc-and-Affiliates 2011). Our study with the combination of
CDK4/6 and autophagy inhibition was able to reduce the dose of palbociclib to one-fifth the
dose - 25mg/kg (1.4uM plasma concentration and corresponds to low and on-target dose used
in cell lines), and still achieve significance tumor inhibition. Thus, the combination treatment
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strategy that we have identified in this study (palbociclib + HCQ) has the potential to
significantly improve palbociclib efficacy, while lowering toxicity mediated by palbociclib.
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CHAPTER 6: BIOMARKER IDENTIFICATION FOR PALBOCICLIB AND ITS
COMBINATION WITH AUTOPHAGY INHIBITOR IN ER+ BREAST CANCER

6.1. INTRODUCTION
6.1.1. RB PROTEIN IN BREAST CANCER
The retinoblastoma (Rb) protein is a major regulator of the G1/S checkpoint of the cell
cycle and consists of two family members, the Rb-like proteins, p107 and p130 (Weinberg
1995). These proteins, known as pocket proteins, bind to the transcription factor, E2F, keeping
it in its inactive state and preventing transcription of E2F target genes (Weinberg 1995). Thus,
Rb serves as a molecular determinant as to whether the cells would pass through the G1/S
checkpoint and a tumor suppressor (Giacinti and Giordano 2006). Given its tumor suppressive
function, Rb is often inactivated in cancers, via mutations or partial deletions among other
mechanism (Giacinti and Giordano 2006). In breast cancer, the inactivation of the Rb pathway
occurs by loss of heterozygosity of the Rb gene, seen in about 20 to 30% of breast cancers, or
due to other mutually exclusive mechanisms that affect the Rb pathway (Ertel, Dean et al.
2010). This includes amplification of the cyclin D genes (CCND1) seen in over 50% of breast
cancers, which results in aberrant phosphorylation and inactivation of Rb (Arnold and
Papanikolaou 2005). Further, inactivation of the CKI, p16 (CDKN2A) also contributes to the
deregulation and silencing of Rb (Dublin, Patel et al. 1998). A recent study showed that in ER
positive breast cancer cells, knockdown of Rb makes the cells resistant to the anti-proliferative
action of tamoxifen in vitro and the anti-tumor effect of the drug in vivo, establishing a link
between deregulation of Rb and endocrine resistance (Bosco, Wang et al. 2007). This was
verified by an analysis of tumor tissues from post-menopausal breast cancer patients treated
with tamoxifen. Which showed that deregulation of Rb correlated with high Ki67 staining, an
indication that there tumors were resistant to tamoxifen treatment (Lehn, Ferno et al. 2011).
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6.1.2. CYCLIN E AND LMWE IN BREAST CANCER
Cyclin E, when bound to CDK2, phosphorylates Rb and is a key regulator of cellular
progression through the G1/S checkpoint (Sherr 1994). Cyclin E is overexpressed
(independent of subtype) and amplified (MDA-MB-157 cell line) in breast cancer cell lines when
compared to normal mammary epithelial cells (Keyomarsi and Pardee 1993). Amplification or
overexpression of cyclin E in breast cancer mediates resistance to trastuzumab and endocrine
therapy, and is a predictor of poor prognosis in these patients (Keyomarsi, Tucker et al. 2002,
Scaltriti, Eichhorn et al. 2011, Caldon, Sergio et al. 2012).
Moreover, post-translational modification (proteolytic cleavage) of the full length cyclin E
by the serine protease, elastase, generates a more oncogenic form of the protein termed as
Low Molecular Weight isoforms of cyclin-E (LMWE) (Keyomarsi, Conte et al. 1995, Wang,
Rosales et al. 2003). Cleavage of full length cyclin E generates four isoforms of the protein,
comprising of two doublets, EL2 and EL3, which are collectively called as Trunk 1 (T1), and
EL5 and EL6, collectively called as Trunk 2 (T2) (Figure 44) (Mull, Cox et al. 2009). LMWE,
which was originally discovered in breast cancer by our laboratory, and subsequently by others
(Taneja, Maglic et al. 2010, Tokai, Maeda et al. 2011, Mombelli, Cochaud et al. 2015,
Montazeri, Bouzari et al. 2015), has recently been the subject of a number of review
articles(Loeb and Chen 2012, Moore 2013, Rath and Senapati 2014). These isoforms are also
found in ovarian (Bedrosian, Lu et al. 2004, Davidson, Skrede et al. 2007), melanoma(Bales,
Mills et al. 2005), colorectal(Corin, Di Giacomo et al. 2006, Milne, Carvalho et al. 2008, Corin,
Larsson et al. 2010, Zhou, Xie et al. 2011), lung(Koutsami, Tsantoulis et al. 2006), and renal
cell carcinomas(Nauman, Turowska et al. 2007). Numerous studies have been conducted to
elucidate the biological role of LMWE. Studies show that while both full length and low forms of
cyclin E can bind to and activate CDK2 kinase activity, the LMWE isoforms are able to bind
stronger to CDK2 and exhibit increases kinase activity (Harwell, Mull et al. 2004).
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Figure 44: Low molecular weight isoforms of cyclin E (LMWE): Schematic
showing how elastase generates LMWE by cleaving the full length cyclin E protein at
two sites

This was detected in both breast cancer cell lines and human tumor tissue samples.
(Harwell, Mull et al. 2004). This results hyperphosphorylation of Rb, which makes the LMWE
resistant tumors resistant to inhibition by the endogenous CKIs, p21 and p27 (Akli, Zheng et al.
2004). Moreover, this makes the cell or tumors resistant to anti-estrogens, induce higher
genomic instability and mediate resistance to fulvestrant and letrozole (Harwell, Porter et al.
2000, Akli, Zheng et al. 2004, Wingate, Puskas et al. 2009, Akli, Bui et al. 2010). To further
understand the significance of LMWE in breast cancer, transgenic animal models with EL and
LMWE under the MMTV promoter were generated, which showed that LMWE transgene
expressing mice had increased mammary tumorigenesis compared to full length (EL)
transgene (Akli, Van Pelt et al. 2007). Further, introduction of LMWE in HMEC cells lines
resulted in increased ability of these cell to form tumors in nude mice compared to EL
expressing cells (Duong, Akli et al. 2013). Cells overexpressing LMWE were also shown to
have enrichment of the of EMT phenotype and increased expression of breast cancer stem
cells (CD44high/CD24low subpopulation of cells) compared to full length (EL) expressing cells
(Duong, Akli et al. 2013).
Our laboratory also reported an analysis of 395 patients with breast cancer in which it
was demonstrated that overexpression of LMWE, as measured by Western blot analysis, is
associated with distant metastases and reduced overall survival (Keyomarsi, Tucker et al.
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2002). Subsequently, our laboratory discovered that LMW-E, which now lacks its N-terminus
nucluear localization signal is now localized predominantly in the cytoplasm, where it binds to
CDK2 and has greater kinase activity than full-length cyclin E (Delk, Hunt et al. 2009). This
finding was further verified by a recent study in 1676 breast cancer patients revealed that 40%
of all breast cancer patients exclusively expressed the cytoplasmic form of cyclin E (Delk, Hunt
et al. 2009). This finding was further verified by a recent study in 1676 breast cancer patients
revealed that 40% of all breast cancer patients exclusively expressed the cytoplasmic form of
cyclin E, with majority of these patients (85.1%) also expressing for cytoplasmic p-CDK2
(Karakas, Biernacka et al. 2016). More importantly, this study also showed that cytoplasmic
expression of cyclin-E (LMWE expression) is strongly associated with higher histologic tumor
grade and worse prognosis compared to other patients, demonstrating the utility of LMWE or
cytoplasmic cyclin E as a reliable prognostic indicator in breast cancer (Karakas, Biernacka et
al. 2016), which can be functionally attributed the overexpression and mislocalization (to the
cytoplasm) of these proteins.

6.1.3. PRE-CLINICAL BIOMARKER STUDIES FOR PALBOCICLIB IN BREAST CANCER
Identification of a reliable biomarker that can predict response is necessary for all
targeted therapy, to improve the selectivity and the efficacy of the drug treatment. Hence,
numerous pre-clinical studies in breast and other cancers have been carried out to identify
reliable predictive biomarkers of response for CDK4/6 inhibitors such as palbociclib (Asghar,
Witkiewicz et al. 2015). Multiple studies have shown that an intact Rb pathway is required for
the CDK4/6 inhibitor mediated cell cycle arrest and senescence and hence proteins belonging
to the Rb pathway proteins such as Rb, cyclin D, p16 and cyclin E have been identified as
biomarkers in vitro (Wiedemeyer, Dunn et al. 2010, Konecny, Winterhoff et al. 2011, Cen,
Carlson et al. 2012). A study examined palbociclib treatment in a range of breast cancer cells
and analyzed the gene expression profile of sensitive cell lines in comparison with resistant
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cells (Finn, Dering et al. 2009). Results revealed that the sensitive cells had significantly higher
expression of cyclin D1, Rb1 and lower expression levels of p16 compared to the resistant cells
(Finn, Dering et al. 2009). Further, studies in glioblastoma and ovarian cancer cell lines and
xenografts showed that the presence of Rb and loss of p16 dictate response to palbociclib
(Konecny, Winterhoff et al. 2011, Cen, Carlson et al. 2012). Moreover, a study in ovarian
cancer shows that expression of cyclin E mediates resistance to palbociclib treatment and can
hence serve as a biomarker (Taylor-Harding, Aspuria et al. 2015). Additionally, a recent study
with palbociclib in breast cancer showed that development of early adaptation (intrinsic
resistance) and acquired resistance to palbociclib is characterized by Rb loss and cyclin E
(CCNE1) amplification (Herrera-Abreu, Palafox et al. 2016). This study also showed the
resistant cells failed to decrease phosphor-Rb upon treatment with palbociclib (Herrera-Abreu,
Palafox et al. 2016). Finally, studies with abemaciclib show that the presence of estrogen
receptor (ER) and Rb can predict response to abemaciclib (Patnaik, Rosen et al. 2016).
Unfortunately, while numerous biomarkers have been suggested based on pre-clinical studies,
none have been effective in predicting CDK4/6 inhibitor response in the clinic and this will be
discussed in detail in the next chapter.

6.1.4. GAP IN KNOWLEDGE
While previous pre-clinical studies have suggested biomarkers for CDK4/6 inhibition, this was
shown to be ineffective in the clinic, highlighting the need for more clinical relevant biomarkers.
Thus, the following questions remain:
1. What is the importance of the G1/S checkpoint in response to CDK4/6 inhibitors?
2. Which proteins within the G1/S checkpoint have the best prediction value for palbociclib
response?
3. Is p53 required for response to palbociclib in ER positive breast cancer?
4. Is Rb required and sufficient to predict sensitivity to palbociclib?
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5. Can cyclin E and its low molecular weight isoforms mediate resistance to palbociclib?
6. Can the status of G1/S checkpoint proteins (Rb and LMWE) be utilized to predict
sensitivity to the combination of palbociclib and autophagy inhibitors?
7. Can the status of Rb and LMWE be utilized to predict sensitivity to the triple
combination of palbociclib, aromatase inhibitor and autophagy inhibitor?
Thus, experiments in this chapter are aimed at directly addressing these gaps in knowledge.
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6.2. RESULTS
6.2.1. GENE SET ENRICHMENT ANALYSIS TO IDENTIFY BIOMARKERS FOR
PALBOCICLIB IN BREAST CANCER
To identify biomarker(s) of response to palbociclib as a single agent and the
combination of palbociclib and HCQ combination, we examined the gene expression of cell
lines known to be sensitive or resistant to palbociclib (Finn, Dering et al. 2009), focusing on the
cell cycle and autophagy pathways. Gene set enrichment analysis (GSEA) of the
Kegg_Regulation_of_Autophagy gene set showed no distinct gene expression signature
between the palbociclib sensitive and the resistant cells (Figure 45A). This indicates that while
breast cancer cells activate autophagy in response to palbociclib treatment, the basal
expression of the autophagy genes in breast cancer cell lines may not be able to predict
responsiveness of the cells to CDK4/6 inhibition.
Examination of the Biocarta_Cell_Cycle Pathway gene set via GSEA analysis produced
a distinct gene expression signature between the palbociclib sensitive and resistant breast
cancer cell lines (Figure 45B). Palbociclib sensitive cell lines exhibited low expression of
CDKN2A / p16 and high expression of Cyclin-D1, which corroborates previous in vitro and preclinical studies with palbociclib in breast and other cancers (Konecny, Winterhoff et al. 2011,
Cen, Carlson et al. 2012) (Figure 45C – highlighted in purple). Notably, a striking correlation
was observed between sensitivity to palbociclib and the expression of both Rb and Cyclin-E;
with the Palbociclib sensitive cell lines displaying high levels of Rb and low expression of
Cyclin-E (Figure 45C - blue arrows).
These results led us to hypothesize that Cyclin-E expression in combination with Rb
may serve as effective biomarkers to predict response to palbociclib as a single agent and the
combination of CDK4/6 and autophagy inhibitors.
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Figure 45: Gene set enrichment analysis to identify biomarkers for palbociclib in breast
cancer: A,B) Heat map constructed using the Gene Set Enrichment Analysis (GSEA) program,
denoting expression of genes from the KEGG Regulation of autophagy (A) and Biocarta Cell Cycle (B)
gene sets in the indicated breast cancer cell lines, classified as being sensitive or resistant to
palbociclib. C) Heat map denoting the top unregulated and downregulated genes within the Biocarta
cell cycle gene set when comparing palbociclib sensitive and resistant cell lines
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6.2.2. ROLE OF p53 IN DETERMINING RESPONSE TO PALBOCICLIB IN ER+ BREAST
CANCER
p53 is a tumor suppressor gene that plays a key role in maintaining the integrity of the
G1/S checkpoint and has been shown to be a predictor of palbociclib response in glioma
(Barton, Misuraca et al. 2013). Given the status of p53 in the two ER positive cells lines utilized
in this study (MCF7- WT p53; T47D- heterozygous p53 mutant), and their comparable
sensitivity to palbociclib, we hypothesized that p53 may not play a role in predicting sensitivity
to the CDK4/6 inhibitor in ER positive breast cancer.
To interrogate this, western blot analysis of the p53 pathway proteins (p53 and Mdm2)
were performed, which revealed no alteration in their protein levels upon treatment with
palbociclib for 6 days (Figure 46A). Further, p53 was downregulated in the MCF7 cell lines
using two independent shRNAs (Figures 46B,C). shRNA mediated p53 knockdown did not
alter the sensitivity of MCF7 cells to palbociclib (Figure 46D), with no significant change in
IC50 values of palbociclib in MCF7 parental p53 knockdown cells (Figures 46E,F).
Thus, these results indicate that p53 does not play a significant role in mediating
sensitivity to CDK4/6 inhibition in ER positive breast cancer.
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6.2.3. ROLE OF RB IN MEDIATING PALBOCICLIB INDUCED ROS AND SENESCENCE
Given the role of Rb and its downstream effectors in regulating senescence, autophagy
and ROS (Macleod 2008, Chicas, Wang et al. 2010, Jiang, Martin et al. 2010, Anders, Ke et al.
2011, Imai, Takahashi et al. 2014), we hypothesized that Rb plays a crucial role in mediating
palbociclib action by regulating ROS, autophagy and senescence, and hence could serve as a
predictor of sensitivity to CDK4/6 inhibition.
To directly test this hypothesis, we downregulated Rb in MCF7 and T47D cells via
shRNA mediated stable knockdown (Figure 47A,B). Treatment of Control (Scrambled – SCR)
or Rb knockdown MCF7 or T47D cells with increasing concentrations of palbociclib revealed a
significant reduction in sensitivity to palbociclib (Figure 47C), with a 4 to 6 fold increase in IC50
values (Figures 47D,E). Further, ablation of Rb abolished the ability of palbociclib mediated
CDK4/6 inhibition to induce a decrease in colony formation (Figure 47F) or a sustained growth
inhibition (Figure 47G) upon treatment for 6 days and recovery for 4 or 6 days, compared to
the scrambled shRNA cells.
Moreover, while palbociclib treatment of Rb knockdown MCF7 and T47D cells induced
a G1 arrest, the cell cycle arrest was readily reversible, indicating the necessity of Rb
expression to mediate palbociclib induced irreversible G1 arrest (Figure 48A). Next, given the
ability of ROS in regulating both palbociclib induced autophagy and senescence, and the role
of Rb in mediating these two processes, we interrogated if Rb also modulates the ability of
palbociclib to induce oxidative stress via ROS. Results revealed that shRNA mediated
knockdown of Rb in MCF7 and T47D cells significantly reduced the ability of ER positive breast
cancer cells to increase cellular ROS levels upon treatment with palbociclib, when compared to
the Scrambled shRNA cells (Figure 48B). Additionally, downregulation of Rb in ER positive
breast cancer cell lines also prevented the induction of senescence upon long term (6 days)
treatment with palbociclib (Figure 48C).

167

Taken together, these results demonstrate the vital role of Rb in mediating palbociclibinduced irreversible growth inhibition, cell cycle arrest, ROS and senescence in ER positive
breast cancer cell lines, highlighting the potential utility of Rb as a biomarker for CDK4/6
inhibition.
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6.2.4. ROLE OF RB IN MEDIATING PALBOCICLIB INDUCED AUTOPHAGY
Since recent studies have demonstrated a role for the Rb-E2F pathway in regulating
autophagy in tumor cells (Tracy, Dibling et al. 2007, Jiang, Martin et al. 2010), we next asked if
Rb might also regulate the induction of autophagy by palbociclib. Monodansylcadavarine
(MDC) staining revealed that shRNA knockdown of Rb abolished the ability of ER positive
breast cancer cells (MCF7 and T47D) to induce autophagy in response to palbociclib
treatment, as demonstrated by the absence of double-membrane autophagic vesicles (Figure
49A) and the lack of a significant increase in MDC staining (Figure 49B).
Further, treatment with the autophagy inhibitor, hydroxychloroquine (HCQ) in
combination with palbociclib had no significant effect on the colony formation of ER positive
cells when Rb was knocked down, compared to treatment with palbociclib alone (Figure 49C).
Additionally, the combination of palbociclib and HCQ had no significant impact on the
proliferation of MCF7 and T47D cells (Figure 49D).
These results suggest that Rb is required for palbociclib-induced autophagy and
substantiates the role of autophagy as a stress response process that is triggered by the ER
positive breast cancer cells only under conditions in which Palbociclib elicits a growth inhibitory
effect. Moreover, this suggests that Rb could serve as a biomarker of sensitivity to the
combination of CDK4/6 and autophagy inhibitors in ER breast cancer
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6.2.5. ROLE OF LMWE IN MEDIATING PALBOCICLIB ACTION
While our findings suggest that Rb is required for the growth inhibitory action of
palbociclib and its combination with autophagy inhibition, results from recent studies focusing
on biomarker discovery indicate that Rb alone may not be sufficient to effectively predict patient
response to palbociclib (DeMichele, Clark et al. 2015). Results from our GSEA analysis (Figure
50) indicate that expression of cyclin E correlates with sensitivity to palbociclib in breast cancer
cell lines. Moreover, since Rb loss is not common in ER positive breast cancer, we also
interrogated the role of cyclin E in predicting sensitivity to CDK4/6 inhibition. As described in
the introduction to this chapter, our laboratory discovered that LMWE, the elastase mediated
proteolytic cleavage products of full length cyclin E, are oncogenic, uniquely expressed in
tumors, hyperphosphorylate Rb, and are strong prognostic indicators in breast cancer.
(Keyomarsi, Conte et al. 1995, Wingate, Puskas et al. 2009, Akli, Bui et al. 2010, Hunt,
Karakas et al. 2016, Karakas, Biernacka et al. 2016).
Hence, to interrogate if high Cyclin-E, particularly the LMWE isoforms could mediate
resistance to palbociclib, we overexpressed either empty vector (Vec), full length Cyclin-E (EL)
or the LMW-E isoforms in MCF7 and T47D cell lines (Figure 50A). Results revealed that
expression of LMW-E, but not full length Cyclin-E significantly reduced the sensitivity of the ER
positive breast cancer cells, MCF7 and T47D to palbociclib (Figure 50B), with a 4 to 6 fold
increase in IC50 values when compared to Vector and full length cyclin E (EL) (Figures 50C,
D). Furthermore, expression of LMW-E, but not full length Cyclin-E, bypasses the ability of
palbociclib to inhibit colony formation (Figure 50E) or exert irreversible growth inhibition
(Figure 50F) in ER positive breast cancer cell lines.
Next, to examine the effect of LMW-E and full length cyclin E expression on palbociclib
mediated cell cycle arrest, we performed flow cytometry and examined the expression of key
cell cycle proteins following palbociclib treatment in EL or LMW-E overexpressing cells. Results
showed that LMW-E expression but not full length cyclin E mediated resistance to palbociclib
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mediated induction of G1 arrest (Figure 51A) and decrease in cell cycle proteins, pRb and Rb
(Figure 51B). Further, expression of LMW-E abolished the ability of palbociclib to induce a
dose-dependent increase in cellular ROS levels, in comparison with Vector and full length
cyclin E (EL) expressing cell lines (Figures 51C,D). Expression of LMW-E thus prevented the
ability of palbociclib mediated CDK4/6 inhibition to induce senescence in the ER positive breast
cancer cells (Figures 52A,B). Finally, to interrogate if Rb downregulation would further
decrease sensitivity of LMW-E expressing cells to palbociclib, we downregulated Rb in the
T47D cells expressing Vector, full length cyclin E (EL) or LMW-E and dose-response studies
showed that downregulation of Rb further decreased sensitivity to palbociclib in the LMW-E
expressing T47D cells, with an increase in IC50 value from ~5.5 to ~7.5uM (Figure 52C).
Collectively, these results demonstrate that expression of the low molecular weight
isoforms of cyclin E (LMWE) mediate resistance to CDK4/6 inhibition via palbociclib, and
indicate that LMWE could serve as a selective biomarker to identify ER positive breast cancer
cells responsive to palbociclib treatment.
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Figure 50: Role of LMWE in mediating palbociclib action: A) Western blot showing levels
of cyclin E protein in MCF7 and T47D cells stably overexpressing full-length cyclin E (EL) or
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6.2.6. LMWE AS A MEDIATOR OF RESISTANCE TO THE COMBINATION OF CDK4/6 AND
AUTOPHAGY INHIBITOR
Having shown that LMWE expression mediates resistance to the growth inhibitory
action of palbociclib as a single agent, and that autophagy is a drug response observed in ER
positive breast cancer cells, we wanted to examine if the LMWE could also serve as a marker
of resistance to the combination of palbociclib and autophagy inhibition. To interrogate this, we
treated MCF7 and T47D cells expressing empty vector, full length cyclin E (EL) or low
molecular weight isoforms of cyclin E (LMWE) with the combination of low-dose (on target
dose) of palbociclib and Hydroxychloroquine. The combination treatment while being
synergistic to mediate irreversible and sustained growth inhibition in Vector and EL expressing
cells, had no impact on the growth of palbociclib treated LMW-E cells (Figure 53).
This indicates that LMWE apart from being a biomarker to identify the ER positive
breast cancer cells that respond to palbociclib as a single agent, can serve as a reliable
biomarker for the combination of CDK4/6 and autophagy inhibition.
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Figure 53: LMWE as a mediator of resistance to the combination of CDK4/6 and
autophagy inhibitors: Cell counting was used to assess growth of MCF7 and T47D cells
stably overexpressing Vector, EL, or LMW-E upon treatment with DMSO, palbociclib, 15μM
hydroxychloroquine (HCQ) or the combination of palbociclib + HCQ for 6 days with recovery
for 4 days to examine reversibility. All data represent mean±SD from three independent
experiments; p-values were calculated in comparison to cells treated with DMSO (Control)
unless indicated. ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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6.2.7. LMWE AS A MEDIATOR OF RESISTANCE TO THE TRIPLE COMBINATION OF
CDK4/6, LETROZOLE AND AUTOPHAGY INHIBITOR
Since the CDK4/6 inhibitor palbociclib is currently used clinically in combination with the
aromatase inhibitor letrozole in advanced ER positive breast cancer patients, we wanted to
interrogate how palbociclib and letrozole combination compares to our proposed combination
of palbociclib and HCQ. Treatment of MCF7 aromatase expressing cells with the combination
of palbociclib and letrozole induced autophagy at levels similar to that of palbociclib treatment
alone (Figure 54A), indicating the potential to examine the effect of the triple combination of
palbociclib, letrozole and HCQ in ER positive breast cancer. Treatment of MCF7 aromatase
expressing cells with the combination of palbociclib and HCQ had a significantly higher growth
inhibitory effect (measured by cell counting and effect on long term colony formation),
compared to palbociclib and letrozole as a single agent or in combination (Figure 54C,D).
Further, treatment with the triple combination of palbociclib, letrozole and HCQ exhibited the
highest reduction in colony formation (Figure 54C) and the induction of irreversible growth
inhibition (Figure 54D).
Further, we overexpressed empty vector (Vector) or LMWE in MCF7 aromatase
expressing cells (Figure 54B), in order to examine the impact of LMWE expression on the
triple combination treatment. Results showed that expression of LMWE, but not empty vector in
MCF7 cells mediated resistance to the ability of the combination of palbociclib and letrozole
and the triple drug combination to inhibit colony formation (Figure 54E) and induce of a
sustained and irreversible growth inhibition (Figure 54F).
Thus, these results show that the proposed combination of CDK4/6 and autophagy
inhibitor is more effective in mediating a sustained growth inhibition than the currently clinically
used combination (i.e. CDK4/6i + aromatase inhibitors), and, and demonstrates that LMWE
expression can also serve as a biomarker for the potential triple combination of CDK4/6,
aromatase and autophagy inhibitor.

180

80

B

****
****

60

ns

0
Letrazole (1µM) Palbociclib (1µM) -

Cell Number ( x105)

D

-

+

-

Cnt

LMW-E

Let

Aromatase

Palbo

Actin

Palbo
+ Let

+
+

+

E

MCF7

50

Cnt
HCQ
Let
Let + HCQ
Palbo
Palbo + HCQ
Palbo + Let
Palbo + Let
+ HCQ

25
8
6
4

*
**

2
0

0

F

3

Cell Number ( x105)

Days

6

10

25
10
8
6
4

*
*

2
0

3

Days

6

+ HCQ

+ HCQ
Cnt

Let

Let

Palbo

Palbo

Palbo
+Let

Palbo
+Let

MCF7 LMW-E

40

Cnt
HCQ
Let
Let + HCQ
Palbo
Palbo + HCQ
Palbo + Let
Palbo + Let
+ HCQ

+ HCQ

MCF7 LMWE

MCF7 Vec

Cnt

MCF7 Vector

50

0

C

Vec LMWE

Full length
Cyclin-E

40
20

Par

Cell Number ( x105)

% of MDC +ve cells

A

20
8
6
4
2
0

10

0

3

Days

6

10

Figure 54: LMWE as a mediator of resistance to the triple combination of CDK4/6,
letrozole and autophagy inhibitor: A) Measurement of monodansylcadavarine (MDC)
positive acidic vesicles, including autophagosomes, by flow cytometry in MCF7 aromatase
expressing cells treated with 1 μM palbociclib in combination with 1 μM letrozole for 6 days. B)
Western blot showing levels of cyclin E and aromatse protein in MCF7 cells stably
overexpressing aromatase (Par) and empty vector (Vec) or low-molecular-weight isoforms of
cyclin E (LMW-E). C,D) Clonogenic (C) and Cell counting (D) assay to assess proliferation
upon treatment with 1µM palbociclib, 1µM letrozole and 15µM HCQ in the indicated
combinations. E,F) Impact of overexpressing empty vector (Vec) or LMWE in MCF7 aromatase
expressing cells measured by clonogenic (E) and cell counting (F) assay following treatment
with 1µM palbociclib, 1µM letrozole and 15µM HCQ in the indicated combinations. All data
represent mean±SD from three independent experiments; p-values were calculated in
comparison to cells treated with DMSO (Control) unless indicated. ns:p>0.05; *p<0.05;
**p<0.01; ***p<0.001; ****p<0.0001. Aromatase expressing cells were generated by Dr. Iman
Doostan, graduate student from the Keyomarsi lab.

181

6.3. DISCUSSION
Taken together, results from this chapter highlight that the G1/ S checkpoint is crucial
for response to palbociclib, and that deregulation the G1/S point pathway proteins, either by
loss of Rb or expression of low molecular weight isoforms of Cyclin E (which deregulates the
checkpoint by hyperphosphorylating Rb) mediates resistance to the drug and its combination
with autophagy inhibitor (Figure 55).
Numerous studies have shown that the expression of Rb protein is required for breast
cancer and other tumors to be sensitive to treatment with the CDK4/6 inhibitors, recent findings
have shown that Rb alone is insufficient to effectively predict patient response to palbociclib
(DeMichele, Clark et al. 2015). Further, since the loss or deregulation of Rb is not common in
the ER positive subtype of breast cancer, it is crucial to identify a secondary or more reliable
biomarker. Thus, results from this chapter show that the Rb and LMWE together can serve as
reliable biomarkers for predicting response to palbociclib and its combination with autophagy
inhibitors in vitro.
Further, while our results suggest that Rb might play a direct role in regulating ROS, the
molecular mechanism by which this occurs remains unclear. Recent reports have shown that
the downstream targets of Rb such as FOXM1 and BIRC5 (Survivin) can negatively regulate
oxidative stress (Kwee, Luque et al. 2008, Park, Carr et al. 2009, Lim, Heo et al. 2015),
providing a novel link between Rb and the ROS machinery. This suggests that downregulation
of FOXM1 and BIRC5, among other ROS regulating proteins might be the potential mechanism
by which Rb regulates oxidative stress, under palbociclib treatment conditions, and this
demands further investigation.
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CHAPTER 7: RB AND CYCLIN E AS PROGNOSTIC BIOMARKERS OF
PALBOCICLIB ACTION IN ADVANCED ER+ BREAST CANCER PATIENTS

7.1. INTRODUCTION
7.1.1. CLINICAL STUDIES AND BIOMARKER ANALYSIS
Based on pre-clinical studies, numerous biomarkers have been tested in breast cancer
patients clinically to examine their ability to predict response to CDK4/6 inhibitors (Sherr, Beach
et al. 2016). A summary of these clinical studies and the biomarkers tested are shown in Table
9.
Despite strong pre-clinical evidence, results from PALOMA-2, the randomized phase II
clinical study testing the efficacy of combining palbociclib and letrozole showed that CCND1
amplification and / or loss of p16 did not predict sensitivity to palbociclib, with no difference in
progression-free survival observed between the groups (Finn, Crown et al. 2015). Further
analysis of response data showed no significant difference in the hazard ratio even when
separated based on the expression levels of cyclin D and p16, indicating that the sample size
might be small to conclude the predictive value of these proteins (Finn, Crown et al. 2015). A
similar analysis following results from a short-term pre-operative trial with palbociclib as a
single agent showed no correlation between response to palbociclib and expression of Rb,
CCND1 or PIK3CA (Monica Arnedos 2016). However, results showed that the non-responders
(measured by change in Ki67) were characterized by no change in pRb levels (Monica Arnedos
2016). A similar result was also seen with the CDK4/6 inhibitor, abemaciclib, which showed a
significant correlation between clinical efficacy and modulation of pRb (Patnaik, Rosen et al.
2016)
Results from PALOMA-3, the phase III clinical trial testing the combination of palbociclib
and fulvestrant showed that while ER positivity is required, that the expression levels of ER do
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Treatment

Setting

Phase

n

Biomarkers studied

Palbociclib

early

Window of
opportunity

100

IHC, phospho-protein, gene
expression, whole exome,
TIL

Palbociclib +
Anastrazole

early

Neoadjuvent
(NeoPalAna)

50

IHC, gene expression,
PIK3CA, NGS

Abemaciclib +
Anastrazole

early

Neoadjuvent
(MONARCH-3)

220

Gene expression, TIL

Palbociclib +
letrozole

Metastatic
ET sensitive

Phase II
randomized
(PALOMA-1)

165

CCND1 / p16 expression

Palbociclib +
letrozole

Metastatic
ET sensitive

Phase III
randomized
(PALOMA-2)

666

Rb, cyclin D, p16

Ribociclib +
letrozole

Metastatic
ET sensitive

Phase III
randomized
(MONALEESA-2)

668

Palbociclib +
fulvestrant

Metastatic
ET resistant

Registration trial

521

ESR1 mutation, PIK3CA

Abemaciclib

Metastatic
resistant

Phase I
(MONARCH-1)

47

Phospho-Rb

Table 9: Clinical studies and biomarker analysis: Summary of clinical studies performed in
ER+ve breast cancer with the CDK4/6 inhibitors and the biomarkers assessed as a part of the study.

not correlate with response (Cristofanilli, Turner et al. 2016). Analysis from this study also
showed that there is no correlation between response to progression-free survival and PIK3CA
mutation or ESR1 mutations (Cristofanilli, Turner et al. 2016, Fribbens, O'Leary et al. 2016),
indicating that palbociclib treatment is equally responsive in these mutant tumors as those not
harboring either mutations. Lastly, results of biomarker analysis from MONALEESA-2, the
phase III combination study between ribociclib and letrozole showed no significant difference in
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the hazard ratio or correlation between progression free survival and expression of Rb protein,
p16 protein, CDKN2A mRNA, CCND1 mRNA, basal Ki67 levels, ESR1 mRNA and PiK3CA
mutation (Hortobagyi, Stemmer et al. 2016). Biomarkers to predict drug sensitivity may be
prognostic or predictive. A prognostic biomarker measure patient outcome without comparing
the effect of the treatment under study, while a predictive biomarker takes into account both the
effect of the treatment and the patient outcome (Justus, Leffler et al. 2014). Thus, a prognostic
biomarker is evaluated from a single arm study of treated patients where the response of
patients in the presence or absence of the marker is examined, as done in this chapter.
However, for a predictive biomarker, a double arm study is needed, to examine the response of
patients in the presence or absence of the marker, in combination with the treatment effect
(Justus, Leffler et al. 2014)

7.1.2. GAP IN KNOWLEDGE
While the completed and ongoing clinical studies investigated numerous biomarkers of
response, there is still no actionable and reliable clinical biomarker that can be used a predictor
of response for palbociclib treatments. Hence this chapter aims at addressing the following
questions:
1. Would the biomarkers identified in our in vitro studies (Rb and cyclin E) be successful in
predicting response to palbociclib in patients?
2. What proportion of the breast cancer patients would benefit from palbociclib treatment
(based on biomarker analysis)?
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7.2. RESULTS
7.2.1. TCGA ANALYSIS SHOWING DEREGULATION OF RB AND CYCLIN E IN BREAST
AND OTHER SOLID CANCER PATIENTS
Our in vitro and in vivo results thus far have shown Rb and cyclin E can serve as
reliable biomarkers to identify which tumors would benefit from treatment with CDK4/6
inhibitors and its potential combination with autophagy inhibitors. Hence, to estimate the
percentage of patients who would benefit from the combination treatment of palbociclib and
hydroxychloroquine, we analyzed the TCGA database for the expression of Rb and cyclin E at
the mRNA levels.
Analysis of mRNA levels from the breast TCGA database, comprising of 817 breast
cancer patients showed that about 85.4% of all breast tumors had measurable expression of
Rb and low (no overexpression) of cyclin E (Figure 56A). Detailed analysis of the subtypes
within breast cancer showed that a higher proportion of the ER positive breast tumors (97.1%)
were Rb positive and cyclin E negative compared to 40.7% within the TNBC subtype (Figure
56A). This indicates that a large proportion of breast cancer tumors are Rb+ve cyclin E-ve, and
that they could benefit from treatment with CDK4/6 inhibitor and its potential combinations.
Next, we performed a similar analysis within the TCGA database for other solid tumor
subtypes analyzed in this study. Results revealed that 80.8%, 89.3% 86.1%, 92.9% and 95.7%
of ovarian, pancreatic, lung, colorectal and prostate cancer patients respectively are positive for
Rb and have low / no expression of Cyclin-E (Figure 56B). This indicates that a large
proportion of patients with these solid tumors could benefit from treatment with the CDK4/6
inhibitor.
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Figure 56: TCGA analysis showing deregulation of Rb and cyclin E in breast and
other solid cancer patients: A) Alterations in Rb and cyclin E RNA levels in all breast
(n=817), ER+/Luminal A and B (n=321) and TNBC/Basal (n=81) tumors from the TCGA
database of breast cancer patients. B) Alterations in Rb and cyclin E RNA levels in tumors
from patients with ovarian (n=557), lung (n=230), pancreas (n=178), colon (n=379), or
prostate (n=333) cancer taken from the TCGA database. C) Plot showing correlation
between mRNA and protein levels of Rb among 817 tumors from the TCGA database of
breast cancer patients.
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7.2.2. ALTERATIONS IN RB AND LMWE PROTEIN IN BREAST CANCER PATIENTS
While the TCGA analysis provides a reliable estimate of the proportion of patients who
could benefit from the CDK4/6 inhibitor therapy, these analyses are based on the RNA levels of
Rb and cyclin E. Hence, the TCGA analysis cannot accurately predict protein expression of Rb
(Figure 56C), nor can it differentiate between full-length cyclin E (nuclear) and LMWE
(cytoplasmic). Thus, a direct analysis based on protein expression of Rb and LMWE is required
to accurately estimate the breast cancer who would benefit from therapy.
To do this, we examined LMWE and Rb protein expression in tissue microarray
samples from a cohort of 879 early stage breast cancer patients from the NCI Cancer
Diagnosis Program (Hunt, Karakas et al. 2016, Karakas, Biernacka et al. 2016). LMWE and Rb
staining was performed by immunohistochemistry in the formalin-fixed paraffin-embedded
slides of breast cancer tumors from this cohort (Figure 57A). Results revealed that 33% of all
breast tumor samples were positive for Rb and negative for LMWE (Figure 57B), indicting the
patients who could benefit from therapy. Further, this percentage of Rb+ve LMWE-ve tumors
was higher (40%) in the ER positive subtype compared to the TNBC (13.5%) subtype (Figure
57B). Moreover, Kaplan Meier analysis showed that the patient groups which had deregulated
cyclin E or LMWE, Rb+ LMWE+ (red lines) and RB- LMWE+ (purple lines) had a worse overall
prognosis compared to the other subgroups which did not express the cytoplasmic cyclin E,
emphasizing the prognostic ability of LMWE in breast cancer (Figure 57C). This was also true
in both the ER positive and the TNBC subtypes (Figure 57C).
These results suggest that over 33% of all breast cancer patients (Figure 57B)
(regardless of ER status) may benefit from treatment with the palbociclib and its combination
with HCQ, thus highlighting the clinical utility of this regimen.
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Figure 57: Alterations in Rb and LMWE protein in breast cancer patients: A) Representative
images from immunohistochemical analysis of Rb and LMW-E in tumors from the NCI patient
cohort (n=879). Scale bars equal 50 μm. B) Percentage of breast cancer patients exhibiting
alterations in Rb and LMW-E as determined via immunohistochemical staining of tumor samples
from the NCI patient cohort (n=879). C) Kaplan Meier curves showing survival of breast cancer
patients from the NCI patient cohort when classified based on Rb and LMW-E. IHC analysis was
performed by Dr. Cansu Karakas from the Keyomarsi lab.
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7.2.3. CORRELATION BETWEEN EXPRESSION OF RB AND LMWE AND RESPONSE TO
PALBOCICLIB IN ADVANCED ER POSITIVE BREAST CANCER PATIENTS
Next, we wanted to directly test the utility of Rb and LMWE protein expression as
prognostic biomarkers in advanced metastatic breast cancer. For this purpose, we utilized a
cohort of 493 patients with advanced ER+ breast cancer who were/are currently being treated
with the combination of palbociclib and letrozole (aromatase inhibitor) or fulvestrant at MD
Anderson Cancer Center (Figure 58A), whose clinical, pathological and treatment
characteristics are detailed in Table 10,11. Since the biopsy blocks for most of these patients
were not available at MD Anderson, the archival, pre-treatment biopsy specimens from 221
patients from primary tumor and/or local or metastatic recurrence were obtained with consent
for each patient. However, only 109 of the tumors obtained had tissues in sufficient amount for
immunohistochemistry (IHC) analysis (Figure 58A). To estimate the protein expression, these
tissues were then subjected to immunohistochemistry staining and scoring for cyclin E and Rb
(Figure 58C).
The majority (102/109) of the samples were positive for Rb, while only 49.5% (54/109)
were positive for LMWE (Figure 58B). Moreover, about 50% of the treated ER breast cancer
patients were Rb+ve and LMWE-ve, which is the group we predicted would respond best to
CDK4/6 inhibitor therapy (Figure 58B). The Rb+ve and LMWE+ve subgroup accounted for
about 43% of patients and Rb-ve and LMWE+ve subgroup accounted for 6.5% of patient
tumors, and no tumors stained negative for both Rb and LMWE in the patient cohort tested
(Figure 58B). Analysis of clinical and pathologic variables revealed that the patients with
LMWE expression or RB loss exhibited higher rates of progression at 6 and 12 months
(assessed by Kaplan Meier methods), with the heavily treated fulvestrant group experiencing
greater progression rate at 12 months as expected (Table 10,11). The significant variable in
this analysis included tumor stage at diagnosis, exposure to adjuvant chemotherapy, PR
status, Rb and LMWE status. Among these, the expression Rb and LMWE as single variables
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correlated significantly with progression rates for both the palbociclib with letrozole group (Rb:
p=0.02, LMWE: p=0.01) and the palbociclib with fulvestrant treatment group (Rb: p=0.03,
LMWE: p=0.009) (Table 10,11). Moreover, a significantly higher correlation was seen when Rb
and LMWE expression were treated as combined variable in palbociclib with letrozole
(p=0.006) and palbociclib with fulvestrant (p=0.009) treatment groups (Table 10,11).
Univariate Cox proportional hazards model showed that the factors that were
significantly associated with progression-free interval included adjuvant chemotherapy, PR
status, Rb and LMWE status, as measured by hazard ratio, which is a measure of the influence
a parameter under study has on the response to therapy (Table 12). Importantly, Rb and
LMWE (as single and combined variables) were significantly associated with the progressionfree interval with in palbociclib with letrozole treatment group, with hazard ratios of 0.2 for Rb
alone, 3.2 for LMWE alone, and 9.2 for Rb and LMWE combined (Table 12). A similar
correlation was also observed in the palbociclib with fulvestrant treatment group, exhibiting
hazard ratios of 0.09 with Rb alone, 5.2 with LMWE alone, and 23.8 with Rb and LMWE
combined (Table 12). Further, results showed that 81.8% (45 out of 55 patients) of Rb+ve
/LMWE-ve patients exhibited stable disease in response to palbociclib treatment, compared to
62.9% in the other patient groups combined (Figure 59A). Separation of the patients based on
their treatment with palbociclib and letrozole or palbociclib and fulvestrant showed a significant
84.2% and 82.4% response rate (stable disease) respectively, in the Rb+ve LMWE-ve patient
subgroup (Figure 59A). This showed that Rb and LMWE in combination have a good
prognostic value for palbociclib treatment in breast cancer.
Kaplan-Meier progression-free survival (PFS) plots for the 109-patient cohort separated
based on the protein expression of Rb and LMWE revealed that the patients with Rb+ve and
LMWE-ve tumors have the longest PFS time (median >36.5 months), compared to
Rb+/LMWE+ patients (median= 13.4 months) and Rb-/LMWE+ patients who had the shortest
PFS time (median= 4.2 months) (Figure 59B). A similar trend was observed when the
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palbociclib treated ER positive breast cancer patients were separated by letrozole (n=78) or
fulvestrant (n=31) treatment in combination, and correlated with Rb/LMWE expression, where
Rb+ and LMWE- patients had the longest PFS time (median >36.5 months with letrozole; 10.7
months with fulvestrant), compared to Rb+/LMWE+ patients (median= 17 months with letrozole
and 4.7 months with fulvestrant) and Rb-/LMWE+ patients (median= 3.5 months with letrozole
and 4.2 months with fulvestrant) (Figure 59B). Additionally, the concordance indices calculated
based on the multivariate analysis model showed substantial gains when Rb and LMWE were
included as single variables, compared to the model without Rb and cyclin E, and a much
larger increase was observed upon including Rb and LMWE as combined variables (Figure
59C and Table 13).
Collectively, these results provide evidence that LMWE and Rb can serve as reliable
prognostic biomarkers for CDK4/6 inhibitors in advanced estrogen receptor positive breast
cancer patients.
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Table 10: Clinical, pathologic, and treatment characteristics of patients
treated with palbociclib + letrozole
N
Variable
78

All patients
Race
White
Others
Clinical tumor stage at diagnosis
0/I
II
III
IV
Unknown
Tumor Histology
Ductal
Others
Lymphatic/vascular invasion
Yes
No
Adjuvant Chemotherapy
No
Yes
Tumor grade
I/II
III
Progesterone receptor status
Positive
Negative
Rb status
Negative
Positive
LMWE status
Negative
Positive
Rb/LMWE status
Rb+/LMWERb+/LMWE+
Rb-/LMWE+
Bone /soft tissue vs. any visceral
Bone / soft tissue
Any visceral
Prior therapy for metastatic disease
None
Hormonal

55
23
12
20
19
25
1
67
11
52
24
64
14
57
21
69
9
5
73
38
40
38
35
5
51
27
56
4
18

Chemotherapy and/or hormonal

12-month
P value
6-month
progression rate progression rate Univariate)
(%)
(%)
22.2
31.0
0.3
25.1
33.2
14.6
24.1
0.004
28.7
52.5
26.3
36.8
38.1
54.2
0
0
0
0
0.9
21.6
31.2
27.1
27.1
0.2
15.2
24.5
37.5
45.3
0.004
16.1
21.5
48.7
69.2
0.4
25.3
38.9
15.3
15.3
0.02
16.2
26.2
70.8
70.8
0.02
66.7
0
20.3
29.2
0.01
14.4
18.0
30.9
44.2
0.006
14.4
18.0
27.4
41.4
66.7
0
0.03
13.7
20.7
37.1
47.6
0.1
16.6
25.8
25.0
25.0
40.9
50.7
0.2

Time from completion of adjuvant hormonal therapy
(years)
None (de novo metastatic)
< 1 year
> 1 year

42
5
31

*p value calculated after excluding unknown.
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15.8
0
33.0

23.5
0
42.9

Table 11: Clinical, pathologic, and treatment characteristics of patients
treated with palbociclib + fulvestrant
N

31

6-month
progression
rate (%)
17.4

25
6

15.9
20.0

63.8
20.0

7
7
11
6

0
20.0
14.3
46.7

33.3
40.0
31.4
-

25
6

15.3
25.0

54.4
-

Variable
All patients

12-month
P value
progression rate Univariate
(%)
58.0
0.9

Race
White
Others
Clinical tumor stage at diagnosis
0/I
II
III
IV
Tumor Histology
Ductal
Others
Lymphatic/vascular invasion
Yes
No
Adjuvant Chemotherapy
No
Yes
Tumor grade
I/II
III
Progesterone receptor status
Positive
Negative
Rb status
Negative
Positive
LMWE status
Negative
Positive
Rb/LMWE status
Rb+/LMWERb+/LMWE+
Rb-/LMWE+
Bone /soft tissue vs. any visceral
Bone / soft tissue
Any visceral
Prior therapy for metastatic disease
None
Hormonal
Chemotherapy and/or hormonal
Time from completion of adjuvant hormonal therapy
(years)
None
< 1 year
> 1 year

0.2

0.7

0.8
15
16

16.4
17.5

61.0
45.0

16
15

25.0
10.0

80.3
25.0

27
4

19.3
0

55.3
-

0.06

0.6

0.6
28
3

18.4
58.6

0
-

2
29

13.7

56.1

17
14

0
58.4

52.1
79.2

0.03

0.009

0.009
17
12
2

0
52.6
-

52.2
76.3
-

20
1

13.2
23.8

62.8
68.3

9
14
8

16.7
16.4
20.0

68.7
46.7

0.2

0.9

0.5
14
7
10

*p value calculated after excluding unknown.
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Figure 58: Expression of Rb and LMWE in advanced ER positive breast cancer patients
treated with palbociclib: A) Schematic showing the total number of palbociclib treated patient
tissues obtained and stained for Rb and cyclin-E. B) Proportion of 107 breast cancer patients
treated with palbociclib with Rb+/LMWE-, Rb+/LMWE+ or Rb-/LMWE+ status. C) Representative
images from immunohistochemical analysis of Rb and LMW-E in tumors from patients with ER+
breast cancer treated with palbociclib, classified on the basis of response and Rb/LMW-E status.
Scale bars equal 50 μm and insert scale bars equal 20 μm. Patient database were created and
maintained by collaborators from Breast Medical Oncology department at MD Anderson - Dr. Debu
Tripathy, Dr. Meghan Karuturi and Akshara Raghavendra. IHC analysis was performed by Dr.
Cansu Karakas from the Keyomarsi lab.

196

Progressive Disease
Stable Disease

B

10

17

3

50
25
0

30

Progressive Disease
Stable Disease

100

75

45

4

Rb+
Rb+
RbLMWE- LMWE+ LMWE+
(n=55) (n=47) (n=7)

6

13

50
25

32
0

22

n= 55

50
n= 47

25
0

Rb+ / LMWERb+ / LMWE+
Rb- / LMWE+

p = 0.0007
0

10

20

30

Palbociclib + Fulvestrant

1

14

8

1

50
25
0

Rb+
Rb+ RbLMWE- LMWE+ LMWE+
(n=17) (n=12) (n=2)

n= 38

50

n= 35
n= 5

25
0

Rb+ / LMWERb+ / LMWE+
Rb- / LMWE+

p = 0.0061
0

10

20

30

Follow-up Time (months)

C

0.8

Model
Model
Model
Model

without Rb/LMWE
with Rb
with LMWE
with Rb + LMWE

75
n= 17

50 n= 2

n= 12

25
0

C-index

Progression Free Survival

4

75

Follow-up Time (months)

100

3

75

Palbociclib + Letrazole

100

Progression Free Survival

Progression Free Survival

75

3

Rb+
Rb+ RbLMWE- LMWE+ LMWE+
(n=38) (n=35) (n=5)

PFS of all Palbo treated patients

Progressive Disease
Stable Disease

100

2

75

100

n= 7

Palbociclib + Fulvestrant

Palbociclib + Letrazole
Response to Palbociclib

100

Response to Palbociclib

Response to Palbociclib

A

0.7

0.6

p = 0.0093
0

10

20

30

0.5

Follow-up Time (months)

Figure 59: Correlation between expression of Rb and LMWE and response to
palbociclib in advanced ER positive breast cancer patients: A) Proportion of 109
breast patients treated with palbociclib with Rb+/LMW-, Rb+/LMWE+ or Rb-/LMWE+
status and their disease progression (response to palbociclib). B) Kaplan-Meier
curves showing progression-free survival duration (in months) among 109 patients
with advanced ER+ breast cancer classified on the basis of their tumoral expression
of Rb and cyclin E and separated based on letrozole and fulvestrant. Survival curves
were censored at disease progression or date of last follow-up. C) Concordanceindex (C-index) of the multivariate cox model with progesterone receptor, prior
therapy for metastatic disease only (without Rb) and the addition of Rb and LMW-E.
ns:p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. IHC analysis was
performed by Dr. Cansu Karakas, Keyomarsi lab. Statistical analysis was performed
Min Yi, Breast Surgical oncolgy.
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Table 12: Cox model for univariate analyses for the factors associated with
PFS
Factor

Palbociclib + letrozole (n=78)

Age at diagnosis, years
Height (cm)
Weight
Race
White
Others

HR
1.0
0.6
1.0

P value
0.06
0.3
0.8

95% CI
0.9-1.0
0.2-1.7
0.9-1.1

0.3

0.96-1.01

0.5
0.7
0.02

0.2-2.2
0.4-3.9
0.01-0.6

Referent
0.99

0.7
1.3
0.1

Others
Lymphatic/vascular invasion

0.9
Referent

No

1.8

P value
1.0
0.02
0.6

95% CI
0.9-1.1
1.02-1.3
0.96-1.02

0.8

0.9

0.1-6.8

0.6
0.7
0.1

0.2-21.9
0.2-18.7
0.7-55.0

0.7

0.3-7.1

0.8

0.2-3.3

0.09

0.1-1.2

0.6

0.2-14.6

Referent
2.0
1.7
6.1
Referent

Referent

Yes

HR
1.0
1.2
1.0
Referent

Clinical tumor stage at diagnosis
0/I
Referent
II
III
IV
Tumor Histology
Ductal

Palbociclib + fulvestrant (n=31)

0.9

0.2-3.8

0.2

0.7-4.2

0.007

1.4-8.2

0.4

0.2-1.8

0.02

1.2-8.9

0.04

0.04-0.9

1.4
Referent
0.9

Adjuvant Chemotherapy
No
Yes
Tumor grade
I/II

Referent

III
Progesterone receptor status

0.6

Positive
Negative
Rb status
Negative
Positive
LMWE status
Negative
Positive
Rb/LMWE status
Rb+/LMWE-

3.4

Referent

Referent

Referent

Referent
3.2

0.02

1.2-8.2

0.09

0.01-1.4

5.2

0.02

1.3-20.3

0.03
0.04

1.1-19.3
1.3-450.1

0.2

0.6-8.3

0.8
0.7

0.1-4.6
0.1-5.5

Referent

Rb+/LMWE+
2.9
9.2
Rb-/LMWE+
Bone /soft tissue vs. any visceral
Referent
Bone / soft tissue

0.03
0.008

1.01-7.6
1.8-47.4

Any visceral
Prior therapy for metastatic
disease
None

0.03

1.1-6.2

0.9
0.04

0.1-6.8
1.03-6.7

4.7
23.8
Referent

Referent

Hormonal
0.9
Chemotherapy and/or 2.6
hormonal
Time from completion of
adjuvant hormonal therapy
(years)
Referent
None

0.09
Referent

Referent

2.6

Referent

Referent
3.2

1.7
Referent

Referent
0.2

0.3

2.2

Referent
0.8
0.6

Referent

< 1 year

7.32e-16

1.0

0-

2.1

0.4

0.3-13.0

>= 1 year

1.9

0.2

0.8-4.4

0.7

0.7

0.2-3.4
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Table 13: Cox model for multivariable analyses for the factors associated
with PFS
Palbociclib + letrozole
Factor
Progesterone receptor status
Positive
Negative
Prior therapy for metastatic
disease
None
Hormonal
Chemotherapy and/or
hormonal
Rb status
Negative
Positive
LMWE status
Negative
Positive
C-index
CPE
AIC

HR

P value 95% CI

Referent
4.5
0.007

Palbociclib + fulvestrant
HR

P value

Referent
1.5-13.4

NS

Referent
2.4
0.4

0.3-21.4

NS

4.1

Referent
1.5-11.2

NS

0.006

Referent
0.2
0.06

0.04-1.03

Referent
3.2

95% CI

Referent
0.2
0.3

0.01-3.3

Referent
0.03

1.1-8.7
0.76
0.73
153.3
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4.7

0.03

1.1-19.3

7.3. DISCUSSION
Identification of reliable predictive biomarkers for palbociclib has proven challenging,
given the large patient sample that would be required, since a predictive biomarker identifies
factors affecting both patient survival and response to the drug. While previous in vitro studies
showed that Rb, cyclin D, and p16 could predict response to palbociclib (Wiedemeyer, Dunn et
al. 2010, Konecny, Winterhoff et al. 2011, Cen, Carlson et al. 2012), results from Phase II/III
trials showed no significant correlation between drug response and the expression of p16
(Finn, Crown et al. 2015), Ki67, CCND1 amplification (Clark, Karasic et al. 2016), PIK3CA or
ESR1 (Turner, Jiang et al. 2016) mutational status, leaving no established prognostic or
predictive biomarkers (Cristofanilli, Turner et al. 2016). Further, a number of recent clinical trials
with ribociclib (MONALEESA-2) and abemaciclib (MONARCH-1) also incorporated extensive
biomarker analysis testing for a potential correlation between expression of Rb, cyclin D, p16,
PIK3CA mutation and ESR1 mutation Hortobagyi, Stemmer et al. 2016)(Maura N. Dickler
2017) . However, no significant difference in the hazard ratios were observed with any of these
genes or proteins as a single molecule biomarker (Maura N. Dickler 2017)Hortobagyi, Stemmer
et al. 2016).
One consistent observation across the clinical studies is that the tumors from the
resistant patients exhibited no decrease in Ki67 and pRb following CDK4/6 inhibitor treatment
Hortobagyi, Stemmer et al. 2016)(Patnaik, Rosen et al. 2016). However, none of the
biomarkers tested can predict the hyperphosphorylation of Rb (Akli, Bui et al. 2010).
Interestingly, the low molecular weight isoforms of cyclin E (LMWE) has been previously
documented to mediate hyperphosphorylation of Rb (Akli, Bui et al. 2010). This is the
mechanism by which LMWE mediate deregulation of the G1/S checkpoint and resistance to
letrozole mediated G1 arrest. This suggests that LMWE (in combination with Rb) might be the
most reliable biomarker for palbociclib and other CDK4/6 inhibitors as shown in this chapter.
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An interesting observation from our immunohistochemistry analysis was the difference
is the difference in the number of subgroups seen when patients were classified based on
protein expression of Rb and LMWE. In the first cohort of 829 early stage patients, we
observed four subgroups, while in the metastatic cohort of patients who received palbociclib,
the subgroup of Rb- LMWE- patients were not present. Interestingly, this subgroup of patients
had the best prognosis, despite the loss of Rb. Hence it is possible that these patients had
lower proliferation and tumor grade, resulting in better response and hence they did not
metastasize or have relapse of tumor.
Thus, results from this chapter use a dual biomarker strategy and show that Rb and
LMWE proteins are reliable prognostic biomarkers in advanced estrogen receptor positive
breast cancers. Since we did not have a parallel treatment arm in the absence of palbociclib
treatment, the effect of the therapy could not be examined and hence Rb and LMWE could not
be evaluated as predictive biomarkers of palbociclib. Future clinical trial investigations in early
stage breast cancer patients, in the neoadjuvant setting, where patients are treated with either
palbociclib + letrozole or letrozole alone, would reveal the predictive utility of these proteins for
palbociclib treatment. Thus, we propose that a simple immunohistochemical assay for Rb and
LMW-E can be used clinically to identify patients who are likely to have a response to
palbociclib and its combination with autophagy inhibitor.

201

CHAPTER 8: SYNERGISM BETWEEN CDK4/6 AND AUTOPHAGY INHIBITION IN
TNBC AND OTHER SOLID TUMORS

8.1. INTRODUCTION
8.1.1. PRE-CLINICAL STUDIES WITH CDK4/6 INHIBITORS IN TNBC
The cell line based screen performed to examine the sensitivity of a range of breast
cancer lines to the CDK4/6 inhibitor showed that the majority of the cells that are sensitive to
palbociclib belonged to the ER positive subtypes (Finn, Dering et al. 2009). These results led to
further pre-clinical and clinical studies using the CDK4/6 inhibitors in the ER positive breast
cancer, which were highly successful (Asghar, Witkiewicz et al. 2015). However, careful
examination of the cell lines used for the original study revealed that there are numerous HER2
positive and a few triple negative breast cancer (TNBC) cell lines (MDA-MB-435, MDA-MB-231,
HCC1395, HS578T) which were seen to be sensitive to palbociclib treatment, albeit, TNBC
cells comprised a smaller proportion of the sensitive cell lines (Finn, Dering et al. 2009). A more
recent study showed that palbociclib has an effect in the TNBC cell line MDA-MB-231 in vitro
and in vivo and inhibits cancer metastasis in these cells through a DUB3-SNAIL mediated
mechanism. Through this mechanism, CDK4/6 directly phosphorylates the deubiquitinase
DUB3, which is essential to stabilize SNAIL1, a key EMT gene (Liu, Yu et al. 2017). Another
study which examined the subtypes of TNBC and their sensitivity to palbociclib showed that the
luminal AR (LAR) TNBC subtype was most sensitive to palbociclib, with the basal subtype
being the most resistant (Uzma Asghar 2016). They also showed that the basal subtype had a
greater CDK2 high population and higher cyclin E expression than the LAR subtype which
enabled caused them to be resistant to palbociclib induced cell cycle arrest (Uzma Asghar
2016). Thus, these studies suggest potential utility for palbociclib in TNBC subtypes of breast
tumors as well, and this requires further investigation.
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8.1.2. PRE-CLINICAL STUDIES WITH CDK4/6 INHIBITORS IN SOLID TUMORS
Over the recent years, several studies have examined the anti-proliferative and antitumor effect of the CDK4/6 inhibitors in cancers other than breast cancer and Table 14
summarizes these pre-clinical studies. Numerous cancers apart from breast cancer exhibit
upregulation or over activation of the G1/S due to amplification or overexpression of proteins
such as cyclin D1 and CDK4, making them susceptible to CDK4/6 inhibition by palbociclib, as
shown by studies in mantle cell lymphoma (Marzec, Kasprzycka et al. 2006), acute myeloid
leukemia (Wang, Wang et al. 2007), multiple myeloma (Baughn, Di Liberto et al. 2006), ovarian
cancer (Konecny, Winterhoff et al. 2011, Taylor-Harding, Aspuria et al. 2015), lung
adenocarcinoma (Sumi, Kuenzi et al. 2015), pancreatic (Franco, Balaji et al. 2016), prostate
(Comstock, Augello et al. 2013), liposarcoma (Zhang, Sicinska et al. 2014), hepatocellular
carcinoma (Rivadeneira, Mayhew et al. 2010), glioblastoma (Michaud, Solomon et al. 2010,
Cen, Carlson et al. 2012), renal cancer melanoma (Yoshida, Lee et al. 2016) and colorectal
cancer (Lee, Helms et al. 2016). All these studies show that palbociclib treatment of the cancer
cell lines in vitro results in the induction of G1 arrest, growth inhibition and senescence, while
inducing significant anti-tumor effects in xenograft tumors in vivo (Table 14). Further, some of
these studies also examined biomarkers of sensitivity to palbociclib, most of which showed the
importance of the Rb positivity and or loss of p16 for drug response (Konecny, Winterhoff et al.
2011, Cen, Carlson et al. 2012, Franco, Balaji et al. 2016). A study in ovarian cancer also
showed that cyclin E expression mediates resistance to CDK4/6 inhibitor treatment (TaylorHarding, Aspuria et al. 2015).
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Cell
culture

Animal
Model

Palbociclib

Yes

Yes

Rb, p16INK4A,
cyclin E

Lung
adenocarcinoma

Palbociclib

Yes

Yes

-

Pancreatic cancer

Palbociclib

Yes

Yes

-

Prostate cancer

Palbociclib

Yes

Yes

-

Liposarcoma

Palbociclib,
ribociclib

Yes

Yes

CDK4

Hepatocellular
carcinoma

Palbociclib

Yes

Yes

Rb, p16INK4A

Glioma

Palbociclib

Yes

Yes

Rb, p16INK4A

Melanoma

Palbociclib,
abemaciclib

Yes

Yes

-

Colon cancer

Palbociclib

Yes

Yes

-

Mantle cell
lymphoma

Palbociclib

Yes

Yes

-

Acute
myeloid
leukemia

Palbociclib

Yes

Yes

-

Multiple
myeloma

Palbociclib

Yes

Yes

-

Cancer type

Drug

Ovarian cancer

Biomarkers

Table 14: Pre-clinical studies with CDK4/6 inhibitors in other cancers: Summary of
pre-clinical studies in cancers with the CDK4/6 inhibitors
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8.1.3. CLINICAL STUDIES WITH CDK4/6 INHIBITORS IN SOLID TUMORS
The pre-clinical studies detailed above has led to numerous clinical studies in solid
tumors and hematological malignancies, a summary of which is described in Table 15. This
includes clinical studies testing for the safety, toxicity and efficacy of the CDK4/6 inhibitors as
single agent in numerous solid tumors (Sherr, Beach et al. 2016). Most of these studies
showed significant clinical response with the CDK4/6 inhibitors, resulting in pathological
complete response or stable disease in over 40% of the patients treated (Sherr, Beach et al.
2016). For example, a phase I study in 17 heavily pre-treated mantle cell lymphoma patients,
palbociclib treatment exhibited significant reduction in tumor proliferation (as measured by Ki67
and fluorothymidine PET) and Rb phosphorylation in most patients, with 5 out of the 17 patients
achieving a progression-free survival of greater than 1 year (Leonard, LaCasce et al. 2012).
Moreover, in a phase II clinical study of 30 liposarcoma patients whose tumors were Rb
positive and CDK4 amplified, 66% of the patients achieved progression-free status at the end
of 12 weeks, with 8 patients remaining on the study for more than 40 weeks (Dickson, Tap et
al. 2013). Further, to improve the selectivity of the drug treatment, several of these clinical trials
are designed to select patients based on biomarkers identified in pre-clinical studies such as
Rb, loss of p16 and cyclin D amplification (O'Leary, Finn et al. 2016). However, it is not clear if
these biomarkers could be predictive indicators of palbociclib, as none of the aforementioned
trials were designed to examine the predictive value of these biomarkers. Finally, some of the
more recent clinical trials have been designed to test the combination of the CDK4/6 inhibitors
with drugs such as MEK inhibitors (Sherr, Beach et al. 2016).
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Cancer type,
Identifier

Drugs, phase

Trial design

Solid tumors
NCT00141297

Palbociclib
(Phase 1)

Drug dose was established; Stable disease
realized in 19 of 74 patients

Advanced solid
tumors
NCT01237236

Ribociclib
(Phase 1)

Drug dose was established; Stable disease in 14%
of patients

Advanced solid
tumors
NCT01394016

Abemaciclib
(Phase 1)

Dose finding and toxicity studies; drug efficiently
crossed blood brain barrier

Advanced tumors
NCT02187783

Ribociclib
(Phase 2)

Determine efficacy of CDK4/6 treatment in tumors
with p16 loss or cyclin D1/D3 amplification

Mantle cell
lymphoma
NCT00420056

Palbociclib
(Phase 1)

most patients out of 17 showed reduction in
proliferation with PFS of > 1 year.

Mantle cell
lymphoma
NCT01739309

Abemaciclib
(Phase 2)

5 out of 22 patients had partial response and 9
patients with stable disease.

Liposarcoma
NCT01209598

Palbociclib
(Phase 2)

66% of 30 patients were progression-free after 12
weeks with 8 patients on study for >40 weeks

Non-small cell
lung cancer
NCT01291017

Palbociclib
(Phase 2)

8 of 16 patients with CDKN2A loss were
progression-free > 4 months.

Non-small cell
lung cancer
NCT01394016

Abemaciclib
(Phase 1)

In 15 of 31 patients, overall disease control rate
was 49% with 6 month PFS in 26%.

Glioblastoma
multiforme
NCT01394016

Abemaciclib
(Phase 1)

2of 17 patients showed prolonged time to
progression.

Melanoma
NCT01394016

Abemaciclib
(Phase 1)

1 out 26 patients with NRAS mutation and
CDKN2A loss achieved partial response

RAS-mutant
cancers
NCT02022982

Palbociclib
PD0325901
(Phase 1/2)

Phase 1 trial with expansion in KRAS mutant
NSCLC; not reported

RAS-mutant
cancers
NCT02065063

Palbociclib
Trametinib
(Phase 1)

Phase 1 trial with expansion in NRAS mutant
melanoma; not reported

Mantle Cell
Lymphoma
NCT02159755

Palbociclib
Ibrutinib
(Phase 1)

Trial of palbociclib and ibrutinib in previously
treated MCL; not reported

Table 15: Clinical studies with CDK4/6 inhibitors in other cancers: Summary of
completed and ongoing clinical studies with the CDK4/6 inhibitors in other cancers
206

8.1.4. GAP IN KNOWLEDGE
While few studies in TNBC have suggested an efficacy for CDK4/6 inhibition by palbociclib, a
detailed analysis has not been conduction with the goal of improving efficacy and identifying
biomarkers. Further, studies in other solid cancers are still preliminary leaving us with several
unanswered questions:
1. Can Rb and cyclin E be used to identify the most responsive TNBC cell lines?
2. Would the addition of autophagy inhibitor improve efficacy of palbociclib treatment in
TNBC cell lines?
3. Can intact G1/S checkpoint (Rb+ LMWE-) be used to identify responders to palbociclib
among other solid tumor cell lines?
4. Will the combination of palbociclib and autophagy inhibitors be synergistic in other solid
cancers?
Thus, this chapter aims at addressing these questions in detail and devising palbociclib based
treatment strategies for TNBC and other solid tumors.
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8.2. RESULTS
8.2.1. PALBOCICLIB MEDIATED GROWTH INHIBITION IN TNBC CELL LINES
While the CDK4/6 inhibitor, palbociclib is currently used clinically for the treatment of
advanced ER positive breast cancer, we wanted to examine the potential of treating other
subtypes of breast cancer, such as Triple Negative Breast Cancer (TNBC) with CDK4/6
inhibitor treatment, when selected based on reliable biomarkers. The Cancer Genome Atlas
(TCGA) analysis showed that about 64% of TNBC patient tumors (CDK4 - 22%, CDK6 – 37%,
cyclin D – 5%) had deregulation in the CDK4/6-Cyclin D pathway, with mRNA upregulation of
CDK4 and CDK6 being the most prevalent alteration in TNBC tumors (Figure 6A,6C). This
highlights the importance of the G1/S checkpoint in these cancers.
To interrogate the response of TNBC cell lines to CDK4/6 inhibition, we examined 7
TNBC cell lines (HCC38, MDA-MB-231, SUM-159, BT-549, MDA-MB-468, HCC-1806 and
MDA-MB-157) with varying protein expression levels of Rb and cyclin E (Figure 60A), and
examined the ability of Rb and LMWE to predict sensitivity to palbociclib. Palbociclib dose
response studies showed that cell lines that were positive for Rb and negative for LMWE
(HCC38, MDA-MB-231, SUM-159) were significantly more sensitive than cell lines with
deregulated Rb and / or LMWE (Figures 60B,C), exhibiting 6-8 fold lower IC50 values (Figure
60D,E). Additionally, palbociclib treatment resulted in a significant dose-dependent irreversible
G1 arrest with 6 days of treatment and 4 days of recovery in cell lines with intact Rb and Cyclin
E, MDA-MB-231 and SUM-159 (Figures 60F,G). This induction of G1 arrest upon palbociclib
treatment was absent in the cell lines with deregulated Rb and / or LMWE +ve status, MDAMB-468 and MDA-MB-157 (Figure 53F). Moreover, palbociclib treatment in cell lines with intact
Rb and Cyclin E (MDA-MB-231 and SUM-159) resulted in a significant dose-dependent
reduction in colony formation (Figure 61A) and induction of sustained growth inhibition (Figure
61B), but not in cell lines with deregulated Rb and / or LMWE + status (MDA-MB-468 and
MDA-MB-157). Finally, long term treatment (6 days) of TNBC cell lines with the CDK4/6
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inhibitor, palbociclib induced dose-dependent senescence (indicated by an increase in SA-ß
gal activity) only in cell lines that are Rb+ve and LMWE-ve, MDA-MB-231 and SUM-159
(Figure 61C)
Thus, these results demonstrate that CDK4/6 inhibition also has the potential to treat
TNBC cell lines, given that they are chosen based on the expression of Rb and LMWE
proteins.
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Figure 60: Palbociclib mediated induction of growth inhibition and cell cycle arrest in TNBC
cell lines: A) Western blot for Rb and Cyclin-E in Triple negative breast cancer (TNBC) cell lines. B)
IC50 values from drug response experiments in TNBC cell lines treated with palbociclib for 6 days. CE) Impact on the growth of the indicated triple-negative breast cancer (TNBC) cell lines of treatment
with DMSO or increasing concentrations (conc) of palbociclib (0.01 to 12 μM) for 6 days. Crystal
violet staining was performed on day 12 to assess viability and determine the half-maximal inhibitory
concentration (IC50) values (E). F,G) MDA-MB-231, SUM-159, MDA-MB-468, and MDA-MB-157
cells were treated with DMSO or varying concetrations of palbociclib 6 days, allowed to recover for
4 days and subjected to F) cell cycle analysis to assess change in G1 phase and G) cell cycle
analysis to determine the effect of recovery (release) on change in the G1 phase. All data represent
mean±SD from three independent experiments; p-values were calculated in comparison to DMSO
(Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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Figure 61: Palbociclib mediated induction of growth inhibition and senescence in TNBC
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examine reversibility. Cells were then subjected to B) cell counting to assess proliferation and C)
Senescence measurement by SA-ß gal staining and representative images. All data represent
mean±SD from three independent experiments; p-values were calculated in comparison to DMSO
(Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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8.2.2. SYNERGISM BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION IN TNBC
CELL LINES
We next asked if the combination of CDK4/6 and autophagy inhibition may be
synergistic in TNBC cell lines and if Rb and LMWE expression could be utilized to identify
response cell lines. First, we wanted to interrogate if CDK4/6 inhibition via palbociclib treatment
induces autophagy, at levels comparable to that induced in ER positive breast cancer cell lines.
Measurement of Monodansylcadavarine (MDC) staining showed that treatment with palbociclib
at low and on-target doses significantly increased the MDC staining in ER positive and TNBC
cell lines that were Rb+ve and LMWE-ve (MDA-MB-231, SUM-159), but not in TNBC cell lines
with a deregulated G1/S checkpoint (MDA-MB-468) (Figure 62A). Moreover, palbociclib
treatment resulted in significant increase in GFP+ve LC3 puncta in the G1/S checkpoint intact
MDA-MB-231 cells, but not in MDA-MB-468 cells that have a deregulated G1/S checkpoint
(Figures 62B,C). Further, treatment with the lysosomal block, chloroquine (CQ) further
increased the GFF-LC3 puncta in MDA-MB-231 cells, indicating that the autophagy induced by
palbociclib has an intact flux (Figure 62B,C), similar to the autophagy induced in ER positive
breast cancer cell lines.
Since palbociclib mediated CDK4/6 inhibition induces autophagy in TNBC cell lines with
an intact G1/S checkpoint, we next examine if the combination of CDK4/6 and autophagy
inhibition would be synergistic in these cells. Treatment with the combination of low or on-target
dose of palbociclib and autophagy inhibitor, HCQ resulted in greater reduction in colony
formation (Figure 63A) and induction of an irreversible growth inhibition (Figure 63B), in TNBC
cell lines which are Rb+ve and LMWE-ve, MDA-MB-231 and Sum-159. This synergistic effect
was not observed in the TNBC cell lines with deregulated Rb or/ and cyclin E (MDA-MB-157
and MDA-MB-468) (Figure 63A,B), which are also resistant to palbociclib as a single agent.
Finally, treatment with the autophagy inhibitor, HCQ further sensitized Rb+/LMWE- cells (MDA-
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MB-231 and SUM-159) to palbociclib, inducing significantly elevated senescence even at lower
palbociclib doses (Figure 63C).
Thus, these results show that TNBC lines with a intact G1/S checkpoint (Rb+ve /
LMWE-ve) are responsive to treatment with the CDK4/6 inhibitor palbociclib and can be
effectively treated by the combination of CDK4/6 and autophagy inhibition.
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Figure 62: Palbociclib mediated induction of autophagy in TNBC cell lines: A)
Measurement of monodansylcadavarine (MDC) positive acidic vesicles, including
autophagosomes, by flow cytometry in ER positive (MCF7, T47D, ZR75-1) and TNBC
(MDA-MB-231, SUM-159, MDA-MB-468) cell lines treated with varying concentrations of
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GFP-LC3 puncta in MDA-MB-231 and MDA-MB-468 cells treated with 1µM palbociclib
and/or 25µM Chloroquine (CQ) for 48 hours. All data represent mean±SD from three
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unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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8.2.3. SYNERGISM BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION IN TNBC
PDX MODEL
Having shown the synergism between palbociclib and autophagy inhibition in TNBC cell
in vitro, we next examined this synergy in vivo, using patient derived xenograft (PDX) tumors
that has been characterized to be Triple Negative and have high levels of Rb and low Cyclin-E.
Once established, the PDX tumors were randomized into four treatment arms i) vehicle, ii)
palbociclib (25 mg/kg/day), iii) hydroxychloroquine (60 mg/kg/day) and iv) combination of
palbociclib and HCQ for 21 days (Figure 64A).
Treatment with the drug combination of palbociclib and HCQ significantly decreased
tumor growth (Figure 64C), resulting in much smaller tumors (Figure 64B), compared to
treatment with vehicle or palbociclib or HCQ as single agent. Combination treatment of the
PDX tumors also resulted in a significant decrease in tumor weights compared to the other
treatment arms (Figure 64D). Moreover, treatment with the combination of palbociclib and
HCQ significantly prolonged the survival of the mice compared to the other treatment arms
(Figure 64E). Finally, to evaluate the toxicity with the drug treatments, we measured the weight
of the mice during the treatment period and found no significant difference in the weight of the
mice with all the treatment arms (Figure 64F), indicating that the treatment including the
combination is well tolerated.
Thus, these results demonstrate that the combination of CDK4/6 and autophagy
inhibitors are synergistic in TNBC tumors in vivo, given that they have an intact G1/S
checkpoint (Rb+ve LMWE-ve).
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Figure 64: Synergism between palbociclib and autophagy inhibition in TNBC PDX model:
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217

8.2.4. PALBOCICLIB TREATMENT IN OTHER SOLID TUMOR CELL LINES
While the CDK4/6 inhibitor is currently approved for clinical use only in ER+/Her2advanced breast cancer, numerous pre-clinical and clinical studies have shown activity for
Palbociclib in other cancers such as Melanoma, Ovarian, Prostate, Glioblastoma, Gastric,
Colorectal (CRC), Head and neck squamous cell carcinoma (HNSCC), Pancreatic ductal
adenocarcinoma (PDAC) and lung adenocarcinoma (Fry, Harvey et al. 2004, Baughn, Di
Liberto et al. 2006, Michaud, Solomon et al. 2010, Konecny, Winterhoff et al. 2011, Cen,
Carlson et al. 2012, Comstock, Augello et al. 2013, Witkiewicz, Borja et al. 2015, Lee, Helms et
al. 2016, Tao, Le Blanc et al. 2016, Yoshida, Lee et al. 2016, Ziemke, Dosch et al. 2016).
With this rationale, we hypothesized that CDK4/6 inhibition would be effective in other
solid tumors as well, given that Rb and cyclin E are used as biomarkers to predict response. To
test this hypothesis, we examined several Ovarian (HeyA8, 59M, FUOV1), Pancreatic (Panc-1,
BxPc-3), Lung (Calu-1, H358, A549), Colorectal (Colo-205, SW-620, HCT116) and Prostate
(PC3, Du145) cancer cell lines, with varied protein levels of Rb and Cyclin-E (Figure 65A).
Palbociclib dose response studies revealed that cell lines with an intact Rb and low cyclin E (no
LMWE) namely HeyA8, 59M, Panc-1, BxPc-3, Calu-1, H358, Colo-205, SW-620 and PC3,
showed significant dose-dependent growth inhibition upon palbociclib treatment, with low
(within the on-target range) IC50 values (<2uM) (Figures 65B,C). In contrast, cell lines with
loss of Rb and / or high levels of LMWE, such as FUOV1, A549, HCT116 and Du145 showed
significant resistance to palbociclib treatment, with higher IC50 values (4 - 10uM) (Figure
65B,C).
Further, palbociclib treatment for 6 days with 6 days of recovery induced a significant
dose-dependent reduction in colony formation in cancer cell lines with intact G1/S checkpoint,
irrespective of the cancer type (Figure 65D). In contrast, cell lines that have deregulated a Rb
and/or LMWE expression exhibited significant resistance to the induction of palbociclib
mediated reduction in colony formation (Figure 65D).
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Thus, these results indicate that palbociclib mediated CDK4/6 inhibition induces a dosedependent sustained growth inhibition in solid tumor cell lines with an intact G1/S checkpoint.
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Figure 65: Palbociclib treatment in other solid tumor cell lines: A) Western blot of Rb and CyclinE in ovarian, pancreatic (PDAC), lung, colon and prostate cancer cell lines. B) IC50 values from drug
response experiments in the mentioned cancer cell lines treated with palbociclib for 6 days and
recovery for 4 days. C) Dose response studies to measure the impact of treatment with increasing
concentrations (conc) of palbociclib (0.01 to 12 μM) on the growth of the indicated ovarian, lung,
pancreatic, colon, and prostate cancer cell lines for 6 days. D) Clonogenic assay in the indicated cell
lines treated with DMSO (Cnt) or palbociclib (1μM, 5μM) for 6 days and allowed to recover for 6 days.
All data represent mean±SD from three independent experiments; p-values were calculated in
comparison to DMSO (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001.
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8.2.5. SYNERGISM BETWEEN PALBOCICLIB AND AUTOPHAGY INHIBITION IN OTHER
SOLID TUMOR CELL LINES
Given that palbociclib treatment was effective in non-breast tumor cell lines with an
intact G1/S transition, we next wanted to examine if the combination of palbociclib and
autophagy inhibitor, HCQ might be synergistic in these solid tumors resulting in sustained and
irreversible growth inhibition. In cancer cell lines exhibiting expression of intact Rb and low
Cyclin E (and no LMWE), such as HeyA8, Panc-1, BxPc-3, Calu-1, SW-620 and PC3,
combination treatment with palbociclib and HCQ resulting in enhanced reduction in colony
formation, compared to treatment with low dose palbociclib alone (Figure 66A). However, cell
lines with a deregulated G1/S checkpoint (loss of Rb and / or high levels of LMWE), namely
FUOV1, A549 and Du145 showed significant resistance to palbociclib mediated reduction in
colony formation (Figure 66A). Moreover, treatment with the autophagy inhibitor, HCQ further
sensitized the Rb positive LMWE negative cells to palbociclib, thus inducing a sustained and
irreversible growth inhibition in ovarian (HeyA8, 59M), pancreatic (Panc-1, BxPc-3), lung (Calu1), colon (SW620) and prostate (PC-3) cancer cell lines (Figure 66B,C).
Collectively, these results demonstrate the utility of combining palbociclib with an
autophagy inhibitor in solid tumors with an intact G1/S checkpoint.
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Figure 66: Synergism between palbociclib and autophagy inhibition in other solid
tumor cell lines: A) Clonogenic assay to measure colony formation in the indicated solid
tumor cell lines treated with DMSO or 1 μM palbociclib (Palbo) and/or HCQ (15 μM) for 6
days and allowed to recover for 6 days. B,C) Cell counting to assess proliferation of the
indicated solid tumor cell lines treated with 1 μM palbociclib and/or 15 μM
hydroxychloroquine (HCQ) for 6 days and allowed to recover for 4 days to examine
reversibility. p-values were calculated in comparison to cells treated with 1 μM palbociclib. All
data represent mean±SD from three independent experiments; p-values were calculated in
comparison to DMSO (Control) unless indicated. ns: p>0.05; *p<0.05; **p<0.01; ***p<0.001;
****p<0.0001.
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8.3. DISCUSSION
Results from the studies described in this chapter are highly translatable and clinically
relevant since they provide strong pre-clinical data to expand the CDK4/6 inhibitor treatment to
other solid tumors other than breast cancer. Further, analysis across all cancer types (breast,
ovarian, lung, colon, pancreatic and prostate) showed a strong correlation between sensitivity
to palbociclib (measured by IC50 values) and the combined expression of Rb and cyclin E
(specifically LMWE) (Figure 67A). This indicates that the immunohistochemistry based dual
biomarker strategy proposed and tested in chapter 7 can also be employed in other solid tumor
to select for patients who would respond to CDK4/6 inhibition. Further inhibition of autophagy
(genetic ablation of autophagy genes Beclin1 and Atg5 or pharmacological inhibition by HCQ)
further decreased the IC50 value of palbociclib in the RB+ LMWE- cell lines across all cancer
types (Figure 67B). This suggests synergy and potential utility of the combination therapy in
TNBC and other solid tumors.
CDK4/6 inhibitors are not used currently in the clinic to treat non-ER positive subtype of
breast cancer, more specifically, the triple negative breast cancer (TNBC) tumors. However,
early preclinical studies in breast cancer show that a small percentage of the TNBC cell lines
do respond to palbociclib treatment (Finn, Dering et al. 2009, Robinson, Liu et al. 2013).
However, has not been investigated further thus far, possibly because only a small proportion
of the TNBC cell lines appeared to be responsive to CDK4/6 inhibition and there are no reliable
biomarkers to predict the population of responsive TNBC patients. The role of CDK4/6
inhibition in TNBC has gained attention with a recent study that examined the utility of
palbociclib in TNBC cell lines and attempted at identifying the subtype of TNBC that would
respond best to this treatment (Uzma Asghar 2016). In this chapter, we have performed
extensive in vitro and in vivo studies, including treatment studies in TNBC patient derived
xenograft (PDX) tumors, which showed that TNBC tumors would also be responsive to
palbociclib. We also show that the drug efficacy in these cell lines and tumors can be further
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Figure 67: Synergism between CDK4/6 and autophagy inhibition in cancers
with an intact G1/S checkpoint: A) Correlation between palbociclib half-maximal
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increased by the addition of autophagy inhibitors and by using the combination of Rb and
LMWE as reliable markers to predict response. The G1/S checkpoint tends to be more often
deregulated in the TNBC tumors, with a higher proportion of the tumors being Rb negative and
expressing LMWE (Giacinti and Giordano 2006, Karakas, Biernacka et al. 2016). While this
indicates that a smaller proportion of tumors are likely to respond to CDK4/6 inhibitor therapy,
the TNBC tumor subtype have no effective treatments thus far, apart from chemotherapy,
highlighting the importance of this study.
Taken together, the results in chapters 4 through 8 demonstrate that the combination
CDK4/6 and autophagy inhibitor can be utilized to effectively treat solid tumors such as breast
(irrespective of subtype), ovarian, pancreatic, prostate, colon and lung cancer, and that the
expression of Rb and Cyclin-E (LMWE) can serve as effective and reliable biomarkers to
predict response to this drug combination (Figure 67C). The model shows that the inhibition of
CDK4/6 via palbociclib in tumors that have Rb and do not express LMWE, increases ROS,
which in turn activates autophagy and prevents the induction of senescence. Hence combined
treatment with CDK4/6 and autophagy inhibitors further increased ROS levels and induces
senescence.
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CHAPTER 9: MECHANISM OF ACQUIRED RESISTANCE TO PALBOCICLIB

9.1. INTRODUCTION
9.1.1. MECHANISMS OF ACQUIRED RESISTANCE TO CDK4/6 INHIBITION
While ER positive breast cancer patients perform well on the CDK4/6 inhibitors, about
25% of the patients become resistant to the drug within 6 months, and it is expected that all
patients will eventually acquire resistance to the treatment. However, there are very few studies
till date that have examined the mechanisms of acquired resistance to palbociclib and other
CDK4/6 inhibitors. Given the importance of the Rb protein, loss of Rb leading to deregulation of
the G1/S checkpoint is a mechanism of acquired resistance to palbociclib (DeMichele A 2016).
A study in ER positive breast cancer cells showed that acquired resistance to palbociclib arises
from bypass or deregulation of the G1/S checkpoint, and this occurs through CCNE1 (cyclin E)
amplification or loss of Rb (Herrera-Abreu, Palafox et al. 2016). A more recent study in
understanding the mechanism of acquired resistance to abemaciclib, showed that the resistant
clones showed amplification of CDK6 kinase, resulting in increased CDK6 expression and
resistance to reduction of pRb with abemaciclib treatment (Yang, Li et al. 2016). This study also
confirmed the loss of Rb and amplification of CCNE1 in the abemaciclib resistant cells (Yang,
Li et al. 2016).
While most current studies on acquired resistance to palbociclib have focused on the
G1/S checkpoint, there are numerous other pathways that can contribute to drug resistance.
Some of the pathways seen with other targeted therapies including aromatase inhibitors are
mutations of the target genes, activation of alternate growth signaling pathways that can enable
the cells to proliferate even in the presence of the drugs and increased EMT and cancer stem
cell phenotype, which has been strongly associated with therapy resistance in breast and other
cancers (Dean, Fojo et al. 2005, Ma, Reinert et al. 2015).
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9.1.2. CANCER STEM CELLS, EMT AND DRUG RESISTANCE
Cancer stem cells (CSCs) are considered as a population of cells within the tumor that
have a high self-renewal capacity (Siminovitch, McCulloch et al. 1963). Studies have shown
that they can mediated resistance to cancer therapy in several tumor types including breast
cancer (Phillips, McBride et al. 2006, Touil, Igoudjil et al. 2014). In 2003, breast cancer stem
cells were first isolated based on the surface markers CD44 and CD24 as being CD44+/high
CD24−/low population of cells (Al-Hajj, Wicha et al. 2003). Later aldehyde dehydrogenase
(ALDH) was identified as a new marker of breast cancer stem cells (Ginestier, Hur et al. 2007).
Breast cancer stem cells are also characterized by their ability to generate tumors in mice even
when transplanted into mammary fat pad with as low as 100 cells were (Al-Hajj, Wicha et al.
2003). Another feature linked with cancer stem cells is their ability to undergo epithelial
mesenchyme transition (EMT) and metastasis to distant organ sites. EMT is typically
accompanied by decrease of epithelial markers like E-cadherin (CDH1) and increase in
mesenchymal markers such as vimentin and N-cadherin, which transforms the cells into being
higher migratory and invasive (Yang, Mani et al. 2004). Several studies have established a link
between EMT and cancer stemness, including a study in immortalized mammary epithelial
cells, where the expression of the EMT, Snail and Twist induced cancer stem cell phenotype,
concomitant with increase in CD44high CD24low population and enhanced tumorigenicity in vivo
(Mani, Guo et al. 2008).
Further studies have established a link between cancer stem cells and resistance to
therapy, both intrinsic and acquired resistance (Dean, Fojo et al. 2005). For example, ALDH
staining of tumor tissue samples before and after chemotherapy showed a significant
association between ALDH staining and resistance to therapy or worse prognosis (Tanei,
Morimoto et al. 2009). A study in Her2 positive breast cancer also showed that tumor tissues
with high expression of CD44 protein were intrinsically resistant to chemotherapy (Li, Lewis et
al. 2008). Moreover, studies have also shown a link between cancer stem cells and resistance
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to anti-estrogen therapy like aromatase inhibitors (Creighton, Li et al. 2009). This study showed
a significant increase in EMT genes such as MMP2 and MMP3 and an increase in CSC gene
signature post treatment with letrozole when compared to matched pre-treatment samples
(Creighton, Li et al. 2009).

9.1.3. IL-6/STAT-3 PATHWAY – ROLE IN CSC AND BREAST CANCER
Signal transducer and activator of transcription 3 (STAT3) belong to the STAT family of
transcription factors that regulates numerous cellular processes (Banerjee and Resat 2016).
STAT3 is constitutively activated in numerous cancers, including about 50 to 60% of breast
cancer (Banerjee and Resat 2016). STAT-3 is activated upon phosphorylation which results in
dimerization of the STAT3 proteins, which then translocate into the nucleus, where it binds to
the promotor sequence of the target genes and initiate their transcription (Yu and Jove 2004).
One of the common upstream activators of STAT-3 is the IL-6 family of cytokines (Dethlefsen,
Hojfeldt et al. 2013). Studies in breast cancer have shown that IL-6 is secreted by the tumor
microenvironment, which activated the STAT-3 signaling in the breast cancer cells in a
paracrine or fashion allowed the STAT-3 signaling to remain constitutively active (Dethlefsen,
Hojfeldt et al. 2013). The tumor tissue specific expression of STAT-3 indicates that the pathway
plays a major role in breast cancer tumorigenesis (Carpenter and Lo 2014). In vitro and tumor
tissue based studies have shown that the downstream target genes of the STAT-3 pathway are
involved in numerous cellular functions including proliferation, apoptosis, survival, EMT and
metastasis, angiogenesis and cancer stem cells (Banerjee and Resat 2016).
The IL-6/STAT-3 pathway has been shown to be preferentially expressed within the
CD44high CD24low population of breast cancer cells, indicating its role in mediating cancer stem
cells (Marotta, Almendro et al. 2011). A study specifically in ER positive HER2 positive tumors,
HER2 mediated phosphorylation and activation of STAT-3, which causes upregulation of
cancer stem cell and EMT markers, leading to resistance to herceptin treatment (Chung, Giehl
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et al. 2014). Further, combined treatment with a STAT-3 inhibitor in combination with herceptin
caused decrease in CD44high CD24low population and migration, thus reversing the resistance to
herceptin (Chung, Giehl et al. 2014). Another study in HER2 positive breast cancer shows that
PTEN deletion activates the IL-6 inflammatory loop, which induces breast cancer stem cell
population with an EMT phenotype, thus making the cells resistant to anti-HER2 therapy via
trastuzumab (Korkaya, Kim et al. 2012). Further, treatment with an anti-IL6R antibody reverses
resistance to trastuzumab in in vitro and in xenograft models (Korkaya, Kim et al. 2012).
Finally, a more recent study in ER positive breast cancer showed that acquired resistance to
hormonal therapy mediates downregulation of ER and abrogation of the OXPHOS pathway,
resulting in increased expression of CD133high cancer stem cells (Sansone, Ceccarelli et al.
2016). Thus, inhibition of the IL-6 / Notch-3 pathway decreases the CD133high cancer stem cells
and re-sensitizes cells to hormonal therapy (Sansone, Ceccarelli et al. 2016).

9.1.4. TARGETING DNA REPAIR PATHWAY IN BREAST CANCER
Targeting the DNA repair defect or deficiency has been a commonly employed
technique of drug targeting in cancers over the years (Kelley, Logsdon et al. 2014). One of the
most promising targeted therapy developed based on this concept are the PARP inhibitors
(Kelley, Logsdon et al. 2014). Poly ADP ribose polymerase (PARP) plays a crucial role in the
alternate DNA repair pathway termed as base excision repair (BER) (Eustermann, Videler et al.
2011, Langelier, Planck et al. 2011). This pathway is usually activated when there is a defect or
mutation in the homologous recombination (HR) pathway, regulated by the genes BRCA1 and
BRCA2 (Moynahan, Chiu et al. 1999). Thus, cells with a mutation in the BRCA gene are unable
to repair double strand breaks in DNA, forcing them to rely on the PARP dependent BER
pathway (Moynahan, Chiu et al. 1999). This results in synthetic lethality between BRCA
mutation and PARP, causing the BRCA mutant breast cancer cells to be sensitive to PARP
inhibitors induced genomic instability and apoptosis (Kelley, Logsdon et al. 2014). Treatment of
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Brca1−/−, p53−/− mouse model (TNBC tumors) respond effectively to PARP inhibitor,
AZD2281 (Rottenberg, Jaspers et al. 2008). Further, combination of the PARP inhibitor with
cisplatin resulted in improved survival compared to the vehicle and single drug treatment arms
(Rottenberg, Jaspers et al. 2008). Further, a phase II clinical trial to examine the safety and
tolerability of the PARP inhibitor, olaparib in 54 advanced breast cancer patients with BRCA1 or
BRCA2 mutation, showed that 41% of patients had objective clinical response (Tutt, Robson et
al. 2010). This has led to the FDA approval of the PARP inhibitors, olaparib, rucaparib and
more recently niraparib have been for the treatment of advanced BRCA mutant ovarian
cancers (2017, Lin and Kraus 2017). They are currently one of the most promising targeted
therapies under investigation for TNBC, and the combination of the PARP inhibitors with
standard chemotherapy have also been shown to be beneficial for breast cancer patients
(2014, 2017, Lin and Kraus 2017).

9.1.5. GAP IN KNOWLEDGE
Given that studies at understanding the mechanisms of acquired resistance to CDK4/6
inhibition are just beginning to emerge, an extensive exploratory study is needed to identify
drugs that can effectively target the acquired resistant tumors. While Rb loss and CCNE1
amplification, which are known mechanisms of G1/S deregulation, are the currently predicted
mechanisms of acquired resistance, it is possible that the resistant cells have alterations that
are beyond the cell cycle. Hence, experiments performed in this chapter aim at answering
these voids in the current literature and devising a durable and effective treatment strategy for
acquired resistance to palbociclib and other CDK4/6 inhibitors.
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9.2. RESULTS
9.2.1. DEVELOPMENT AND CHARACTERIZATION OF PALBOCICLIB RESISTANT CELLS
To interrogate the mechanism of acquired resistance to palbociclib, the ER positive
breast cancer cell lines, MCF7 and T47D were treated with increased with increasing doses of
palbociclib over a 6-month period (Figure 68A). The treatment was started at the IC50 value of
palbociclib, at 1uM. Once the cells began proliferating at this dose, the concentration was
increased by 2-fold (i.e. to 2uM) and maintained at that dose until the cells proliferate at that
dose. This was continued until the cells reached a dose of 6uM, to generate the palbociclib
resistant cell lines (pool). With the goal of identifying multiple different mechanisms by which
cells might acquire resistance to the drugs, numerous clones were isolated from the resistant
cell pools, of which 3 from each cell lines were utilized for further analysis.
Next, dose response study was performed to examine the proliferation of the three
MCF7 and T47D resistant clones in the presence of palbociclib and results showed a
significant (upto 10-fold difference compared to the parental cells) resistance to palbociclib
(Figure 68B – left and middle panels). Moreover, one of the most resistant clones in each cell
lines (cl3 for MCF7 and cl2 for T47D) were chosen for further analysis and henceforth referred
to as MCF7 Res and T47D Res (Figure 68B – right panel). Additionally, clonogenic assays
showed that palbociclib treatment had no significant on the proliferation of MCF7 and T47D
resistant cells, while inducing a dose-dependent reduction in colony formation the parental cell
(Figure 68C). Moreover, cell cycle analysis showed that palbociclib treatment did not induce a
G1 arrest in the MCF7 and T47D cells (Figure 68D), indicating that the resistant cells are
indeed resistant to palbociclib induced G1 arrest. Finally, to examine if the palbociclib resistant
cells are also resistant to the other CDK4/6 inhibitors such as ribociclib and abemaciclib, dose
response studies were performed, which showed that the palbociclib resistant MCF7 and T47D
cells were also significantly cross resistant to ribociclib and abemaciclib (Figure 68E),
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exhibiting a >5-fold and >10-fold increase in IC50 values respectively (Figure 68F), when
compared to the parental cells.
Thus, these results showed that the acquired resistant cells developed are resistant to
palbociclib and cross-resistant to the other CDK4/6 inhibitors as well.
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Figure 68: Development and characterization of palbociclib resistant cells: A) Schematic
showing the method by which the resistant cells were developed from MCF7 and T47D parental cells.
B) Dose response studies measuring the impact of treating with varying concentrations of palbociclib
(0.01 to 12 uM) on the proliferation of MCF7 and T47D parental and resistant cell lines. MCF7 and
T47D cells parental and resistant cells were treated with palbociclib (Palbo) for 6 days and and
subjected to C) clonogenic assay to measure impact on cell proliferation and D) flow cytometry to
measure effect on cell cycle. E,F) Dose response studies measuring the impact of treating with
varying concentrations of ribociclib or abemaciclib (0.01 to 12 uM) on the proliferation of MCF7 and
T47D parental and palbociclib resistant cell lines, and their corresponding IC50 values (F).
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9.2.2. GENE EXPRESSION PROFILE OF PALBOCICLIB RESISTANT CELLS
Understanding the changes in gene and protein expression between the sensitive
(parental) and the resistant cell lines will help design treatments to overcome drug resistance.
Hence, we performed genome-wide expression analysis via mRNA-seq on the isolated clones
belonging to MCF7 and T47D cell lines to detect change in mRNAs and examine the pathways
altered between the parental and the resistant cell lines (Figure 69A). Results from the RNA
seq analysis by non-hierarchical clustering (clustering based on gene expression) revealed that
2888 genes were differentially expressed (p<0.05) when compared to parental (sensitive)
(Figure 69B), showing that acquired resistance significantly alters the gene expression profile
of the ER positive breast cancer cells.
To understand the functional significance of these mRNA alterations and identify the
pathways that are altered, gene set enrichment analysis (GSEA) was performed which
compared the change in expression between the parental and the resistant T47D cells,
focusing on the 50 hallmark gene sets (Figure 69C). This showed that some of the top
upregulated pathways in the resistant cells include epithelial mesenchymal transition (EMT)
and developmental or cancer stem cell (CSC) associated pathways such as IL-6/STAT-3,
Notch and Wnt signaling pathways (Figure 69C). Further, one of the crucial and actionable
downregulated pathways includes the DNA repair and the double DNA repair pathways (Figure
69C). The estrogen response (early and late) pathways were also shown to be downregulated
in the resistant cells (Figure 69C), indicating that the ER positive breast cancer cells may not
be less dependent on estrogen signaling. Moreover, the list of upregulated pathways also
includes numerous immune response pathways such as Interferon alpha, Interferon gamma,
TNF alpha via NFKb, cytokine biosynthesis and production, cytokine chemokine signaling and
IL-6 STAT-3 pathway (Figure 69C). This indicates that resistance to palbociclib might be
activating an immune response in these cells, and can be investigated in the future as a
potential avenue for therapy.
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Thus, gene expression analysis study showed a distinctly altered gene expression
profile in the resistant cells and identifies numerous pathways that can be potentially targeted
upon acquired resistance to CDK4/6 inhibitors.
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Figure 69: Gene expression profile of palbociclib resistant cells: A) Schematic
showing how the resistant cells and clones were developed and utilized for RNA-seq
analysis. B) Heat map constructed by non-hierarchical clustering to show the differential
expression of genes between the parental and resistant cells as determined by RNA-seq
analysis. Heat map shows genes with FDR < 25% and p-value <0.05. C) Graph showing
the top 12 upregulated and downregulated pathways in the palbociclib resistant cells as
obtained from Gene set enrichment analysis (GSEA) in comparison with the parental cells
from the RNA-seq data.
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9.2.3. EMT AND CANCER STEM CELL PROPERTIES IN PALBOCICLIB RESISTANT
CELLS
Given the phonotypic changes observed in the resistant cells (resistant cells have a
more mesenchymal phenotype compare to the epithelial MCF7 and T47D parental cells), and
the upregulation of the EMT pathway by GSEA analysis (Figure 70A), we next wanted to
directly examine if the resistant cells have acquired an EMT phenotype. To test this, we first
examined the mRNA levels of EMT markers and transcriptional factors in the parental vs
resistant cells via qRT-PCR, which showed a significant decrease in the epithelial marker, Ecadherin and a significant increase in the mesenchymal markers, Vimentin and N-cadherin
(Figure 70B). Further, there was a significant increase in the mRNA levels of the known EMT
transcription factors such as Snail, Twist and Slug in the resistant cells compared to parental
cells (Figure 70B). We also examined the migratory ability of the resistant cells via scratch
assay, which showed that the MCF7 and T47D palbociclib resistant cells had a much higher
percentage of wound closure compared to the parental cells (Figure 70C).
Cancer stem cells (CSCs) are known to mediate resistance to numerous therapies
including aromatase inhibitors in ER positive breast cancer. This, along with the enrichment of
numerous developmental pathways in the resistant cells measured by GSEA analysis (Figure
69C), led us to examine any changes in the cancer stem cell population. First, we examined
the CSC markers and transcription factors, which showed significant upregulation CD133, a
cancer stem cells, CD44, FoxC2 and ALDH1, markers of breast cancer stem cells and other
known stem cell makers, Oct4, Sox2 and Nanog (Figure 70D). Next, we used flow cytometry
analysis to measure the percentage of CD44high/CD24low and ALDH+ve population in the
resistant cells, both established markers and measures of breast cancer stem cells. Results
showed that the palbociclib resistant MCF7 and T47D cells have a significantly CD44high/
CD24low (Figure 71A) and ALDH+ve population (Figure 71B) compared to the respective
parental cell lines, indicating increased cancer stem cells with drug resistance. To further
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confirm this, we performed the mammosphere assay, which measures the sphere forming
ability of the cells, another measure of breast cancer stem cells, with mammosphere formation
over passages (primary and secondary mammosphere) being a better indictor (Rota, Lazzarino
et al. 2012). Results showed that the palbociclib resistant cells have a significantly increased
ability (larger and greater number of mammospheres) to form both primary and secondary
mammospheres compared to the MCF7 and T47D parental cells (Figure 71C).
Thus, these results show that the palbociclib resistant cells have increased EMT and
cancer stem cell phenotype, which might be the significant contributor of resistance in these
cells. Hence, targeting these processes might prove as an ideal strategy to combat drug
resistance.
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Figure 70: EMT properties in palbociclib resistant cells: A) Enrichment plot of the Epithelial
Mesenchymal Transition (EMT) pathway obtained by Gene set enrichment analysis (GSEA)
between T47D resistant and parental cell lines. B) qRT-PCR measuring the mRNA expression
of EMT genes relative to GAPDH in palbociclib sensitive vs resistant cells C) Scratch assay
used to measure migration ability of the MCF7 and T47D parental vs resistant cells and its
quantification (% wound closure). D) qRT-PCR measuring the mRNA expression of cancer stem
cell related genes relative to GAPDH in palbociclib sensitive vs resistant cells. p-values were
calculated in comparison to Parental (sensitive) unless indicated. ns: p>0.05; *p<0.05; **p<0.01;
***p<0.001; ****p<0.0001.
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9.2.4. TARGETING IL-6/STAT-3 PATHWAY IN PALBOCICLIB RESISTANT CELLS
Next, we utilized the gene expression and GSEA data (Figure 62) to identify which
cancer stem cell regulating pathway can be targeting in the palbociclib resistant cells. Given the
recently elucidated role of the IL-6/STAT-3 pathways in modulating cancer stem cells and drug
resistance (Lin, Hutzen et al. 2013, Sansone, Ceccarelli et al. 2016), and the observed
increase in the IL-6/STAT-3 pathway in the palbociclib resistant cells from GSEA analysis
(Figure 72A), we focused on this pathway. As a first step, we examined IL-6 mRNA levels,
which exhibited a >12-fold in the palbociclib resistant cells compared to the MCF7 and T47D
parental cells (Figure 72B). Further, to interrogate the role of STAT-3 in the palbociclib
resistant cells, we treated with two known STAT-3 inhibitors, Stattic and napabucasin
(Marcucci, Rumio et al. 2016), which significantly decreased proliferation of the MCF7 and
T47D resistant cells and these drugs were relatively more specific to the resistant cells
compared to parental (Figure 72C). Napabucasin is a recently developed STAT-3 inhibitor that
has been specifically shown to target cancer stem cells (Marcucci, Rumio et al. 2016, Zhang,
Jin et al. 2016). Hence, we interrogated the role of STAT-3 in increasing cancer stem cells and
mediating drug resistance by CD44high/CD24low measurement and mammosphere assay.
Results showed that treatment with a STAT-3 inhibitor, napabucasin significantly decreased the
CD44high/CD24low CSC population (Figure 72D) and mammosphere formation (Figure 72E).
Thus, these results indicate that the IL-6/STAT-3 pathway plays a crucial role in driving
cancer stem cells and palbociclib acquired resistance ER positive breast cancer.
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Figure 72: Targeting IL-6/STAT-3 in palbociclib resistant cells: A) Enrichment plot of the
IL-6 STAT-3 pathway pathway obtained by Gene set enrichment analysis (GSEA) between
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relative to GAPDH in palbociclib sensitive vs resistant cells C) Dose response studies
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9.2.5. TARGETING DNA REPAIR DEFICIENCY IN PALBOCICLIB RESISTANT CELLS
Given that the DNA repair and double stranded break repair are one of the top
downregulated pathways in the RNA-seq and GSEA analysis (Figure 66A), and that cells
deficient in DNA repair can be hypersensitive to DNA damaging agents and PARP inhibitors,
we examined the possibility of targeting DNA repair deficiency in palbociclib resistant cells.
First, we examined the expression of crucial double strand break repair genes, Rad51, BRCA1
and BRCA2, all of which significantly decreased in the palbociclib resistant MCF7 and T47D
cells compared to the parental (Figure 73B). Further, the sensitivity of the resistant cell to the
PARP inhibitors, olaparib and niraparib were examined through a dose-response assay (72
hour treatment and 9 days recovery), which caused significant dose-dependent reduction in
cellular proliferation specifically in the palbociclib resistant cells compared to the parental
(Figure 73C). A similar response was seen with the Wee1 kinase inhibitor, AZD1775 (shown
previously to induce genomic instability (Vriend, De Witt Hamer et al. 2013), where the resistant
cells exhibit durable and increased sensitivity (Figure 73C). However, as expected, treatment
with the PARP inhibitors (olaparib and niraparib) or the Wee1 kinase inhibitor did not affect the
increase cancer stem cell population in the resistant cells (Figure 73D), indicating these drugs
possible affect the proliferation of the non-cancer stem cell population in the resistant cells.
This indicates that targeting the DNA repair deficiency with PARP inhibitors could be an
effective therapy to treat palbociclib resistance.
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9.2.6. COMBINED TREATMENT WITH STAT-3 AND PARP INHIBITORS IN PALBOCICLIB
RESISTANT CELLS
While PARP inhibitors have anti-proliferative effects in palbociclib resistant cells, they
do not affect the cancer stem cell population, which comprises of >60% of the cells in the
resistant cell lines. Hence we examined if combining the PARP inhibitors with the drugs
targeting the IL-6/STAT-3 pathway would facilitate killing of both the cancer stem cells and noncancer stem population within the resistant cells.
First, to examine the synergy between the two drugs, olaparib (PARP inhibitor) and
napabucasin (STAT-3 inhibitor), we performed dose response studies with 72 hour treatment
(and 9 days of recovery) of both the drugs, followed by calcusyn analysis in the palbociclib
resistant MCF7 and T47D cells. The calcusyn software measures the combined effectiveness
of two drugs from growth inhibition curves, generating combination index (CI) values, with
values CI>1 as meaning antagonism, CI=1 meaning additivity and CI<1 meaning synergism
between the two drugs being tested (Bijnsdorp, Giovannetti et al. 2011). Results indicated that
the combination of the two drugs were highly synergistic, with CI values of 0.65 and 0.75 in the
MCF7 and T47D resistant cells respectively (Figure 74A). Further, the combination of olaparib
and napabucasin significantly decreased colony formation (Figure 74B) and inhibited growth
(Figure 74C), compared to no treatment or treatment with either drugs as a single agent, in
MCF7 and T47D palbociclib resistant cells. Finally, combined treatment with olaparib and
napabucasin increased cell death via apoptosis in the palbociclib resistant cells (Figure 84D),
when compared to no-treatment or single treatment controls. The increase in apoptosis was
observed both at the end of treatment and 72 hour (in the absence of drug) post treatment,
which showed further increase in apoptosis (Figure 74D).
Thus, these results indicate that combined treatment with the STAT-3 and PARP
inhibitors is effective in targeting the palbociclib resistant cells.
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9.3. DISCUSSION
Studies in this chapter have identified novel mechanisms by which the ER positive
breast cancer cells acquire resistance to palbociclib and through detailed gene expression
arrays and validations, found treatment options that could work effectively in the resistant
tumors. Taken together, the results show that targeting IL-6/STAT-3 mediated cancer stem
cells and DNA repair deficiency by PARP inhibitors in combination can effective treat acquired
resistance to palbociclib.
GSEA analysis of the RNA-seq data showed upregulation of numerous cytokine
pathways including the IL-6/STAT-3 pathway. However, the origin or source of the IL-6 has not
been interrogated in this chapter. One possibility is that the IL-6 is secreted by the tumor cells
and undergoes autocrine activation of the pathway. Alternatively, the cytokines including IL-6
may be secreted by cells when they undergo senescence in response to palbociclib in the early
stage of development of the resistant cells. This phenomenon of the senescent cells secreting
cytokines is terms as senescence associated secretory phenotype (SASP), and helps recruit
immune cells to the tumor and eliminate the senescent cells (Coppe, Desprez et al. 2010).
Further, while studies in this chapter show that the IL-6 / STAT-3 pathway mediate the
induction of cancer stem cells, there could be other pathways involved in this process. Results
from chapter 4 show that CDK4/6 inhibition and palbociclib treatment triggers autophagy in the
ER positive cells, which limit the efficacy of palbociclib. Moreover, studies have shown that
autophagy induces and maintains cancer stem cells, mediating chemo-resistance, tumor
recurrence and metastasis (Ojha, Bhattacharyya et al. 2015, Vitale, Manic et al. 2015). Hence,
it is possible that apart from IL-6 / STAT-3, the autophagy pathway might also play a role in the
induction of cancer stem cells in the palbociclib resistant cells.
Finally, GSEA analysis from the RNA-seq show the abundance of immune response
pathways that are upregulated in the palbociclib resistant cells. While breast cancer tumors are
not inherent tumorigenic, recent efforts have focused on making the breast tumors immune hot,
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such that they recruit tumor infiltrating lymphocytes (TILs) and are made sensitive to
immunotherapy such as checkpoint blockade, PD-1, PDL-1 and CTLA-4 therapy (Hartkopf,
Taran et al. 2016). Thus, it is possible that the upregulation of these pathways might be
indicative of immune response in these resistant tumors, which in turn can be targeted by
immunotherapy. However, the model used for resistance studies have limitations since it a
breast cancer cell lines model and is devoid of the system needed to study the effect of the
microenvironment.
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CHAPTER 10: CONCLUSIONS AND FUTURE DIRECTIONS

10.1. MAJOR FINDINGS
Deregulation of the cell cycle is a common hallmark of cancer leading to uncontrolled
proliferation and tumorigenesis. This makes the cell cycle an attractive target for drug
development and have led to the development of the CDK4/6 inhibitors in the recent years. The
CDK4/6 inhibitors, palbociclib and ribociclib are currently FDA approved in combination with
aromatase inhibitors, for the treatment of ER positive breast cancer. Further, they are currently
under clinical investigation for other indications and other cancers, while a third drug,
abemaciclib is under FDA review. Despite these promising clinical advances with CDK4/6
inhibitors, the treatment has some major clinical limitations, addressing which was the main
goal of the project.
First, to understand the mechanism by which the CDK4/6 inhibitor acts, we utilized ER
positive breast cancer cells, MCF7 and T47D and xenograft mouse models developed from the
MCF7 cell lines. Our results showed that palbociclib treatment induced a dose-dependent
induction of sustained growth inhibition, cell cycle arrest (G1 arrest) and ROS-mediated
senescence in vitro and in vivo. The study further demonstrated that on-target (low doses)
inhibition of CDK4/6 via palbociclib failed to mediate a durable and irreversible growth inhibition
or significant senescence in this model system. Upon investigation, it was found that these
doses of palbociclib or genetic inhibition of CDK4/6 triggers autophagy, a stress response
process, that enables the cells to proliferate and survive even in the presence of the inhibitor.
This phenomenon was seen in cell lines in vitro and xenograft tumors in vivo, and mediates
resistance to the induction of senescence by palbociclib (Figure 75).
More significantly, molecular ablation or pharmacological inhibition of autophagy
significantly improves the efficacy of the CDK4/6 inhibitors, palbociclib, ribociclib and
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Figure 75. Overall working model: Schematic depicting the role of CDK4/6
inhibition (i.e., palbociclib [Palbo]) and combined CDK4/6 and autophagy inhibition in
regulating autophagy, reactive oxygen species (ROS), and senescence in cancer
cells with intact G1/S transition.

abemaciclib, resulting in the induction of an irreversible growth inhibition, cell cycle arrest and
senescence even at low doses of the palbociclib. This synergistic effect between palbociclib
and autophagy inhibitors was verified in vivo using two different autophagy inhibitors,
hydroxychloroquine and Lys-05, both of which showed significant improved tumor growth
inhibition and senescence in combination with low dose palbociclib. This synergistic effect
of the combination was also observed in triple negative breast cancer (TNBC) cell lines in vitro
and TNBC PDX models in vivo. Synergism between palbociclib and autophagy inhibition was
also observed in other cancers such as ovarian, lung, colon, pancreatic and prostate
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cancer, where the combination induced a sustained and irreversible growth inhibition even with
low dose of palbociclib.
Further, biomarker identification studies showed that an intact G1/S checkpoint is
crucial for the cancer cells to response to CDK4/6 inhibition and mediate a sustained growth
inhibition and senescence. We show that the intact G1/S checkpoint can be identified by
presence of Rb and absence or low expression of LMWE (low molecular weight isoforms of
cyclin E). This ability of Rb and LMWE (cytoplasmic cyclin E) in combination to predict
response to palbociclib was performed in tumor tissues from palbociclib treated patients, which
showed that Rb and LMWE are reliable prognostic markers for palbociclib, Our immediate
goals are to evaluate the predictive values of Rb/LMWE in pre and post palbociclib treated
patients and interrogate if those patients with an intact G1 to S transition respond better to
therapy as compared to those patients whose tumors show a deregulation of the G1/S
transition. Further, since autophagy induction is a response to palbociclib mediated drug action,
we show that Rb and LMWE can also serve as biomarkers for the combination of CDK4/6
and autophagy inhibitors.
Finally, studies to identify acquired resistance to palbociclib showed that the acquired
resistant cells had a significantly different gene expression profile compared to the parental
(sensitive) cells, with numerous upregulated and downregulated pathways. Functionally, we
show that the resistant cells exhibit IL-6/STAT-3 mediated upregulation of EMT and cancer
stem cell pathways and downregulation of the DNA repair pathway. Thus, targeting these
pathways in combination using STAT-3 and PARP inhibitors proved highly effective in reducing
the cancer stem cell population and inducing cell death in the palbociclib resistant cells. We
also show that there is a strong cross resistance between palbociclib and other CDK4/6
inhibitors, suggesting that alternative drug strategies need to be devised to treat all the patients
who are being treated with any of the CDK4/6 inhibitors.
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10.2. SIGNIFICANCE
Results from this study are highly translatable and clinically relevant with the potential of
making a significant impact on the lives of patients with breast and other cancers.
While there are numerous mechanistic studies with the CDK4/6 inhibitors, no study till
date has examined in the detail dose dependent effect of the drug and its reversibility. Further,
most studies examine a short-term effect of the drug (72 hour treatment with concentrations
lower than 1uM), which based on our studies can only induce a reversible growth inhibition and
G1 arrest. Thus, our study addresses this limitation by examining the time and dose-dependent
effect, making it a very clinically relevant model system to understand palbociclib mechanism.
Notably, the study unravels a novel link between palbociclib mediated CDK4/6
inhibition, ROS, autophagy and senescence. This is the first detailed study till date to examine
the ability of CDK4/6 inhibitors to induce autophagy in breast and other cancers. Given the
protective nature of autophagy, this result has great therapeutic implications, which have been
extensively analyzed in this study. With autophagy inhibitors, such as chloroquine and
hydroxychloroquine being FDA approved, it makes translation of the combination therapy
between CDK4/6 and autophagy inhibitors feasible and highly clinically relevant. Details of the
proposed clinical trial are mentioned in the next section and a draft of the clinical trial protocol is
in the appendix of this thesis.
The proposed clinical trial with the drug combination would significantly improve the
efficacy of the current treatment with CDK4/6 and aromatase inhibitors, and even improve the
overall survival of patients – a result that has not been achieved with the current CDK4/6
inhibitor treatments. This is based on our in vitro and in vivo preclinical data which showed that
the drug combination improves efficacy not just in the presence of the drug, but helps achieve a
lasting or durable effect even after drug removal. Further, the enhanced anti-tumor effect
achieved in the ER positive xenografts and the TNBC PDX tumors in vivo were at a palbociclib
dose of 25mg/kg, which is on-fifth the dose (150mg/kg), used in most pre-clinical studies with
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palbociclib thus far. This suggests that the drug combination can help decrease the dose of
palbociclib in the clinic, which would help lower adverse events in patients and prevent the
need for any therapy discontinuation.
This study also has identified reliable biomarkers for palbociclib, which is the need of
the hour given that none of the previously predicted pre-clinical biomarkers were effective in the
clinical setting. The study is novel since it proposes a dual biomarker strategy, that is simple to
use in the clinical and can effectively identify responsive patients. Moreover, recent
unpublished clinical data shows that the only reliable predictor of drug resistance in patients is
the resistance to reduction in the phosphorylation or the hyperphosphorylation of Rb. Low
molecular weight isoforms of cyclin E (LMWE), one of our proposed biomarkers is known to
hyperphosphorylate Rb, making a clinically relevant biomarker.
Finally, given that CDK4/6 inhibitors are currently the standard of care for ER positive
breast cancer patients, and even responsive patients would eventually acquire resistance to
therapy, understanding the mechanisms of acquired resistance to the drug is important. Thus,
results from this study have identified two clinically relevant and druggable pathways that can
be targeted in combination to effectively combat drug resistance. Further, the gene expression
analysis performed also provided avenues for future research and drug development to target
acquired resistance to CDK4/6 inhibitors.
Taken together, this is a highly comprehensive study that improves the selectivity and
efficacy of CDK4/6 inhibitor treatment in the sensitive setting and has identified ways to target
acquired resistance to the drug.

10.3. FUTURE DIRECTIONS
We report here that cancer cells activate autophagy in response to palbociclib, and that
blockade of autophagy significantly improves the efficacy of CDK4/6 inhibition in vitro and in
vivo in cancers with an intact G1/S transition.
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Thus, this study provides strong pre-clinical data for a biomarker integrated clinical trial
utilizing hydroxychloroquine (or other autophagy inhibitors such as Lys05) to potentiate the
action of palbociclib. Given that HCQ is well tolerated and is currently in clinical trials to reverse
hormonal and cytotoxic drug resistance, we first propose a Phase II clinical trial (in the
neoadjuvant setting) in postmenopausal advanced ER+/HER2- breast cancer patients, treating
them with the combination of low-dose palbociclib (75mg/day compared to the current standard
dose of 125mg/day), HCQ, and letrozole using surrogate biomarkers such as Ki67 staining.
Eligible patients will be selected on the basis of Rb and LMW-E expression assessed from
baseline biopsy specimens. Prior to the combination treatment, patients would receive
palbociclib for a week following which the levels of LC3 would be evaluated by IHC, comparing
it to pre-treatment biopsy tissues. This would help confirm that autophagy is being induced in
the patients upon treatment with palbociclib and provide a clinical rationale for the combination
treatment. Details of this clinical trial protocol, which is currently under evaluation is attached to
the appendix of this thesis.
Results from this clinical trial would further support initiation of a definitive Phase III trial
for the triple combination, possibly even extending this treatment to the TNBC subtype of
breast cancer and other tumors evaluated in this study. Additionally, this would also support the
utility of palbociclib + HCQ combination to treat RB+/LMWE- ER+ve breast cancer in the neoadjuvant setting. We predict that the combination of continuous low-dose palbociclib and HCQ
would be more beneficial than standard-dose palbociclib (21 days on, 7 days off), allowing us
to minimize palbociclib-mediated toxicities, avoid proliferative bursts that occur when
palbociclib is stopped, and prolong overall patient survival – a goal that has not yet been met
with currently approved palbociclib treatment combinations. Finally, given the pre-clinical data
from this study, the combination of CDK4/6 and autophagy inhibition can be extended to the
other CDK4/6 inhibitors as well clinically, further expanding the applicability of the study.
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While results from this study show that CDK4/6 inhibition induces autophagy, the
molecular mechanism by which this occurs is not known. Some of the crucial autophagy genes
such as Beclin-1 or class III PI3K proteins that are present in complex with Beclin-1, such as
Vps34, are phophorylated as a mechanism of regualting autophagy induction (Hammond,
Brunet et al. 1998). These proteins have direct CDK phosphorylation sites, although the role of
CDK4 or CDK6 has not been shown in this process (Abrahamsen, Stenmark et al. 2012).
Moreover, treatment with palbociclib was synergistic with the autophagy inhibitor Spautin-1,
which regulates Beclin-1 through USP proteins (Shao, Li et al. 2014), suggesting that
palbociclib mediated regulation of autophagy might occur at the initiation step. Hence, it is
possible that the drug directly regulates autophagy by phosphorylating and regulating the
activation of the autophagy proteins, Beclin-1 and Vps34, a potential mechanism that needs to
be investigated further.
Another important application of the study would be in the acquired resistance setting.
Results the gene expression and GSEA analysis of the acquired resistant cells showed a
significant enrichment in the immune response pathways. While, the system is not optimal to
examine immune regulation due to the absence of the microenvironment, it still suggests that
acquired resistance might be making the cells immune responsive. This would potentially make
the ER positive breast tumors that have progressed on CDK4/6 inhibitors responsive to
immune checkpoint blockade drugs such as PD-1, PDL-1 or CTLA-4 antibodies among others.
This would open put a new avenue of treatment options for these patients and further advance
the field immunotherapy in breast cancer.
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STUDY SYNOPSIS
Title

Potentiation of palbociclib and letrozole with autophagy inhibition using
hydroxychloroquine in the neoadjuvant setting (title on Pfizer IIT application)
Phase I/II Safety and Efficacy Study of Autophagy Inhibition with Hydroxychloroquine
to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib
plus Letrozole for Stage I-III estrogen receptor-positive and HER2-negative Breast
Cancer

Study Type

Phase I/II, Open Label, Interventional with biomarkers

Overall
Goal

To demonstrate the clinical and biological impact of adding autophagy inhibition using
hydroxychloroquine to palbociclib and letrozole in estrogen receptor-positive and
HER2-negative early stage breast cancer

Objectives
(Phase I)

Primary:
Secondary:
•

Objectives
(Phase II)

Primary:
To determine whether hydroxychloroquine added to low dose palbociclib and letrozole
can increase the proportion of patients whose tumors achieve complete cell cycle arrest
(CCCA, proportion with Ki67 ≤ 2.7%)
Secondary
• To determine the impact of adding hydroxychloroquine to low dose palbociclib and
letrozole on breast tumor indices of proliferation, autophagy, senescence, cell cycle
control and other intersecting pathways
• Determine longer term clinical tumor responsiveness and tumor biomarkers indices
(for patients who have extended pre-operative therapy, maximum 24 weeks)
• To perform exploratory studies on blood-based tumor protein, DNA and RNA
biomarkers
• Obtain additional safety information for the combination of low dose palbociclib,
letrozole and hydroxychloroquine

Design

Single center pre-operative (neoadjuvant)/”window” study, open-label with a lead-in
Phase I dose escalation/safety/feasibility and dose-finding study, followed by a single
arm Phase II efficacy study using primary endpoint of validated surrogate tumor
biomarker of change in Ki67-based complete cell cycle arrest (CCCA)

Sample
Size

Phase I: 18 patients
Phase II: 30 patients

Inclusion
Criteria

1. Signed written informed consent
2. ECOG performance status 0-1
3. Stage I-III estrogen invasive breast cancer, estrogen receptor-positive and HER2negative by ASCO/CAP criteria1, 2. If Stage I, clinical tumor size must be ≥1.5 cm.
4. Female and age ≥ 18 years and postmenopausal defined by:
a. Age ≥ 55 years and 1 year or more of amenorrhea
259

b. Age < 55 years and 1 year or more of amenorrhea with LH and/or FSH
levels in the postmenopausal range
c. Age < 55 with prior hysterectomy but intact ovaries with LH and/or FSH
levels in the postmenopausal range
d. Status after bilateral oophorectomy (≥ 28 days prior to first study treatment)
5. Surgical candidate and appropriate for pre-operative endocrine (endocrine) therapy
6. Normal hematological, renal, hepatic function
a. ANC ≥ 1500 cells/µl
b. Platelet count ≥ 100,000/µl
c. Serum creatinine concentration < 1.5 x ULN
d. Bilirubin level < 1.5 x ULN
e. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3 x
ULN
Exclusion
Criteria

1. Inoperable or metastatic breast cancer based on standard evaluation
2. Inflammatory breast cancer or any clinical T4 disease
3. History of retinal disease or active visual disturbances(normal baseline retinal exam
required)
4. Prior therapy for breast cancer (medical, surgical or radiation therapy)
5. Acute illness, including infections requiring medical therapy, known bleeding
diathesis or need for anticoagulation
6. Treatment with any of the following medications within 4 weeks before the
baseline diagnostic biopsy is taken:
a. Oral estrogens, including hormone replacement therapy (but prior depot
estrogen use not allowed);
b. Investigational agents (or 5 half-lives, whichever is longer)
7. Psychological, familial, sociological or geographical conditions that do not
permit compliance with the study protocol.
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1.0 INTRODUCTION
1.1 Background
1.1.1

Hormone receptor-positive breast cancer

Breast cancer is the most common female cancer in the United States. It is estimated
that 252,710 American women will be diagnosed with breast cancer and 40,610 will die from
the disease in 2017.3 A major cause of death in these patients is disease progression and
incurable metastasis. The SEER database estimates that ~40,000 breast cancer patients a
year either present at diagnosis (n=13,900) with metastatic disease or exhibit progression with
metastatic disease, sometimes many years after completing therapy for early stage disease
(n=36,000).4 Of these, an estimated 30,000 have estrogen receptor (ER)-positive breast
cancers.4 Hence, patients with ER+ metastatic breast cancer (MBC) represent a majority of
breast cancer who die of their disease, the vast majority due to metastatic progression.
1.1.2

Therapies for hormone receptor-positive breast cancer

In early stage estrogen receptor-positive (ER+) breast cancer, the use of adjuvant
endocrine therapy (tamoxifen or aromatase inhibitors) lowers the relative risk of recurrence at
10 years by 45 to 50% and that of mortality by breast cancer death by 30%.5 In the metastatic
setting endocrine therapy can induce responses and delay progression of disease. However, in
the metastatic setting, it has been difficult to demonstrate a survival benefit of endocrine
therapy. Few modern-day trials have compared endocrine therapy to no endocrine therapy in
the absence of chemotherapy since treatment induces clear palliation. More recent trials
comparing single-agent to combination endocrine therapy agents (e.g. aromatase inhibitors
plus the ER downregulator fulvestrant) have yielded mixed results.6, 7 In the last few years, the
addition of biological therapies that were designed to address mechanisms of resistance or with
demonstration of preclinical synergy have shown improvements in disease-free survival when
added to endocrine therapy, but no impact on overall survival - although these trials were not
designed with the statistical power to survival differences, with disease-free survival designated
as the primary endpoint. The addition of the mTOR inhibitor everolimus doubled median
disease-free survival from 4.1 to 10.6 months when added to the aromatase inhibitor
exemestane as second-line therapy and was approved by the FDA with final survival analysis
showing no significant difference in that outcome (median survival of 31.0 vs. 26.6 months).8, 9
Other biological agents such as PI3 kinase inhibitors, histone deacetylase inhibitors and cyclindependent kinase CDK) inhibitors are being actively tested in first, second and later lines of
therapy - so far CDK 4/6 inhibitor palbociclib has been approved by the FDA as outlined in the
next section.
In summary, the treatment of ER+ breast cancer is focused on using endocrine therapy
initially as trials have not shown clear benefits of more aggressive chemotherapy up front, and
such approaches are only recommended for rapidly progressing visceral and high burden
disease. Sequential use of endocrine therapies (including with approved biological drugs
everolimus and palbociclib) upon progression is the standard approach, with a switch to
chemotherapy when it is felt that the tumor is unresponsive to any endocrine therapy.10 In
contrast to HER2+ breast cancer, where the use of HER2-targeted drugs, particularly the
antibodies trastuzumab and pertuzumab have yielded significant survival benefits, the same
advances are lacking in ER, HER2-negative breast cancer, representing a majority of all cases
and hence representing a clear unmet need. Finally, it should be noted that the definition of
hormone receptor-positive breast cancer includes tumors that are positive for either estrogen or
progesterone receptor (ER or PR).1 While the ER+/PR- subgroup is relatively common, about
one third of all cases, and is clearly responsive to endocrine therapy, the same cannot be said
for the rare ER-/PR+ group and hence this trial is only focusing on ER+ cases.
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1.1.3

Palbociclib and use in breast cancer

Palbociclib is a potent and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitor and antiproliferative agent that induces G1 arrest and prevents breast cancer cell growth, most notably in ER+
cell lines and other preclinical models, which led to the clinical development of this class of inhibitors in
hormone receptor-positive breast cancer.11-13 Palbociclib was approved by the FDA in February, 2015
based on improved time to disease progression in the first and second-line settings for ER+/HER2negative metastatic breast cancer (MBC).14-17 In the pivotal first-line Phase III trial, progression-free
survival (primary endpoint) was improved from 14.5 to 24.8 months with the addition of palbociclib to
the standard first-line aromatase inhibitor letrozole.15 In the second-line setting, the addition of
palbociclib to the standard second-line estrogen downregulate fulvestrant in a Phase III trial also
demonstrated a significant improvement in time to progression from 3.8 to 9.2 months.
However in the first line setting, 66% of patients on the palbociclib experienced grade 3 and 4
neutropenia, and adverse events necessitate a palbociclib dose reduction in 36% and discontinuation in
7.4% of patients.15 Additionally, palbociclib must be dosed with a 7-day break, which was shown to be
associated with a proliferative burst in a separate neoadjuvant serial biopsy study.18 Also, a precise
biological mechanism of palbociclib’s action is still unknown and there are no known independent
biomarkers to predict response and/or resistance to palbociclib – many patients do not respond to
therapy, and most importantly, virtually all eventually develop resistance. Biomarkers that may
influence response to endocrine therapy and CDK inhibitors including estrogen receptor-alpha (ESR1)
and PIK3CA mutations, loss of the retinoblastoma protein function, proliferative antigen Ki67
expression, cyclin D 1 amplification or loss of the cyclin-dependent kinase inhibitor p16 have not shown
to be related to palbociclib-associated response or time to progression.13, 17, 19 Importantly, no survival
benefit yet observed in either of the larger randomized trials or smaller Phase II trial, although these
trials were not powered for survival differences and diversity of therapies that patients may receive in
their subsequent management may cloud future survival update analyses.

1.2 Mechanisms of Resistance to Endocrine Therapy and Rationale for the use of Autophagy
inhibition with Hydoxychloroquine
While specific mechanisms of resistance to palbociclib have not been well characterized, there
are several mechanisms of resistance to conventional endocrine therapies such as tamoxifen and
aromatase inhibitors, which include activation of receptor tyrosine kinase signaling pathways (notably
the PI3K/Akt/mTOR pathway), activation mutations in ESR1 and other more general alterations such as
epigenetic regulation of gene expression other intersecting pathways like NFKB and JAK/STAT.20 As
described earlier, mTOR and CDK4/6 inhibition with everolimus and palbociclib are now approved as
biological agents in combination with endocrine therapy, while strategies using inhibitors of PI3K, Akt,
histone deacetylase are undergoing testing, none so far has been able to induce durable enough
responses to affect survival, and clinical resistance still emerges with all available therapies.
Our laboratory research group, led by Khandan Keyomarsi, PhD, Professor of Experimental
Radiation Oncology at MD Anderson, has an extensive investigational track record in area the cell cycle
pathways in breast cancer. We have shown that at low concentrations of the palbociclib, ER+ breast
cancer cells arrest in the G1 phase of the cell cycle, but this arrest is reversible due to the activation of
autophagy. However, at high concentrations of palbociclib, the cells are arrested irreversibly in G1, do
not undergo autophagy and instead undergo senescence. The low concentration of palbociclib are ontarget and are specific for inhibition of CDK4 and CDK6, as shown with siRNA assays where CDK4 and
CDK6 where knocked down. The high concentrations of palbociclib, induce senescence, but these are
off target effects of the drug. We also demonstrated that if we combine palbociclib with an autophagy
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inhibitor such as hydroxychloroquine (HCQ), we can achieve senescence at a much lower (i.e. ontarget) and continuous dosing of palbociclib, in both in vitro and in vivo models. Moreover, concomitant
treatment with HCQ and palbociclib can mediate a synergistic response in ER+ xenograft (MCF7) mouse
tumor volume and weight compared to palbociclib alone. More strikingly, the tumor volumes with
combination treatment did not increase even after the treatment was stopped, while the tumor
volumes with either palbociclib or HCQ alone continuously increased during both the treatment and
recovery phases of the experiment. Combination treatment showed the desired and expected
impairment in autophagic flux. Decrease in Rb phosphorylation, a direct readout of CDK 4/6 inhibition,
was more pronounced with the addition of HCQ. These results suggest that autophagy inhibition
significantly improves the efficacy of low dose (on target) palbociclib in vivo and facilitates the
induction of an irreversible tumor growth inhibition. We propose that palbociclib activates the
autophagy pathway to protect ER+ breast cancer cells from palbociclib-induced senescence and
inhibition of autophagy sensitizes cells to lower doses of palbociclib in vitro and in vivo (Figure 1).
We therefore propose using HCQ to inhibit autophagy in patients treated with low dose (on
target) palbociclib and letrozole to demonstrate enhanced
Figure 1: Model for Hydroxychloroquine to
anti-proliferative effect. An antiInhibit Autophagy and Potentiate Palbociclib
proliferative effect of endocrine therapy
using quantification of the proliferative
Ki67 antigen has been validated as a longterm predictor of outcome. HCQ is a
commonly used and generally safe drug
used to treat malaria and as a remittive
agent for various autoimmune diseases
(see more expanded description in Section
6.2). This trial will therefore provide
evidence of a promising therapeutic effect
with lower dose palbociclib plus letrozole
for a greater therapeutic effect with less
side effects. This is needed before
proceeding with a more definitive trial that
could be potentially practice-changing.
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1.3 Rationale for the Use of Pre-operative (Neoadjuvant) or “Window” Endocrine Therapy
We have chosen to perform this trial using the combination of letrozole, palbociclib and HCQ in the preoperative (neoadjuvant) “window” setting after careful deliberation internally and advice from both
internal and external advisory board members during the process of a grant proposal submission that
led to the successful funding of both the laboratory and clinical trial aims of this project.
The following rationale support this approach:
• Palbociclib is already FDA-approved for metastatic breast cancer with an excellent safety
record. It is currently in several clinical trials in both the neoadjuvant and adjuvant settings.
• Treatment will include letrozole, a standard endocrine therapy as is used clinically for early
stage breast cancer.
• HCQ is an approved drug commonly used for malaria and autoimmune disease and particularly
safe when used at the doses and timeframes proposed (see more expanded description in
Section 6.2).
• This model allows for safe biopsies as needed for the correlative tissue aims and eliminates
artifact and variability due to prior therapies as all patients will be previously untreated.
• The design gives patients and their physicians the option of a brief “window” trial with 4 weeks
on study drug (2 weeks on low dose palbociclib plus letrozole, then 2 weeks with the addition
of HCQ) then to proceed with surgery follow by standard of care, or, if there is a proliferative
benefit with complete cell cycle arrest (CCCA) at the 4 week timepoint, patients can stay on
treatment with the typical full duration of neoadjuvant endocrine therapy, up to 12-20 weeks
longer then proceed with surgery as long as there is no clinical progression or significant side
effect of therapy. This longer duration may allow clinically significant downstaging that has
been shown to improve breast conserving rates and from the study standpoint will allow
additional exploratory observations of the more prolonged effects of palbociclib, letrozole and
HCQ on tumor size and tumor biological endpoints.
There is ample clinical experience and clinical trial to support the use of neoadjuvant endocrine
therapy as method to downstage tumors and allow more patients to undergo breast-conserving
surgery.21 Additionally, the neoadjuvant model is a well-established research tool to assess newer drugs
when added to endocrine therapy to evaluate both clinical as well as biomarker based-responses.22 For
hormone receptor-positive and HER2-negative breast cancer, the use of change in the proliferative
antigen Ki67 pre to post treatment has been extensively validated as index that correlates with the
likelihood of achieving a complete pathological response and with longer term outcomes specifically in
trials.23-31 The key metrics using this model in both the Phase I and Phase II portion are obtained after 2
weeks of low dose palbociclib and then 2 addition weeks with the addition of HCQ (see Sections 2.0 and
3.1).
Therefore, patients can come off study after 4 weeks and proceed with standard therapy
(“window” approach), which would include standard neoadjuvant endocrine therapy (typically
aromatase inhibitor), neoadjuvant chemotherapy if the patient is known to have the stage, grade and
other indices that warrant chemotherapy. Alternatively they can proceed with definitive breast/axillary
node surgery. In addition, if the biopsy after both 2 and 4 weeks show suppression of proliferative index
that is used as the main endpoint of the study (see Section 2.2.1), patient can stay on therapy for the
typical full neoadjuvant endocrine therapy course which is typically 16-24 weeks. These pragmatic
alternatives will maximize accrual and allow patients and their physicians to opt for the best path that
matches the patient’s clinical situation.
Expected results, alternative strategies.
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We expect that autophagy effects will be seen even at low doses of HCQ. However, if our indices
(changes in LC3B/p62 ratio from T1 to T2) do not suggest autophagy inhibition, then we will consider
adding a cohort at 1200 and even 1600 mg day, doses that have been used in other trials. We can also
consider the use of alternative autophagy inhibitors such as Lys05, a more potent chloroquine analog
poised to soon enter clinical trials. In the phase I trials, if we observe too high a rate of CCCA prior to
the addition of HCQ, (eg. 4 or more of 6 in the first cohort), we will lower the PD dose to 75 mg twice a
week (Mon/Thurs). We may encounter problems with compliance or patient refusal to complete all
biopsies. However, in our experience with similar trials, this is rare and we engage the help of patient
advocates for education and outreach. If there are safety concerns raised by the IRB regarding the use
of this experimental, albeit low-risk treatment in a curable population, we will amend our dose-limiting
toxicity (DLT) criteria for dose escalation to be more stringent, and/or only escalate dose if no DLTs (as
opposed to 0-1) are seen in each cohort of six patients.

1.4 Risk/Benefit Assessment
Patients on this study will be receiving standard of care therapy (endocrine therapy with
letrozole) and palbociclib, an FDA-approved and relatively non-toxic therapy that doubles time to
progression in the metastatic setting, but not approved in the adjuvant or neoadjuvant setting (see
additional description of palbociclib in Section 6.1). HCQ is an approved drug used for malaria and
autoimmune disorders that also had a very good safety profile (see additional description of HCQ in
Section 6.2). One concern of retinal toxicity that is typically seen only after prolonged exposure, will be
mitigated by baseline ophthalmological exam covered by the study funding, and exclusion of those who
are felt to be at risk for retinal toxicity as established by the by the American Academy of
Ophthalmology to exclude preexisting maculopathy.32
The benefits of participation of this trial cannot be fully ascertained, but the addition of
palbociclib has been shown to achieve a high rate of complete cell cycle arrest, a surrogate biomarker
of long-term benefit.18 While short term exposure (4 weeks) may not affect outcome, patients who stay
on study for a total of 16-24 weeks prior to surgery may have a greater degree of downstaging and
more conservative surgery (e.g. breast conservation, sentinel node biopsy as opposed to axillary
dissection).

2.0 STUDY AIMS AND OBJECTIVES
2.1 Phase I Safety Component (metastatic disease) Objectives and Endpoints
2.1.1 The primary objective of the Phase I portion in the metastatic cohorts
is to determine the safety of adding hydroxychloroquine to standard
dose palbociclib and letrozole and to determine the recommended
phase 2 dose for hydroxychloroquine.
Primary endpoint is safety, to be assessed continuously using CTCAE
V4.03, with physical examination and laboratory assessments as
indicated on the study schedule
2.2 Phase II Window/Neo-adjuvant Component Objectives and Endpoints
2.2.1

Phase II - Part 1 Primary Objectives and Endpoints
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•

2.2.2

To determine the dose responsiveness of 2 dose levels of hydroxychloroquine added to low
dose palbociclib and letrozole on breast tumor indices of proliferation (including Ki67),
autophagy, senescence and cell cycle control.
Phase II - Part 1 Secondary and Additional Objective and Endpoints

•

Determine longer term clinical tumor responsiveness (tumor volume) and tumor biomarker
indices (for patients who have extended pre-operative therapy, maximum 24 weeks).

•

To perform exploratory studies on blood-based tumor protein, DNA and RNA biomarkers.

2.2.3

Phase II Part 2 Primary Objective and Endpoints

To determine whether hydroxychloroquine added to low dose palbociclib and letrozole can increase
the proportion of patients whose tumors achieve complete cell cycle arrest (CCCA, proportion
with Ki67 ≤ 2.7% comparing T1 to T1 as shown in Figure 2, see Section 5.3.4).
The primary endpoint is the increase in percentage of all patients who achieve CCCA with low dose
palbociclib and letrozole (at week 2, time T1) compared to that of low dose palbociclib and
letrozole with the addition of HCQ (at 4 weeks, time T2).
A previously conducted trial of neoadjuvant aromatase inhibitor (anastrozole) plus standard dose PD
estimated the CCCA probability to be 44% with aromatase inhibitor alone and powered their
study to detect a 50% increase of 44% to 66%6. A 26% CCCA probability was seen with
anastrozole alone and 86% with the addition of standard dose PD. We will aim for a CCCA
reference probability of 50% with low-dose PD + letrozole (T1), adjusting the PD dose from
phase I if needed after the first ten patients (Subaims 1a and 1b).
2.2.4 Phase IIPart 2 Secondary Objectives and Endpoints
• To determine the impact of adding hydroxychloroquine to low dose palbociclib and letrozole
on breast tumor indices of proliferation, autophagy, senescence, cell cycle control and other
intersecting pathways.
• Determine longer term clinical tumor responsiveness and tumor biomarkers indices (for
patients who have extended pre-operative therapy, maximum 24 weeks).
• To perform exploratory studies on blood-based tumor protein, DNA and RNA biomarkers.
• Obtain additional safety information for the combination of low dose palbociclib, letrozole and
hydroxychloroquine.

3.0 INVESTIGATIONAL PLAN
3.1 Overall Design
This is an open label Phase I/II prospective interventional trial with a safety component in metastatic
disease and a “window” component in the neo-adjuvant setting.

Phase I Safety Component:
The Phase I is designed to evaluate the safety and tolerability of adding hydroxychloroquine to standard
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dose palbociclib and letrozole in the metastatic setting and to determine the recommended phase 2
dose for hydroxychloroquine.
This safety component will be completed before the initiation of the window trial (Phase II) in the preoperative setting.

Phase II Pre-operative “Window” Component:
The “window” component of the trial evaluates the combination of pre-operative palbociclib plus
letrozole followed by the addition of hydroxychloroquine (HCQ) for postmenopausal patients with
Stage I-III estrogen receptor-positive and HER2-negative breast cancer ( Figure 2).
Correlative studies using baseline and follow up breast biopsies and blood work are included in the
research plan. The Phase II portion will assess the change in the percentage of all patients who achieve
CCCA when adding HCQ to the palbociclib/letrozole combination.

3.2 Trial Schemata
3.2.1 Trial Overview Schema
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3.2.2 Window Component Schema

FIGURE 2. Schema for pre-operative “window”/neoadjuvant trial. Part 1 dose
responsiveness evaluation followed by Part 2 fixed dose cohort using same design and biopsy
timepoints (T0 [baseline/pretreatment, T1 [after 2 weeks P+L], T2 [after addition of HCQ]),
with option to proceed with surgery right after T2 biopsy or up to 24 weeks from initiation of
therapy. P= continuous low dose palboclib at 75 mg three times a week (Mon/Wed/Fri);
L=letrozole at 2.5 mg daily; HCQ=hydroxychloroquine continuous daily at assigned dose;
N=number of patients; U/S = ultrasound; DLT=dose limiting toxicity.
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Design for the Safety Component/Phase I
A cycle will be defined as 28 days.
The dose of letrozole and palbociclib will be fixed for the safety cohorts at
• Palbociclib: 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days
off treatment to comprise a complete cycle of 28 days
• Letrozole: 2.5mg/d taken orally once daily continuously
Hydroxychloroquine Dose Escalation Scheme
Dose Level (DL) HydroxychloroquineLetrozole
-1

200 mg/d

2.5 mg/d

0 (Starting Dose)

400 mg/d

2.5 mg/d

+1

600 mg/d

2.5 mg/d

+2

800 mg/d

2.5 mg/d

Palbociclib
125 mg capsule taken orally once daily for
21 consecutive days followed by 7 days off
treatment to comprise a complete cycle of
28 days
125 mg capsule taken orally once daily for
21 consecutive days followed by 7 days off
treatment to comprise a complete cycle of
28 days
125 mg capsule taken orally once daily for
21 consecutive days followed by 7 days off
treatment to comprise a complete cycle of
28 days
125 mg capsule taken orally once daily for
21 consecutive days followed by 7 days off
treatment to comprise a complete cycle of
28 days

The dose escalation portion will use a 3+3 dose escalation design to evaluate escalating dose levels of
hydroxychloroquine in combination with palbociclib and letrozole (see dose level table below). enroll 3
patients in the first dose level of the triplet combination. At least 3 patients must complete a treatment
cycle (28 days) with the triple combination and undergo toxicity assessment before any additional
patients are enrolled into higher dosing cohorts. Intrapatient dose escalation or change of dosing
schedule is not allowed. At least 6 evaluable patients are to be treated at a dose level for an MTD/RP2D
to be declared.
•

If 0 out of 3 patients in a dose level experience a DLT in the defined timeframe another 3
patients will be enrolled at the next higher dose level.
• If no more than 1 patient experienced a DLT at a dose level, then more patients will be added
to that cohort to increase the cohort up to six patients at the same dose level
• If no more than one of the first 6 patients treated experiences a DLT, then 3 patients will be
enrolled at the next higher dose level.
• If two or more of the first 6 patients treated within a cohort experience DLT, then this dose
level will be considered not tolerated and the dose escalation will be halted. If two DLTs are
seen in any cohort, no further patients will be enrolled at that level and next level lower will be
declared the RP2D.
The RP2D is defined as the highest dose level at which 6 patients have been treated with at most 1
instance of DLT.
If dose level -1 is found to have unacceptable rates of DLT, accrual will be discontinued.
269

If two DLTs are seen at the starting dose (DL 0), then the HCQ dose will be lowered to 200 mg daily and
six patients will be enrolled and if one or no DLTs are seen, this will be declared the recommended
phase II dose (RP2D).
A Safety Monitoring Committee (SMC) comprised of the PI, Co-PI, Biostatistician and collaborators will
be established to monitor safety throughout the study, review patient data and make decisions prior to
advancing to the next dose cohort.
The SMC will review, at a minimum, the following safety data:
• Vital signs
• Clinical laboratory values
• Physical examination findings
• Adverse events/serious adverse events
• ECOG performance status
The SMC will meet prior to dose escalations in Phase I, prior to opening the Phase II Stage 1 for
determination of the RP2D and prior to opening Phase I Stage 2.After the Phase I has been completed
the SMC will review aggregate safety data on a regular basis approximately every 2 months and on an
ad hoc basis as needed. The study SMC will review all available safety data to determine if this dose
should be declared not tolerated or if any further dose escalation should occur. While dose escalation
decisions will be made based upon data from the first cycle of treatment for each patient within a given
cohort, the SMC will also review safety data from patients receiving additional treatment cycles of the
triple combination.
Based on the review of the data, the SMC will recommend that the study continue as planned,
or may alternatively recommend that the study be placed on hold, that the dose of study drug be
de-escalated, or that the study be terminated. A recommendation of study hold, study drug dose
de-escalation, or study termination would be made in the event of the discovery of an
unexpected, serious, or unacceptable risk to the subjects in the study.
For the purpose of the SMC review, a patient will be considered evaluable if s/he has received at least
75% of the planned dosing of the triplet combination during Cycle 1. If the reason for not receiving 75%
or more of the planned doses is dose-limiting toxicity (DLT), or if a patient has received a dose
reduction, a patient will still be considered evaluable for this SMC review. Patients considered nonevaluable will be replaced.
3.3 Dose Limiting Toxicity Definition
A DLT will be defined as any grade 3 toxicity deemed attributable to either palbociclib or HCQ occurring
in the first 28 day study treatment period, with the exception of neutropenia, for which any of grade 4
or febrile neutropenia event defines a DLT. All adverse events will be classified and graded using CTCAE
V 4.03 criteria.
The decision to open the Phase II window part of the trial will be made after all 6 patients on the
highest dose level All Safety Data will be reviewed and input from the SMC will be used to determine
whether the study proceeds to the “window” part of the trial in the neo-adjuvant setting.

3.4 Phase II Part 1 (neo-adjuvant cohorts)
Pre-operative “Window” Component:
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The “window” component of the trial evaluates the combination of pre-operative palbociclib
plus letrozole followed by the addition of hydroxychloroquine (HCQ) for postmenopausal
patients with Stage I-III estrogen receptor-positive and HER2-negative breast cancer ( Figure 2).
Correlative studies using baseline and follow up breast biopsies and blood work are included in
the research plan. The Phase II portion will assess the change in the percentage of all patients
who achieve CCCA when adding HCQ to the palbociclib/letrozole combination.
To determine the dose responsiveness in the pre-operative setting 2 groups of 6 patients each
will be enrolled at the following dose levels:
Dose Level (DL)
neo- adjuvant cohorts

Hydroxychloroquine

Letrozole

Palbociclib

Group 1
400 mg/d
2.5 mg/d
75 mg/tiw
Group 2
800 mg/d or RP2D
2.5 mg/d
75 mg/tiw
Should the RP2D be < 800mg/d the second group will be receive the RP2D of hydroxychloroquine in
the combination as determined in the Phase I.

3.5 Phase II Part 2 Window/Neo-adjuvant Component
The dose defined in the Phase I portion as RP2D will be used in the Phase II Stage 2 part of the study.
The design for both Phase II Stage 1 and 2 components are the same except for the 2 HCQ dose levels in
Stage 2 whereas the HCQ dose is fixed at the recommended Phase II dose for the Phase II portion.
The dose of palbociclib for both Stage 1 and 2 is fixed at a dose of at a dose of 75 mg orally three times
a week (Mon/Wed/Fri) continuously without a break. After 4 weeks (T2), the primary endpoint will
have been obtained. If the T1 and T2 Ki67 determination show CCCA (Ki67 ≤ 2.7%) that patient may
elect to stay on therapy for an additional 3 to 5 four-week cycles (week 16 to 24 as shown on Table X)
before proceeding with definitive surgery. Details on dosing and dose adjustments are shown in
Sections 6.14 and 6.23.Using the same population, treatment and biopsy schema, 30index patients will
be enrolled for the phase II Stage 2 portion of the trial.
3.6 Phase II Patient Evaluability
Patients who meet the eligibility criteria and complete a full 4 weeks of therapy (14 days of low-dose
palbociclib plus letrozole and 14 days of dose palbociclib plus letrozole with HCQ) will be considered
evaluable for Phase II. In addition, the completion of biopsies at T0, T1 and T2 with interpretability of
Ki67 are required for evaluability.
3.7 Replacement of Patients
Patientswho are not evaluable for dose-limiting toxicity in the Phase I portion and those not evaluable
for Ki67 at T0, T1 and T2 in the Phase II portion will be replaced.
3.8 Target Accrual
A total of 60 patients will be enrolled to the study. This includes 18 patients (6 per dose cohort at 400,
600 and 800 mg of HCQ daily) in the Phase I metastatic portion, 12 patients in the neo-adjuvant Phase II
Part 1 and 30 patients (25 needed for statistical plan and 5 expected to drop out) for the Phase II Part 2
portion.

4.0 PATIENT SELECTION
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4.1 Inclusion Criteria
Patient eligibility criteria include all of the following:
1. Signed written informed consent
2. ECOG performance status 0-1
3. Female and age ≥ 18 years and postmenopausal defined by:
a. Age ≥ 55 years and 1 year or more of amenorrhea
b. Age < 55 years and 1 year or more of amenorrhea with LH and/or FSH levels in the
postmenopausal range
c. Age < 55 with prior hysterectomy but intact ovaries with LH and/or FSH levels in the
postmenopausal range
d. Status after bilateral oophorectomy (≥ 28 days prior to first study treatment)
4. Adequate hematological, renal, hepatic function defined as follows:
a. ANC ≥ 1500 cells/μl
b. Platelet count ≥ 100,000/μl
c. Serum creatinine concentration < 1.5 x ULN
d. Bilirubin level < 1.5 x ULN
e. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3 x ULN
f.

Alkaline phosphatase ≤ 2.5 ULN

5. Metastatic cohorts (Phase I): Diagnosis of Stage IV estrogen positive breast cancer, estrogen
receptor-positive and HER2-negative by ASCO/CAP criteria1,2
6. Metastatic cohorts: Must be a candidate for treatment with CDK4/6 inhibitor as standard of care
7. Metastatic cohorts (Phase I): No prior exposure to CDK 4/6 inhibitors.
8. Neoadjuvant cohorts (Phase II): Diagnosis of Stage I-III estrogen positive breast cancer, estrogen
receptor-positive and HER2-negative by ASCO/CAP criteria1, 2. If Stage I, clinical tumor size must
be ≥1.5 cm.
9. Neo-adjuvant cohorts(Phase II): Surgical candidate and appropriate for pre-operative endocrine
therapy

4.2 Exclusion Criteria
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Patient exclusion criteria include any of the following:
1. Neo-adjuvant cohorts (Phase II): Inoperable or metastatic breast cancer based on standard
evaluation
2. Inflammatory breast cancer
3. Neo-adjuvant cohorts: clinical T4 disease
4. History of retinal disease
5. History of active visual disturbances (normal baseline study-specified retinal exam required)
6. Neo-adjuvant cohorts: Prior therapy for breast cancer (medical, surgical or radiation therapy)
7. Acute illness, including infections requiring medical therapy,
8. Known bleeding diathesis or need for anticoagulation
9. Neo-adjuvant cohorts: Treatment with any of the following medications within 4 weeks
before the baseline diagnostic biopsy is taken:
a. Oral estrogens, including hormone replacement therapy (but prior depot estrogen use not
allowed)
b. Investigational agents (or 5 half-lives, whichever is longer)
10. Required concomitant use of any drug that is a strong CYP3A inhibitor.
11. Psychological, familial, sociological or geographical conditions that do not permit
compliance with the study protocol.

5.0

STUDY PROCEDURES AND SCHEDULE OF ASSESSMENTS

5.1 Patient Identification
Eligible patients will be referred by members of the MD Anderson Department of Breast
Medical Oncology or screened through electronic medical records and our Departmental database.

5.2 Schedule of Assessments
Table 1 – Study Procedures and Assessments Phase I
Baseline
Day
Scheduling
Window
Laboratory

-14d

C1
W2

C1
W3

C1
W4

C2
W5

C2
W6

C2
W7

C2
W8

C3+
W1

D1

D8
+/- 2

D15
+/- 2

D22
+/- 2

D1
+/- 2

D8
+/- 2

D15
+/- 2

D22
+/- 2

D1
+/- 2

+/- 2

X

X

X

X

X

X

X

X

X

Within
30d
X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

+/- 2

XA

Adverse event
assessment)
Physical Exam/
Weight/Vital Signs
ECOG performance
status evaluation
Ophthalmologic
Exam
Imaging

C1
W1

XA

Off
Study

X
XB

X

XA

X
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Assessments
Palbociclib

X

X

HCQ
Letrozole

x

x

X

X

X

X

X

X

X

X

X

X

X

X

X

X

x

x

x

x

x

x

x

x
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Table 2 – Study Procedures and Assessments Phase II
Surgery (“window” option)
Baseline
Day
Scheduling
Window
Laboratory
Adverse event
assessment)
Physical Exam/
Weight/Vital Signs
ECOG performance
status evaluation
Ophthalmologic
Exam

-14d

Off
Study

W1

W2

W3

W4

W6

W8

W12

W16

W20

W24

D1

D8
+/- 2

D15
+/- 2

D22
+/- 2

D36
+/- 2

D50
+/- 2

D64
+/- 2

D96
+/- 2

D124
+/- 2

D152
+/- 2

X

X

X

X

X

X

X

X

X

Within
30d
X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

+/- 2

XA

XA
X
XB

Breast ultrasound

XA

Research blood

XA

Research biopsy
Low dose palbo +
letrozole
HCQ

Surgery (extended option)

X

X
X
X

A

X

X
X

X

X

X
X

X

X

X
X

X

C

X
X

X

C

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Abbreviations: W=week (week 1 is the same as day 1 prior to starting palbociclib); palbo = palbocilib; HCQ = hydroxychloroquine
Laboratory assessments: Baseline, W2, W4 and every 4 weeks thereafter until off study labs include CBC/differential, electrolytes, BUN, creatinine,
AST, ALT, Total Bilirubin, Alkaline Phosphatase. CBC/diff done with every lab draw at the timepoints described in the study calendar. Baseline only: PT,
PTT, urinalysis with microscopic exam
Superscripts:
A=Phase II: done within 2 weeks prior to starting therapy (low dose palbociclib/letrozole); Phase I: Any imaging assessments already completed during
the regular work-up of the patient within 28 days prior to starting study treatment, including before signing the main study ICF can be considered as
the baseline images for this study
B= done within 8 weeks of starting study medication;
C=third biopsy done either at W4 for patients going on to surgery at that time, for those waiting until between week 20-24, biopsy done preoperatively. Patients who know in advance that they will proceed with surgery at T2 will not need a biopsy and biomarkers will be measured
on the surgical specimen.

5.2.1 Baseline Assessments
All patients will undergo a baseline standard evaluation for newly diagnosed breast cancer
including (note that some baseline tests can be done prior to day 1 (week 1) as shown on Table 1):
• Review of systems all organ systems will be examined.
• Physical examination, vital signs, weight, height, and evaluation of ECOG performance status.
• Standard of care pathological diagnosis of breast cancer, imaging (Phase II:breast ultrasound;
Phase II: CT, MRI) and clinical staging.
• Laboratory studies: CBC/differential, electrolytes, BUN, creatinine, AST, ALT, Total Bilirubin,
Alkaline phosphatase, PT, PTT
• Urinalysis
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•

Ophthalmological exam per latest guidelines of the American Academy of Ophthalmology
(AAO) for baseline screening with HCQ treatment.
Fresh Tumor Biopsy (Phase II only)
Research blood draw (Phase II only)

•
•

ECOG performance status
Grade ECOG status
0 - Fully active, able to carry on all pre-disease performance without restriction
1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary
nature e.g., light house work, office work
2 - Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about
more than 50% of waking hours
3 - Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
4 - Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
5 - Dead

5.2.2

Evaluation During Study Phase II
Patients will be evaluated with an organ-specific review of systems and physical exam at
weeks 2, 3, 4, and those who choose and are eligible to go beyond the “window period” (as
described in Sections 1.3, 3.2 and 5.2.3) and stay on study until definitive surgery at week 16
to 24 will undergo additional evaluation at weeks 6, 8 and every 4 weeks thereafter until the
last pre-operative visit between week 16 and 24 at the discretion of the medical and surgical
oncologist as shown on Table 1.

5.2.3

Treatment Duration
5.2.3.1 Phase I
Patients will receive treatment for a maximum of 24 weeks if receiving clinical benefit as
determined by the treating physician.

5.2.3.2 Phase II
Following the study schema (Figure 2) patients are expected to complete 28 days of study
treatment followed by surgery for the “window option”, with an off study visit after surgery,
and will be monitored for adverse events up to 30 days after the last dose of study drug.
Patients whose tumors at T1 biopsy show Ki67 > 10% will be required to come off study and per
standard of care would typically be recommended to proceed to definitive surgery or standard
neoadjuvant chemotherapy. All other patients will continue on study therapy and at T2 (week
4), patients and their physicians can opt to either come off study and proceed with definitive
surgery or continue for 12 to 20 additional weeks (between weeks 16 and 24 as shown on Table
1) if CCCA (Ki67 ≤ 2.7%) is achieved at both T1 and T2 and there is no evidence of clinical
progression (25% increase in volume by ultrasound) up until the time of definitive surgery.
5.2.4

End of treatment visit and Follow up assessments
Patients who discontinue study treatment, will be followed for 30 days after stopping the study
drugs for assessment of safety (i.e., assessment of AEs and/or serious AEs [SAEs] and
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concomitant medications) and resolution of any treatment related toxicity. Patients continuing
to experience toxicity at this point following discontinuation of treatment will continue to be
followed at least every 4 weeks until resolution or determination, in the clinical judgment of
the investigator, that no further improvement is expected.
5.2.5

5.2.6

Early discontinuation
Patients who come off trial early will be asked to return for the off-study assessments as
detailed in Table XX. In the event of a continuing AE, the patient will be asked to return for
follow-up until resolution or stabilization of the AE..
Review of Systems and Physical Exam
A full review of systems that covers all of the domains and systems represented in CTCAE C
4.03 toxicity criteria will be performed at screening/baseline. Subsequent physical exams may
be limited and should be focused on sites of disease to explore clinical signs and symptoms.

5.2.7

Laboratory Assessments
CBC/differential, electrolytes, BUN, creatinine, AST, ALT, Total Bilirubin, Alkaline
Phosphatase,

5.2.8

Imaging assessments Phase I
Tumor response will be assessed according to RECIST Version 1.1. Patients should have at
least one documented measurable lesion (per RECIST v1.1) or in the absence of measurable
disease, have at least one lytic or mixed (blastic/lytic) bone lesion at study entry.
Imaging assessments will be performed as per standard of care at screening within 28 days
prior to first dose of study treatment, at 8 weeks (+/- 1 week) from day one of study
treatment and subsequently every 8-12 weeks (+/- 2 weeks) thereafter.
Tumor response should be assessed using the same imaging method throughout the study.

5.2.9

Imaging assessments Phase II
Methods for ultrasound evaluation and volumetric measure of response
Grayscale and power Doppler ultrasound will be performed on the breast and regional nodal
basins using a Philips iU22 system or Sonoline Antares systems equipped with a 5- to 13-MHz
broadband linear transducer. Ultrasound images of the index tumors and index nodes will be
captured in the longitudinal and transverse planes with three dimensions measured. The size
of the index tumors and index nodes will be reported in three dimensions to allow for
volumetric calculation. The percent change in volume will then be calculated and reported to
determine response.

5.3 Correlative Biomarker Studies
5.3.1

Biopsies, Tissue Handling and Analysis

All biopsies will be done under ultrasound guidance by a member of the research
team using standard of care imaging-guided biopsy. Local anesthesia and
hemostasis protocols will be used as per standard protocol. Core needles of
18 of 16G size will be used and 3-4 core biopsies will be obtained. The first
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core will be placed in standard 10% formalin, and all other cores will be placed
in a cryovial and snap frozen in liquid nitrogen.
All of the correlative studies (unless otherwise indicated) will be performed in the
laboratory of Dr. Khandan Keyomarsi located in the Zayed building at 6565 MD
Anderson Blvd, Houston, Texas, 77030. For all the correlative analysis we will
use tumor tissues collected from the biopsies and at surgical resections.
Cyclin E, and Rb immunohistochemistry (IHC) assays. FFPE tumor tissue slides will be
prepared from paraffin imbedded blocks per standard methodologies and subjected
to IHC analysis with 2 different antibodies: cyclin E and Rb:
Cyclin E: the anti-human C-19 polyclonal antibody (Santa Cruz Biologicals) at 1:2000
dilution will be used to stain each slide. Each slide will be scored for percent nuclear
and percent cytoplasmic positive staining. Only tumor cells with greater than 5%
nuclear or cytoplasmic positivity are considered as cyclin E positive. Nuclear and
cytoplasmic staining scores are assigned according to the staining intensity (0 = no
staining, 1 = blush staining, 2 = weak staining, 3 = intermediate staining and 4= strong
staining). The nuclear and cytoplasmic scores are then combined, and four
immunophenotypes are identified. First, breast tumors will be considered to be
negative for cyclin E when staining is not detected in the nuclei or cytoplasm
(phenotype 1). Second, in cases determined to be cyclin E+, if the nuclear staining
score exceeded the cytoplasmic score, cyclin E expression is defined as predominantly
nuclear (phenotype 2). Third, when the nuclear and cytoplasmic staining scores are
equal, cyclin E expression is considered to be both nuclear and cytoplasmic
(phenotype 3). Fourth, if the cytoplasmic staining score is higher than the nuclear
score, cyclin E expression is considered to be predominantly cytoplasmic (phenotype
4).
Rb: The anti-human Clone 4H1 mouse monoclonal antibody (Cell Signaling
Technology, Denvers, MA) at 1:100 dilution will be used to stain each slide. Each slide
will be scored separately for intensity of staining and percentage of positive cells.
Staining intensity will be scored as follows: 0, no staining; 1, weak positive (faint
yellow staining); 2, intermediate positive; and 3, strong positive (brown staining). The
number of positive cells will visually be evaluated and stratified as follows: <1%, 0
(negative); 1 to <5% positive cells, 1 (weak); 5-50% positive cells, 2 (moderate); >50%
positive cells, 3 (strong). The sum of the staining intensity and percentage of positive
cell scores will be used to determine the staining index for each section, with a
minimum score of 0 and maximum score of 6; scores >1 will be defined as Rb
positivity.
5.3.2

Whole Blood/Plasma Biospecimens
Blood specimen will be collected as shown on Table 1 at baseline, week 2 and week for
patients on the “window” option and for those who stay on study until surgery will be
collected at weeks 6, 8 and every weeks thereafter until surgery. Each blood draw will be to
collect 2 7.5 mL tubes – one for plasma (green top) and the other for serum (red top).
Blood will be processed immediately following collections – tubes will be gently inverted
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and kept at room temperature prior to centrifuging, and clotted tube (red top) will have
serum aspirated, while the green top tube will have plasma aspirated – both being
aliquoted in 0.5 mL cryovials and placed in a -20⁰C freezer (and stored long term at -80⁰C).

5.3.3

Ki67 Tumor Assay and Scoring

CLIA-approved Ki67 staining will be performed using anti-Ki67 rabbit monoclonal antibody (isotype
IgG1κ, clone MIB-1, DAKO) in the diagnostic Immunohistochemistry Laboratory of Department of
Pathology using an established protocol. Briefly this protocol includes de-paraffinization (30 minutes
at 72°C)and rehydration with antigen retrieval performed at 100°C for 20 minutes with Tris-EDTA
buffer, pH 6.0. Endogenous peroxidase is blocked with 3% peroxide for 5 minutes. Primary anti-Ki67 antibody (Dako, clone MIB-1) is applied at 1:100 dilution for 15 minutes. Post primary antibody
detection is carried out using a commercial polymer system (Bond Polymer Refine Detection, Leica),
and stain development is achieved by incubation with DAB and DAB Enhancer (Leica).
Ki67 staining will be evaluated in whole tissue sections without focusing on the hot spots. The
staining will be quantitatively assessed by automated image analysis using the Aperio ScanScope AT2
scanner (Leica Biosystems, Inc., 1700 Leider Lane, Buffalo Grove IL, 60089). All Ki67 immunostained
slides will be scanned at 20 X magnification. As Ki67 is a nuclear stain, the Genie nuclear v9.1
algorithm will be used to create a custom-made classifier. A color graphic phase of image analysis is
afterward performed using red, orange, and yellow (high, medium, and low reaction, respectively)
to represent positive cells, and blue to represent negative ones. A curvature threshold adjustment is
made to de-cluster or break up large groups of closely apposed nuclei when needed. The original
factory algorithm is also adjusted to avoid false positives by lowering the Cytoplasmic Intensity
settings. All algorithm adjustments are tested to assure accurate detection of positive and negative
nuclei.

5.4 Concomitant Medications
In general, the use of any concomitant medication or therapies deemed necessary for the care of
the patient is permitted.
5.5 Banked biospecimens
Leftover blood and tumor samples which are not consumed for planned study testing will be
retained for potential additional testing at a later date (i.e. if newer technologies become available)
under the same objectives. Samples will be retained at a secure storage facility ( ) in case there is
need for retesting or additional testing. Samples will be stored for up to 10 years or until termination
of this study.

6.0 INVESTIGATIONAL AND NON-INVESTIGATIONAL AGENTS
6.1 Palbocilib
6.1.1

Description of palbociclib
Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6, which are downstream of
signaling pathways that lead to cellular proliferation. In vitro, palbociclib reduced cellular
proliferation of ER-positive breast cancer cell lines by blocking progression of the cell from G1
into S phase of the cell cycle. Treatment of breast cancer cell lines with the combination of
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palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb)
phosphorylation resulting in reduced E2F expression and signaling, and increased growth
arrest compared to treatment with each drug alone. In vitro treatment of ER-positive breast
cancer cell lines with the combination of palbociclib and antiestrogens leads to increased cell
senescence, which was sustained for up to 6 days following drug removal. In vivo studies
using a patient-derived ER-positive breast cancer xenograft model demonstrated that the
combination of palbociclib and letrozole increased the inhibition of Rb phosphorylation,
downstream signaling and tumor growth compared to each drug alone (Pfizer Pharma United
States product insert (USPI), (2015). Highlights of Prescribing Information; IBRANCE®
(palbociclib) for oral use. New York: Pfizer, Inc).20
Complete information for Palbociclib may be found in the single reference safety document
(SRSD), which for this study is the Pfizer Investigator Brochure for Palbociclib (PD-0332991).
6.1.2

Source of palbociclib
Palbociclib will be provided by Pfizer Inc. Palbociclib commercial supply will be supplied as 75
mg capsules in High Density Polyethylene (HDPE) bottles, labeled according to local
regulatory requirements.

6.1.3

Preparation and dispensing
Qualified site personnel will provide adequate palbociclib supplies for patient to take home
until next scheduled visit.
Patients will receive a drug diary to document dosing. The completed diary must be returned to
the site at the next study visit

6.1.4

Dosing of palbociclib and dose adjustments for palbociclib (holding, discontinuation)
Patients should be instructed to swallow palbociclib capsules whole and not to manipulate or
chew them prior to swallowing. No capsule should be ingested if it is broken, cracked, or
otherwise not intact. Patients should be encouraged to take their dose at approximately the
same time each day. Patients should be instructed to record daily administration in the
patient diary.
Patients should take palbociclib with food.
• Patients who miss a day’s dose entirely must be instructed NOT to “make it up” the next
day.
• Patients who vomit any time after taking a dose must be instructed NOT to “make it up,”
and to resume treatment the next day as prescribed
• Patients who inadvertently take 1 extra dose during a day must be instructed to skip the
next day’s dose.
Dosing of palbociclib will follow recommendations listed on the package insert based on
hematological and other major side effects.
For Phase 2 palbociclib dosing:
•
On the day of or day prior to administration of day 1 of palbociclib (Weeks 4, 8 and every 4
weeks thereafter while on study drug) for grade 3 or 4 neutropenia, palbociclib will be
held and CBC/diff will be checked in one week intervals, with treatment resumed at the
same dose when neutropenia has recovered to Grade ≤2. If more than two weeks are
required for recovery to Grade ≤2, the dose will be lowered to 75 mg p.o. twice a week.
•
On weeks 2 and 6, for Grade 3 neutropenia without fever ≥38.5 °C, treatment will
continue and CBC/diff will be repeated 1 week later. At these timepoints and at another
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•

•

other time, Grade 4 neutropenia or Grade 3 neutropenia with fever ≥38.5 °C, palbociclib
will be held until recovery to Grade ≤2.
For Grade ≥3 non-hematologic toxicity attributed to palbociclib, palbociclib will be held
until the toxicity in question resolves to Grade ≤1 or Grade ≤2 if not considered a risk to
the patient.
Once palbociclib dose has been lowered, it will not be re-escalated

6.2 Hydroxychloroquine
6.2.1

Description of hydroxychloroquine (HCQ)
Hydroxychloroquine (HCQ) is a small molecule drug that is indicated for the suppressive
treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P.
ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid
and systemic lupus erythematosus, and rheumatoid arthritis, and often used for overlap
connective tissue disorders. Although the exact mechanism of action is unknown, it may be
based on ability of HCQ to bind to and alter DNA. HCQ has also has been found to be taken up
into the acidic food vacuoles of the parasite in the erythrocyte. This increases the pH of the
acid vesicles, interfering with vesicle functions and possibly inhibiting phospholipid
metabolism. In suppressive treatment, HCQ inhibits the erythrocytic stage of development of
plasmodia. In acute attacks of malaria, it interrupts erythrocytic schizogony of the parasite.
Its ability to concentrate in parasitized erythrocytes may account for their selective toxicity
against the erythrocytic stages of plasmodial infection. As an anti-rheumatic, HCQ is thought
to act as a mild immunosuppressant, inhibiting the production of rheumatoid factor and
acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal
membranes and inhibiting the activity of many enzymes, including collagenase and the
proteases that cause cartilage breakdown.
HCQ is also known to inhibit autophagy, a cellular process that may also lead to resistance to
several cancer drugs, and as such, several trials have been conducted and shown safety of
HCQ combined with several antineoplastic agents.34-37 However, no trials have tested HCQ in
the setting and with the rationale and drug combination proposed in this trial.

6.2.2

Source and dispensing of hydroxychloroquine
Generic HCQ will be obtained from a commercial source, Quality Prescription Drugs (Suite
#245, 7360 137th Street, Surrey, B.C. V3W 1A3), a Canada-based company that uses U.S.
sources that is both CIPA certified and PharmacyChecker approved. The drug will be ordered
for direct delivery to the Investigational Pharmacy at MD Anderson in batches to maintain at
least a 3 months of supply on hand and will be dispensed as an investigational drug with
standard logging of drug acquisition, dispensation and final accounting for disposition.
Unused or returned drug will be destroyed. Drug will be dispensed to patients with the name
and dosage drug, date dispensed, name of patients, name of study and instructions for use.

6.2.3

Dosing of hydroxychloroquine and dose adjustments for hydroxychloroquine

HCQ will be given at the assigned dose for the Phase I dose escalation and Phase II fixed dose
parts of the trial The dose of 400 mg daily was chosen as the starting dose for the Phase I
portion as this is the usual dose used clinically and has been combined with hormonal and
other and cancer therapies at this does in prior studies.34-37 There will be no dose adjustments
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for HCQ, and any grade 3 toxicity that is attributed to HCQ will require discontinuation of
drug and for the patient to come off study. Subsequent treatment will be as per standard of
care. For patients on the Phase I portion, any Grade III toxicity attributed to HCQ will also be
counted as a dose-limiting toxicity if occurring in the first 28 days

6.3 Letrozole
Letrozole at the standard approved dose of 2.5 mg by mouth daily continuous dosing will be prescribed
as standard of care for neoadjuvant endocrine therapy through MD Anderson’s or the patient’s choice
of pharmacy. There will be no dose adjustments for letrozole. If the patient is felt to be having
unacceptable toxicities due to letrozole, then treatment will be stopped and the patient will come off
study. Subsequent treatment will be as per standard of care.

7.0 ADVERSE EVENT MONITORING AND REPORTING
7.1 Definition of an Adverse Event

An adverse event is the appearance or worsening of any undesirable sign, symptom or medical
condition occurring after starting protocol intervention, up to 30 days after the last dose of the
study therapy, even if the event is not considered to be related to the study drug.
This includes the following:
• AEs not previously observed in the patient that emerge during the protocol-specified
AE reporting period, including signs or symptoms that were not present prior to the AE
reporting period
•

Complications that occur as a result of protocol-mandated interventions (e.g., invasive
procedures such as cardiac catheterizations)

•

If applicable, AEs that occur prior to assignment of study treatment associated with
medication washout, no treatment run-in, or other protocol-mandated intervention

•

Pre-existing medical conditions (other than the condition being studied) judged by the
investigator to have worsened in severity or frequency or changed in character during
the protocol-specified AE reporting period

7.2 Definition Serious Adverse Event

An adverse event or suspected adverse reaction is considered “serious” if, in the view of either
the investigator or the sponsor, it results in any of the following outcomes:
• Death
• A life-threatening adverse drug experience – any adverse experience that places the
patient, in the view of the initial reporter, at immediate risk of death from the adverse
experience as it occurred. It does not include an adverse experience that, had it
occurred in a more severe form, might have caused death.
• Inpatient hospitalization or prolongation of existing hospitalization.
• A persistent or significant incapacity or substantial disruption of the ability to conduct
normal life functions.
• A congenital anomaly/birth defect.

Medical conditions/disease present before starting study drug are only considered adverse
events if they worsen after starting study drug. Abnormal laboratory values of test results
constitute adverse events only if they induce clinical signs or symptoms, are considered
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clinically significant or require therapy. Information about common side effects already known
about the investigational drug can be found in the Investigators’ Brochure.

7.3 Adverse Event Reporting Period

The study period during which all AEs and SAEs must be reported begins after informed consent
is obtained and starting protocol intervention and ends 30 days following the last administration
of study treatment or study discontinuation/termination, whichever is earlier. After this period,
investigators should only report SAEs that are attributed to prior study treatment.

7.4 Recording of Adverse Events

Medical events that may not result in death, be life-threatening, or require hospitalization may be
considered a serious adverse drug experience when, based upon appropriate medical judgment,
they may jeopardize the patient or subject and may require medical or surgical intervention to
prevent one of the outcomes listed in this definition. Examples of such medical events include
allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood
dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of
drug dependency or drug abuse (21 CFR 312.32).
•

Important medical events as defined above, may also be considered serious adverse events.
Any important medical event can and should be reported as an SAE if deemed appropriate by
the Principal Investigator.

•

All events occurring during the conduct of a protocol and meeting the definition of a SAE must
be reported to the IRB in accordance with the timeframes and procedures outlined in “The
University of Texas M. D. Anderson Cancer Center Institutional Review Board Policy for
Investigators on Reporting Serious Unanticipated Adverse Events for Drugs and Devices”.
Unless stated otherwise in the protocol, all SAEs, expected or unexpected, must be reported to
the IND Office, regardless of attribution (within 5 working days of knowledge of the event).

•

Serious adverse events will be captured from the time of the first protocol specific intervention,
until 30 days after the last dose of drug, unless the participant withdraws consent. Serious
adverse events must be followed until clinical recovery is complete and laboratory tests have
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returned to baseline, progression of the event has stabilized, or there has been acceptable
resolution of the event.
It is the responsibility of the PI and the research team to ensure serious adverse events are reported
according to the Code of Federal Regulations, Good Clinical Practices, the protocol guidelines, the
sponsor’s guidelines, and Institutional Review Board policy.

7.5 Assessment of Adverse Events
The PI or designee will be responsible for assigning attribution of adverse events to the study agent. As
far as possible, each adverse event should be evaluated to determine:
• The severity grade (mild, moderate, severe) or grade (1-4)
• Its relationship to the study drug(s) (suspected/not suspected)
• Its duration (start and end dates or if continuing at the final exam)
• Action taken (no action taken; study drug dosage adjusted/temporarily interrupted; study drug
permanently discontinued due to this adverse event; concomitant medications taken; non-drug
therapy given; hospitalization/prolonged hospitalization.
• Whether it constitutes a serious adverse events (SAE).
All AEs and SAEs, whether volunteered by the patient, discovered by study personnel during
questioning, or detected through physical examination, laboratory test, or other means, will be
reported appropriately.
Expected AEs are those AEs that are listed or characterized in the Package Insert (PI) or current
Investigator’s Brochure.
Unexpected AEs are those not listed in the PI or current Investigator’s Brochure or not
identified. This includes AEs for which the specificity or severity is not consistent with the description in
the PI or Investigator’s Brochure. For example, under this definition, hepatic necrosis would be
unexpected if the PI or Investigator’s Brochure only referred to elevated hepatic enzymes or hepatitis.

7.6 Communications between the Investigator and Supporting Company Pfizer
SAEs that occur after completion of the reporting time period as defined above are reportable to Pfizer
if the Investigator suspects a causal relationship between the Pfizer product and the SAE.

8.0 STATISTICAL CONSIDERATIONS
Phase I:
For the phase I portion, six patients for each cohort for better statistical power in the doseresponse biomarker analysis and expanded safety data.
Phase II:
For phase II, we will use a 2-stage Simon optimal design, looking to increase the CCCA rate from
50% to 75%. This design requires 11 patients in the first stage and 14 patients in the 2nd stage. It
would stop after the 1st stage if no more than six patients with CCCA are seen and declare the
treatment promising if at least 17 out of 25 total evaluable patients with CCCA are seen.
This design has alpha = 4%, 81% power, and a probability of 0.73 of terminating after the 1st stage
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if the true CCCA rate=50%. We therefore plan a sample size of 30 patients over 12-15 months,
accounting for patient dropout (including those with Ki67 >10% at T1). We have a large eligible
patient population and have led national accruals in other multi-center neoadjuvant endocrine
trials in post menopausal women (eg. ALTERNATE Trial). In addition, recent local experience of
conducting window of opportunity trials in this setting have demonstrated the feasibility of accrual
at a rate of ~2 patients per month. Thus, we expect to achieve accrual goals.
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